




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Classification: A1</p> <p>C07D 401/04, A61K 31/415, 31/44, 31/505, C07D 401/14, 409/14, 413/14, 405/14, 471/04, 417/14, 453/02 // (C07D 471/04, 237:00, 231:00) (C07D 471/04, 237:00, 233:00)</p>	<p>(11) International Publication Number: WO 98/52940</p> <p>(43) International Publication Date: 26 November 1998 (26.11.98)</p>	<p>Avenue, Skokie, IL 60076 (US); KOSZYK, Francis, J. [US]; 11 Wildwood Drive South, Prospect Heights, IL 60070 (US); LIAO, Shuyuan [CN]; 2N 500 Diane Avenue, Glen Ellyn, IL 60137 (US); PARTIS, Richard, A. [US]; 2221 Noyes Street, Evanston, IL 60201 (US); RAO, Shashidhar, N. [IN]; 43 Windsor Place, Mundelein, IL 60060 (US); SELNESS, Shaun, Raj [US]; Apartment 1, 12387 Great Creek Cove, St. Louis, MO 63141 (US); SOUTH, Richard [US]; 11111 Chertland Drive, St. Louis, MO 63141 (US); STRAUB, Mark A. [US]; 502 Juniper Parkway, Libertyville, IL 60088 (US); WEBER, Richard, M. [US]; 240 Hickory Court, Lake Bluff, IL 60044 (US); XU, Xiangdong [CN]; Apartment 715, 855 Human Avenue, Evanston, IL 60202 (US).</p> <p>(74) Agents: ROEBEL, John, K., Jr. et al.; Semmiger, Powers, Leavitt and Roedel, 16th floor, One Metropolitan Square, St. Louis, MO 63102 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>
<p>(21) International Application Number: PCT/US98/10436</p> <p>(22) International Filing Date: 22 May 1998 (22.05.98)</p> <p>(30) Priority Data: 60047.570 22 May 1997 (22.05.97) US</p>	<p>(71) Applicant (for all designated States except US): G.D. SEARLE AND CO. [US]; P.O. Box 5110, Chicago, IL 60680 (US).</p> <p>(72) Inventors and (73) Inventor/Rightsholder (for US only): ANANTANARAYAN, [US]; 54 Lick Drive, Hainesville, IL 60140 (US); CLARE, Michael [GB]; 5154 West Brown Street, Skokie, IL 60077 (US); COLLINS, Paul, W. [US]; 1557 Hawthorne Place, Deerfield, IL 60015 (US); CRICH, Joyce, Zaewu [CN]; 1501 G Topp Lane, Glenview, IL 60025 (US); DEVRAI, Rajesh [IN]; 41 Westmeade Court, Chesterfield, MO 63017 (US); FLYNN, Daniel, L. [US]; 16868 Kenedale Drive, Clarkson Valley, MO 63005 (US); GENG, Lifeng [CN]; 5300 Davis Street, Skokie, IL 60077 (US); HANSON, Gunter, J. [US]; 7410 Keystone</p>	<p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p> <p>(54) Title: SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS</p> <p>(57) Abstract A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (1) wherein R¹, R², R³ and R⁴ are as described in the specification.</p> <div style="text-align: center;">  <p>(1)</p> </div>

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Armenia	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GB	United Kingdom	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GE	Georgia	MC	Monaco	TD	Togo
BA	Bosnia and Herzegovina	GR	Greece	MD	Republic of Moldova	TG	Togo
BB	Barbados	HN	Honduras	ME	Montenegro	TM	Turkmenistan
BF	Burkina Faso	HU	Hungary	MK	Republic of Macedonia	TR	Turkey
BG	Bulgaria	IE	Ireland	ML	Mali	TT	Trinidad and Tobago
BR	Brazil	IL	Israel	MN	Mongolia	UA	Ukraine
BS	Bahamas	IS	Iceland	MR	Mauritania	UG	Uganda
BT	Bhutan	IT	Italy	MW	Malawi	US	United States of America
CA	Canada	JP	Japan	NE	Niger	UZ	Uzbekistan
CH	Switzerland	KE	Kenya	NL	Netherlands	VN	Viet Nam
CI	Cote d'Ivoire	KG	Kyrgyzstan	NO	Norway	YU	Yugoslavia
CM	Cameroon	KZ	Kazakhstan	NZ	New Zealand	ZW	Zimbabwe
CN	China	KG	Kyrgyzstan	PL	Poland		
CZ	Czech Republic	KR	Republic of Korea	PT	Portugal		
DE	Germany	LC	Liechtenstein	RO	Romania		
DK	Denmark	LI	Liechtenstein	RU	Russian Federation		
EE	Estonia	LK	Sri Lanka	SD	Sudan		
		LR	Liberia	SE	Sweden		

BEST AVAILABLE COPY

SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS

5 Cross-Reference to Related Application

This application claims priority from U.S. Provisional Application Serial No. 60/047,570 filed May 22, 1997.

10 Field of the Invention

This invention relates to a novel group of pyrazole compounds, compositions and methods for treating p38 kinase mediated disorders.

15 Background of the Invention

Mitogen-activated protein kinases (MAP) is a family of proline-directed serine/threonine kinases that activate their substrates by dual phosphorylation. The kinases are activated by a variety of signals including nutritional and osmotic stress, UV light, growth factors, endotoxin and inflammatory cytokines. The p38 MAP kinase group is a MAP family of various isoforms, including p38 α , p38 β and p38 γ , and is responsible for phosphorylating and activating transcription factors (e.g. ATF2, CHOP and MEF2C) as well as other kinases (e.g. MAPKAP-2 and MAPKAP-3). The p38 isoforms are activated by bacterial lipopolysaccharide, physical and chemical stress and by pro-inflammatory cytokines, including tumor necrosis factor (TNF- α) and interleukin-1 (IL-1). The products of the p38 phosphorylation mediate the production of inflammatory cytokines, including TNF and IL-1, and cyclooxygenase-2.

35 TNF- α is a cytokine produced primarily by activated monocytes and macrophages. Excessive or unregulated TNF production has been implicated in mediating a number of diseases. Recent studies indicate that TNF has a causative role in the pathogenesis of rheumatoid

arthritis. Additional studies demonstrate that inhibition of TNF has broad application in the treatment of inflammation, inflammatory bowel disease, multiple sclerosis and asthma.

5 TNF has also been implicated in viral infections, such as HIV, influenza virus, and herpes virus including herpes simplex virus type-1 (HSV-1), herpes simplex virus type-2 (HSV-2), cytomegalovirus (CMV), varicella-zoster virus (VZV), Epstein-Barr virus, human herpesvirus-6 (HHV-6), human herpesvirus-7 (HHV-7), human herpesvirus-8 (HHV-8), pseudorabies and rhinotracheitis, among others.

10 IL-8 is another pro-inflammatory cytokine, which is produced by mononuclear cells, fibroblasts, endothelial cells, and keratinocytes, and is associated with conditions including inflammation.

15 IL-1 is produced by activated monocytes and macrophages and is involved in the inflammatory response. IL-1 plays a role in many pathophysiological responses including rheumatoid arthritis, fever and reduction of bone resorption.

20 TNF, IL-1 and IL-8 affect a wide variety of cells and tissues and are important inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines by inhibition of the p38 kinase is of benefit in controlling, reducing and alleviating many of these disease states.

25 Various pyrazoles have previously been described. U.S. Patent No. 4,000,281, to Beller and Binon, describes 4,5-aryl/heteroaryl substituted pyrazoles with antiviral activity against both RNA and DNA viruses such as myxoviruses, adenoviruses, rhinoviruses, and various viruses of the herpes group. WO 92/19615, published November 12, 1992, describes pyrazoles as novel fungicides. U. S. Patent No. 3,984,431, to Cuernery and Renault, describes derivatives of pyrazole-5-acetic acid as having anti-inflammatory activity. Specifically, [1-

isobutyl-3,4-diphenyl-1H-pyrazol-5-yl)acetic acid is described. U. S. Patent No. 3,245,093 to Hinsgen et al., describes a process for preparing pyrazoles. WO 83/00330, published February 3, 1983, describes a new process for the preparation of diphenyl-3,4-methyl-5-pyrazole derivatives. WO 95/06036, published March 2, 1995, describes a process for preparing pyrazole derivatives. US patent 5,589,439, to T. Goto, et al., describes tetrazole derivatives and their use as herbicides. EP 515,041 describes pyrimidyl substituted pyrazole derivatives as novel agricultural fungicides. Japanese Patent 4,145,081 describes pyrazolecarboxylic acid derivatives as herbicides. Japanese Patent 5,345,772 describes novel pyrazole derivatives as inhibiting acetylcholinesterase.

Pyrazoles have been described for use in the treatment of inflammation. Japanese Patent 5,017,470 describes synthesis of pyrazole derivatives as anti-inflammatory, anti-rheumatic, anti-bacterial and anti-viral drugs. EP 115640, published Dec 30, 1983, describes 4-imidazolyl-pyrazole derivatives as inhibitors of thromboxane synthesis. 3-(4-isopropyl-1-methylcyclohex-1-yl)-4-(imidazol-1-yl)-1H-pyrazole is specifically described. WO 97/01551, published Jan 16, 1997, describes pyrazole compounds as adenosine antagonists. 4-(3-oxo-2,3-dihydropyridazin-6-yl)-3-phenylpyrazole is specifically described. U.S. Patent No. 5,134,142, to Matsuo et al. describes 1,5-diaryl pyrazoles as having anti-inflammatory activity.


U.S. Patent No. 5,559,137 to Adams et al., describes novel pyrazoles (1,3,4,-substituted) as inhibitors of cytokines used in the treatment of cytokine diseases. Specifically, 3-(4-fluorophenyl)-1-(4-methylsulfinylphenyl)-4-(4-pyridyl)-5H-pyrazole is described. WO 96/03385, published February 8, 1996, describes 3,4-substituted pyrazoles, as having anti-

inflammatory activity. Specifically, 4-[1-ethyl-4-(4-pyridyl)-5-trifluoromethyl-1H-pyrazol-3-yl]benzenesulfonamide is described.

The invention's pyrazolyl compounds are found to show usefulness as p38 kinase inhibitors.

Description of the Invention

A class of substituted pyrazolyl compounds useful in treating p38 mediated disorders is defined by Formula I:




wherein

R¹ is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkenoxyalkenyl, aryloxyalkyl, heterocyclioxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, heterocyclylalkylene,

5

alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, arylloxycarbonylalkylene, alkoxycarbonylalkylene, arylloxycarbonylalkylene, heterocyclyloxycarbonylalkylene, alkoxycarbonylarylene, arylloxycarbonylarylene, heterocyclyloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocyclylcarbonyloxyarylene; or

Rⁱ has the formula



wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, arylloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylalkylene; and
R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and
R²⁷ is selected from alkyl, cycloalkyl, aralkyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, aralkylalkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, arylloxyarylene, aralkoxyarylene,

SUBSTITUTE SHEET (RULE 26)

6

alkoxyheterocyclylalkylene, arylloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, arylloxycarbonylarylene, alkylarylloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, arylcarbonylarylene, heterocyclylarylene, alkoxycarbonylheterocyclylarylene, alkoxycarbonylalkoxyarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, heterocyclylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalkylarylene, arylsulfonylaminoalkylene, alkylsulfonylarylene, alkylaminoalkoxyarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, arylloxyarylene, arylaminocarbonylalkylene, arylloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, heterocyclylthioarylene, arylthioalkylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or
R²⁷ is -CHR²⁸R²⁹ wherein R²⁸ is alkoxycarbonyl, and R²⁹ is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocyclyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or
R²⁶ and R²⁷ together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more

SUBSTITUTE SHEET (RULE 26)

radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclalkylene, alkylheterocyclalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl,

heterocyclalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R² is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclalkyl,

alkylamino, alkenylamino, alkynylamino, arylamino,

heterocyclylamino, heterocyclalkylamino, aralkylamino, aminoalkyl, aminoaryl, aminoalkylamino, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkylaminoalkylamino, cycloalkyl,

cycloalkenyl, alkoxy, heterocyclloxy, alkylthio, arylthio, heterocyclthio, carboxy, carboxyalkyl, carboxycycloalkyl, carboxycycloalkenyl,


carboxyalkylamino, alkoxycarbonyl, heterocyclcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylheterocycl, alkoxycarbonylheterocyclcarbonyl, alkoxyalkylamino, wherein the aryl, heterocycl, and heterocyclalkyl,

substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl,

aryl, heterocycl, aralkyl, heterocyclalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino,

alkylaminoalkylamino, heterocyclalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R² has the formula:



wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁰ and R³¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R³² is selected from hydrogen, alkyl, aralkyl, heterocyclalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclcarbonylaminoalkylene;

R³³ is selected from hydrogen, alkyl, -C(O)R³⁵, -C(O)OR³⁶, -SO₂R³⁶, -C(O)NR³⁷R³⁸, and -SO₂NR³⁷R³⁸, wherein R³⁵, R³⁶, R³⁷, R³⁸ and R³⁹ are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

R³⁴ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R² is -CR³⁹R⁴² wherein R³⁹ is aryl, and R⁴² is hydroxy; and

R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,



(IV)

(V)

9

wherein R⁴ is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; and

5 wherein the R³ pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl,

aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl,

10 aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocyclylamino, aminoalkenylamino, cyano, hydroxy, hydroxyalkyl,

15 alkoxy, carbonyl, aryloxy, carbonyl, heterocyclyloxy, carbonyl, alkoxy, carbonylamino, alkoxy, aralkylamino, aminoalkenyl, aminoalkenyl, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, heterocyclylalkylamino,

20 aralkylheterocyclylamino, nitro, alkylaminocarbonyl, alkylaminocarbonyl, haloalkyl, haloalkyl, alkylaminocarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or -NR⁴R⁵ wherein R⁴ is alkyl, carbonyl or amino, and R⁵ is alkyl or aralkyl; and

25 R¹ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R¹ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl,

30 alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene,

35 arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxy, carbonyl, aryloxy, carbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminocarbonyl, arylaminocarbonyl, aminoalkylamino, and hydroxy; provided R³ is not 2-pyridinyl when R⁴ is a phenyl

SUBSTITUTE SHEET (RULE 26)

10

ring containing a 2-hydroxy substituent and when R¹ is hydrido; further provided R¹ is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R¹ is hydrido; and further provided R¹ is not methylsulfonylphenyl; or

5 a pharmaceutically-acceptable salt or tautomer thereof.

10 Compounds of Formula I would be useful for, but not limited to, the treatment of any disorder or disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated TNF or p38 kinase production by such mammal. Accordingly, the present invention provides a method of treating a cytokine-mediated disease which comprises administering an effective cytokine-interfering amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.

15 Compounds of Formula I would be useful for, but not limited to, the treatment of inflammation in a subject, and for use as antipyretics for the treatment of fever. Compounds of the invention would be useful to treat

20 arthritis, including but not limited to, rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, osteoarthritis, gouty arthritis and other arthritic conditions. Such compounds would be useful for the treatment of pulmonary disorders or lung

25 inflammation, including adult respiratory distress syndrome, pulmonary sarcoidosis, asthma, silicosis, and chronic pulmonary inflammatory disease. The compounds are also useful for the treatment of viral and bacterial infections, including sepsis, septic shock, gram negative sepsis, malaria, meningitis, cachexia secondary to infection or malignancy, cachexia secondary to immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), pneumonia, and herpesvirus. The

SUBSTITUTE SHEET (RULE 26)

compounds are also useful for the treatment of bone resorption diseases, such as osteoporosis, endotoxic shock, toxic shock syndrome, reperfusion injury, autoimmune disease including graft vs. host reaction and allograft rejections, cardiovascular diseases including

atherosclerosis, thrombosis, congestive heart failure, liver disease and nephritis, and myalgias due to infection. The compounds are also useful for the

10 treatment of influenza, multiple sclerosis, cancer, diabetes, systemic lupus erythematosus (SLE), skin-

related conditions such as psoriasis, eczema, burns, dermatitis, keloid formation, scar tissue formation, and angiogenic disorders. Compounds of the invention also

15 would be useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease,

gastritis, irritable bowel syndrome and ulcerative

colitis. The compounds would also be useful in the

treatment of ophthalmic diseases, such as retinitis,

20 retinopathies, uveitis, ocular photophobia, and of acute injury to the eye tissue. Compounds of the invention

also would be useful for treatment of angiogenesis,

including neoplasia; metastasis; ophthalmological

conditions such as corneal graft rejection, ocular

25 neovascularization, retinal neovascularization including neovascularization following injury or infection,

diabetic retinopathy, retrolental fibroplasia and

neovascular glaucoma; ulcerative diseases such as gastric

ulcer; pathological, but non-malignant, conditions such

30 as hemangiomas, including involutional hemangiomas,

angiofibroma of the nasopharynx and avascular necrosis of

bone; diabetic nephropathy and cardiomyopathy; and

disorders of the female reproductive system such as

endometriosis. The compounds of the invention may also

35 be useful for preventing the production of

cyclooxygenase-2.

Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred

5 animals include horses, dogs, and cats.

The present compounds may also be used in co-therapies, partially or completely, in place of other conventional anti-inflammatories, such as together with steroids, cyclooxygenase-2 inhibitors, DMARD's,

10 immunosuppressive agents, NSAIDs, 5-lipoxygenase inhibitors, LTB₄ antagonists and LTA₄ hydrolase inhibitors.

As used herein, the term "TNF mediated disorder" refers to any and all disorders and disease states in which TNF plays a role, either by control of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disorder mediated by TNF.

As used herein, the term "p38 mediated disorder" refers to any and all disorders and disease states in which p38 plays a role, either by control of p38 itself, or by p38 causing another factor to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to p38, would therefore be considered a disorder mediated by p38.

As TNF- β has close structural homology with TNF- α (also known as cachectin) and since each induces similar biologic responses and binds to the same cellular receptor, the synthesis of both TNF- α and TNF- β are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF" unless


13

specifically delineated otherwise.

A preferred class of compounds consists of those compounds of Formula I wherein

- 5 R^1 is selected from hydrido, lower alkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, lower heterocyclyl, lower cycloalkylalkylene, lower haloalkyl, lower hydroxyalkyl, lower aralkyl, lower alkoxyalkyl, lower mercaptoalkyl, lower alkylthioalkylene, amino, lower alkylamino, lower arylamino, lower

- 10 alkylaminoalkylene, and lower heterocyclalkylene; or R^1 has the formula



wherein:

i is 0, 1 or 2; and

- 15 R^2 is selected from hydrogen, lower alkyl, lower phenylalkyl, lower heterocyclalkyl, lower alkoxyalkylene, lower phenoxyalkylene, lower aminoalkyl, lower alkylaminoalkyl, lower phenoxylaminoalkyl, lower heterocyclcarbonylalkylene, lower phenoxycarbonylalkylene, and lower heterocyclcarbonylaminoalkylene; and
- 20 R^3 is selected from hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkylalkylene, lower phenylalkyl, lower alkoxycarbonylalkylene, and lower alkylaminoalkyl; and
- 25 R^4 is selected from lower alkyl, lower cycloalkyl, lower alkynyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower cycloalkylalkylene, lower cycloalkenylalkylene, lower cycloalkylarylene, lower cycloalkylcycloalkyl, lower heterocyclalkylene, lower alkylphenylene, lower alkylphenylalkyl, lower phenylalkylphenylene, lower alkylheterocyclyl, lower alkylheterocyclalkylene, lower
- 30

SUBSTITUTE SHEET (RULE 26)

14

- alkylheterocyclylphenylene, lower phenylalkylheterocyclyl, lower alkoxyalkylene, lower alkoxyphenylene, lower alkoxyphenylalkyl, lower alkoxyheterocyclyl, lower alkoxyalkoxyphenylene, lower phenoxyphenylene, lower phenylalkoxyphenylene, lower alkoxyheterocyclalkylene, lower phenoxyalkoxyphenylene, lower alkoxycarbonylalkylene, lower
- 5 alkoxycarbonylheterocyclyl, lower aminoalkyl, lower alkylaminoalkylene, lower alkoxyphenylaminocarbonylalkylene, lower aminocarbonylalkylene, arylaminocarbonylalkylene, lower alkylaminocarbonylalkylene, lower phenylcarbonylalkylene, lower alkoxyphenylaminocarbonylalkylene, lower
- 10 aminocarbonyl, lower alkylaminoalkylene, lower phenylaminocarbonylalkylene, lower alkoxyphenylaminocarbonylphenylene, lower alkylphenoxycarbonylphenylene, lower phenylcarbonylphenylene, lower alkylphenylcarbonylphenylene, lower alkoxycarbonylheterocyclylphenylene, lower alkoxycarbonylalkoxyphenylene, lower
- 15 heterocyclcarbonylalkylphenylene, lower alkythioalkylene, cycloalkylthioalkylene, lower alkylthiophenylene, lower phenylalkylthiophenylene, lower heterocyclthiophenylene, lower phenylthioalkylphenylene, lower phenylsulfonylaminocarbonylalkylene, lower
- 20 alkylnifonylphenylene, lower alkylaminosulfonylphenylene; wherein said lower alkyl, lower cycloalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower heterocyclalkylene, lower alkylheterocyclylphenylene, lower alkoxyphenylene, lower phenoxyphenylene, lower phenylaminocarbonylalkylene, lower
- 25 phenoxycarbonylphenylene, lower phenylcarbonylphenylene, lower alkylthiophenylene, lower
- 30
- 35

SUBSTITUTE SHEET (RULE 26)

17

heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

5 R^3 is selected from hydrogen, alkyl, $-C(O)R^5$, $-C(O)OR^5$, $-SO_2R^5$, $-C(O)NR^5R^6$, and $-SO_2NR^5R^6$;

wherein R^5 is selected from alkyl, cycloalkyl, haloalkyl, alkenyl, aryl, heterocyclyl, aralkyl, arylcycloalkyl, cycloalkenylalkylene, heterocyclylalkylene, alkylarylene, alkylheterocyclyl, arylarylene, arylheterocyclyl, alkoxy, alkenoxy, alkoxyalkylene, alkoxyaralkyl, alkoxyarylene, aryloxyalkylene, aralkoxyalkylene, cycloalkyloxyalkylene, alkoxycarbonyl, heterocyclylcarbonyl,

10 alkylcarbonyloxyalkylene, alkylcarbonyloxyarylene, alkylcarbonylalkylene, alkoxycarbonylarylene, aralkoxycarbonylheterocyclyl, alkylcarbonylheterocyclyl, arylcarbonyloxyalkylarylene, and alkylthioalkylene; wherein said aryl, heterocyclyl, aralkyl, alkylarylene, arylheterocyclyl, alkoxyarylene, aryloxyalkylene, cycloalkoxyalkylene, alkoxycarbonylalkylene, and alkylcarbonylalkylene, are optionally substituted with one or more radicals independently

15 selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; or

R^5 is $CH_2R^6R^7$ wherein R^6 is arylsulfonylamino or alkylarylsulfonylamino, and R^7 is selected from aralkyl, amino, alkylamino, and aralkylamino; or

20 R^5 is $-NR^6R^7$ wherein R^6 is alkyl, and R^7 is aryl; and

wherein R^6 is selected from alkyl, haloalkyl, aryl, heterocyclyl, cycloalkylalkylene, alkylarylene, alkenylalkylene, arylarylene, aralkyl, aralkenyl, heterocyclylheterocyclyl, carboxyarylene, alkoxyarylene, alkoxycarbonylarylene, alkylcarbonylaminoarylene, alkylcarbonylaminoheterocyclyl.

SUBSTITUTE SHEET (RULE 26)

18

arylcarbonylaminoalkylheterocyclyl, alkylaminoarylene, alkylamino, alkylaminoarylene, alkylsulfonylarylene, alkylsulfonylaralkyl, and arylsulfonylheterocyclyl; wherein said aryl, heterocyclyl, cycloalkylalkylene, aralkyl, alkylcarbonylaminoheterocyclyl, and

5 alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

10 wherein R^3 is selected from hydrogen and alkyl; and

wherein R^3 is selected from hydrogen, alkyl, alkenyl, aryl, heterocyclyl, aralkyl, alkylarylene, arylcycloalkyl, arylarylene, cycloalkylalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, aryloxyarylene, arylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkylene, alkoxycarbonylarylene, alkylcarbonylcarbonylalkylene, alkylaminoalkylene, alkylaminoaralkyl, alkylcarbonylaminoalkylene, alkylthioarylene, alkylsulfonylaralkyl, and

15 aminoalkyl; wherein said aryl, heterocyclyl, aralkyl, and heterocyclylalkylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; or

20 R^3 is $-CR^6R^7$ wherein R^6 is alkoxycarbonyl, and R^7 is alkylthioalkylene; or

R^3 and R^7 together with the nitrogen atom to which they are attached form a heterocycle; and

25 R^3 and R^7 have the same definition as R^6 and R^7 in claim 1; or

R^3 is $-CR^6R^7$ wherein R^6 is phenyl and R^7 is hydroxy; or

30 R^3 is selected from the group consisting of

SUBSTITUTE SHEET (RULE 26)

21

phenylalkyl; and

R' is selected from hydrido, lower cycloalkyl, lower cycloalkenyl, aryl selected from phenyl, biphenyl, and naphthyl, and 5- or 6- membered heterocyclyl; wherein the lower cycloalkyl, lower cycloalkenyl, aryl and 5-10 membered heterocyclyl groups of R' are optionally substituted with one or more radicals independently selected from lower alkylthio, lower alkylsulfonyl, lower alkylsulfinyl, halo, lower alkyl, lower alkenyl, lower alkoxy, lower arylloxy, lower aralkoxy, lower heterocyclyl, lower haloalkyl, amino, cyano, nitro, lower, loweralkylamino, and hydroxy; or a pharmaceutically-acceptable salt or tautomer thereof.

A class of compounds of particular interest consists of these compounds of Formula I wherein

R¹ is selected from hydrido, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, propenyl, ethynyl, propargyl, 1-propynyl, 2-propynyl, piperidinyl, piperazinyl, morpholinyl, benzyl, phenylethyl, morpholinylmethyl, morpholinylethyl, pyridinylmethyl, piperazinylmethyl, piperidinylmethyl, pyridinylmethyl, thienylmethyl, methoxymethyl, ethoxymethyl, amino, methylamino, dimethylamino, phenylamino, methylaminomethyl, dimethylaminomethyl, methylaminoethyl, dimethylaminoethyl, ethylaminoethyl, diethylaminoethyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, hydroxymethyl, hydroxyethyl, mercaptomethyl, and methylthiomethyl; and

R² is selected from hydrido, chloro, fluoro, bromo,

SUBSTITUTE SHEET (RULE 26)

22

- 15 methy1, ethy1, propy1, isopropyl, tert-butyl, isobutyl, phenyl, biphenyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoromethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxymethyl, hydroxyethyl, pyridinyl, isothiazolyl, isoxazolyl, thienyl, thiazolyl, oxazolyl, pyrimidinyl, guanolyl, isoguaninolyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, piperidinyl, piperazinyl, morpholinyl, N-methylpiperazinyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-n-propylamino, N,N-dimethylamino, N-methyl-N-phenylamino, N-phenylamino, piperidinylamino, N-benzylamino, N-propargylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, N,N-aminoethylamino, aminoethylamino, N,N-dimethylaminopropylamino, dimethylaminoethylamino, N,N-dimethylaminopropylamino, morpholinylethylamino, morpholinylpropylamino, carboxymethylamino, methoxyethylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, 1,1-dimethylethoxycarbonyl, 1,1-dimethylethoxycarbonylaminoethylamino, 1,1-dimethylethoxycarbonylaminoethylamino, 1,1-dimethylethoxycarbonylaminoethylamino, 1,1-piperazinylethoxycarbonyl, and 1,1-piperazinylethoxycarbonylaminoethylamino, dimethylethoxycarbonylpiperazinylcarbonyl; wherein the aryl, heteroaryl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals
- 30 independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, isopropyl, tert-butyl, isobutyl, benzyl, carboxy, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl, difluoromethyl, dimethylamino, methoxycarbonyl, ethoxycarbonyl, and 1,1-dimethylethylcarbonyl; or

R² is -CR³R³³ wherein R³⁴ is phenyl and R³⁵ is hydroxy; and

R³ is selected from pyridinyl, pyrimidinyl, and purinyl; wherein R³ is optionally substituted with one or more radicals independently selected from methylthio,

methylsulfonyl, methylsulfonyl, fluoro, chloro, bromo, aminosulfonyl, methyl, ethyl, isopropyl, tert-butyl, isobutyl, cyano, methoxycarbonyl, ethoxycarbonyl,

aminocarbonyl, methylcarbamoyl, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, hydroxy,

fluorophenylmethyl, fluorophenylethyl, chlorophenylmethyl, chlorophenylethyl, fluorophenylethyl, chlorophenylethyl,

fluorophenylpyrazolyl, chlorophenylethenyl, methoxy, ethoxy, propyloxy, n-butoxy, methylamino,

ethylamino, dimethylamino, diethylamino, 2-methylbutylamino, propargylamino, aminomethyl,

aminoethyl, N-methyl-N-phenylamino, phenylamino, diphenylamino, benzylamino, phenethylamino,

cyclopropylamino, nitro, chlorosulfonyl, amino, methylcarbamoyl, methoxycarbonylamino,

ethoxycarbonylamino, methoxyphenylmethylamino, N,N-dimethylaminoethoxyamino, hydroxypropylamino,

hydroxyethylamino, imidazolylethylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylethylamino, pyridinylethylamino,

phenylmethylpiperidinylethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino,

methylaminocarbonyl, ethylaminocarbonyl, methylcarbamoyl, methoxyphenylmethylamino, hydrazinyl, 1-methyl-

hydrazinyl, or -NR³R³³ wherein R³⁴ is methylcarbamoyl or amino, and R³⁵ is methyl, ethyl or phenylethyl; and

R¹ is selected from hydrido, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, phenyl,

SUBSTITUTE SHEET (RULE 26)

biphenyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, pyridinyl, thienyl, isothiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isquinolinyl, imidazolyl, benzimidazolyl, furyl,

pyrazinyl, dihydropyranyl, dihydropyridinyl, dihydrofuryl, tetrahydropyranyl, tetrahydrofuryl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl

groups of R¹ are optionally substituted with one or more radicals independently selected from methylthio,

methylsulfonyl, methylsulfonyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, tert-butyl, isobutyl, ethynyl,

methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl, difluoromethyl, amino, cyano, nitro,

dimethylamino, and hydroxy; or a pharmaceutically-acceptable salt or tautomer thereof.

Another class of compounds of particular interest consists of these compounds of Formula I wherein

R¹ is hydrido, methyl, ethyl, propargyl, hydroxyethyl, dimethylaminoethyl, diethylaminoethyl or morpholinylethyl;

R² is selected from hydrido, methyl, ethyl, propyl, phenyl, trifluoromethyl, methoxycarbonyl, N,N-

dimethylamino, N-phenylamino, piperidinyl, piperazinyl, pyridinyl, N-methylpiperazinyl, and piperazinylamino;

wherein the phenyl, piperidinyl, and pyridinyl groups are optionally substituted with one or more radicals

independently selected from fluoro, chloro, bromo, methyl, ethyl, and trifluoromethyl;

R³ is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R³ is optionally substituted with one or more radicals independently selected from fluoro,

bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy,

SUBSTITUTE SHEET (RULE 26)

25

dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl;

R^4 is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R^4 are optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or
a pharmaceutically-acceptable salt or tautomer thereof.

15 A class of compounds of specific interest consists of those compounds of Formula I wherein

R^1 is hydrido or methyl;

R^2 is selected from hydrido, methyl or ethyl;

20 R^3 is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R^3 is optionally substituted with one or more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy,

25 dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl;

R^4 is selected from phenyl which is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or
a pharmaceutically-acceptable salt or tautomer thereof.


35 Still another class of compounds of particular interest consists of those compounds of Formula I wherein R^1 is selected from hydrido, methyl, ethyl, propyl,

SUBSTITUTE SHEET (RULE 26)

26

isopropyl, tert-butyl, isobutyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoromethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, propenyl, ethynyl, propargyl, 1-propynyl, 2-propynyl, piperidinyl, piperazinyl, morpholinyl, benzyl, phenylethyl, morpholinylmethyl, morpholinylethyl, pyrrolidinylmethyl, piperazinylmethyl, piperidinylmethyl, pyridinylmethyl, thienylmethyl, methoxymethyl, ethoxymethyl, amino, methylamino, dimethylamino, phenylamino, methylaminomethyl, dimethylaminomethyl, methylaminomethyl, dimethylaminomethyl, ethylaminomethyl, dimethylaminomethyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, hydroxymethyl, hydroxyethyl, mercaptomethyl, and methylthiomethyl; and

R^3 has the formula:



20

wherein:

j is 0, 1 or 2; and

m is 0; and

25 R^{30} and R^{31} are independently selected from hydrogen and lower alkyl;

30 R^{32} is selected from hydrogen, lower alkyl, lower phenylalkyl, lower heterocyclalkyl, lower alkoxyalkylene, aryloxyalkylene, aminoalkyl, lower alkylaminoalkyl, lower phenylaminoalkyl, lower alkylcarbonylalkylene, lower phenylcarbonylalkylene, and lower heterocyclcarbonylaminoalkylene;

R^{33} is selected from hydrogen, lower alkyl, $-C(O)R^{35}$, $-C(O)OR^{35}$, $-SO_2R^{36}$, $-C(O)NR^{37}R^{38}$, and $-SO_2NR^{37}R^{38}$;

SUBSTITUTE SHEET (RULE 26)

wherein R³ is selected from lower alkyl, lower cycloalkyl, lower haloalkyl, lower alkenyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower phenylcycloalkyl, lower cycloalkenylalkylene, lower heterocyclylalkylene, lower alkylphenylene, lower alkylheterocyclyl, phenylphenylene, lower phenylheterocyclyl, lower alkoxy, lower alkenoxy, lower alkoxyalkylene, lower alkoxyphenylalkyl, lower alkoxyphenylene, lower phenoxyalkylene, lower phenylalkoxyalkylene, lower lower alkoxyalkylene, lower cycloalkoxyalkylene, lower alkoxyphenyl, lower heterocyclylcarbonyl, lower alkylcarbonyloxyalkylene, lower

10 phenylalkoxyalkylene, lower cycloalkoxyalkylene, lower alkoxyphenyl, lower heterocyclylcarbonyl, lower alkylcarbonyloxyalkylene, lower

15 lower alkoxyphenylphenylene, lower lower alkoxyphenylphenylene, lower phenylalkoxyphenylheterocyclyl, lower alkylcarbonylheterocyclyl, lower

phenylcarbonyloxyalkylphenylene, and lower alkylthioalkylene; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower

20 phenylalkyl, lower alkylphenylene, lower phenylheterocyclyl, lower alkoxyphenylene, lower phenoxyalkylene, lower cycloalkoxyalkylene, lower alkoxyphenylalkylene, and lower

alkylcarbonylalkylene, and lower alkylcarbonylheterocyclyl groups are optionally

25 substituted with one or more radicals independently selected from lower alkyl, halo, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; or

30 R³ is CHR⁴R⁵ wherein R⁴ is phenylsulfonylamino or lower alkylphenylsulfonylamino, and R⁵ is selected from lower phenylalkyl, amino, lower alkylamino, and lower phenylalkylamino; or

35 R³ is -NR⁶R⁷ wherein R⁶ is lower alkyl, and R⁷ is aryl selected from phenyl, biphenyl and naphthyl; and wherein R³ is selected from lower alkyl, lower haloalkyl, aryl selected from phenyl, biphenyl and

SUBSTITUTESHEET (RULE 26)

naphthyl, lower heterocyclyl, lower cycloalkylalkylene, lower alkylphenylene, lower alkenylphenylene, phenylphenylene, lower phenylalkyl, lower phenylalkenyl, lower heterocyclylheterocyclyl, carboxyphenylene, lower alkoxyphenylene, lower alkoxyphenylphenylene, lower

5 alkylcarbonylaminophenylene, lower alkylcarbonylaminoheterocyclyl, lower phenylcarbonylaminoheterocyclyl, lower phenylaminophenylene, lower alkylamino, lower

10 alkylaminophenylene, lower alkylsulfonylphenylene, lower alkylsulfonylphenylalkyl, and lower phenylsulfonylphenylalkyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower cycloalkylalkylene, lower phenylalkyl, lower

15 alkylcarbonylaminoheterocyclyl, and lower alkylsulfonylphenylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower

alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

20 wherein R³ is selected from hydrogen and lower alkyl; and

wherein R³ is selected from hydrogen, lower alkyl, lower alkenyl, aryl selected from phenyl, biphenyl and

25 naphthyl, lower heterocyclyl, lower phenylalkyl, lower alkylphenylene, lower phenylcycloalkyl, phenylphenylene, lower cycloalkylalkylene, lower heterocyclylalkylene, lower alkylheterocyclylalkylene, lower

30 phenylalkylheterocyclyl, lower alkoxyalkylene, lower alkylphenylene, lower phenoxyphenylene, phenylcarbonyl, lower alkoxyphenyl, lower alkoxyphenylalkylene, lower

alkoxyphenylphenylene, lower alkylcarbonylphenylphenylene, lower alkylaminophenylalkylene, lower

35 alkylcarbonylaminophenylene, lower alkylthiophenylene, lower alkylsulfonylphenylalkyl, and lower

SUBSTITUTESHEET (RULE 26)


29

aminosulfonylphenylalkyl, wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, and lower heterocyclylalkylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; or

R^u is $-CR^{37}R^{38}$ wherein R_{37} is lower alkoxy, carbonyl, and R_{38} is lower alkylthioalkylene; or

R^{37} and R^{38} together with the nitrogen atom to which they are attached form a 4-8 membered ring heterocycle; R^{39} and R^{40} have the same definition as R^{36} and R^{37} in claim 2; or

R^2 is selected from the group consisting of



15

(VI)

(VII)

(VIII)

wherein

k is an integer from 0 to 2; and

R^{36} is hydrogen or lower alkyl; and

R^{37} is hydrogen or lower alkyl; and

R^{38} is selected from hydrogen, lower alkyl, lower phenylalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower heterocyclylalkyl, lower alkoxy, carbonyl, lower alkylsulfonyl, lower phenylalkylsulfonyl, lower phenylsulfonyl, $-C(O)R^{39}$, $-SO_2R^{40}$, and $-C(O)NHR^{41}$;

wherein R^{39} is selected from lower alkyl, lower haloalkyl, lower cycloalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower

30

alkylphenylene, lower phenylalkyl, lower alkylheterocyclyl, lower alkoxy, lower alkenoxy, lower alkoxyphenylene, lower alkoxyalkylene, lower alkoxyphenylene, lower alkoxyphenylalkyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, and lower phenylalkyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R^{40} is selected from lower alkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower alkylphenylene, lower heterocyclyl, lower alkylphenylene, lower

heterocyclylheterocyclyl, lower alkoxyphenylene, lower alkylamino, lower alkylaminophenylene, lower alkylsulfonylphenylene, and lower

phenylsulfonylheterocyclyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, and lower phenylalkyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R^{41} is selected from lower alkyl, aryl selected from phenyl, biphenyl and naphthyl, lower alkylphenylene, and lower alkoxyphenylene; wherein said aryl group is optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

R^3 is selected from pyridinyl, pyrimidinyl, and purinyl; wherein R^3 is optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, aminosulfonyl, methyl, ethyl, isopropyl, tert-butyl,

SUBSTITUTE SHEET (RULE 26)


SUBSTITUTE SHEET (RULE 26)

isobutyl, cyano, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylcarbamoylamino, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, hydroxy, 5 fluorophenylmethyl, fluorophenylethyl, chlorophenylmethyl, chlorophenylethyl, fluorophenylethenyl, chlorophenylethenyl, fluorophenylpyrazolyl, chlorophenylpyrazolyl, carboxy, methoxy, ethoxy, propyloxy, n-butoxy, methylamino, 10 ethylamino, dimethylamino, diethylamino, 2-methylbutylamino, propargylamino, aminomethyl, aminoethyl, N-methyl-N-phenylamino, phenylamino, diphenylamino, benzylamino, phenethylamino, cyclopropylamino, nitro, chlorosulfonyl, amino, 15 methylcarbamoyl, methoxycarbonylamino, ethoxycarbonylamino, methoxyphenylmethylamino, N,N-dimethylaminoethylethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylethylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, 20 piperidinylamino, pyridinylethylamino, phenylmethylpiperidinylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, ethylaminocarbonyl, methylcarbamoyl, methoxyphenylmethylamino, hydrazinyl, 1-methyl- 25 hydrazinyl, or -NR³⁰R³¹ wherein R³⁰ is methylcarbamoyl or amino, and R³¹ is methyl, ethyl or phenylmethyl; and R¹ is selected from hydrido, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, phenyl, 30 biphenyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, pyridinyl, thienyl, isothiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isquinolinyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, dihydropyranyl, dihydropyridinyl, 35 dihydrofuryl, tetrahydropyranyl, tetrahydrofuryl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein

the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R¹ are optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, 5 methyl, ethyl, isopropyl, tert-butyl, isobutyl, ethynyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl; difluoromethyl, amino, cyano, nitro, dimethylamino, and hydroxy; or a pharmaceutically-acceptable salt or tautomer 10 thereof.

Still another class of compounds of particular interest consists of those compounds of Formula I wherein R¹ is hydrido, methyl, ethyl, propargyl, 15 hydroxyethyl, dimethylaminoethyl, diethylaminoethyl or morpholinylethyl;

R² has the formula:



wherein:

20 j is 0, 1 or 2; and

m is 0; and

R³⁰ is hydrogen; and

R³¹ is selected from hydrogen and lower alkyl; and

R³² is selected from hydrogen and lower alkyl; and


25 R³³ is selected from lower alkyl, -C(O)R³⁵, -C(O)OR³⁵, -SO₂R³⁶, -C(O)NR³⁷R³⁸, and -SO₂NR³⁹R⁴⁰;

wherein R³⁵ is selected from lower alkyl, lower cycloalkyl, phenyl, lower heterocyclyl, lower alkylphenylene, lower alkoxy, lower alkenoxy, lower alkoxyalkylene, lower phenoxyalkylene, and lower phenylalkoxyalkylene; wherein said phenyl and lower phenoxyalkylene groups are optionally substituted with

33

- one or more radicals independently selected from lower alkyl, halo, and lower haloalkyl; and wherein R^6 is selected from lower alkyl, phenyl, lower heterocyclyl, lower alkylphenylene, phenylphenylene, lower phenylalkyl, lower alkylheterocyclyl, lower heterocyclylheterocyclyl, lower alkoxyphenylene, and lower alkylamino; wherein said phenyl and lower heterocyclyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and wherein R^7 is hydrogen; and wherein R^8 is selected from lower alkyl, phenyl, and lower alkylphenylene; wherein R^9 and R^{10} have the same definition as R^6 , and R^{11} in claim 2; or

R^2 is selected from the group consisting of



- (VI) wherein k is an integer from 0 or 1, and R^{36} is hydrogen; and R^{37} is hydrogen; and R^{38} is selected from $-C(O)R^{39}$ and $-SO_2R^{40}$; wherein R^{39} is selected from lower alkyl, lower cycloalkyl, phenyl, lower alkylphenylene, and lower alkoxyalkylene; wherein said phenyl group is optionally substituted with one or more radicals independently

SUBSTITUTE SHEET (RULE 26)

34

- selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and wherein R^{10} is selected from lower alkyl, and quinoliny; wherein R^1 is optionally substituted with one or more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl; and R^2 is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R^1 are optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or a pharmaceutically-acceptable salt or tautomer thereof.
- Still another class of compounds of specific interest consists of those compounds of Formula I wherein R^1 is hydrido or methyl; and R^2 is selected from pyridinyl, pyrimidinyl or quinoliny; wherein R^3 is optionally substituted with one or more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbonyl; and R^4 is selected from phenyl which is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl,

SUBSTITUTE SHEET (RULE 26)

ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or a pharmaceutically-acceptable salt or tautomer thereof.

In one embodiment of the present invention, the compounds of Formula I satisfy one or more of the following conditions:

R^1 is hydrido or lower alkyl; more preferably, R^1 is hydrido or methyl; and still more preferably, R^1 is hydrido;

R^2 is hydrido or lower alkyl; more preferably, R^2 is hydrido or methyl; and still more preferably, R^2 is hydrido;

R^3 is substituted or unsubstituted pyridinyl; and preferably, the pyridinyl is a 4-pyridinyl; or

R^4 is substituted or unsubstituted phenyl; and preferably, R^4 is phenyl substituted with halo.

In addition, where R^1 is substituted pyrimidinyl, preferably at least one R^1 substituent is attached to the carbon atom positioned between two nitrogen atoms of the pyrimidinyl ring.

A family of specific compounds of particular

interest within Formula I consists of compounds, tautomers and pharmaceutically-acceptable salts thereof as follows:

4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;

4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;

4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine;

4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;

4-[5-methyl-3-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine;

4-[5-methyl-3-[4-(methylthio)phenyl]-1H-pyrazol-4-yl]pyridine;

4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;

4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;

4-[5-(2,5-dimethylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;

4-[5-(1,3-benzodioxol-5-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;

4-(3-methyl-5-(4-phenoxyphenyl)-1H-pyrazol-4-yl)pyridine;

4-[5-[(1,1'-biphenyl)-4-yl]-3-methyl-1H-pyrazol-4-yl]pyridine;

4-(3-methyl-5-[3-(phenoxyphenyl)-1H-pyrazol-4-yl]pyridine;

4-[3-methyl-5-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine;

4-(3-methyl-5-[2-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine;

2-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol;

3-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol;

1-hydroxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridinium;

5-(4-fluorophenyl)-N, N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;

5-(4-fluorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;

4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine;

4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine;

4-[3-(5-bis(3-methylphenyl)-1H-pyrazol-4-yl)pyridine;

4-[4-methyl-2-(2-trifluorophenyl)-1H-pyrazol-4-yl]pyridine;

4-[3-(2-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;

4-[5-methyl-3-(2,4-dimethylphenyl)-1H-pyrazol-4-yl]pyridine;

37

- y1]pyridine;
4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-fluoro-2-methylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3,5-dimethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3,5-dimethoxyphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-methyl-3-(3-nitrophenyl)-1H-pyrazol-4-yl]pyridine;
N,N-dimethyl-4-[5-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]benzenamine;
4-[3-(2,3-dihydrobenzofuran-5-yl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-bromophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(2-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine;
4-[3-ethyl-4-phenyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-ethyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[5-(3,4-difluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-ethoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine;
4-[3-methyl-5-(3-thienyl)-1H-pyrazol-4-yl]pyridine;
4-[5-(2,4-dichlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-chloro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
ethyl 3-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazole-5-propanoate;
4-[3-(4-fluorophenyl)-1-methyl-pyrazol-4-yl]pyridine;

SUBSTITUTE SHEET (RULE 26)

38

- 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxy-pyridine;
2-methoxy-5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
2-methoxy-5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxy-pyridine;
2-methoxy-4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;

SUBSTITUTE SHEET (RULE 26)

- 2-methoxy-4-(3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl)pyridine;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
2-methoxy-4-(3-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl)pyridine;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-ol;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-ol;
4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-ol;
4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-ol;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-ol;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-ol;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-ol;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-ol;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;

SUBSTITUTE SHEET (RULE 26)

- 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(4-fluoro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(4-chloro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(2,3-dihydrobenzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(benzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-chloro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(1-cyclohexen-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(1,3-cyclohexadien-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-(5-cyclohexyl-3-methyl-1H-pyrazol-4-yl)pyridine;
4-[5-(4-methoxy-3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;

SUBSTITUTE SHEET (RULE 26)

41

- 4 - (5 - (3 - methoxy - 4 - methylphenyl) - 3 - methyl - 1H - pyrazol - 4 - yl) pyridine;
4 - (5 - (3 - methoxy - 5 - methylphenyl) - 3 - methyl - 1H - pyrazol - 4 - yl) pyridine;
4 - (5 - (3 - furyl) - 3 - methyl - 1H - pyrazol - 4 - yl) pyridine;
2 - methyl - 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyridine;
2 - methoxy - 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyridine;
methyl 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyri - dine - 2 - carboxylate;
4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyridine - 2 - carboxamide;
1 - (4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyridin - 2 - yl) ethanone;
N, N - dimethyl - 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 2 - methyl - 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyridine;
3 - methoxy - 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyridine;
methyl 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4yl) pyridine - 3 - carboxylate;
4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyridine - 3 - carboxamide;
1 - (4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyridin - 3 - yl) ethanone;
3 - bromo - 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyridine;
N, N - dimethyl - 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 2 - yl) pyridin - 3 - amine;
2 - methyl - 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyrimidine;
4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyrimidine;
2 - methoxy - 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyrimidine;
4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyrimidin - 2 - amine;
N, N - dimethyl - 4 - (3 - methyl - 5 - phenyl - 1H - pyrazol - 4 - yl) pyrimidin - 2 - amine;
4 - (5, 6 - dihydro - 2H - pyran - 4 - yl) - 3 - methyl - 5 - phenyl - 1H - pyrazole;
3 - methyl - 5 - phenyl - 4 - (3 - thienyl) - 1H - pyrazole;

SUBSTITUTE SHEET (RULE 26)

42

- 4 - (3 - furyl) - 3 - methyl - 5 - phenyl - 1H - pyrazole;
3 - methyl - 5 - phenyl - 4 - (2 - thienyl) - 1H - pyrazole;
4 - (2 - furyl) - 3 - methyl - 5 - phenyl - 1H - pyrazole;
4 - (3 - isochiazolyl) - 3 - methyl - 5 - phenyl - 1H - pyrazole;
4 - (3 - isoxazolyl) - 3 - methyl - 5 - phenyl - 1H - pyrazole;
4 - (5 - isochiazolyl) - 3 - methyl - 5 - phenyl - 1H - pyrazole;
4 - (5 - isoxazolyl) - 3 - methyl - 5 - phenyl - 1H - pyrazole;
3 - methyl - 5 - phenyl - 4 - (5 - thiazolyl) - 1H - pyrazole;
3 - methyl - 4 - (5 - oxazolyl) - 5 - phenyl - 1H - pyrazole;
4 - (3 - (4 - fluorophenyl) - 1H - pyrazol - 4 - yl) pyridine;
2 - methyl - 4 - (3 - (3 - methylphenyl) - 1H - pyrazol - 4 - yl) pyridine;
4 - (1 - methyl - 3 - phenyl - 1H - pyrazol - 4 - yl) pyridine;
4 - (3 - phenyl - 1H - pyrazol - 4 - yl) pyridine;
2 - methyl - 4 - (3 - phenyl - 1H - pyrazol - 4 - yl) pyridine;
4 - (3 - (3 - chlorophenyl) - 1 - methyl - pyrazol - 4 - yl) pyridine;
4 - (3 - (4 - chlorophenyl) - 1 - methyl - pyrazol - 4 - yl) pyridine;
4 - (3 - (3 - chlorophenyl) - 1H - pyrazol - 4 - yl) pyridine;
4 - (3 - (4 - chlorophenyl) - 1H - pyrazol - 4 - yl) pyridine;
4 - (3 - (3 - fluorophenyl) - 1 - methyl - 1H - pyrazol - 4 - yl) pyridine;
4 - (3 - (3 - fluorophenyl) - 1H - pyrazol - 4 - yl) pyridine;
4 - (3 - (3 - chlorophenyl) - 1 - methyl - pyrazol - 4 - yl) - 2 - methylpyridine;
5 - (4 - chlorophenyl) - N - phenyl - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - amine;
5 - (4 - chlorophenyl) - N - methyl - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - amine;
5 - (4 - chlorophenyl) - N - methyl - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - amine;
5 - (4 - chlorophenyl) - N, N - dimethyl - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - amine dihydrate;
5 - (3 - fluorophenyl) - N, N - dimethyl - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - amine;
N, N - dimethyl - 5 - (3 - methylphenyl) - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - amine;
N - methyl - 5 - (3 - methylphenyl) - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - amine;
N - ethyl - 5 - (3 - methylphenyl) - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 -

SUBSTITUTE SHEET (RULE 26)

amine;
 N,N-diethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;
 5 5-(4-chlorophenyl)-N,N-diethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine;
 5-(4-chlorophenyl)-N-propyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
 5-(4-chlorophenyl)-N-(phenylmethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine hydrate (2:1);
 5-(4-chlorophenyl)-N-(2-methoxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine monohydrate;
 1,1-dimethylethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
 15 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride;
 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine;
 20 1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
 1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride;
 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine;
 25 N-[5-(4-chlorophenyl)-4-[2-(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride;
 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(phenylmethyl)piperazine;
 30 4-[3-(4-fluorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine, dihydrochloride;
 1,1-dimethylethyl 3-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]aminopropyl carbamate;
 35 N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride monohydrate;

SUBSTITUTE SHEET (RULE 26)

1,1-dimethylethyl 2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]ethyl carbamate;
 1,1-dimethylethyl 4-[5-(4-chlorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
 5 1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
 1,1-dimethylethyl 3-[[5-(4-chlorophenyl)-4-(2-fluoropyridinyl)-1H-pyrazol-3-yl]amino]propyl carbamate;
 10 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-ethylpiperazine;
 N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-ethanediamine;
 4-[3-(2,6-difluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
 15 4-[3-(3-ethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(3-chlorophenyl)-5-ethyl-1H-pyrazol-4-yl]pyridine;
 4-[3-ethyl-5-(3-ethylphenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-chlorophenyl)-5-(1-methylethyl)-1H-pyrazol-4-yl]pyridine;
 20 4-[3-cyclopropyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine;
 4-[5-(cyclopropyl-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 25 5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
 3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
 30 4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone;
 1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone;
 35 Ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate;

SUBSTITUTE SHEET (RULE 26)

45

- 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid;
3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
4-[3-(4-chloro-3-methylphenyl)-1H-pyrazol-4-yl]pyridine
5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid;
5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol;
1-[(5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)carbonyl]piperazine;
1,1-dimethylethyl 4-[(5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)carbonyl]-1-piperazinecarboxylate;
4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine;
4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine;
4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine;
4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-2-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(2-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
3-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-1-ethanol;
4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
2-[(4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl)amino]-1-butanol;
4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-

SUBSTITUTE SHEET (RULE 26)

46

- yl]pyridine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide;
4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine;
3-(4-fluorophenyl)-1-methyl- α -phenyl-4-(4-pyridinyl)-1H-pyrazole-5-methanol;
N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholineethanamine;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyridinone hydrazone;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyridinamine;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide;
Methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide;
4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(1,3-benzodioxol-5-yl)-1H-pyrazol-4-yl]pyridine4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(1,3-benzodioxol-5-yl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methylpyridine;
4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;

SUBSTITUTE SHEET (RULE 26)

- 4-[5-(3-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 2-methyl-4-[1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
 -yl]pyridine;
 2-methyl-4-[1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
 4-(3-phenyl-1H-pyrazol-4-yl)pyridine;
 4-[3-(3-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl]pyridine;
 ;
 4-[1-methyl-3-(3-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine;
 4-[3-(4-bromophenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 ne;
 4-[3-(4-bromophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 (E)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-(2-phenyleth-
 enyl)pyridine;
 (S)-4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-methylbut-
 yl)-2-pyridinamine;
 4-(3-(4-chlorophenyl)-1H-pyrazol-4-yl)-N-[(4-methoxy-
 phenyl)methyl]-2-pyridinamine;
 N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-
 pyridinemethanamine;
 N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-2-
 pyridinemethanamine;
 2-fluoro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-iodophenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-iodophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 4-[1-methyl-3-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl]
]pyridine;
 N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;
 N-[3-(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-(1-

SUBSTITUTE SHEET (RULE 86)

- methylhydrazino)pyridine;
 2-fluoro-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methylpyridine;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-methylpyridine;
 4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-fluoropyridine;
 3-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine;
 2-[2-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]-2-pyridinamine;
 N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl-1,2-ethanediamine;
 2,4-bis[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
 N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-morpholineethanamine;
 3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanol;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]-2-pyridinamine;
 4-[2-[3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine;
 (E)-3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethenyl]-4-pyridinyl]-1H-pyrazole-1-ethanol;
 3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-N,N-dimethyl-1H-pyrazole-1-ethanamine;
 3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-1H-pyrazole-1-ethanol;
 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyridinamine;
 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-

SUBSTITUTE SHEET (RULE 86)

49

- pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine;
3-(4-fluorophenyl)-4-[2-(2-(4-fluorophenyl)ethyl)-4-
pyridinyl]-N,N-dimethyl-1H-pyrazole-1-ethanamine;
N-[(4-fluorophenyl)methyl]-4-[3-(or 5)-(4-fluorophenyl)-1-
[(2-(4-morpholinyl)ethyl)-1H-pyrazol-4-yl]-2-
pyridinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl-2-
pyridinamine;
N,N-diethyl-3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-
pyrazole-1-ethanamine;
4-[1-(2-(diethylamino)ethyl)-3-(4-fluorophenyl)-1H-
pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine;
2-[(4-[3-(4-(fluorophenyl)-1H-pyrazol-4-yl]-2-
pyridinyl)amino]ethanol;
2-[(4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-
pyridinyl)amino]ethanol;
3-[(4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-
pyridinyl)amino]ethanol;
3-(4-fluorophenyl)-4-[2-[(4-fluorophenyl)methyl]amino]-
pyridinyl]amino]-1-propanol;
4-pyridinyl]-1H-pyrazole-1-ethanol;
5-(4-fluorophenyl)-4-[2-[(4-fluorophenyl)methyl]amino]-
4-pyridinyl]-1H-pyrazole-1-ethanol;
N,N-diethyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-
pyrazole-1-ethanamine;
N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-
morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine;
N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-
morpholinepropanamine;
N'-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-
N,N-dimethyl-1,3-propanediamine;
5-(4-fluorophenyl)-N-2-propenyl-4-(4-pyridinyl)-1H-
pyrazol-3-amine;
3-(4-fluorophenyl)-4-[2-[(4-fluorophenyl)methyl]amino]-
4-pyridinyl]-1H-pyrazole-1-ethanol;
5-(4-fluorophenyl)-4-[2-[(4-fluorophenyl)methyl]amino]-
4-pyridinyl]-1H-pyrazole-1-ethanol;

SUBSTITUTE SHEET (RULE 26)

50

- 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]quinoline;
N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-
yl]glycine methyl ester;
N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-
yl]glycine;
4-[3-(4-fluorophenyl)-1-(2-propenyl)-1H-pyrazol-4-
yl]pyridine;
4-[5-(4-fluorophenyl)-1-(2-propenyl)-1H-pyrazol-4-
yl]pyridine;
4,4'-(1H-pyrazole-3,4-diyl)bis(pyridine);
4-[3-(3,4-dichlorophenyl)-1H-pyrazol-4-yl]pyridine;
N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-
piperidinamine;
2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-
yl]pyrimidine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-(1H)-pyrimidinone
hydrate;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-
pyrimidinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-
pyrimidinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-
2-pyrimidinamine;
N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-
pyrimidinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-
methoxyphenyl)methyl]-2-pyrimidinamine;
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine;
N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-
N-(phenylmethyl)acetamide;
Ethyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-
pyrimidinyl]carbamate;
4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidine;
4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyrimidine;
4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine; and
4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine.

SUBSTITUTE SHEET (RULE 26)

53

hydroxyethyl and propargyl; and

R² is selected from hydrido, methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl,

methoxycarbonyl, ethoxycarbonyl, N-methylamino,

N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-

propylamino, N-phenylamino, aminomethyl, aminoethyl,

aminoethylamino, aminopropylamino, propargylamino,

benzylamino, dimethylaminopropylamino,

morpholinylpropylamino, morpholinylethylamino,

piperidinyl, piperazinyl, imidazolyl, morpholinyl,

pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-

dimethyl)ethylcarbonyl, (1,1-

dimethyl)ethylcarbonylamino, (1,1-

dimethyl)ethylcarbonylaminoethylamino,

piperazinylcarbonyl, 1,1-dimethyl-

ethylpiperazinylcarbonyl; wherein the phenyl,

piperidinyl, piperazinyl, imidazolyl, morpholinyl, and

pyridinyl groups are optionally substituted with one or

more radicals independently selected from fluoro, chloro,

bromo, keto, methyl, ethyl, trifluoromethyl, benzyl,

methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-

dimethyl)ethoxycarbonyl; and

R¹ is selected from cyclohexyl, cyclohexenyl,

cyclohexadienyl, phenyl, quinoyl, biphenyl, pyridinyl,

thienyl, furyl, dihydropyranyl, benzofuryl,

dihydrobenzofuryl, and benzodioxolyl; wherein R¹ is

optionally substituted with one or more radicals

independently selected from methylthio, fluoro, chloro,

bromo, methyl, ethyl, methoxy, ethoxy, phenoxy,

benzyloxy, trifluoromethyl, nitro, dimethylamino, and

hydroxy; and

R¹ is selected from fluoro, chloro, bromo, methyl,

fluorophenylethyl, fluorophenylethenyl,

fluorophenylpyrazolyl, cyano, methoxycarbonyl,

aminocarbonyl, acetyl, hydroxy, carboxy, methoxy,

methylamino, dimethylamino, 2-methylbutylamino,

54

ethylamino, dimethylaminoethylamino, hydroxypropylamino,

hydroxyethylamino, imidazolylamino,

morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino,

piperidinylamino, pyridinylethylamino,

phenylmethylpiperidinylamino, aminomethyl,

cyclopropylamino, amino, hydroxy, methylcarbonyl,

ethoxycarbonylamino, methoxyphenylethylamino,

phenylmethylamino, fluorophenylethylamino,

fluorophenylethylamino, methylaminocarbonyl,

methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or -


NR²R³ wherein R² is methylcarbonyl or amino, and R³ is

methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer

thereof.

Within Formula I there is another subclass of compounds of high interest represented by Formula X:



wherein

Z represents a carbon atom or a nitrogen atom; and

R¹ is selected from lower alkyl, lower hydroxyalkyl,

lower alkynyl, lower aminoalkyl and lower

alkylaminoalkyl; and

R² is selected from hydrido, lower alkyl, aryl

RESTITUTE SHEET (RULE 26)

RESTITUTE SHEET (RULE 26)

- selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxy carbonyl, lower alkylamino, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower alkylaminoalkyl, lower aminoalkyl, lower aminoalkylamino, lower alkoalkyl, lower heterocyclylamino, lower alkynylamino, lower heterocyclylalkyl, lower heterocyclylalkylamino, lower alkylheterocyclyl, lower carboxycycloalkyl, lower carboxyalkylamino, lower alkoxyalkylamino, lower alkoxy carbonylaminoalkylamino, lower heterocyclylcarbonyl, lower alkoxy carbonyl heterocyclyl, and lower alkoxy carbonyl heterocyclylcarbonyl; wherein the aryl and heteroaryl groups are optionally substituted with one or more radicals independently selected from halo, lower alkyl, keto, aralkyl, carboxy, lower alkylaminoalkylamino, lower alkylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxy carbonyl; or

R^1 is $-CR^aR^b$ wherein R^a is phenyl and R^b is hydroxy; and

- R^1 is selected from 5- or 6-membered heteroaryl, and aryl selected from phenyl, biphenyl, and naphthyl; wherein R^1 is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and R^1 is selected from halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxy carbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower alkoxy carbonylamino, lower alkoxy aralkylamino, lower

SUBSTITUTE SHEET (RULE 26)

- alkylaminoalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxy aralkylamino, hydrazinyl, and lower alkylhydrazinyl, or $-NR^aR^b$ wherein R^a is lower alkylcarbonyl or amino, and R^b is lower alkyl or lower phenylalkyl; or a pharmaceutically-acceptable salt or tautomer thereof.

- 10 A preferred class of compounds consists of those compounds of Formula X
 R^1 is selected from methyl, ethyl, hydroxyethyl and propargyl; and
 R^2 is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, piperidinylamino, dimethylaminoethylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, N-methylpiperazinyl, carbomethoxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, and 1,1-dimethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl; and

SUBSTITUTE SHEET (RULE 26)

57


R⁴ is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R⁴ is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R⁵ is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethoxy, hydroxypropylamino, hydroxyethylamino, propargylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl, ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or -NR⁶R⁶, wherein R⁶ is methylcarbonyl or amino, and R⁶ is methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

Within Formula I there is another subclass of compounds of high interest represented by Formula XI:

58



wherein

Z represents a carbon atom or a nitrogen atom; and

R¹ is selected from lower alkyl, lower hydroxyalkyl, lower aminoalkyl, lower aminoalkyl and lower

alkylaminoalkyl; and

R² is selected from hydrido, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxyalkyl, lower alkylamino, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower alkylaminoalkylamino, lower aminoalkyl, lower aminoalkyl, lower aminocyclylalkyl, lower heterocyclylamino, lower heterocyclylalkyl, lower heterocyclylalkylamino, lower alkylheterocyclyl, lower carboxycycloalkyl, lower carboxyalkylamino, lower alkoxyalkylamino, lower alkoxyalkylaminoalkylamino, lower heterocyclylcarbonyl, lower lower heterocyclylcarbonyl, and lower alkoxyalkylaminoalkylamino, and lower alkoxyalkylaminoalkylamino; wherein the aryl and heterocyclyl groups are optionally substituted with one or more radicals independently selected from halo, lower

SUBSTITUTESHEET (RULE 26)

SUBSTITUTESHEET (RULE 26)

alkyl, keto, aralkyl, carboxy, lower alkylaminoalkylamino; lower alkynylamino, lower heterocyclalkylamino, lower alkylcarbonyl and lower alkoxy carbonyl; or

5 R^3 is $-CR^4R^5$ wherein R^4 is phenyl and R^5 is hydroxy; and

R^4 is selected from 5- or 6-membered heteroaryl, and aryl selected from phenyl, biphenyl, and naphthyl;

wherein R^4 is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and

R^5 is selected from halo, amino, cyano,

aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower

aralkylamino, lower alkoxy carbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower

arylheterocycl, carboxy, lower cycloalkylamino, lower

alkoxy carbonylamino, lower alkoxy aralkylamino, lower

alkylaminoalkylamino, lower heterocyclamino, lower

heterocyclalkylamino, lower aralkylheterocyclamino,

lower alkylaminocarbonyl, lower alkylcarbonyl, lower

alkoxy aralkylamino, hydrazinyl, and lower

alkylhydrazinyl, or $-NR^6R^6$ wherein R^6 is lower

25 alkylcarbonyl or amino, and R^3 is lower alkyl or lower phenylalkyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

30 A preferred class of compounds consists of those compounds of Formula XI

R^1 is selected from methyl, ethyl, hydroxyethyl and propargyl; and

R^2 is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonyl, ethyl,

ethoxycarbonyl, N-methylamino, N,N-dimethylamino, N-

SUBSTITUTE SHEET (RULE 26)

ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminomethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylamino, (1,1-dimethyl)ethylcarbonylpropylamino, (1,1-dimethyl)ethylcarbonylaminopropylamino, (1,1-dimethyl)ethylcarbonylaminopropylamino,

10 piperazinylcarbonyl, 1,1-dimethyl-ethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy; methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl;

R^4 is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyran, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R^4 is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R^5 is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminocarbonyl, hydroxypropylamino, hydroxyethylamino, imidazolylamino,

morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino,

35 phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl,

SUBSTITUTE SHEET (RULE 26)

61

ethoxycarbonylamino, methoxyphenylmethylanino, phenylmethylanino, fluorophenylmethylanino, fluorophenylethylanino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or -NR⁴R⁵ wherein R⁴ is methylcarbonyl or amino, and R⁵ is methyl or benzyl; or
a pharmaceutically-acceptable salt or tautomer thereof.

10 A preferred class of compounds consists of those compounds of Formula IX wherein
Z represents a carbon atom or a nitrogen atom;

and
15 R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower alkenyl, lower aminoalkyl and lower alkylaminoalkyl; and
R² is selected from hydrido, lower alkyl, aryl

20 selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxy carbonyl, lower alkylamino, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower

25 aminoalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkenylamino, lower heterocyclalalkyl, lower heterocyclalalkylamino, lower alkylheterocyclyl, lower carboxycycloalkyl, lower carboxyalkylamino, lower alkoxyalkylamino, lower alkoxy carbonylaminoalkylamino, lower

30 lower heterocyclalcarbonyl, lower alkoxy carbonyl heterocyclyl, and lower alkoxy carbonyl heterocyclalcarbonyl; wherein the aryl and heteroaryl groups are optionally substituted with one or more radicals independently selected from halo, lower alkyl, keto, aralkyl, carboxy, lower

35 alkylaminoalkylamino, lower alkenylamino, lower

SUBSTITUTE SHEET (RULE 26)

62

heterocyclalalkylamino, lower alkylcarbonyl and lower alkoxy carbonyl; or

R² is -CR⁴R⁵ wherein R⁴ is phenyl and R⁵ is hydroxy; and

5 R⁴ is phenyl that is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryl, alkoxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and

10 R⁵ is selected from halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxy carbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower

15 arylheterocyclyl, carboxy, lower cycloalkylamino, lower alkoxy carbonylamino, lower alkoxy aralkylamino, lower alkylaminoalkylamino, lower heterocyclalalkylamino, lower heterocyclalalkylamino, lower aralkylheterocyclalalkylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxy aralkylamino, hydrazinyl, and lower alkylhydrazinyl, or -NR⁴R⁵ wherein R⁴ is lower alkylcarbonyl or amino, and R⁵ is lower alkyl or lower phenylalkyl; or

20 a pharmaceutically-acceptable salt or tautomer thereof.

25 A class of compounds of specific interest consists of those compounds of Formula IX wherein

R¹ is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl;

30 R² is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, amineoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino,

SUBSTITUTE SHEET (RULE 26)

dimethylaminopropylamino, morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-dimethyl)ethylcarbonylamino, (1,1-dimethyl)ethylcarbonylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, 1,1-dimethyl-ethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl;

15 R⁴ is phenyl that is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

20 R⁵ is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl,

fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, hydroxyethylamino, imidazolylamino, hydroxypropylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino,

phenylmethylpiperidinylamino, aminomethyl,

30 cyclopropylamino, amino, hydroxy, methylcarbonyl, ethoxycarbonylamino, methoxyphenylmethylamino,

phenylmethylamino, fluorophenylmethylamino,

fluorophenylethylamino, methylaminocarbonyl,

methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or -

35 NR⁶R⁶ wherein R⁶ is methylcarbonyl or amino, and R⁶ is methyl or benzyl; or

SUBSTITUTESHEET (RULE 26)

a pharmaceutically-acceptable salt or tautomer thereof.

5 Another class of compounds of specific interest consists of those compounds of Formula IX wherein

Z represents a carbon atom or a nitrogen atom; and

10 R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl and lower alkynyl; and

R² is selected from hydrido and lower alkyl; and

R⁴ is selected from phenyl and benzodioxolyl; wherein phenyl is optionally substituted with one or more halo radicals; and

R⁵ is selected from hydrido, halo and

15 alkylhydrazinyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

20 Still another class of compounds of specific interest consists of those compounds of Formula IX wherein

Z represents a carbon atom; and

R¹ is selected from hydrido, methyl, hydroxyethyl, propargyl; and

25 R² is hydrido; and

R⁴ is selected from phenyl and benzodioxolyl; wherein phenyl is optionally substituted with one or more radicals independently selected from chloro, fluoro and bromo; and

30 R⁵ is selected from hydrido, fluoro, and 1-methylhydrazinyl; or

a pharmaceutically-acceptable salt or tautomer thereof.

35 A preferred class of compounds of specific interest consists of those compounds of Formula IX wherein

SUBSTITUTESHEET (RULE 26)

65

2 represents a carbon atom; and
 R¹ is selected from hydrido and methyl; and
 R² is hydrido; and
 R¹ is selected from phenyl that is optionally
 substituted with one or more radicals independently
 selected from chloro, fluoro and bromo; and
 R¹s selected from hydrido and fluoro; or
 a pharmaceutically-acceptable salt or tautomer
 thereof.

10 The term "hydrido" denotes a single hydrogen atom
 (H). This hydrido radical may be attached, for example,
 to an oxygen atom to form a hydroxyl radical or two
 hydrido radicals may be attached to a carbon atom to form
 a methylene (-CH₂-) radical. Where used, either alone or
 15 within other terms such as "haloalkyl", "alkylsulfonyl",
 "alkoxyalkyl" and "hydroxyalkyl", "cyanoalkyl" and
 "mercaptoalkyl", the term "alkyl" embraces linear or
 branched radicals having one to about twenty carbon atoms
 or, preferably, one to about twelve carbon atoms. More
 20 preferred alkyl radicals are "lower alkyl" radicals
 having one to about ten carbon atoms. Most preferred are
 lower alkyl radicals having one to about six carbon
 atoms. Examples of such radicals include methyl, ethyl,
 25 n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-
 butyl, pentyl, iso-amyl, hexyl and the like. The term
 "alkenyl" embraces linear or branched radicals having at
 least one carbon-carbon double bond of two to about
 30 twenty carbon atoms or, preferably, two to about twelve
 carbon atoms. More preferred alkenyl radicals are "lower
 alkenyl" radicals having two to about six carbon atoms.
 Examples of alkenyl radicals include ethenyl, allyl,
 propenyl, butenyl and 4-methylbutenyl. The terms
 35 "alkenyl" and "lower alkenyl", embrace radicals having
 "cis" and "trans" orientations, or alternatively, "E" and
 "Z" orientations. The term "alkynyl" embraces linear or

SUBSTITUTE SHEET (RULE 26)

66

branched radicals having at least one carbon-carbon
 triple bond of two to about twenty carbon atoms or,
 preferably, two to about twelve carbon atoms. More
 preferred alkynyl radicals are "lower alkynyl" radicals
 5 having two to about six carbon atoms. Examples of
 alkynyl radicals include propargyl, 1-propynyl, 2-
 propynyl, 1-butyne, 2-butenyl and 1-pentynyl. The term
 "cycloalkyl" embraces saturated carbocyclic radicals
 having three to about twelve carbon atoms. The term
 10 "cycloalkyl" embraces saturated carbocyclic radicals
 having three to about twelve carbon atoms. More
 preferred cycloalkyl radicals are "lower cycloalkyl"
 radicals having three to about eight carbon atoms.
 Examples of such radicals include cyclopropyl, 2-
 15 cyclobutyl, cyclopentyl and cyclohexyl. The term
 "cycloalkylalkylene" embraces alkyl radicals substituted
 with a cycloalkyl radical. More preferred
 cycloalkylalkylene radicals are "lower
 cycloalkylalkylene" which embrace lower alkyl radicals
 20 substituted with a lower cycloalkyl radical as defined
 above. Examples of such radicals include
 cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl
 and cyclohexylmethyl. The term "cycloalkenyl" embraces
 partially unsaturated carbocyclic radicals having three
 25 to twelve carbon atoms. Cycloalkenyl radicals that are
 partially unsaturated carbocyclic radicals that contain
 two double bonds (that may or may not be conjugated) can
 be called "cycloalkyldienyl". More preferred
 cycloalkenyl radicals are "lower cycloalkenyl" radicals
 30 having four to about eight carbon atoms. Examples of
 such radicals include cyclobutenyl, cyclopentenyl and
 cyclohexenyl. The term "halo" means halogens such as
 fluorine, chlorine, bromine or iodine. The term
 "haloalkyl" embraces radicals wherein any one or more of
 35 the alkyl carbon atoms is substituted with halo as
 defined above. Specifically embraced are monohaloalkyl,

SUBSTITUTE SHEET (RULE 26)

dihaloalkyl and polyhaloalkyl radicals. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals.

"Lower haloalkyl" embraces radicals having one to six carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl,

chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl,

10 difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. The term "hydroxyalkyl" embraces linear or branched alkyl radicals having one to about ten carbon

15 atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. The terms "alkoxy" and "alkyloxy" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The term "alkoxyalkyl" embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The "alkoxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals. The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term "aryl" embraces

SUBSTITUTE SHEET (RULE 26)

aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from

5 halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfonylalkylene, arylsulfinylalkylene, alkylsulfonyl,

10 alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxy, cyano, nitro, alkylamino, arylamino,

15 aminocarbonylalkylene, acyl, carboxy, and aralkoxycarbonyl. The term "heterocyclyl" embraces saturated, partially unsaturated and unsaturated heteroatom-containing ring-shaped radicals, which can also be called "heterocyclyl", "heterocycloalkenyl" and "heteroaryl" correspondingly, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl radicals include saturated 3 to 6-membered heteromonocyclic group containing 1 to 4 nitrogen atoms (e.g. pyrrolidinyl, imidazolidinyl,

20 piperidino, piperazinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. morpholinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially unsaturated heterocyclyl radicals include dihydrothiophene, dihydropyran, dihydrofuran and dihydrothiazole. Heterocyclyl radicals may include a pentavalent nitrogen, such as in tetrazolium and pyridinium radicals. The term "heteroaryl" embraces unsaturated heterocyclyl radicals. Examples of heteroaryl radicals include unsaturated 3 to

SUBSTITUTE SHEET (RULE 26)

69

6 membered heteromonocyclic group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.); etc.;

5 unsaturated condensed heterocyclyl group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.), etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group containing a sulfur atom, for example, thieryl, etc.; unsaturated 3- to 6-

10 membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g., benzoxazolyl, benzoxadiazolyl, etc.); unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., benzothiazolyl, benzothiadiazolyl, etc.) and the like. The term

30 "heterocycle" also embraces radicals where heterocyclyl radicals are fused with aryl or cycloalkyl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. Said "heterocyclyl group" may have 1 to 3 substituents such as alkyl, hydroxyl, halo, alkoxy, oxo, amino, alkylthio and alkylamino. The term "heterocyclalalkylene" embraces

SUBSTITUTE SHEET (RULE 26)

70

heterocyclyl-substituted alkyl radicals. More preferred heterocyclalalkylene radicals are "lower heterocyclalalkylene" radicals having one to six carbon atoms and a heterocyclyl radicals. The term "alkylthio" embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms attached to a divalent sulfur atom. More preferred alkylthio radicals are "lower alkylthio" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, butylthio and hexylthio. The term "alkylthioalkylene" embraces radicals containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms. More preferred alkylthioalkylene radicals are "lower alkylthioalkylene" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylthioalkylene radicals include methylthiomethyl. The term "alkylsulfinyl" embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms, attached to a divalent -S(=O)- radical. More preferred alkylsulfinyl radicals are "lower alkylsulfinyl" radicals having alkyl radicals of one to six carbon atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and hexylsulfinyl. The term "sulfonyl", whether used alone or linked to other terms such as "alkylsulfonyl", "halosulfonyl" denotes a divalent radical, -SO₂-. "Alkylsulfonyl" embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are "lower alkylsulfonyl" radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include methylsulfonyl, ethylsulfonyl and propylsulfonyl. The "alkylsulfonyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl

SUBSTITUTE SHEET (RULE 26)

radicals. The term "halosulfonyl" embraces halo radicals attached to a sulfonyl radical. Examples of such halosulfonyl radicals include chlorosulfonyl, and bromosulfonyl. The terms "sulfamyl", "aminosulfonyl" and "sulfonamidyl" denote $\text{NH}_2\text{O}_2\text{S}-$. The term "acyl" denotes a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aryl radicals. Examples of such

5 alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, and radicals formed from succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, mandelic, pantothenic, β -hydroxybutyric, galactaric and

10 alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, and radicals formed from succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, mandelic, pantothenic, β -hydroxybutyric, galactaric and

15 galacturonic acids. The term "carbonyl", whether used alone or with other terms, such as "alkoxycarbonyl", denotes $-(\text{C}=\text{O})-$. The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as

20 "carboxyalkyl", denotes $-\text{CO}_2\text{H}$. The term "carboxyalkyl" embraces alkyl radicals substituted with a carboxy radical. More preferred are "lower carboxyalkyl" which embrace lower alkyl radicals as defined above, and may be additionally substituted on the alkyl radical with halo. Examples of such lower carboxyalkyl radicals include

25 carboxymethyl, carboxyethyl and carboxypropyl. The term "alkoxycarbonyl" means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical. More preferred are "lower

30 alkoxycarbonyl" radicals with alkyl portions having one to six carbons. Examples of such lower alkoxycarbonyl (ester) radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl. The term

35 "alkoxycarbonylalkyl" embraces alkyl radicals substituted with a alkoxycarbonyl radical as defined above. More preferred are "lower alkoxycarbonylalkyl" radicals with

alkyl portions having one to six carbons. Examples of such lower alkoxycarbonylalkyl radicals include substituted or unsubstituted methoxycarbonylmethyl, ethoxycarbonylmethyl, methoxycarbonyl-ethyl and

5 ethoxycarbonylmethyl. The term "alkylcarbonyl", includes radicals having alkyl, hydroxylalkyl, radicals, as defined herein, attached to a carbonyl radical. Examples of such radicals include substituted or unsubstituted

10 methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hydroxymethylcarbonyl, hydroxyethylcarbonyl. The term "aralkyl" embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl. The aryl in said aralkyl may be

15 additionally substituted with one or more substituents selected independently from halo, alkyl, alkoxy, haloalkyl, haloalkoxy, amino and nitro. The terms benzyl and phenylmethyl are interchangeable. The term "heterocyclylalkylene" embraces saturated and partially unsaturated heterocyclyl-substituted alkyl radicals (also

20 can be called heterocycloalkylalkylene and heterocycloalkenylalkylene correspondingly), such as pyrrolidinylmethyl, and heteroaryl-substituted alkyl radicals (also can be called heteroarylalkylene), such as pyridylmethyl, quinolylmethyl, thienylmethyl, furylethyl, and quinolylethyl. The heteroaryl in said heteroarylalkyl may be additionally substituted with halo, alkyl, alkoxy,

25 haloalkyl and haloalkoxy. The term "aryloxy" embraces aryl radicals attached through an oxygen atom to other radicals. The term "aralkoxy" embraces aralkyl radicals attached through an oxygen atom to other radicals. The term "aminoalkyl" embraces alkyl radicals substituted with amino radicals. More preferred are "lower

30 aminoalkyl" radicals. Examples of such radicals include aminomethyl, aminoethyl, and the like. The term "alkylamino" denotes amino groups which are substituted

73

with one or two alkyl radicals. Preferred are "lower alkylamino" radicals having alkyl portions having one to six carbon atoms. Suitable lower alkylamino may be monosubstituted N-alkylamino or disubstituted N,N'-alkylamino, such as N-methylamino, N-ethylamino, N,N'-dimethylamino, N,N'-diethylamino or the like. The term "arylamino" denotes amino groups which are substituted with one or two aryl radicals, such as N-phenylamino. The "arylamino" radicals may be further substituted on the aryl ring portion of the radical. The term "aminocarbonyl" denotes an amide group of the formula -C(=O)NH₂. The term "alkylaminocarbonyl" denotes an aminocarbonyl group which has been substituted with one or two alkyl radicals on the amino nitrogen atom. Preferred are "N-alkylaminocarbonyl" and "N,N'-dialkylaminocarbonyl" radicals. More preferred are "lower N-alkylaminocarbonyl" and "lower N,N'-dialkylaminocarbonyl" radicals with lower alkyl portions as defined above. The term "alkylcarbonylamino" embraces amino groups which are substituted with one alkylcarbonyl radicals. More preferred alkylcarbonylamino radicals are "lower alkylcarbonylamino" having lower alkylcarbonyl radicals as defined above attached to amino radicals. The term "alkylaminoalkylene" embraces radicals having one or more alkyl radicals attached to an aminoalkyl radical.

The "hydrocarbon" moieties described herein are organic compounds or radicals consisting exclusively of the elements carbon and hydrogen. These moieties include alkyl, alkenyl, alkynyl, and aryl moieties. These moieties also include alkyl, alkenyl, alkynyl, and aryl moieties substituted with other aliphatic or cyclic hydrocarbon groups, such as alkaryl, alkenaryl and alkynaryl. Preferably, these moieties comprise 1 to 20 carbon atoms.

The heterosubstituted hydrocarbon moieties described

SUBSTITUTE SHEET (RULE 26)

74


herein are hydrocarbon moieties which are substituted with at least one atom other than carbon, including moieties in which a carbon chain atom is substituted with a hetero atom such as nitrogen, oxygen, sulfur, or a halogen atom. These substituents include lower alkoxy such as methoxy, ethoxy, butoxy; halogen such as chloro or fluoro; ethers; acetals; ketals; esters; heterocyclyl such as furyl or thienyl; alkanoxo; hydroxy; protected hydroxy; acyl; acyloxy; nitro; cyano; amino; and amido.

The additional terms used to describe the substituents of the pyrazole ring and not specifically defined herein are defined in a similar manner to that illustrated in the above definitions. As above, more preferred substituents are those containing "lower" radicals. Unless otherwise defined to contrary, the term "lower" as used in this application means that each alkyl radical of a pyrazole ring substituent comprising one or more alkyl radicals has one to about six carbon atoms; each alkenyl radical of a pyrazole ring substituent comprising one or more alkenyl radicals has two to about six carbon atoms; each alkynyl radical of a pyrazole ring substituent comprising one or more alkynyl radicals has two to about six carbon atoms; each cycloalkyl or cycloalkenyl radical of a pyrazole ring substituent comprising one or more cycloalkyl and/or cycloalkenyl radicals is a 3 to 8 membered ring cycloalkyl or cycloalkenyl radical, respectively; each aryl radical of a pyrazole ring substituent comprising one or more aryl radicals is a monocyclic aryl radical; and each heterocyclyl radical of a pyrazole ring substituent comprising one or more heterocyclyl radicals is a 4-8 membered ring heterocyclyl.

The present invention comprises the tautomeric forms of compounds of Formulas I and IX. As illustrated below, the pyrazoles of Formula I and I' are magnetically and structurally equivalent because of the prototropic

SUBSTITUTE SHEET (RULE 26)

tautomeric nature of the hydrogen:



The present invention also comprises compounds of Formula I, IX, X and XI having one or more asymmetric carbons. It is known to those skilled in the art that those pyrazoles of the present invention having asymmetric carbon atoms may exist in diastereomeric, racemic, or optically active forms. All of these forms are contemplated within the scope of this invention.

More specifically, the present invention includes enantiomers, diastereomers, racemic mixtures, and other mixtures thereof.

The present invention comprises a pharmaceutical composition for the treatment of a TNF mediated disorder, a P38 kinase mediated disorder, inflammation, and/or arthritis, comprising a therapeutically-effective amount of a compound of Formula I, or a therapeutically-acceptable salt or tautomer thereof, in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

The present invention further encompasses substituted pyrazoles that specifically bind to the ATP binding site of p38 kinase. Without being held to a particular theory, applicants hypothesize that these substituted pyrazoles interact with p38 kinase as set forth below. As the substituent at the 3-position of the pyrazole ring approaches the ATP binding site of p38

kinase, a hydrophobic cavity in the p38 kinase forms around the 3-position substituent at the binding site. This hydrophobic cavity is believed to form as the 3-position substituent binds to a specific peptide sequence of the enzyme. In particular, it is believed to bind to the sidechains of Lys₅₂, Glu₄₈, Leu₇₁, Ile₅₁, Leu₄₄, Leu₁₀₁ and the methyl group of the Thr₁₀₃ sidechain of p38 kinase at the ATP binding site (wherein the numbering scheme corresponds to the numbering scheme conventionally used for ERK-2). Where the 3-position substituent is aryl or heteroaryl, such aryl or heteroaryl may be further substituted. It is hypothesized that such ring substituents may be beneficial in preventing hydroxylation or further metabolism of the ring.

The substituent at the 4-position of the pyrazole ring is one that is a partial mimic of the adenine ring of ATP, although it may be further elaborated. Preferably, it is a planar substituent terminated by a suitable hydrogen bond acceptor functionality. It is hypothesized that this acceptor hydrogen bonds to the backbone N-H of the Met₁₀₄ residue while one edge of this substituent is in contact with bulk solvent.

Substitution at the 5-position of the pyrazole ring is well tolerated and can provide increased potency and selectivity. It is hypothesized that such substituents extend out in the direction of the bulk solvent and that suitable polar functionality placed at its terminus can interact with the sidechain of Asp¹⁰⁹, leading to increased potency and selectivity.


Similarly, substitution on the nitrogen atom at the 1- or 2-position of the pyrazole ring is well tolerated and can provide increased potency. It is hypothesized that a hydrogen substituent attached to one of the ring nitrogen atoms is hydrogen bonded to Asp₁₄₅. Preferably, the nitrogen atom at the 2-position is double bonded to the carbon atom at the 3-position of the pyrazole while

77

the nitrogen atom at the 1-position of the pyrazole is available for substitution with hydrogen or other substituents.

The 5-position substituent and the 1- or 2-position substituent of the pyrazole can be selected so as to improve the physical characteristics, especially aqueous solubility and drug delivery performance, of the substituted pyrazole. Preferably, however, these substituents each have a molecular weight less than about 360 atomic mass units. More preferably, these substituents each have a molecular weight less than about 250 atomic mass units. Still more preferably, these substituents have a combined molecular weight less than about 360 atomic mass units.

A class of substituted pyrazoles of particular interest consists of those compounds having the formula:



wherein

R¹ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units; and

R² is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical that binds with p38 kinase at said ATP binding site of p38 kinase; and

R³ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a hydrogen bond acceptor functionality; and

78

R¹ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units;

provided R¹ is not 2-pyridinyl when R¹ is a phenyl ring containing a 2-hydroxy substituent and when R¹ is hydrido; further provided R² is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R¹ is hydrido; and further provided R¹ is not methylsulfonylphenyl; or a pharmaceutically-acceptable salt or tautomer thereof.

A class of substituted pyrazoles of particular interest consists of those compounds of Formula XI wherein

R¹ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units; and

R² is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical wherein said radical binds with lysine, glutamine, leucine, and threonine sidechains at said ATP binding site of p38 kinase, said radical being substantially disposed within a hydrophobic cavity formed during said binding by p38 kinase at the ATP binding site; and

R³ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a hydrogen bond acceptor functionality that hydrogen bonds with the N-H backbone of Met¹⁰⁶ of p38 kinase; and

R¹ is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units.

The present invention also comprises a therapeutic method of treating a TNF mediated disorder, a p38 kinase mediated disorder, inflammation and/or arthritis in a subject, the method comprising treating a subject having

SUBSTITUTESHEET (RULE 26)

SUBSTITUTESHEET (RULE 26)

81

aryloxycarbonylarylene, alkylaryloxycarbonylarylene, arylcarbonylarylene, alkylarylcarbonylarylene, alkoxycarbonylheterocyclarylene, alkoxycarbonylalkoxyarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalkylarylene, arylsulfonylaminoalkylene, alkylsulfonylarylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene, aryloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, heterocyclylthioarylene, arylthioalkylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

R^{2*} is $-\text{CHR}^2\text{R}^3$, wherein R^{2*} is alkoxycarbonyl, and R^{2*} is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocyclyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R^6 and R^7 together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, aryloxyalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and aryloxyalkylene radicals are


SUBSTITUTE SHEET (RULE 26)

82

optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R^2 is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, aminoalkyl, aminoaryl, aminoalkylamino, arylaminooalkylene, alkylaminooalkylene, arylaminooalkylene, alkylaminooalkylene, alkylaminooalkylamino, cycloalkyl, cycloalkenyl, alkoxy, heterocyclyoxy, alkylthio, arylthio, heterocyclylthio, carboxy, carboxylalkyl, carboxycycloalkenyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylamino, and heterocyclylsulfonyl; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminooalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R^2 has the formula:



wherein:

j is an integer from 0 to 8; and

SUBSTITUTE SHEET (RULE 26)

85

Also included in the family of compounds of Formula I are the pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, *p*-hydroxybenzoic, phenylacetic, mandelic, embonic (pantoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, β -hydroxybutyric, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts and organic salts. More preferred metallic salts include, but are not limited to appropriate alkali metal (group Ia) salts, alkaline earth metal (group IIA) salts and other physiological acceptable metals. Such salts can be made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc. Preferred organic salts can be made from tertiary amines and quaternary ammonium salts, including in part, tromethamine, diethylamine, *N,N'*-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (*N*-


86

methylethylenediamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formulas I-III by reacting, for example, the appropriate acid or base with the compound of Formulas I-III.

General Synthetic Procedures

The compounds of the invention can be prepared according to the following procedures of Schemes I-VIII wherein R^1 , R^2 , R^3 , R^4 , R^5 and Ar^1 are as previously defined for the compounds of Formula I, IX, X and XI except where expressly noted.

SCHEME I




15 Scheme I shows the synthesis of pyrazole 5 by two

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

- routes. Condensation of the pyridylmethyl ketone 1 with aldehyde 2 in the presence of a base, such as piperidine, in a solvent, such as toluene or benzene, either in the absence or the presence of acetic acid at reflux, provides the α,β -unsaturated ketone 3. In route 1, ketone 3 is first converted to epoxide 4, such as by treatment with hydrogen peroxide solution at room temperature, in the presence of base such as sodium hydroxide. Treatment of epoxide 4 with hydrazine in ethanol or other suitable solvent at a temperature ranging up to reflux, yields pyrazole 5. In route 2, ketone 3 is condensed directly with tosyl hydrazide in the presence of an acid such as acetic acid, at reflux, to provide pyrazole 5. Alternatively, the intermediate tosyl hydrazone 6 may be isolated, conversion of it to pyrazole 5 is effected by treatment with a base, such as potassium hydroxide, in a suitable solvent, such as ethylene glycol, at a temperature ranging from 25 °C up to 150 °C.

SCHEME II




- Scheme II shows the synthesis of pyrazole 12 of the present invention. The treatment of pyridine derivative 7 with ester 8 in the presence of a base, such as sodium bis(trimethylsilyl)amide, in a suitable solvent, such as tetrahydrofuran, gives ketone 9. Treatment of ketone 9 or a hydrohalide salt of ketone 9 with a halogenating agent, such as bromine, N-bromosuccinimide or N-chlorosuccinimide, in suitable solvents, such as acetic acid, methylene chloride, methanol, or combinations thereof, forms the α -halogenated ketone 10 (wherein X is halo). Examples of suitable hydrohalide salts include the hydrochloride and hydrobromide salts. Reaction of haloketone 10 with thiosemicarbazide 11 (where R⁶ and R⁷ can be hydrido, lower alkyl, phenyl, heterocyclyl and the like or where R⁶ and R⁷ form a heterocyclyl ring optionally containing an additional heteroatom) provides pyrazole 12. Examples of suitable solvents for this

reaction are ethanol and dimethylformamide. The reaction may be carried out in the presence or absence of base or acid at temperatures ranging from room temperature to 100 °C.

Thiosemicarbazides which are not commercially available may be conveniently prepared by one skilled in the art by first reacting an appropriate amine with carbon disulfide in the presence of a base, followed by treatment with an alkylating agent such as methyl iodide. Treatment of the resultant alkyl dithiocarbamate with hydrazine results in the desired thiosemicarbazide. This chemistry is further described in E. Lieber and R.C. Orlowski, *J. Org. Chem.*, Vol. 22, p. 88 (1957). An alternative approach is to add hydrazine to appropriately substituted thiocyanates as described by Y. Nomoto et al., *Chem. Pharm. Bull.*, Vol. 39, p.86 (1991). The Lieber and Nomoto publications are incorporated herein by reference.


SCHEME III



SUBSTITUTE SHEET (RULE 26)

Scheme III shows the synthesis of pyrazole 19 in more general form by three routes. In Route 1, ketone 13 is condensed with hydrazine 14 to give the substituted hydrazone 16, which is then reacted with acyl halide or anhydride 17 at low temperature to provide acyl hydrazone 18. Upon heating at a temperature up to 200°C, acyl hydrazone 18 is converted to pyrazole 19. In Route 2, acyl hydrazone 18 is formed directly by reaction of ketone 13 with acyl hydrazone 15, formed by reaction of hydrazine with a carboxylic acid ester, at room temperature. Heating acyl hydrazone 18 as above then provides pyrazole 19. In Route 3, ketone 13 is treated with acyl hydrazone 15 at a suitable temperature, ranging from room temperature to about 200 °C, to give pyrazole 19 directly. Alternatively, this condensation may be carried out in an acidic solvent, such as acetic acid, or in a solvent containing acetic acid.


SCHEME IV



SUBSTITUTE SHEET (RULE 26)

Synthetic Scheme IV describes the preparation of pyrazole 19.

SCHEME V




X = halyl, alkyl
R¹ = Me, CH₂CH₂OH
R⁴ = cyclopropyl, 4-pyridyl,
4-imidazolyl

5

Scheme V shows the two step synthesis of the 3-substituted 4-pyridyl-5-arylpyrazoles 33 of the present invention by cyclization of hydrazone dianions with carboxylates. In step 1, the reaction of substituted pyridylmethyl ketones 31 (prepared, for example, as later described in Scheme IX) with hydrazines in the presence of solvents such as ethanol gives ketohydrazones 32. Examples of suitable hydrazines include, but are not limited to, phenylhydrazine and p-methoxyphenylhydrazine. In step 2, the hydrazones 32 are treated with two equivalents of a base such as sodium bis(trimethylsilyl)amide in a suitable solvent such as tetrahydrofuran to generate dianions. This reaction may be carried out at temperatures of about 0 °C or lower.

In the same step, the dianions then are condensed with esters such as methyl isonicotinate, methyl cyclopropanecarboxylate, to give the desired pyrazoles 33. It may be necessary to treat the product from this step with a dehydrating agent, such as a mineral acid, to produce the target pyrazole in some instances.



SUBSTITUTE SHEET (RULE 26)


Scheme VI shows an alternative method for synthesizing pyrazoles which are unsubstituted at the 5 position of the ring. In accordance with this method, a heteroarylmethyl ketone 34 is synthesized by first treating a heteroaryl methane with a strong base such as lithium hexamethyldisilazide or lithium diisopropylamide. Examples of suitable heteroaryl methanes are 4-methylpyridine, 4-methylpyrimidine, 2,4-dimethylpyridine, 2-chloro-4-methylpyrimidine, 2-chloro-4-methylpyridine and 2-fluoro-4-methylpyridine. The resulting heteroaryl[methyl] lithium species is then reacted with a substituted benzoate ester to produce ketone 34. Examples of suitable benzoate esters are methyl and ethyl p-fluorobenzoate and ethyl and methyl p-chlorobenzoate. Ketone 34 is converted to the aminomethylene derivative 35 by reaction with an aminomethylenating agent such as dimethylformamide dimethyl acetal or tert-butoxybis(dimethylamino)methane. Ketone 35 is converted to pyrazole 36 by treatment with hydrazine.

A modification of this synthetic route serves to regioselectively synthesize pyrazole 38 which contains a substituted nitrogen at position 1 of the ring. Ketone 34 is first converted to hydrazone 37 by reaction with the appropriate substituted hydrazine. Examples of suitable hydrazines are N-methylhydrazine and N-(2-hydroxyethyl)hydrazine. Reaction of hydrazone 37 with an aminomethylenating agent produces pyrazole 38. Examples of suitable aminomethylenating agents include dimethylformamide dimethyl acetal and tert-butoxybis(dimethylamino)methane.

In cases where the R^1 substituent of pyrazoles 36 and 38 bears a leaving group such as a displaceable halogen, subsequent treatment with an amine produces an amino-substituted heteroaromatic derivative. Examples of such amines include benzylamine, cyclopropylamine and ammonia.

SUBSTITUTE SHEET (RULE 26)

The leaving group may also be replaced with other nucleophiles such as mercaptides and alkoxides. Examples of substitutable R³ groups include, but are not limited to, 2-chloropyridinyl and 2-bromopyridinyl groups.




SCHEME VII

97

Scheme VII describes the preparation of derivatives from pyrazole 5 (prepared in accordance with Scheme I) when $R^2 = CH_3$. Oxidation of pyrazole 5 gives carboxylic acid 39, which is then reduced to hydroxymethyl compound 40, or coupled with amine NR^1R^{11} (wherein R^{10} and R^{11} are independently selected, for example, from hydrogen, alkyl and aryl, or together with the nitrogen atom to which they are attached form a 4-8 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur) to form amide 41 followed by reduction to generate amine derivative 42.

SCHEME VIII




Scheme VIII illustrates the synthesis of pyrazoles 44 and 45 from pyrazole 43. The alkylation of the ring nitrogen atoms of pyrazole 43 can be accomplished using conventional techniques. Treatment of pyrazole 43 with an appropriate base (for example, sodium hydride) followed by treatment with an alkyl halide (for example, CH_3I) yields a mixture of isomers 44 and 45.

SUBSTITUTE SHEET (RULE 26)

98

SCHEME IX




SUBSTITUTE SHEET (RULE 26)

Scheme IX illustrates the synthesis of 3-aryl-4-pyridyl-pyrazoles of the present invention. Benzoate 46 is reacted with pyridine 47 in the presence of a strong base, such as an alkali metal hexamethyldisilazide (preferably sodium hexamethyldisilazide or lithium hexamethyldisilazide), in a suitable solvent, such as tetrahydrofuran, to give desoxybenzoin 48. Desoxybenzoin 48 is then converted to ketone 49 by treatment with an excess of dimethylformamide dimethyl acetal. Ketone 49 is then reacted with hydrazine hydrate in a suitable solvent such as ethanol to yield pyrazole 50. In Scheme IX, R¹ represents one or more radicals independently selected from the optional substituents previously defined for R¹. Preferably, R¹ is hydrogen, alkyl, halo, trifluoromethyl, methoxy or cyano, or represents methylenedioxy.

The 3-aryl-4-pyrimidinyl-pyrazoles of the present invention can be synthesized in the manner of Scheme IX by replacing pyridine 47 with the corresponding pyrimidine. In a similar manner, Schemes X through XVII can be employed to synthesize 3-aryl-4-pyrimidinyl-pyrazoles corresponding to the 3-aryl-4-pyrimidinyl-pyrazoles shown in those schemes.

SCHEME X




Scheme X illustrates one variation of Scheme IX that can be used to synthesize 3-aryl-4-pyridyl-pyrazoles that are further substituted on the nitrogen atom at position 1 of the pyrazole ring. If desoxybenzoin 48 (prepared in accordance with Scheme IX) instead is first converted to hydrazone 51 by treatment with hydrazine and hydrazone 51 is then treated with dimethylformamide dimethyl acetal, then the resulting product is pyrazole 52.


Schemes XI through XVIII illustrate further modifications that can be made to Scheme IX to synthesize other 3-aryl-4-pyridyl-pyrazoles having alternative substituents.

101

SCHEME XI



SCHEME XII




In Scheme XII, X is chloro, fluoro or bromo; R^{12} is, for example, hydrogen, alkyl, phenyl, aralkyl, heteroarylalkyl, amino or alkylamino; and R^{20} is, for example, hydrogen or alkyl.


SUBSTITUTE SHEET (RULE 26)

102

SCHEME XIII




SCHEME XIV



SUBSTITUTE SHEET (RULE 26)

SCHEME XV




5

In Scheme XV, n is 1, 2, 3, 4 or 5; and R¹⁴ and R¹⁵ are independently selected from, for example, hydrogen, alkyl or aryl, or together with the nitrogen atom to which they are attached form a 4-7 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur.

10

SCHEME XVI




57

SUBSTITUTE SHEET (RULE 26)

In Scheme XVI, R¹⁶ is selected, for example, from hydrogen, alkyl and phenyl.

5

SCHEME XVII




In Scheme XVII, R¹⁷ is selected, for example, from alkyl, phenylalkyl and heterocyclylalkyl.

10

SUBSTITUTE SHEET (RULE 26)

105

SCHEME XVIII



Compounds wherein the 2-position of the pyridine ring is substituted by a carboxyl group or a carboxyl derivative may be synthesized according to the procedures outline in Scheme XVIII. The starting pyridyl pyrazole 67 is converted to the 2-cyano derivative 68 by first

SUBSTITUTE SHEET (RULE 26)

106

conversion to its pyridine N-oxide by reaction with an oxidizing agent such as m-chloroperoxybenzoic acid. Treatment of the pyridine N-oxide with trimethylsilyl cyanide followed by dimethylcarbamoyl chloride produces the 2-cyano compound 68. Compound 68 is converted to its carboxamide 69 by reaction with hydrogen peroxide in the presence of a suitable base. Examples of suitable bases include potassium carbonate and potassium bicarbonate. Carboxamide 69 is converted to its methyl ester 70 by reaction with dimethylformamide dimethyl acetal in methanol. The ester 70 is converted to its carboxylic acid 71 by saponification. Typical saponification conditions include reaction with a base such as sodium hydroxide or potassium hydroxide in a suitable solvent such as ethanol or ethanol and water or methanol and water or the like. Ester 70 is also convertible to substituted amide 72 by treatment with a desired amine, such as methylamine at a suitable temperature. Temperatures may range from room temperature to 180°C. In Scheme XVIII, R¹ and R² are independently selected, for example, from hydrogen, alkyl and aryl, or together with the nitrogen atom to which they are attached form a 4-8 membered ring that may contain one or more additional heteroatoms selected from oxygen, nitrogen or sulfur.

The following examples contain detailed descriptions of the methods of preparation of compounds of Formulas I, XI, X and XI. These detailed descriptions fall within the scope, and serve to exemplify, the above described General Synthetic Procedures which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention. All parts are by weight and temperatures are in Degrees Centigrade unless otherwise indicated. All compounds showed NMR spectra consistent with their assigned structures. In some cases, the assigned structures were confirmed by

SUBSTITUTE SHEET (RULE 26)

107

nuclear Overhauser effect (NOE) experiments.

The following abbreviations are used:

HCl - hydrochloric acid

MgSO₄ - magnesium sulfate

Na₂SO₄ - sodium sulfate

NaIO₄ - sodium periodate

NaHSO₃ - sodium bisulfite

NaOH - sodium hydroxide

KOH - potassium hydroxide

P₂O₅ - phosphorus pentoxide

Me - methyl

Et - ethyl

MeOH - methanol

EtOH - ethanol

HOAc (or AcOH) - acetic acid

EtOAc - ethyl acetate

H₂O - water

H₂O₂ - hydrogen peroxide

CH₂Cl₂ - methylene chloride

K₂CO₃ - potassium carbonate

KMnO₄ - potassium permanganate

NaHDS - sodium hexamethyldisilazide

DMF - dimethylformamide

EDC - 1-(3-dimethylaminopropyl)3-ethylcarbodiimide

hydrochloride

HOBT - 1-hydroxybenzotriazole

MCPBA - 3-chloroperoxybenzoic acid

Ts - tosyl

TMSCN - trimethylsilyl cyanide

Me₃NOCCl - N,N-dimethylcarbamoyl chloride

SEM-Cl - 2-(trimethylsilyl)ethoxymethyl chloride

h - hour

hr - hour

min - minutes

THF - tetrahydrofuran

TLC - thin layer chromatography

SUBSTITUTE SHEET (RULE 26)

108

DSC - differential scanning calorimetry


b.p. - boiling point

m.p. - melting point

eq - equivalent

RT - room temperature

Example A-1



4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine

10 Step 1: Preparation of 4-(3-fluoro-4-methoxyphenyl)-3-pyridyl-3-butene-2-one

A solution of 4-pyridylacetone (1.0 g, 7.4 mmol), 3-fluoro-*p*-anisaldehyde (1.25 g, 8.1 mmol), and piperidine (0.13 g, 1.5 mmol) in toluene (50 ml) was heated to reflux. After 18 hours, the reaction was cooled to room temperature and the solvent was removed under reduced pressure. The crude product (3.0 g) was purified by column chromatography (silica gel, 65:35 ethyl acetate/hexane) to give 4-(3-fluoro-4-methoxyphenyl)-3-pyridyl-3-butene-2-one as a pale yellow solid (1.60 g, 80%).


25 Step 2: Preparation of 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine

To a solution of 3-pyridyl-4-(3-fluoro-4-methoxyphenyl)-3-butene-2-one (step 1) (0.99 g, 3.65 mmol) in acetic acid (25 ml), *p*-toluenesulfonyl hydrazide (0.68 g, 3.65 mmol) was added. The reaction solution was heated to reflux for 6 hours. Acetic acid was removed by distillation from the reaction solution. The resulting residue was diluted with CH₂Cl₂ (150 ml), washed with H₂O

SUBSTITUTE SHEET (RULE 26)

109

(2x100 ml), dried (Na₂SO₄), filtered, and concentrated. The crude product (1.5 g) was purified by chromatography (silica gel, ethyl acetate) to give 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine as a pale yellow solid (213 mg, 20.7%): Anal. Calc'd for C₁₆H₁₄N₃O₂·0.1 H₂O: C, 67.41; H, 5.02; N, 14.74. Found: C, 67.37; H, 4.88; N, 14.35.

Example A-2

4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)
pyridine

Step 1: Preparation of 4-pyridylacetone

4-pyridylacetone was prepared according to the method of Ippolito et al, U.S. Patent 4,681,944.

Step 2: Preparation of 4-phenyl-3-(4-pyridyl)-3-butene-2-one

Using the procedure of Example A-1, step 1, 4-pyridylacetone (step 1) (1 g, 7.4 mmol) was condensed with benzaldehyde (790 mg, 7.4 mmol) in benzene (15 mL) containing piperidine (50 mg) at reflux. The desired 4-phenyl-3-(4-pyridyl)-3-butene-2-one (1.3 g, 78 %) was obtained as a crystalline solid; m. p. 101-103 °C. Anal. Calc'd for C₁₅H₁₃NO (223.28): C, 80.69; H, 5.87; N, 6.27. Found: C, 80.59; H, 5.79; N, 6.18.

Step 3: Preparation of 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone

Using the procedure of Example A-1, step 2, a solution of 4-phenyl-3-(4-pyridyl)-3-butene-2-one (step 2) (1.25 g, 5.6 mmol) in methanol (20 mL) was treated


SUBSTITUTE SHEET (RULE 26)

110

with 30% aqueous hydrogen peroxide (1 mL) in the presence of sodium hydroxide (230 mg, 5.7 mmol). The crude product was purified by chromatography (silica gel, 1:1 ethyl acetate/hexane) to give 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone (270 mg, 20%).

Step 4: Preparation of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine

Using the procedure of Example A-1, step 3, a solution of 4-phenyl-3-(4-pyridyl)-3,4-epoxy-2-butanone (step 3) (250 mg, 1 mmol) in ethanol (15 mL) was treated with anhydrous hydrazine (50 mg, 1.5 mmol) and heated to reflux for 4 hours. The crude product was purified by chromatography (silica gel, 1:1 acetone/hexane). The product was recrystallized from ethyl acetate and hexane to give 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (81 mg, 35%) as a crystalline solid; m. p. 212-214 °C. Anal. Calc'd for C₁₅H₁₃N₃ (235.29): C, 76.57; H, 5.57; N, 17.86. Found: C, 76.49; H, 5.42; N, 17.39.

Example A-3

4-[5-methyl-3-(2-methylphenyl)-1H-
pyrazol-4-yl]pyridine

Step 1: Preparation of 4-(2-methylphenyl)-3-(4-pyridyl)-3-butene-2-one

A solution of 4-pyridylacetone (Example A-5, step 1) (0.75 g, 5.56 mmol), o-tolualdehyde (0.73 g, 5.56 mmol) and piperidine (100 mg) in toluene (50 mL) was heated to reflux. Water generated during the reaction was removed by a Dean-Stark trap. After heating at

SUBSTITUTE SHEET (RULE 26)

111

reflux for 5 hours, the reaction mixture was stirred at room temperature for 15 hours. The mixture was concentrated to an orange color oily residue. The crude ketone was purified by chromatography to give 4-(2-methylphenyl)-3-(4-pyridyl)-3-butene-2-one: Anal. Calc'd for $C_{16}H_{15}NO$ (237.30): C, 80.98; H, 6.37; N, 5.90. Found: C, 80.78; H, 6.61; N, 5.85.

10 Step 2: Preparation of 4-(2-methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone

To a solution of 4-(2-methylphenyl)-3-(4-pyridyl)-3-butene-2-one (step 1) (1.0g, 4.2 mmol) in methyl alcohol (18 ml), a solution of H_2O_2 (30% by wt.) (0.95 g, 8.4 mmol) and sodium hydroxide (0.18 g 4.6 mmol) in water (4 ml) was added. The reaction was stirred at room temperature for 70 hours. After methyl alcohol was removed, water (25 ml) and ethyl acetate (100 ml) were added and the two phase mixture was stirred for 30 minutes. The layers were separated, and the aqueous layer was washed with ethyl acetate (100 ml). The combined organic layer was dried with Na_2SO_4 , filtered and concentrated to give an oil. 4-(2-Methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone was isolated from the oil residue by chromatography.


25 Step 3: Preparation of 4-[5-methyl-3-(2-methylphenyl)]-1H-pyrazol-4-ylpyridine

A solution of 4-(2-methylphenyl)-3-(4-pyridyl)-3,4-epoxy-2-butanone (step 2) (0.11 g, 0.434 mmol) and hydrazine hydrate (0.043 g, 0.868 mmol) in ethyl alcohol (50 ml) was heated at reflux for 20 hours. The solvent was removed and the resulting residue was purified by chromatography to give 4-[5-methyl-3-(2-methylphenyl)]-1H-pyrazol-4-ylpyridine: Anal. Calc'd for $C_{16}H_{15}N_3$ (249.32): C, 77.08; H, 6.06; N, 16.85. Found: C, 76.66; H, 5.91; N, 16.84.

SUBSTITUTE SHEET (RULE 26)

112

Example A-4




4-[5-methyl-3-(4-fluorophenyl)]-1H-pyrazol-4-ylpyridine

By following the method of Example A-3 and substituting *p*-fluorobenzaldehyde for *o*-tolualdehyde, the titled compound was prepared: Anal. Calc'd for $C_{15}H_{12}N_3F$ + 0.1 H_2O : (249.32): C, 70.63; H, 4.82; N, 16.47. Found: C, 70.63; H, 4.78; N, 16.40.

10

Example A-5



4-[5-methyl-3-(4-methylphenyl)]-1H-pyrazol-4-ylpyridine


By following the method of Example A-3 (with one minor modification: in Step 2, the preparation of the intermediate epoxide was accomplished at 0-10 °C for 1 hour, and the reaction was quenched by being partitioned

15

SUBSTITUTE SHEET (RULE 26)

113

between water, containing 2 eq. sodium disulfite, and ethyl acetate) and substituting *p*-tolualdehyde for *o*-tolualdehyde, the titled product was isolated: Anal. Calc'd for $C_{16}H_{15}N_3$ (249.32): C, 77.08; H, 6.06; N, 16.85. Found: C, 76.97; H, 6.09; N, 16.90.


Example A-6

10

By following the method of Example A-5 and substituting 4-(methylnitro)benzaldehyde for *p*-tolualdehyde, the titled product was prepared: Anal. Calc'd for $C_{16}H_{15}N_3$ (281.38): C, 68.30; H, 5.37; N, 14.93. Found: C, 68.34; H, 5.09; N, 14.78.

SUBSTITUTE SHEET (RULE 26)


114

Example A-7

5

By following the method of Example A-5 and substituting *p*-chlorobenzaldehyde for *p*-tolualdehyde, the titled product was obtained. Anal. Calc'd for $C_{15}H_{12}N_3Cl$ (269.77): C, 66.79; H, 4.48; N, 15.58. Found: C, 66.43; H, 4.44; N, 15.78.

10

Example A-8


15

By following the method of Example A-5 and substituting *m*-tolualdehyde for *p*-tolualdehyde, the titled product was obtained: Anal. Calc'd for $C_{16}H_{15}N_3 + 0.2H_2O$: C, 75.99; H, 6.14; N, 16.61. Found: C, 76.06; H,

SUBSTITUTE SHEET (RULE 26)

6.05; N, 16.38.

Example A-9




4-[5-(2,5-dimethylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine

5

By following the method of Example A-5 and substituting 2,5-dimethylbenzaldehyde for *p*-tolualdehyde, the titled product was obtained: Anal. Calc'd for $C_{17}H_{17}N_3 + 0.1H_2O$: C, 77.01; H, 6.54; N, 15.85. Found: C, 76.96; H, 6.81; N, 15.51.

10

Example A-10



4-[5-(1,3-benzodioxol-5-yl)-3-methyl-1H-pyrazol-4-yl]pyridine

15 4-Pyridylacetone (1.5 g, 12 mmol), piperonal (1.6 g, 10.6 mmol), acetic acid (110 mg, 1.8 mmol), and piperidine (110 mg, 1.3 mmol) were dissolved in toluene


(30 mL) and heated for 2 hours at reflux in a flask equipped with a Dean-Stark trap. The solution was cooled to room temperature, and ethyl acetate was added to precipitate a solid, which was collected on a filter plate (1.25 g). A sample (500 mg) of this solid was heated with *p*-toluenesulfonyl hydrazide (348 mg, 1.81 mmol) in acetic acid (5 mL) at 80 °C for 1 hour. The reaction was heated to reflux for 1 hour. The reaction was cooled to room temperature and the solvent was evaporated. The residue was dissolved in ethyl acetate, washed with 5% aqueous potassium carbonate, and water. The organic layer was dried ($MgSO_4$), filtered and evaporated to obtain a yellow solid. This solid was triturated with methylene chloride, yielding 4-[5-(1,3-benzodioxol-5-yl)-3-methyl-1H-pyrazol-4-yl]pyridine which was collected on a filter plate (220 mg, 42% yield). Anal. Calc'd for $C_{16}H_{13}N_3O_2$: C, 68.81; H, 4.69; N, 15.04. Found: C, 68.02; H, 4.54; N, 14.76. MS (M^+H): 280 (base peak).

10

15

20

Example A-11




4-[3-methyl-5-(4-phenoxypyridyl)-1H-pyrazol-4-yl]pyridine

4-Pyridylacetone (1.5 g, 12 mmol), 4-phenoxybenzaldehyde (92.1 g, 10.6 mmol), acetic acid (110 mg, 1.8 mmol), and piperidine (110 mg, 1.3 mmol) were dissolved in toluene (30 mL) and heated for 2 hours at

25


117

reflux in a flask equipped with a Dean-Stark trap. The solution was cooled to room temperature and ethyl acetate was added to precipitate a solid, which was collected on a filter plate. A sample (223 mg) of this solid was heated with p-toluenesulfonyl hydrazide (348 mg, 1.81 mmol) in ethylene glycol with potassium hydroxide (77 mg) at 110 °C for 0.5 hour. The work up procedure was the same as that in Example A-10. 4-[3-Methyl-5-(4-phenoxyphenyl)-1H-pyrazol-4-yl]pyridine was obtained (100 mg, 66% yield): Anal. Calc'd for C₂₁H₁₇N₃O + 0.1 H₂O: C, 76.62; H, 5.27; N, 12.76. Found: C, 76.37; H, 5.19; N, 12.64. MS (M⁺H): 328 (base peak).

Example A-12


15

The same procedure as for the preparation of Example A-10 was used, substituting 4-formylbiphenyl in place of piperonal, to give 4-[5-[[1,1'-biphenyl]-4-yl]-3-methyl-1H-pyrazol-4-yl]pyridine as a white solid. MS (M⁺H): 312 (base peak).

Example A-13**SUBSTITUTESHEET (RULE 28)**


118

The same procedure for the preparation of Example A-10 was used, substituting 3-phenoxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[3-(phenoxyphenyl)-1H-pyrazol-4-yl]pyridine as a white solid.

Example A-14

10

The same procedure for the preparation of Example A-10 was used, substituting 3-benzoyloxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine as a white solid. MS (M⁺H): 342 (base peak).

Example A-15


15

The same procedure for the preparation of Example A-10 was used, substituting 2-benzoyloxybenzaldehyde in place of piperonal, to give 4-[3-methyl-5-[2-

SUBSTITUTESHEET (RULE 28)

(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine. MS
(M⁺H): 342 (base peak).


5

Example A-16

2-[3-methyl-4-(4-pyridinyl)-1H-
pyrazol-4-yl]phenol

The same procedure for the preparation of Example A-10 was used, substituting 2-hydroxybenzaldehyde in place of piperonal, to give 2-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol: MS (M⁺H): 252 (base peak).


10

Example A-17

3-[3-methyl-4-(4-pyridinyl)-1H-
pyrazol-4-yl]phenol

The same procedure for the preparation of Example A-10 was used, substituting 3-hydroxybenzaldehyde in place of piperonal, to give 3-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol: MS (M⁺H): 252 (base peak).


15

Example A-18

1-hydroxy-4-[3-methyl-5-phenyl-1H-
pyrazol-4-yl]pyridinium

To a solution of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (Example A-2) (2.06 g, 8.76 mmol) in a mixture of CH₂Cl₂ (10 mL) and MeOH (20 mL), was added 3-chloroperoxybenzoic acid (57-86%) (2.65 g, 8.76 mmol). The reaction was stirred at room temperature for 2h, quenched with K₂CO₃ solution (25%, 15 mL), and concentrated. The resulting residue was partitioned between EtOAc (2.0 L) and H₂O (500 mL). The organic layer was separated, washed with H₂O (500 mL), dried over MgSO₄, filtered and concentrated to give 1-hydroxy-4-[3-methyl-5-phenyl-1H-pyrazol-4-yl]pyridinium (1.12 g, 54.5%): MS (M⁺H): 252 (base peak).

15

Example A-19

5-(4-fluorophenyl)-N,N-dimethyl-4-(4-
pyridinyl)-1H-pyrazol-3-amine

121

Step 1: Preparation of 1-fluoro-4-(4'-pyridyl)benzene

To a solution of sodium bis(trimethylsilyl)amide (200 mL, 1.0 M in THF) at 0 °C was added a solution of 4-picoline (18.6 g, 0.20 mol) in dry THF (200 mL) over 30 minutes. The reaction mixture was stirred at 0-10 °C for another 30 minutes, then was added to a solution of ethyl 4-fluorobenzoate (16.8 g, 0.10 mol) in dry THF (200 mL) at such a rate that the internal temperature didn't exceed 15 °C. After the addition, the resulting yellow suspension was stirred at room temperature for 3 hours. Water (600 mL) was added and the aqueous phase was extracted with ethyl acetate (3 X 200 mL). The combined organic layers were washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo to give 1-fluoro-4-(4'-pyridyl)benzene (19.9 g, 92 %) as an oil which solidified upon standing: m.p.: 90-91 °C; Anal. Calc'd for $C_{13}H_{10}FNO$: C, 72.55; H, 4.68; N, 6.51. Found: C, 72.07; H, 4.66; N, 6.62.

Step 2: Preparation of 1-fluoro-4-(4'-pyridyl)bromobenzene

To a solution of 1-fluoro-4-(4'-pyridyl)benzene (step 1) (10.0 g, 0.046 mol) in acetic acid (200 mL) was added a solution of bromine (8.2 g, 0.052 mol) in acetic acid (20 mL) dropwise. The reaction mixture was stirred at room temperature overnight. After the solvent was removed, the residue was triturated with ethyl acetate. A yellow solid formed, which was filtered and air-dried to give 1-fluoro-4-(4'-pyridyl)bromobenzene (14.5 g). The compound was used in next step without further purification.


SUBSTITUTE SHEET (RULE 26)

122

Step 3: Preparation of 5-(4-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine

A mixture of 1-fluoro-4-(4'-pyridyl)bromobenzene (step 2) (3.8 g, 0.01 mol) and 4,4-dimethylamino-3-thiosemicarbazide (1.2 g, 0.01 mol) in ethanol (10 mL) was heated at reflux for 30 minutes. The dark green solution was cooled and poured into water (100 mL). The aqueous phase was extracted with methylene chloride (100 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. The resulting residue was purified by chromatography (silica gel, ethyl acetate) to give 0.3 g 5-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine (0.3 g, 11 %) as a light yellow solid: m.p.: 245-247 °C. Anal. Calc'd for $C_{16}H_{15}FN_4$: C, 68.07; H, 5.36; N, 19.84. Found: C, 68.00; H, 5.37; N, 19.61.

Example A-20




5-(4-(4-fluorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine

5-(4-(4-fluorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine was prepared by the same procedure as described for Example A-19: m.p. 218-219 °C. Anal. Calc'd for $C_{20}H_{15}FN_4 + 0.1 H_2O$: C, 72.33; H, 4.61; N, 16.87. Found: C, 72.16; H, 4.56; N, 16.77.

SUBSTITUTE SHEET (RULE 26)

Example A-21



4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 1-fluoro-4-(4'-pyridylacetyl)benzene N-benzoylhydrazide


To a solution of benzoic hydrazide (1.36 g, 0.01 mol) in THF (20 mL) was added 1-fluoro-4-(4'-pyridylacetyl)benzene (2.15 g, 0.011 mol) in one portion followed by a drop of conc. HCl. The reaction mixture was stirred at room temperature overnight. There was white precipitate formed, which was filtered, washed with ether and air-dried to give 1-fluoro-4-(4'-pyridylacetyl)benzene N-benzoylhydrazide (2.90 g, 79 %) as a mixture of cis and trans (ratio, 1:9) isomers.

Step 2: Preparation of 4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine

1-Fluoro-4-(4'-pyridylacetyl)benzene N-benzoylhydrazide (step 1) (0.50 g, 1.5 mmol) was heated at 180 °C under N₂ for 15 minutes, then cooled. The resulting solid was purified by chromatography (silica gel, 1:1 ethyl acetate/hexane) to give 4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine (0.25 g, 53 %) as a pale yellow solid: m.p.: 265-267 °C. Anal. Calc'd for C₂₀H₁₄FN₃ + 0.25 H₂O: C, 75.10; H, 4.57; N, 13.14. Found: C, 74.98; H, 4.49; N, 12.87.

SUBSTITUTESHEET (RULE 26)

Example A-22



4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 3-(4'-pyridylacetyl)toluene

3-(4'-Pyridylacetyl)toluene was prepared by the same method as described for Example A-19, step 1 in 70% yield.

Step 2: Preparation of trifluoroacetyl hydrazide

A mixture of ethyl trifluoroacetate (14.2 g, 0.10 mol) and hydrazine hydrate (5.54 g, 0.11 mol) in ethanol (25 mL) was heated at reflux for 6 hours. Solvent was removed and the resulting residue was dried in vacuum to give trifluoroacetyl hydrazide (12.3 g, 96 %) as a clear oil which solidified upon standing.


Step 3: Preparation of 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine

A mixture of 3-(4'-pyridylacetyl)toluene (2.11 g, 0.01 mol) and trifluoroacetyl hydrazide (step 2) (1.0 g, 0.01 mol) was heated at 200 °C under N₂ for 15 minutes. The crude residue was purified by chromatography (silica gel, 35:65 ethyl acetate/hexane) to give 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine (0.56 g) as a white solid: m.p. 237-239 °C. Anal. Calc'd for C₁₆H₁₂F₃N₃: C, 63.36; H, 3.99; N, 13.85.

SUBSTITUTESHEET (RULE 26)

125

Found: C, 63.6; H, 4.00; N, 13.70.

Example A-23

A mixture of 1-fluoro-4-(4'-pyridylacetyl)benzene (1.0 g, 4.6 mmol) and isonicotinic hydrazide (0.63 g, 4.6 mmol) in THF (25 mL) was heated to dissolution and then evaporated to dryness. The resulting solid was heated first to 140 °C, which caused a phase change, and subsequently melted on further heating until 180 °C whereupon a solid crystallized out. The reaction was immediately cooled, diluted with 10 % HCl (50 mL) and washed with chloroform. The aqueous layer was neutralized with bicarbonate and a tan colored solid was precipitated out. The solid was purified by treatment with activated carbon (Darco®) in boiling MeOH (100 mL), followed by filtration and concentration, to give 4-[3-(4-fluorophenyl)-2-(4-(4-pyridinyl)-1H-pyrazol-5-yl)]pyridine (1.05 g, 69 %) as a shiny tan solid: m.p. 304 °C (DSC). Mass (MH⁺) 337 (100%). Anal. Calc'd for C₁₉H₁₃N₄F.1/4H₂O: C, 71.13; H, 4.24; N, 17.46. Found: C, 70.88; H, 3.87; N, 17.38.

SUBSTITUTE SHEET (RULE 26)


126

Example A-24**Step 1: Preparation of 4-(5-cyclohexyl)-3-pyridyl-3-butene-2-one**

4-Cyclohexyl-3-pyridyl-3-butene-2-one was prepared by the method of Example A-1, step 1 by replacing of 3-fluoro-*p*-anisaldehyde with cyclohexanecarboxaldehyde.

Step 2: Preparation of 4-(5-cyclohexyl)-3-methyl-1H-pyrazol-4-yl]pyridine

4-(5-Cyclohexyl)-3-methyl-1H-pyrazol-4-yl]pyridine was prepared by the method for Example A-1, step 2, by replacing 4-(3-fluoro-4-methoxyphenyl)-3-pyridyl-3-butene-2-one with 4-cyclohexyl-3-pyridyl-3-butene-2-one (step 1): Anal. Calc'd for C₁₅H₁₉N₃: C, 73.56; H, 7.98; N, 17.16. Found: C, 73.72; H, 7.91; N, 19.98.

Example A-25**SUBSTITUTE SHEET (RULE 26)**

4-{5-(3-Fluoro-5-methoxyphenyl)-3-methyl-3-methyl-1H-pyrazol-4-yl}pyridine was prepared by the method of Example A-1, steps 1 and 2 by replacing 3-fluoro-*p*-anisaldehyde with 3-fluoro-*m*-anisaldehyde: Anal. Calc'd for C₁₆H₁₄N₃O₂F: C, 67.83; H, 4.98; N, 14.83. Found: C, 67.68, H, 4.92; N, 14.92.

The following examples (No 26-55) listed in Table 1 were prepared by the procedures described above:

No	R ¹	R ²	R ³	R ⁴	m.p. or DSC(°C)	Anal. Calcd Formula	Anal. Calcd (calcd/found)
							C H N
26	H				185-186	C ₁₈ H ₁₉ N ₃	77.95/ 77.51 6.90/ 6.93 15.15/ 14.73
27	H				142-144	C ₁₆ H ₁₄ N ₃	75.70/ 75.69 6.16/ 6.11 15.55/ 16.49
28	H				240-242	C ₂₂ H ₁₉ N ₃ 0.25H ₂ O	80.09/ 79.74 5.96/ 5.90 12.74/ 13.01
29	H				228.8	C ₁₆ H ₁₂ N ₃ F	63.36/ 63.28 3.99/ 3.73 13.85/ 13.69
30	H				189.6	C ₁₅ H ₁₂ N ₃ C 0.15H ₂ O	66.13/ 65.98 4.55/ 4.31 15.42/ 15.74
31	H				171.6	C ₁₇ H ₁₇ N ₃ 0.25H ₂ O	76.49/ 76.69 6.57/ 6.53 15.74/ 15.61
32					88.6	C ₁₆ H ₁₄ N ₃ C	67.72/ 67.35 4.97/ 5.29 14.81/ 15.02
33	H				188.8	C ₁₆ H ₁₄ N ₃ F	71.89/ 71.72 5.28/ 5.45 15.72/ 15.77
34	H				215.7	C ₁₇ H ₁₇ N ₃	77.54/ 77.24 6.51/ 6.80 15.96/ 15.71
35	H				201.4	C ₁₇ H ₁₇ N ₃ O ₂ 0.25H ₂ O	68.10/ 67.92 5.88/ 5.65 14.01/ 13.65
36	H				210.7	C ₁₅ H ₁₂ N ₃ O ₂ 0.25H ₂ O	63.26/ 63.59 4.42/ 4.39 19.67/ 19.31
37	H				252.5	C ₁₇ H ₁₄ N ₄	73.35/ 72.61 6.52/ 6.79 20.13/ 19.59
38	H				196.3	C ₁₇ H ₁₅ N ₃ O	73.63/ 73.43 5.45/ 5.46 15.15/ 15.19
39	H				232.8	C ₁₅ H ₁₂ N ₃ Br	57.34/ 57.09 3.85/ 3.79 13.37/ 13.06
40	H				198.5	C ₁₅ H ₁₂ N ₄ F	71.13/ 71.23 4.78/ 5.01 16.59/ 16.76
41	H				225.6	C ₁₅ H ₁₂ N ₃ F	71.13/ 70.74 4.78/ 4.66 16.59/ 16.44
42	H				219.5	C ₁₆ H ₁₂ F ₂ N ₃	63.36/ 63.19 3.99/ 4.07 13.85/ 13.38
43	H				227.7	C ₁₆ H ₁₄ N ₃ 0.1H ₂ O	76.53/ 76.53 6.10/ 6.20 16.73/ 16.49

No	R ¹	R ²	R ³	R ⁴	m.p. or DSC/°C	Anal./Calcd Formula	Anal. Calcd (calcd./found)			
A	C	H	N							
44	H				175.6	C ₁₆ H ₁₃ N ₃ O 0.15H ₂ O	71.70/ 71.92	5.75/ 5.76	15.68/ 15.29	
45	H				—	C ₁₇ H ₁₃ N ₃	77.54/ 77.13	6.51/ 6.28	15.96/ 15.69	
46	H				412.1	C ₁₇ H ₁₁ N ₃ F ₂	66.62/ 66.12	4.09/ 3.86	15.49/ 15.25	
47	H				168.5	C ₁₇ H ₁₁ N ₃ O 0.15H ₂ O	72.40/ 72.39	6.18/ 5.87	14.90/ 14.50	
48	H				211.2	C ₁₆ H ₁₂ N ₃ F ₃ 0.2H ₂ O	62.62/ 62.64	4.07/ 4.06	13.69/ 13.35	
49	H				—	C ₁₆ H ₁₁ N ₃ S	64.71/ 64.44	4.59/ 4.58	17.41/ 17.27	
50	H				189.2	C ₁₇ H ₁₁ N ₃ Cl	59.23/ 59.22	3.65/ 3.24	13.81/ 13.81	
51	H				211.7	C ₁₆ H ₁₂ N ₃ Cl 0.15H ₂ O	66.13/ 66.33	4.55/ 4.62	15.42/ 15.05	
52	H				219.8	C ₁₆ H ₁₀ N ₃ Cl	64.11/ 63.85	4.71/ 4.69	14.02/ 13.95	
53	H				163.4	C ₁₆ H ₁₀ N ₃ OCl	64.32/ 63.98	4.83/ 5.08	11.84/ 11.80	
54					—	C ₁₆ H ₉ N ₃ F 0.25H ₂ O	70.15/ 70.18	4.86/ 4.60	16.35/ 16.47	
55	H				—	C ₁₄ H ₁₀ N ₃ F	70.28/ 69.97	4.21/ 3.84	17.56/ 17.53	

SUBSTITUTESHEET (RULE 28)

The following pyrazoles could be prepared by the procedures described above:

- 5 Example A-56 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-57 5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-58 5-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-59 5-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-60 5-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-61 5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-62 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
Example A-63 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-64 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-65 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-66 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-67 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-68 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
Example A-69 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
Example A-70 2-methoxy-5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
Example A-71 2-methoxy-5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-72 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-

SUBSTITUTESHEET (RULE 28)

- 4-yl]pyridine-2-methoxypyridine;
Example A-73 2-methoxy-4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
Example A-74 2-methoxy-4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine;
5 1H-pyrazol-4-yl]pyridine;
Example A-75 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
Example A-76 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxypyridine;
10 Example A-77 2-methoxy-4-[3-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine;
Example A-78 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
Example A-79 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
15 Example A-80 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
Example A-81 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
Example A-82 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
20 Example A-83 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
Example A-84 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
25 Example A-85 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
Example A-86 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
30 Example A-87 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
Example A-88 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
Example A-89 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
35 Example A-90 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-

- 4-yl]pyridine-2-methanamine;
Example A-91 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
Example A-92 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
5 4-yl]pyridine-2-carboxamide;
Example A-93 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
Example A-94 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
10 Example A-95 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
Example A-96 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
Example A-97 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
15 Example A-98 4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
Example A-99 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-1H-pyrazol-4-yl]pyridine;
20 Example A-100 4-[5-(4-fluoro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-101 4-[5-(4-chloro-3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-102 4-[5-(2,3-dihydrobenzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
25 Example A-103 4-[5-(benzofuran-6-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-104 4-[5-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-105 4-[5-(3-chloro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-106 4-[5-(1-cyclohexen-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
30 Example A-107 4-[5-(1,3-cyclohexadien-1-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-108 4-[5-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-

133

- 1H-pyrazol-4-yl]pyridine;
Example A-109 4-(5-cyclohexyl-3-methyl-1H-pyrazol-4-yl)pyridine;
Example A-110 4-[5-(4-methoxy-3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-111 4-[5-(3-methoxy-4-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-112 4-[5-(3-methoxy-5-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-113 4-[5-(3-furanyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
Example A-114 2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-115 2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-116 methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxylate;
Example A-117 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-2-carboxamide;
Example A-118 1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-2-yl]ethanone;
Example A-119 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-2-yl)pyridin-2-amine;
Example A-120 3-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-121 3-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-122 methyl 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-3-carboxylate;
Example A-123 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine-3-carboxamide;
Example A-124 1-[4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridin-3-yl]ethanone;
Example A-125 3-bromo-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
Example A-126 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-

SUBSTITUTE SHEET (RULE 26)

134

- pyrazol-2-yl]pyridin-3-amine;
Example A-127 2-methyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;
Example A-128 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;
Example A-129 2-methoxy-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidine;
Example A-130 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine;
Example A-131 N,N-dimethyl-4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine;
Example A-132 4-(5,6-dihydro-2H-pyran-4-yl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-133 3-methyl-4-(3-thienyl)-1H-pyrazole;
Example A-134 4-(3-furanyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-135 3-methyl-5-phenyl-4-(2-thienyl)-1H-pyrazole;
Example A-136 4-(2-furanyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-137 4-(3-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-138 4-(3-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-139 4-(5-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-140 4-(5-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole;
Example A-141 3-methyl-5-phenyl-4-(5-thiazolyl)-1H-pyrazole;
Example A-142 3-methyl-4-(5-oxazolyl)-5-phenyl-1H-pyrazole;
Example A-143 2-methyl-4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
Example A-144 4-(1-methyl-3-phenyl-1H-pyrazol-4-yl)pyridine;

SUBSTITUTE SHEET (RULE 26)

135


- Example A-145 4-(3-phenyl-1H-pyrazol-4-yl)pyridine;
 Example A-146 2-methyl-4-(3-phenyl-1H-pyrazol-4-yl)pyridine;
 Example A-147 4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
 Example A-148 4-[3-(4-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
 Example A-149 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
 Example A-150 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
 Example A-151 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2-methylpyridine;
 Example A-152 4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 Example A-153 4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine; and
 Example A-154 4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]-2-methylpyridine.

20

The compounds of Examples A-155 through A-172 were synthesized in accordance with the chemistry described above (particularly Scheme II) and illustrated by many of the previously disclosed Examples by selection of the corresponding starting reagents:

25

Example A-155



5-(4-chlorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-


SUBSTITUTE SHEET (RULE 26)

136

pyrazol-3-amine: DSC 261 °C. Anal. Calc'd for $C_{16}H_{13}ClN_4$ + 0.25 H_2O (MW 351.32): C, 68.38, H, 4.30, N, 15.95. Found: C, 68.25, H, 4.41, N, 15.74.

5


Example A-156



5-(4-chlorophenyl)-N-methyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 260 °C. Anal. Calc'd for $C_{17}H_{15}ClN_4$ + 0.125 H_2O (MW 287.00): C, 62.77, H, 4.57, N, 19.52. Found: C, 62.78, H, 4.33, N, 19.22.

10

Example A-157




5-(4-chlorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine dihydrate: DSC 230 °C. Anal. Calc'd for $C_{19}H_{17}ClN_4$ + 2 H_2O (MW 334.81): C, 57.40, H, 4.52, N, 16.73. Found: C, 57.72, H, 4.85, N, 16.54.


15

SUBSTITUTE SHEET (RULE 26)

1.37

Example A-158


5-(3-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 227 °C. Anal. Calc'd for $C_{16}H_{15}FN$, + 0.125 H_2O (MW 284.57): C, 67.53, H, 5.31, N, 19.69. Found: C, 67.60, H, 5.20, N, 19.84.

Example A-159


10 N,N-dimethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 222 °C. Anal. Calc'd for $C_{17}H_{18}N_2$, + 0.25 H_2O (MW 282.86): C, 72.19, H, 6.41, N, 19.81. Found: C, 71.99, H, 6.46, N, 19.90.

SUBSTITUTE SHEET (RULE 26)

1.38

Example A-160

5 N-methyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 226 °C. Anal. Calc'd for $C_{16}H_{16}N_2$, + 0.125 H_2O (MW 266.58): C, 72.09, H, 6.05, N, 21.02. Found: C, 72.12, H, 6.12, N, 20.83.


Example A-161

10 N-ethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 227 °C. Anal. Calc'd for $C_{17}H_{18}N_2$, + 0.125 H_2O (MW 280.61): C, 72.77, H, 6.47, N, 19.97. Found: C, 72.63, H, 6.40, N, 19.73.

SUBSTITUTE SHEET (RULE 26)


139

Example A-162



N,N-diethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 234 °C. Anal. Calc'd for $C_{18}H_{22}N_4$ (MW 306.41): C, 74.48, H, 7.24, N, 18.29. Found: C, 74.12, H, 7.18, N, 18.13.

Example A-163




10 5-(4-chlorophenyl)-N,N-diethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: m.p. 260-261°C. Anal. Calc'd for $C_{18}H_{19}ClN_4$ (MW 326.83): C, 66.15, H, 5.86, N, 17.14. Found: C, 66.03, H, 5.72, N, 17.23. [

SUBSTITUTESHEET (RULE 28)


140

Example A-164



4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]morpholine: DSC 279 °C. Anal. Calc'd for $C_{18}H_{17}ClN_5O$ + 0.25 H_2O (MW 345.32): C, 62.61, H, 4.96, N, 16.23. Found: C, 62.52, H, 4.77, N, 16.52.


Example A-165




10 5-(4-chlorophenyl)-N-propyl-4-(4-pyridinyl)-1H-pyrazol-3-amine: DSC 244 °C. Anal. Calc'd for $C_{19}H_{17}ClN_4$ + 0.125 H_2O (MW 315.06): C, 64.81, H, 5.44, N, 17.78. Found: C, 64.94, H, 5.43, N, 17.78.

SUBSTITUTESHEET (RULE 28)

141

Example A-166

- Isolated as 5-(4-chlorophenyl)-N-(phenylmethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine hydrate (2:1): DSC 237 °C.
 Anal. Calc'd for $C_{21}H_{16}ClN_4$ + 0.5 H_2O (MW 369.86): C, 68.20, H, 4.63, N, 15.15. Found: C, 68.09, H, 4.55, N, 15.15.


Example A-167

- Isolated as 5-(4-chlorophenyl)-N-(2-methoxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine monohydrate: DSC 223 °C.
 Anal. Calc'd for $C_{17}H_{16}ClN_4O$ + H_2O (MW 346.82): C, 58.87, H, 4.94, N, 16.15. Found: C, 58.59, H, 4.79, N, 16.02.

10


SUBSTITUTE SHEET (RULE 26)

142

Example A-168

- 1,1-dimethylethyl 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate: DSC 251 °C.
 Anal. Calc'd for $C_{29}H_{30}ClN_6O$ (MW 439.95): C, 62.79, H, 5.96, N, 15.92. Found: C, 62.40, H, 5.82, N, 15.82.

10


Example A-169

- Isolated as 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride: DSC 99 °C.

SUBSTITUTE SHEET (RULE 26)

143


Anal. Calc'd for $C_{18}H_{18}ClN_3 + 3 HCl$ (MW 449.21): C, 48.13, H, 4.71, N, 15.59. Found: C, 47.76, H, 5.07, N, 15.51.

Example A-170

5

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine: m.p. 247-249 °C. Anal. Calc'd for $C_{18}H_{18}ClN_3 + 0.75 H_2O$ (MW 367.33): C, 62.12, H, 5.49, N, 19.06. Found: C, 62.45, H, 5.86, N, 19.32.

10


Example A-171

1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate: m.p. 243-244

SUBSTITUTE SHEET (RULE 26)

144

°C. Anal. Calc'd for $C_{23}H_{18}FN_3O_2 + 0.5 CH_3CO_2CH_2CH_3$ (MW 467.55): C, 64.22, H, 6.47, N, 14.98. Found: C, 63.90, H, 6.61, N, 14.88.

Example A-172

1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride: m.p. 204-206 °C. Anal. Calc'd for $C_{18}H_{18}FN_3 + 3 HCl + 0.5 H_2O$ (MW 441.77): C, 48.94, H, 4.79, N, 15.85. Found: C, 48.66, H, 4.88, N, 15.50.

10

1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine: m.p. 264-265 °C. Anal. Calc'd for $C_{18}H_{18}ClN_3 + 0.125 H_2O$ (MW 342.08): C, 63.20, H, 5.30, N, 20.47. Found: C, 63.04, H, 5.36, N, 20.33.

15

Additional compounds that were synthesized in accordance with the chemistry described in Scheme II by selection of the corresponding starting reagents further include the compounds disclosed in Table 2.

20


SUBSTITUTE SHEET (RULE 26)

TABLE 2

Example	General Procedure	Formula	Microanalysis						DSC deg C
			C calc	C found	H calc	H found	N calc	N found	
A-173	Sch. II	C ₂₄ H ₂₅ ClN ₆ •1.5H ₂ O	50.63	50.58	4.96	5.03	14.76	14.68	182
A-174	Sch. II	C ₂₅ H ₂₄ ClN ₅ •0.125H ₂ O	69.47	69.33	5.60	5.56	16.20	16.11	259
A-175	Sch. II	C ₁₇ H ₁₇ FN ₆ •1.25H ₂ O	48.64	48.45	4.56	4.86	20.02	20.24	82
A-176	Sch. II	C ₂₂ H ₂₆ ClN ₅ O ₂	61.75	61.57	6.12	6.04	16.37	16.34	217
A-177	Sch. II	C ₁₇ H ₁₈ ClN ₅ •3HCl•H ₂ O	44.85	44.96	4.65	4.87	15.38	15.17	220
A-178	Sch. II	C ₂₁ H ₂₄ ClN ₅ O ₂ •0.125H ₂ O	60.61	60.51	5.81	5.81	16.83	16.64	232
A-179	Sch. II	C ₂₅ H ₃₀ ClN ₅ O ₃	62.04	61.76	6.25	6.25	14.47	14.37	220
A-180	Sch. II	C ₂₂ H ₂₅ FN ₆ O ₂ •0.5H ₂ O	60.96	60.86	5.81	6.21	19.39	19.47	N.D.
A-181	Sch. II	C ₂₂ H ₂₅ ClFN ₅ O ₂	59.26	58.98	5.65	5.55	15.71	15.36	210
A-182	Sch. II	C ₂₀ H ₂₂ ClN ₅ •0.75H ₂ O	62.98	62.97	5.81	5.64	18.36	17.83	271
A-183	Sch. II	C ₁₆ H ₁₉ Cl ₄ N ₅ •3HCl	45.41	45.37	4.53	4.74			120

145


Example A-173



146

5 N-[5-(4-chlorophenyl)-4-[2-(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride


Example A-174



10


1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(phenylmethyl)piperazine

147

Example A-175

Isolated as 4-[3-(4-fluorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine, dihydrochloride


5

Example A-176


1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate

SUBSTITUTE SHEET (RULE 26)

148

Example A-177


Isolated as N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride monohydrate

Example A-178


1,1-dimethylethyl [2-[[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]amino]ethyl]carbamate

SUBSTITUTE SHEET (RULE 26)

149

Example A-179


1,1-dimethylethyl 4-[5-(4-chlorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate

Example A-180


1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate

SUBSTITUTE SHEET (RULE 26)

150


Example A-181

1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate

Example A-182


1,1-dimethylethyl [3-[[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl]carbamate

SUBSTITUTE SHEET (RULE 26)

Example A-183

- 5 N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-ethanediamine


The compounds of Examples A-184 through A-189 were synthesized in accordance with the chemistry described above (particularly in Schemes I and IV) and illustrated by the previously disclosed Examples by selection of the corresponding starting reagents:

Example A-184

- 15 4-[3-(2,6-difluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{16}H_{11}F_2N_3$: C, 66.42; H, 4.09; N, 15.49. Found: C, 66.20; H, 3.94; N, 15.16; m.p.


SUBSTITUTESHEET (RULE 28)

236.67 °C.

Example A-185

- 5 4-[3-(3-ethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{17}H_{15}N_3$: C, 77.54; H, 6.51; N, 15.96. Found: C, 77.16; H, 6.27; N, 15.69. m.p. (DSC): 189.25 °C.


10

Example A-186


- 15 4-[3-(3-chlorophenyl)-5-ethyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{18}H_{15}ClN_3$: 0.1 mole H_2O : C, 67.15; H, 4.91; N, 14.33. Found: C, 66.95; H, 5.00; N, 14.36. DSC: 176.18 °C.

SUBSTITUTESHEET (RULE 28)

153

Example A-187


5 4-[3-ethyl-5-(3-ethylphenyl)-1H-pyrazol-4-yl]pyridine:
 Anal. Calc'd for $C_{20}H_{19}N_3 \cdot 0.1$ mole H_2O : C, 77.44; H, 6.93;
 N, 15.05. Found: C, 77.39; H, 6.94; N, 14.93. m.p.:
 (DSC) : 192.66 °C.

Example A-188

10 4-[3-(4-chlorophenyl)-5-(1-methyl-1H-pyrazol-4-yl)pyridine:
 Anal. Calc'd for $C_{21}H_{16}ClN_3 \cdot 0.4M$ EtOAc: C,
 67.08; H, 5.81; N, 12.62. Found: C, 67.40; H, 6.15; N,
 12.34.

SUBSTITUTE SHEET (RULE 26)


154

Example A-189

5 4-[3-cyclopropyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine:
 Anal. Calc'd for $C_{20}H_{16}FN_3$: C, 73.1; H, 5.05;
 N, 15.04. Found: C, 73.23; H, 4.89; N, 14.63; m.p.: 239-
 240 °C.

10 The compound of Example A-190 was synthesized in
 accordance with the chemistry described above

(particularly in Scheme III) and illustrated by the
 previously disclosed Examples by selection of the
 corresponding starting reagents:

Example A-190

15 4-[3-(4-fluorophenyl)-5-(trifluoromethyl-1H-pyrazol-4-yl)pyridine

20 This compound was prepared by the same procedure as


SUBSTITUTE SHEET (RULE 26)

described for Example A-22 by replacing 3-(4'-pyridylacetyl)toluene with 1-fluoro-4-(4'-pyridylacetyl)benzene (prepared as set forth in Example A-19).

- 5 Anal. Calc'd for $C_{15}H_{11}FN_3$: C, 58.64; H, 2.95; N, 13.68. Found: C, 58.57; H, 3.07; N, 13.31. m.p. (DSC): 281.94 °C.


The compounds of Examples A-191 through A-198 were synthesized in accordance with the chemistry described above (particularly in Scheme V) by selection of the corresponding starting reagents:

Example A-191



4-[5-(cyclopropyl-3-(4-(fluorophenyl))-1-methyl-1H-pyrazol-4-yl)pyridine

- 20 Step 1: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone



1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone

SUBSTITUTE SHEET (RULE 26)

To a solution of 4-fluorobenzoyl-4'-pyridinyl methane (8.60 g, 0.04 mol) and methyl hydrazine (2.14 g, 0.044 mol) in 50 mL of ethanol was added two drops of concentrated sulfuric acid. The reaction mixture was stirred at room temperature overnight. After the removal of solvent, the residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, saturated sodium carbonate solution, washed with brine, and dried over magnesium sulfate. The filtrate was concentrated and the crude product was recrystallized from diethyl ether and hexane to afford 7.5 g of a yellow solid product (77% yield), 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone methylhydrazone.


- 15 Step 2: Preparation of 4-[5-(cyclopropyl-3-(4-(fluorophenyl))-1-methyl-1H-pyrazol-4-yl)pyridine

To a solution of sodium hexamethyldisilazide (5.5 mL, 1.0 M in THF) at 0 °C was added a solution of the compound prepared in step 1 (0.67 g, 0.0028 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of methyl cyclopropanecarboxylate (0.34 g, 0.0034 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 3 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane/acetone, 10:9:1) to give 0.45 g of product, 4-[5-(cyclopropyl-3-(4-(fluorophenyl))-1-methyl-1H-pyrazol-4-yl)pyridine], as a light yellow solid (55% yield), mp: 129-130 °C; 1H NMR ($CDCl_3$): δ 8.53 (m, 2H), 7.32 (m, 2H), 7.14 (m, 2H), 6.97 (m, 2H), 4.00 (s, 3H), 1.83 (m, 1H), 0.95 (m, 2H), 0.36 (m, 2H); Anal. Calc'd For $C_{24}H_{24}FN_3$: C, 73.70; H, 5.50; N, 14.32. Found: C,

SUBSTITUTE SHEET (RULE 26)


157

73.63; H, 5.57; N, 14.08.

Example A-192

5 5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

Step 1: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone



10


1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone

To a flask containing hydroxyethyl hydrazine (3.4 g, 0.04 mol) at 80 °C was added 4-fluorobenzoyl-4'-pyridinyl methane (8.6 g, 0.04 mol) portionwise. The yellow oil was stirred at this temperature overnight. The cooled reaction mixture was dissolved with hot ethyl acetate and then triturated with hexane to give 8.9 g of product, 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone, as a yellow crystal (81%), mp: 122-123 °C.

SUBSTITUTE SHEET (RULE 26)

158

Step 2: Preparation of 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone [2-[(1,1-dimethylethyl)dimethylsilyl]oxyethyl]hydrazone




5

1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone [2-[(1,1-dimethylethyl)dimethylsilyl]oxyethyl]hydrazone

To a solution of the 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone (2-hydroxyethyl)hydrazone prepared in step 1 (2.73 g, 0.01 mol) and (1,1-dimethylethyl)dimethylsilyl chloride (1.5 g, 0.01 mol) in 25 mL of DMF was added imidazole portionwise. The reaction mixture was stirred at room temperature overnight. Water was added and extracted with ethyl acetate, the organic layer was washed with water, washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated to give 3.8 g of crude product, 1-(4-fluorophenyl)-2-(4-pyridinyl)ethanone [2-[(1,1-dimethylethyl)dimethylsilyl]oxyethyl]hydrazone, as a yellow oil that was used in the next step without further purification.

SUBSTITUTE SHEET (RULE 26)

Step 3: 5-cyclopropyl-1-[2-[[[1,1-dimethylethyl]dimethylsilyloxy]ethyl]-3,4-diphenyl-1H-pyrazole




5-cyclopropyl-1-[2-[[[1,1-dimethylethyl]dimethylsilyloxy]ethyl]-3,4-diphenyl-1H-pyrazole

To a solution of sodium hexamethyldisilazide (4.2 mL, 1.0 M in THF) at 0 °C was added a solution of the compound prepared in step 2 (0.78 g, 0.002 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of methyl cyclopropanecarboxylate (0.27 g, 0.0026 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 3 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 0.30 g of product, 5-cyclopropyl-1-[2-[[[1,1-dimethylethyl]dimethylsilyloxy]ethyl]-3,4-diphenyl-1H-pyrazole, as a light yellow oil (35% yield), ¹H NMR (CDCl₃): δ 8.53 (m, 2H), 7.32 (m, 2H), 7.14 (d, J = 5.6 Hz, 2H), 6.97 (m, 2H), 4.47 (t, J = 4.8 Hz, 2H), 4.14 (t, J = 4.8 Hz, 2H), 1.93 (m, 1H), 0.95 (m, 2H), 0.87 (s, 9H), 0.41 (m, 2H); Anal. Calc'd For C₂₃H₂₃FN₂OSi: C, 68.61; H, 7.37; N, 9.60. Found: C, 68.39; H, 7.81; N, 9.23.

Step 4: Preparation of 5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of the compound prepared in step 3 (0.27 g, 0.00062 mol) in 5 mL of THF was added 5 tetrabutylammonium fluoride (1.9 mL of 1.0 M THF solution) at room temperature. After 1 hour, water was added and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 9:1) to give 0.16 g of product, 5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol, as a pale yellow solid, mp: 155-157 °C; ¹H NMR (CDCl₃): δ 8.53 (br s, 2H), 7.32 (m, 2H), 7.14 (d, J = 5.6 Hz, 2H), 6.97 (m, 2H), 4.42 (t, J = 4.8 Hz, 2H), 4.14 (t, J = 4.8 Hz, 2H), 1.83 (m, 1H), 0.93 (m, 2H), 0.35 (m, 2H); Anal. Calc'd For C₁₉H₁₈FN₃O: C, 70.57; H, 5.61; N, 12.99. Found: C, 70.46; H, 5.87; N, 12.84.

Example A-193



3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of sodium hexamethyldisilazide (7.4 mL, 1.0 M in THF) at 0 °C was added a solution of the

161


compound prepared in step 2 of Example A-192 (1.25 g, 0.0034 mol) in 15 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes.

Then a solution of methyl 4-(2-

methoxy)pyridinecarboxylate (0.059 g, 0.0035 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 3 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was

washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 1:1) to give 0.28 g of product, 3-(4-fluorophenyl)-5-(2-

methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol, as a yellow solid, mp: 168-169 °C; ¹H NMR (CDCl₃): δ 8.42 (m, 2H), 8.20 (dd, J = 0.7, 5.2 Hz, 1H), 7.37 (m, 2H), 7.02 (m, 2H), 6.95 (m, 2H), 6.71 (dd, J = 1.4, 5.2 Hz, 1H), 6.66 (t, J = 0.7 Hz, 1H), 4.20 (m, 2H), 4.14 (m, 2H), 3.95 (s, 3H); Anal. Calcd for C₂₂H₁₈FN₅O₂: C, 67.86; H, 4.91; N, 14.35. Found: C, 67.46; H, 5.08; N, 14.03.




4-[1-[2-[[[(1,1-dimethyl)ethyl]dimethylsilyl]-oxy]ethyl]-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2-methoxypyridine

SUBSTITUTE SHEET (RULE 26)

162

A second compound, 4-[1-[2-[[[(1,1-dimethyl)ethyl]oxy]ethyl]-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2-methoxypyridine also was isolated from the above reaction as a yellow oil by chromatography. ¹H NMR (CDCl₃): δ 8.45 (m, 2H), 8.20 (m, 1H), 7.40 (m, 2H), 7.04 (m, 2H), 6.93 (m, 2H), 6.81 (m, 2H), 4.24 (m, 2H), 4.14 (m, 2H), 3.98 (s, 3H), 0.63 (s, 9H), 0.02 (s, 6H).

Example A-194



4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone


To a solution of 3-(4-fluorophenyl)-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol (0.28 g, 0.0006 mol) in 5 mL of acetic acid was added 3 mL of 48% hydrobromic acid. The reaction mixture was heated at reflux for 3 hours. The cooled mixture was then treated with water, basified with ammonium hydroxide and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (MeOH/CH₂Cl₂/NH₄OH, 5:94:1) to give 0.07 g of product, 4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-

SUBSTITUTE SHEET (RULE 26)

163

pyridinone, as a yellow solid (32% yield), mp: 250-251 °C; ¹H NMR (DMSO-d₆): δ 11.74 (s, 1H), 8.45 (d, J = 5.0 Hz, 2H), 7.35 (m, 3H), 7.16 (m, 2H), 7.03 (d, J = 5.0 Hz, 2H), 6.37 (s, 1H), 6.05 (d, J = 5.2 Hz, 1H), 5.0 (m, 1H), 4.13 (m, 2H), 3.81 (m, 2H); Anal. Calc'd for C₂₁H₁₇FN₃O₃•0.2 H₂O: C, 66.06; H, 4.65; N, 14.67. Found: C, 66.31; H, 4.49; N, 14.27.

Example A-195



10


1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone

1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone was obtained as a byproduct of the reaction of Example A-194 in the form of a yellow solid (38% yield), mp: 220-221 °C; ¹H NMR (CDCl₃): δ 8.50 (m, 2H), 7.39 (m, 3H), 7.02 (m, 4H), 6.59 (m, 1H), 6.08 (dd, J = 1.4, 5.2 Hz, 1H), 4.52 (t, J = 6.0 Hz, 2H), 4.43 (t, J = 6.0 Hz, 2H), 2.04 (s, 3H); Anal. Calc'd for C₂₃H₁₉FN₃O₃•0.3 H₂O: C, 65.46; H, 4.63; N, 13.28. Found: C, 65.09; H, 4.64; N, 12.99.

SUBSTITUTESHEET (RULE 28)

164

Example A-196



Ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate

5

To a solution of sodium hexamethyldisilazide (17.0 mL, 1.0 M in THF) at 0 °C was added a solution of the compound prepared in step 1 of Example A-192 (1.37 g, 0.005 mol) in 20 mL of dry THF dropwise. The dark brown

10 solution was stirred at this temperature for 30 minutes. Then a solution of diethyl 1,2-cyclopropanedicarboxylate (1.12 g, 0.006 mol) in 10 mL of dry THF was added. The reaction mixture was allowed to warm up to room

15 temperature and stirred for 2 hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl


20 acetate/hexane, 8:2) to give 0.18 g of product, ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate, as a light yellow oil (35% yield), ¹H NMR (CDCl₃): δ 8.55 (m, 2H), 7.32 (m, 2H), 7.11 (m, 2H), 6.97 (m, 2H), 4.38 (m, 2H), 4.16 (m, 4H), 2.47 (m, 1H), 1.53 (m, 2H), 1.26 (t, J=7.0 Hz, 3H), (m, 2H), 0.90 (m, 2H); Anal. Calc'd for

25 C₂₃H₂₂FN₃O₅•0.25 H₂O: C, 66.07; H, 5.67; N, 10.51. Found: C,

SUBSTITUTESHEET (RULE 28)

165

65.89; H, 5.80; N, 9.95.

Example A-197


5 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid

To a solution of ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate prepared in accordance with Example A-196 (0.21 g, 0.00045 mol) in 10 mL of methanol was added a solution of sodium hydroxide (0.09 g, 0.0022 mol) in 2 mL of water. The reaction mixture was stirred at reflux for 6 hours. After the solvent was removed, the residue was dissolved with 10 mL of 1N HCl and stirred for 30 minutes. The pH was then adjusted to 5-6 by addition of 1N sodium hydroxide solution and then extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium and filtered. The filtrate was concentrated and the crude was purified by recrystallization from ethanol and ether to give 0.1 g of product, 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid, as a white solid (60% yield), mp: 253-255 °C; ¹H NMR (CD₃OD): δ 8.46 (m, 2H), 7.32 (m, 2H), 7.25 (m, 2H), 7.04 (m, 2H), 4.39 (t, J = 5.0 Hz, 2H), 4.03 (m, 2H), 2.60 (m, 1H), 1.51 (m, 2H), 0.97 (m, 2H); Anal. Calcd for

SUBSTITUTESHEET (RULE 26)


166

C₂₆H₁₈FN₃O₃; C, 65.39; H, 4.94; N, 11.44. Found: C, 64.92; H, 4.77; N, 11.20.

Example A-198

3-[4-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethyl]ethoxymethyl 1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrole-3-carboxylate

Step 1: Preparation of methyl 1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrole-3-carboxylate




methyl 1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrole-3-carboxylate
To a suspension of sodium hydride (1.0 g, 0.025 mol) in 50 mL of DMF was added methyl 4-imidazolecarboxylate (2.95 g, 0.023 mol) portionwise at room temperature. The mixture was stirred at room temperature for 0.5 hours. Then SEM-Cl (4.17 g, 0.025 mol) was added dropwise over 5 minutes. The reaction mixture was stirred for 4 hours and quenched by adding water. The aqueous phase was extracted with ethyl acetate and the organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude

SUBSTITUTESHEET (RULE 26)

was purified by chromatography on silica gel (ethyl acetate/hexane, 8:2) to give 4.0 g of the major regioisomer as a clear oil.

- 5 Step 2: Preparation of 4-[1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-(4-fluorophenyl)-5-[1-[[2-trimethylsilyl]ethoxy]methyl]-1H-imidazol-4-yl]-1H-pyrazol-4-yl]pyridine



- 10 4-[1-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-(4-fluorophenyl)-5-[1-[[2-trimethylsilyl]ethoxy]methyl]-1H-imidazol-4-yl]-1H-pyrazol-4-yl]pyridine

To a solution of sodium hexamethyldisilazide (4.5 mL, 1.0 M in THF) at 0 °C under Ar was added a solution of the compound prepared in step 2 of Example A-192 (0.8 g, 0.002 mol) in 10 mL of dry THF dropwise. The dark brown solution was stirred at this temperature for 30 minutes. Then a solution of the compound prepared in step 1 of the present Example (0.54 g, 0.0021 mol) in 5 mL of dry THF was added. The reaction mixture was allowed to warm up to room temperature and stirred for 1 hour. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was

washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate/hexane, 8:2) to give 0.98 g of product as a light yellow oil which

- 5 solidified upon standing (91% yield), mp: 79-80 °C; ¹H NMR (CDCl₃): δ 8.48 (d, J = 6.0 Hz, 2H), 7.68 (d, J = 1.3 Hz, 1H), 7.38 (d, J = 6.0 Hz, 2H), 7.10 (m, 2H), 7.00 (m, 2H), 6.93 (d, J = 1.3 Hz, 1H), 5.25 (s, 2H), 4.53 (t, J = 6.0 Hz, 2H), 4.12 (t, J = 6.0 Hz, 2H), 3.84 (t, J = 8.0 Hz, 2H), 0.92 (t, J = 8.0 Hz, 2H), 0.84 (s, 9H), 0.021 (s, 18H); Anal. Calc'd For C₃₁H₄₄FN₅O₃Si₃: C, 62.70; H, 7.47; N, 11.79. Found: C, 62.98; H, 7.74; N, 11.88.

- 15 Step 3: Preparation of 3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

To a solution of the compound prepared in step 2 of the present Example (0.54 g, 0.001 mol) in 10 mL of THF was added a solution of tetrabutylammonium fluoride (1.0 M in THF). After the mixture was heated at reflux for 3 hours, the solvent was removed and the residue was

partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the

crude product was purified on silica gel (methylene chloride/methanol, 95:5) to give 0.22 g of the product, 3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol, as a white solid (63% yield), mp:


227-228 °C; ¹H NMR (DMSO-d₆): δ 8.45 (m, 2H), 7.83 (s, 1H), 7.35 (m, 2H), 7.15 (m, 4H), 7.09 (s, 1H), 5.20 (br s, 1H), 4.32 (s, 2H), 3.81 (m, 2H); Anal. Calc'd For C₂₁H₁₈FN₅O: C, 65.32; H, 4.62; N, 20.05. Found: C, 64.98; H, 4.55; N, 19.79.

The compound of Example A-199 was synthesized in accordance with the chemistry described above (particularly in Scheme VI) by selection of the

169

corresponding starting reagents:

Example A-199



5 4-[3-(4-chloro-3-methylphenyl)-1H-pyrazol-4-yl]pyridine


Anal. Calc'd for $C_{14}H_{11}N_3Cl$ (269.74): C, 66.79; H, 4.48; N, 15.58. Found: C, 66.57; H, 4.15; N, 15.54. m.p. (DSC): 198.17 °C.

10

The compounds of Examples A-200 through A-202 were synthesized in accordance with the chemistry described above (particularly in Scheme VII) by selection of the corresponding starting reagents:

15

Example A-200



5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid


SUBSTITUTE SHEET (RULE 26)

170

A mixture of 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine prepared as set forth in Example A-4 (5.83 g, 24.0909 mmol) and potassium permanganate (7.6916 g, 48.1818 mmol) in water (7.5 ml) and tert-butanol (10 ml) was heated at reflux for 6 hours (or until all the potassium permanganate was consumed). The mixture was then stirred at room temperature overnight and then diluted with water (150 ml). Manganese dioxide was removed from the mixture by filtration. The filtrate was extracted with ethyl acetate to remove unreacted starting material. The aqueous layer was acidified with 1N HCl to increase the pH to about 6. A white precipitate formed, was collected by filtration, washed with water, and dried in a vacuum oven to give 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid (isolated as the monohydrate salt) (2.9777 g, 43.7 %). Anal. Calc'd for $C_{14}H_{10}FNO_3$ (283 + 18): C, 59.80; H, 4.01; N, 13.95; Found: C, 59.48; H, 3.26; N, 13.65. MS (MH⁺): 284 (base peak).

20

Example A-201



5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol


25

To a suspension of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate prepared in accordance with Example A-200 (0.526 g, 2.0 mmol) in dry THF (15 ml) at reflux under nitrogen, a solution of 1N lithium aluminum hydride in THF (4.0 ml,

SUBSTITUTE SHEET (RULE 26)

- 4.0 mmol) was added dropwise over 15 minutes. A precipitate formed. The mixture was boiled for an additional hour. Excess lithium aluminum hydride was then decomposed by cautiously adding a solution of 4N potassium hydroxide in water (0.5 ml). Upon hydrolysis, a white salt precipitated. After the addition was complete, the mixture was heated at reflux for 15 minutes. The hot solution was filtered by suction through a Buchner funnel, and remaining product was extracted from the precipitate by refluxing with THF (15 ml) for 1 hour, followed again by suction filtration. The combined filtrates were concentrated under reduced pressure. The resulting residue was taken into ethyl acetate, washed with water and brine, dried over MgSO_4 , to give a crude product (0.45 g). Recrystallization of the crude product from methanol gave 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol (0.2808 g, 56.5%). DSC: 260.26 °C; Anal. Calc'd for $\text{C}_{13}\text{H}_{10}\text{N}_4\text{FO}$ (269): C, 66.91; H, 4.49; N, 15.60; Found: C, 66.07; H, 4.63; N, 15.20. MS (MH⁺): 270 (base peak).


Example A-202



- 25 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine

SUBSTITUTE SHEET (RULE 26)

- Step 1: Preparation of 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate



- 5 To a solution of 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid, monohydrate prepared in accordance with Example A-200 (0.9905 g, 3.5 mmol) and 1-hydroxybenzotriazole (0.4824 g, 3.57 mmol) in DMF (20 ml) at 0 °C under nitrogen, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.6984 g, 3.57 mmol, Aldrich Chemical Co.) was added. The solution was stirred at 0 °C under nitrogen for 1 hour then 1-butoxycarbonylpiperazine (0.6585 g, 3.5 mmol) was added followed by N-methylmorpholine (0.40 ml, 3.6 mmol). The reaction was stirred from 0 °C to room temperature overnight. After 19 hours, the solvent was removed under reduced pressure, and resulting residue was diluted with ethyl acetate, washed with saturated NaHCO_3 solution, water and brine, and dried over MgSO_4 . After filtration, the solvent was removed under reduced pressure to give a crude product (1.7595 g). 1,1-Dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate (1.2372 g, 78.4%) was obtained by chromatography. Anal. Calc'd for $\text{C}_{24}\text{H}_{32}\text{N}_6\text{O}_4\text{F}$ (451): C, 63.85; H, 5.80; N, 15.51; Found: C, 63.75; H, 5.71; N, 15.16. MS (MH⁺): 452 (base peak).

SUBSTITUTE SHEET (RULE 26)


173

Step 2. Preparation of 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine bis(trifluoroacetate), monohydrate

- 5 A solution of the compound prepared in step 1 (0.1804 g, 0.4 mmol) in methylene chloride (1.0 ml) and TPA (0.3 ml) was stirred at room temperature under nitrogen for 2 hours. The solvent was removed under reduced pressure and TPA was chased by methylene chloride and methanol. The resulting colorless oily residue was dried in a vacuum oven overnight to give 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine (isolated as the
- 10 bis(trifluoroacetate), monohydrate salt) (0.2400g, 100%) as a white solid. Anal. Calc'd for $C_{21}H_{18}N_6O_2 \cdot 2CF_3COOH \cdot H_2O$ (351 + 228 + 18): C, 46.24; H, 3.71; N, 11.72; Found: C, 45.87; H, 3.43; N, 11.45. MS (MH⁺): 352 (base peak).

- 20 The compounds of Examples A-203 through A-206 were synthesized in accordance with the chemistry described above (particularly in Scheme VIII) by selection of the corresponding starting reagents:


Example A-203



4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine

SUBSTITUTE SHEET (RULE 26)

174




4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)pyridine


- 5 A 60% dispersion of sodium hydride (41 mg, 0.00172 moles) (prewashed with hexane) in mineral oil (69 mg) was added with 5 ml of dioxane to a stirred solution of 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine (200 mg, 0.00086 moles) (prepared as set forth in Example A-2) in 50 ml of dioxane. After 3 hours a solution of CH_3I (122 mg, 0.00086 mole) in 10 ml dioxane was added and the mixture was stirred at room temperature for 20 hours. The mixture was concentrated to a solid. The products were partitioned between water (15 ml) and ethyl acetate (50 ml). The organic layer was dried over Na_2SO_4 , filtered and concentrated to a solid. The products were purified and separated by radial chromatography. NMR (NOE experiments) showed that the first component off the column (the minor component) was 4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)pyridine, and the second material off the column was 4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine.
- 20 Major isomer (4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine): m.p.: 94-99 °C. Anal. calc'd for $C_{18}H_{18}N_4 \cdot 0.1H_2O$: C, 77.08; H, 6.06; N, 16.85. Found: C, 76.59; H, 5.70; N, 16.62

SUBSTITUTE SHEET (RULE 26)

175

Example A-204

4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine



5

4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine (the compound of Example A-32)

- 10 4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine and 4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine were prepared by the same procedure as described for Example A-203 by replacing 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine with 4-(3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl)pyridine (prepared as set forth in Example A-7).


- Major Isomer 4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine: Anal. calc'd for $C_{16}H_{14}N_4Cl$ (283.76): C, 67.72; H, 4.97; N, 14.81; Found: C, 67.45; H, 4.71; N, 14.63. m.p. (DSC): 190.67 °C.

SUBSTITUTE SHEET (RULE 26)


176

Minor Isomer 4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine: m.p.: 82-88 °C. Anal. calc'd for $C_{16}H_{14}N_4Cl$: C, 67.72; H, 4.97; N, 14.81; Found: C, 67.56; H, 4.96; N, 14.73.

5

Example A-205

4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine



10

4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine

- 4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine and 4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine were prepared by the same procedure as described for Example A-203 by replacing 4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine with 4-(3-(4-methylphenyl)-5-ethyl-1H-pyrazol-4-yl)pyridine (prepared


SUBSTITUTE SHEET (RULE 26)

177


as set forth in Example A-45).

Major Isomer (4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine): Anal. Calc'd for $C_{18}H_{18}N_4O$: C, 75.73; H, 7.03; N, 14.77. Found: C, 76.03; H, 6.87; N, 14.28.

Minor Isomer (4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine): Anal. Calc'd for $C_{18}H_{18}N_4O \cdot 0.30H_2O$: C, 76.46; H, 6.99; N, 14.86. Found: C, 76.58; H, 6.98; N, 14.63.

Example A-206


4-[3-(4-chlorophenyl)-1-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{18}H_{16}N_4Cl$ (297.79): C, 68.57; H, 5.42; N, 14.11. Found: C, 68.33; H, 5.27; N, 14.08; m.p. (DSC) 164.36 °C.

Example A-207**SUBSTITUTE SHEET (RULE 26)**

178

4-[3-(4-chlorophenyl)-2-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine: Anal. Calc'd for $C_{19}H_{18}N_4Cl$ (297.79): C, 68.57; H, 5.42; N, 14.11. Found: C, 68.25; H, 5.36; N, 13.74; m.p. (DSC) 153.46 °C.

The compounds of Examples A-208 and A-209 were prepared in accordance with the chemistry described above (particularly in Scheme IX):

Example A-208

4-[3-(4-fluorophenyl)-1-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine

Step 1: Preparation of 4-fluorobenzoyl-4'-pyridyl methane

To a mixture of 4-picoline (32.6 g, 0.35 moles) and ethyl-4-fluorobenzoate (50.45g, 0.3 moles), maintained at 20 °C, was added lithium bis(trimethylsilyl)amide (600 mL (1M)) in a steady but rapid stream so as to maintain ambient temperature. The initial yellow solution turned into a suspension which was then stirred for an additional 2 hours. Toluene (250 mL) was added and the mixture cooled to 0 °C. The reaction mixture was quenched with concentrated HCl at 0 °C to lower the pH to about 7. The organic layer was separated and the aqueous layer re-extracted with of toluene (100 mL). The organic layer was dried (sodium sulfate) and concentrated, to furnish a yellow solid which on trituration with hexanes (200 mL) provided the pure desoxybenzoil, 4-

SUBSTITUTE SHEET (RULE 26)

179

fluorobenzoyl-4'-pyridyl methane, in 90% yield (58g). ¹H NMR was consistent with the proposed structure.

Step 2:

To a suspension of the desoxybenzoin prepared in step 1 (30g, 0.14 moles) in tetrahydrofuran (50 mL) was added dimethylformamide dimethyl acetal (50 mL) and the mixture stirred at ambient temperature for two days. The solution was then concentrated to dryness and the solid paste obtained was triturated with hexanes (150 mL) to furnish a yellow solid which was of sufficient purity (as determined by NMR) and was used for the next step without additional purification. Yield: 33.9 g (90%). ¹H NMR was consistent with the proposed structure.

15


Step 3:

The vinyl amine prepared in step 2 (33.9g, 0.1255 moles) was dissolved in 125 mL of ethanol and cooled to 0 °C. Hydrazine hydrate (8.0g of anhydrous or 16.0g. of hydrate, 0.25 moles) was then added in one portion. The mixture was stirred well and allowed to warm up to ambient temperature for a total reaction time of 3 hours. The mixture was concentrated and taken up in 200 mL of chloroform. After washing with water (100 mL), the organic layer was extracted with 150 mL of 10% HCl. The water layer was then treated with 0.5 g of activated charcoal at 70 °C for 10 minutes, filtered through celite and neutralized cautiously to pH 7 - 8 with vigorous stirring and cooling (20% sodium hydroxide was used). The fine off-white precipitate was filtered and dried to give 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine. Yield: 27.3g. (91%). Mass spectrum: m/z = 240. ¹H NMR was consistent with the proposed structure. Anal. calc'd for C₁₄H₁₀FN: C, 70.28; H, 4.21; N, 17.56. Found: C, 70.11; H, 4.33; N, 17.61.

35

180

Example A-209




4-[3-(2-chlorophenyl)-1H-pyrazol-4-yl]pyridine

This compound was prepared by the same procedure described for Example A-208 using the corresponding starting reagents.

Anal. Calc'd for C₁₄H₁₀ClN₃: C, 65.76; H, 3.94; N, 16.43. Found: C, 65.22; H, 3.91; N, 16.50. m.p. (DSC): 208.46 °C.

The compounds of Examples A-210 and A-211 illustrate were prepared in accordance with the chemistry described above (particularly in Scheme X):

Example A-210



3-(4-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol


181

The desoxybenzoin prepared in step 1 of Example A-208, 4-fluorobenzoyl-4'-pyridyl methane, (12.7g, 0.059 moles) was mixed with 90% hydroxyethyl hydrazine (5.3g, 0.062 moles) in 30 mL of ethanol containing 0.5 mL of acetic acid in a 500 mL Erlenmeyer flask. After gentle boiling (1 hour), a small sample was evacuated at high vacuum and examined by ¹H NMR to confirm completion of hydrazone formation. On cooling to ambient temperature, the reaction mass solidified to a yellow cake. DMF dimethylacetel (36 mL, 0.27 moles) was then added and the mixture heated to 80°C for 10 min, at which point all the solids dissolved and a clear yellow viscous solution was obtained. The reaction mixture was immediately allowed to cool slowly to 25 °C, and water (20 mL) was added dropwise with stirring, at which point a cloudy yellow oily suspension was obtained. The solution was now warmed to approximately 50-60 °C, whereupon the solution turned clear yellow. Slow cooling to ambient temperature with stirring (a crystal seed if available speeds up the process) results in a copious formation of crystals. Suction filtration followed by washing with 10% ethanol-water (50 mL), followed by drying, furnishes 3-(4-fluorophenyl)-4-(4-pyridyl)-1H-pyrazole-1-ethanol as a light yellow crystalline solid. Re-heating the filtrate to clarity as before, followed by cooling, yields additional product. The third and fourth recovery from the mother liquor on standing overnight furnishes the remaining 3-(4-fluorophenyl)-4-(4-pyridyl)-1H-pyrazole-1-ethanol. Total yield: (12.3 + 3.3 + 0.4 + 0.4) = 16.4g. (97.6%). Mass spectrum, m/z = 284. ¹H NMR was consistent with the proposed structure. Anal. calc'd for C₁₄H₁₄FN₃O + H₂O: C, 63.78; H, 5.35; N, 13.95. Found: C, 63.55; H, 5.07; N, 13.69.

SUBSTITUTE SHEET (RULE 26)

182


Example A-211



This compound was prepared by the same procedure as described for Example A-210 except that the 4-picoline used to synthesize the desoxybenzoin was replaced with 4-methyl-pyrimidine.

The compound of Example A-212 was prepared in accordance with the chemistry of Scheme XI:

Example A-212



4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine


The vinyl amine prepared in Step 2 of Example A-208 (5.0g, 0.0185 moles) was taken up in ethanol (75mL) and cooled to 0 °C. Methyl hydrazine (1.7g, 0.037 moles) in ethanol (75mL) was added in one portion while maintaining the temperature at 0 to 10 °C. After 3 hours at ambient temperature the solvent was removed and the residue taken up in methylene chloride (150 mL) and water (100 mL). The organic layer was separated, dried and concentrated to provide the crude regio-isomeric mixture as a light tan colored solid (80:20 by NMR in favor of the title compound). The crude isomeric mixture was taken up in 10% HCl (100 mL) and washed with methylene chloride (100

SUBSTITUTE SHEET (RULE 26)

mL) and the water layer treated with activated charcoal (0.5g). After filtration through Celite, the solution was neutralized with sodium hydroxide (20%) to pH 8 with good stirring and cooling. The cream colored precipitate was filtered, washed with water and dried. The solid (5 g) was dissolved in hot 10% heptane/toluene (70 mL) and allowed to cool slowly, first to ambient temperature and then to 15 °C. Scratching the sides of the flask starts the crystallization process. After 2 hours of standing, the solids formed were filtered, washed with cold 50% toluene/heptane (25 mL) followed by hexane (25 mL) and dried to yield the pure title compound. ¹H NMR confirmed the structure (including regiochemistry using NOE experiments). Yield: 2.1g. (45%). Mass spectrum, m/z = 254 (base peak). Anal. calc'd for C₁₅H₁₄FN, + 0.2 H₂O: C, 70.15; H, 4.86; N, 16.4. Found: C, 70.18; H, 4.6; N, 16.47.

The compound of Example A-213 was prepared in accordance with the chemistry of Scheme XII:

Example A-213




2-[(4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl)amino]-1-butanol

SUBSTITUTE SHEET (RULE 26)

An intimate mixture of 2-fluoro-pyridinyl pyrazole (0.2g, (prepared by the same procedure as described for Example A-210 except that the 4-picoline used to synthesize the desoxybenzoin was replaced with 2-fluoro-4-methylpyridine) and (R,S)-2-amino-1-butanol (4 fold molar excess) was heated to 210-220 °C in a sealed vial for 1.5 hours. After cooling to 100 °C the vial was cautiously opened and 5 mL of toluene and 5 mL of water were added and stirred well for 1 hour. The solid obtained, 2-[(4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl)amino]-1-butanol, was suction-filtered and washed with an additional 5 mL of water followed by toluene and dried. Yield: 190mg. (71%). Mass spectrum, m/z = 343. ¹H NMR was consistent with the proposed structure.

The compound of Example A-214 was prepared in accordance with the chemistry of Scheme XIII:

Example A-214



4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

To a solution of 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (2.7 g, 10.67 mmol) (prepared in accordance with Example A-212) in acetic acid (30 mL) and DMF (13 mL) was added bromine (19.5 g, 122.0 mmol). The solution was heated at 80 °C overnight. TLC indicated


SUBSTITUTE SHEET (RULE 26)

185

that the reaction was complete. The mixture was quenched slowly with K_2CO_3 (25g). When pH was about 5, a precipitate was formed. The precipitate was washed with water (50 mL x 5) to give 4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (1.24g, 35%); mp 174.38°C; Mass spectrum m/z = 332, 334; 1H NMR was consistent with the proposed structure. Anal. Calc'd for $C_{14}H_{11}N_5Br \cdot 0.2 H_2O$: C, 53.66; H, 3.42; N, 12.51. Found: C, 53.58; H, 3.12; N, 12.43.

10

The compound of Example A-215 was prepared in accordance with the chemistry of Scheme XIV:

Example A-215

15

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile

Step 1:

To a solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine (4.3g, 17.97 mmol) (prepared in accordance with Example A-208) in methanol (100 mL) was added 3-chloroperoxybenzoic acid (5.44 g in 57 & purily, 17.97 mmol). The solution was stirred at 25 °C for overnight. The mixture was concentrated. K_2CO_3 (10%, 100 mL) was added to the residue. A precipitate was formed, filtered and washed with water (30 mL x 3) to give the

25

SUBSTITUTE SHEET (RULE 26)

186

corresponding N-oxide (3.764g, 81.66%).


Step 2:

To a suspension of the N-oxide prepared in step 1 (0.40 g, 1.567 mmol) in DMF (5 mL) was added trimethylsilyl cyanide (0.3 mL, 2.25 mmol). The mixture was stirred for 15 minutes at 25 °C. Dimethylcarbamyl chloride (0.8 mL, 8.69 mmol) was added. The mixture was stirred at 25 °C for 2 hours. TLC indicated that the starting materials were gone. The mixture was partitioned into ethyl acetate:water (100 mL:20 mL). The organic layer was washed with K_2CO_3 (10%, 20 mL), water (50 mL), brine (50 mL), dried over $MgSO_4$, filtered and concentrated to give 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile (0.23 g, 56 % yield): mp 209.22 °C; Mass spectrum (chemical ionization): m/z = 265; 1H NMR was consistent with the proposed structure. Anal. Calc'd for $C_{14}H_{11}N_5 \cdot 0.2 H_2O$: C, 67.26; H, 3.54; N, 20.92. Found: C, 67.44; H, 3.40; N, 20.69.

15

20

The compound of Example A-216 was prepared in accordance with the chemistry of Scheme XV:

Example A-216

25

4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine

SUBSTITUTE SHEET (RULE 26)


Step 1:

3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol (prepared in accordance with Example A-210) (10.0 g, 0.0353 moles) was suspended in pyridine (100 mL) and cooled to 0 °C. Methane sulfonyl chloride (4.4 g, 0.0388 moles) was added slowly while maintaining the temperature at 0 °C. After stirring overnight at 10 °C, chilled water (100 mL) and methylene chloride (150 mL) was added and the two layers separated. The water layer was re-extracted with 100 mL of methylene chloride and the organic layer dried and concentrated to a paste. After drying at high vacuum, a light tan colored cake was obtained which was triturated with ether (75 mL), filtered and dried to furnish a cream colored solid in 79% yield (10.1g). ¹H NMR was consistent with the proposed structure. The compound was used as such for step 2.

Step 2:

The mesylate prepared in step 1 (5.0 g, 0.0138 moles) was dissolved in an eight fold excess of morpholine (9.6 g, 0.11 moles) in methanol (50 mL) and heated at reflux for 3 to 4 hours. After an NMR sample confirmed completion, the mixture was concentrated and taken up in methylene chloride (150 mL) and washed with water (100 mL) and then with 75 mL of 5% HCl. The water layer was neutralized to pH 8 and extracted with methylene chloride (100 mL). On drying and concentration a light yellow pasty solid was obtained which was triturated with 25 mL of ether to furnish a solid. Recrystallization from toluene/hexane provided 4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine as a solid. Yield: 4.5g (86%). Mass spectrum, m/z = 353. ¹H NMR was consistent with the proposed structure. Anal. calc'd for C₁₈H₁₇FN₃O: C, 68.16; H, 6.01; N, 15.90. Found: C, 68.20; H, 6.21; N, 15.80.

The compound of Example A-217 was prepared in accordance with the chemistry of Scheme XVI:

Example A-217

3-(4-fluorophenyl)-1-methyl-4-(4-pyridinyl)-1H-pyrazole-5-methanol


To solid magnesium (60 mg, 5 mmol) under nitrogen

- 10 was added a solution of 4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine (450 mg, 1.35 mmol) (prepared in accordance with Example A-214) in tetrahydrofuran (7 mL). The mixture was heated at 40 °C for 2 hours. Benzaldehyde (1 mL) was added. The mixture was heated to 45 °C for 2 hours. It was quenched with HCl (10 mL, 1N) and washed with ethyl acetate. The aqueous acid layer was basified and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over MgSO₄, filtered and concentrated to give a residue. The residue was purified with a silica gel column to give the title compound (59 mg, 12% yield). MS: m/z = 360 (M+1); ¹H NMR was consistent with the proposed structure. Anal. Calc'd for C₂₁H₁₆N₄O: C, 71.1; H, 5.6; N, 10.2; Found: C, 70.9; H, 5.47; N, 10.2.
- 20

189

The compound of Example A-218 was prepared in accordance with the chemistry described above (particularly Scheme XVII):

5 **Example A-218**



N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholineethanamine

10 The starting desoxybenzoic prepared in step 1 of Example A-208, 4-fluorobenzoyl-4'-pyridyl methane, (1.0 g, 0.0046 moles) was dissolved in 10 mL of DMF and cooled to -10 °C (dry ice-aqueous isopropanol). N-chlorosuccinimide (0.62 g, 0.0046 moles) was added in one portion while maintaining the temperature at -10 °C.

15 After 5 minutes the thiosemicarbazide (0.0046 moles) was added in one portion at 0 °C and allowed to warm to ambient temperature slowly over 1 hour. After stirring overnight, the solvent was removed at high vacuum and water and toluene (25 mL each) added and stirred well.

20 The toluene layer was separated and the water layer (starting pH of 5.5) treated with bicarbonate to pH 8. The fine precipitate formed was filtered and washed with water, toluene and ether. A final trituration with ether (25 mL) furnished an off white solid, N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholineethanamine, which was re-filtered and dried.


SUBSTITUTE SHEET (RULE 26)

190

Yield: 0.95g. (56%). Mass Spec. m/z: 368 (base peak). Anal. Calc'd for $C_{24}H_{22}FN_5O$. C, 65.38; H, 6.04; N, 19.06. Found: C, 64.90; H, 5.92; N, 18.67.


5

Example A-219



4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2-(1H)-pyridinone hydrazone

10 **Step 1: Preparation of (E)-2-(2-bromo-4-pyridinyl)-N,N-dimethylethanamine**



4-Methyl-2-bromopyridine (1.0 g, 5.8 mmol) and t-butoxybis(dimethylamino)methane (5 mL) were heated to 150 °C for 16 hours. 4-Methyl-2-bromopyridine was prepared as set forth in B. Adger et al., *J. Chem. Soc., Perkin Trans. 1*, pp. 2791-2796 (1988), which is incorporated herein by reference. The contents were evaporated and the residue dissolved in ethyl acetate and washed with water. The organic layer was dried over magnesium sulfate and solvent removed in vacuo to give 1.0 g of (E)-2-(2-bromo-4-pyridinyl)-N,N-dimethylethanamine as an


15

20

SUBSTITUTE SHEET (RULE 26)

oil suitable for use in step 2.

Step 2: Preparation of (Z)-2-(2-bromo-4-pyridinyl)-1-(3-chlorophenyl)-3-(dimethylamino)-2-propen-1-one



5

The product from step 1 (1.0 g, 4.4 mmol) was dissolved in methylene chloride (15 ml). Triethylamine (900 mg, 8.8 mmol) was added at 0 °C, followed by the addition of 3-chlorobenzoyl chloride (350 mg, 4.5 mmol). The mixture was stirred under nitrogen for 16 hours.


10

Solvent was evaporated in vacuo and the residue was dissolved in ether (25 ml), stirred with magnesium sulfate (500 mg) and silica gel (500mg), and filtered. Ether was evaporated and the residue was chromatographed on silica gel using mixtures of acetone and methylene chloride as eluents to give 670 mg of the product, (Z)-2-(2-bromo-4-pyridinyl)-1-(3-chlorophenyl)-3-(dimethylamino)-2-propen-1-one, as a glass which was used in step 3 without further purification.

15

20

Step 3: Preparation of 2-bromo-4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine



SUBSTITUTESHEET (RULE 26)


A solution of the product from step 2 (650 mg, 1.8 mmol) and hydrazine monohydrate (100 mg) in ethanol (10 ml) was refluxed for 24 hours. Solvent was evaporated and the residue was chromatographed on silica gel using mixtures of ethyl acetate and toluene as eluents to give 2-bromo-4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine (190 mg, 31%) as an oil. Anal. Calc'd for $C_{14}H_{10}BrClN_3$: C, 50.25; H, 2.71; N, 12.56. Found: C, 50.10; H, 2.60; N, 12.40.

10

Continued elution with mixtures of ethyl acetate and methanol gave 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyridinone hydrazone (190 mg, 36%) as a crystalline solid; m.p. 163-164 °C.; MS (M+H) = 286. Anal. Calc'd for $C_{14}H_{10}N_4Cl$: C, 59.85; H, 4.23; N, 24.51. Found: C, 58.53; H, 4.28; N, 24.87.

15

Example A-220



20 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (150 mg, 0.5 mmol) in benzylamine (5 ml) was heated at 175 °C for six hours. After cooling, excess benzylamine was removed by high vacuum distillation and ethyl acetate added to the residue. After washing the organic phase with water and drying over magnesium sulfate, the solvent was removed in vacuo


25

SUBSTITUTESHEET (RULE 26)

193

and the residue chromatographed on silica gel using mixtures of ethyl acetate and toluene to give 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine (110 mg, 61%) as a solid, m.p. 179-180 °C.

Anal. Calc'd For $C_{21}H_{19}ClN_4$: C, 69.90; H, 4.75; N, 15.53. Found: C, 69.69; H, 4.81; N, 15.11.

Example A-221


4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (250 mg, 0.75 mmol) in phenethylamine (5 ml) was heated at 175 °C for six hours under a nitrogen atmosphere. The excess amine was distilled off under high vacuum and the residue was dissolved in ethyl acetate and washed with water. After drying over magnesium sulfate and removal of solvent, the residue was chromatographed on silica gel with mixtures of ethyl acetate and toluene to give 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylethyl)-2-pyridinamine (230 mg, 81%) as a solid, m.p. 185-186 °C.

Anal. Calc'd For $C_{22}H_{21}ClN_4$: C, 70.49; H, 5.11; N, 14.95. Found: C, 70.29; H, 5.15; N, 14.66.

SUBSTITUTESHEET (RULE28)

194

Example A-222


4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine

A solution of the bromopyridine compound prepared in step 3 of Example A-219 (300 mg, 0.9 mmol) in ethylamine (3.5 ml) and ethanol (5 ml) as heated at 150 °C in a sealed tube for 9 hours. The solvent was removed in vacuo and the residue chromatographed on silica gel with ethyl acetate/toluene to give 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl-2-pyridinamine (125 mg, 46%) as a solid, m.p. 186-187 °C.

Anal. Calc'd For $C_{18}H_{17}ClN_4$: C, 64.32; H, 7.06; N, 18.75. Found: C, 64.42; H, 7.01; N, 18.45.

The compounds of Examples A-223 through A-226 were synthesized in accordance with the chemistry described above (particularly in Scheme XVII) by selection of the corresponding starting reagents:

SUBSTITUTESHEET (RULE28)

Example A-223

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-
pyridinecarboxamide

5

Step 1:

To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine (prepared as set forth in Example A-208) (8.8 g, 0.037 mol) in methylene chloride was added m-chloroperoxybenzoic acid (mCPBA) in one portion at room temperature. After stirring for 16 hours, solvent was removed and the residue was treated with saturated sodium bicarbonate solution. The precipitate was filtered, air-dried to give 8.2 g of a product as a white solid (87%), mp: 207-209°C.

10

15

Step 2: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxitrile

To a solution of the product of step 1 (5.1 g, 0.02 mol) in 20 mL of DMF was added trimethylsilyl cyanide (2.5 g, 0.025 mol), followed by a solution of N, N-dimethylcarbamoyl chloride (2.7 g, 0.025 mol) in 5 mL of DMF at room temperature. After stirring overnight, the

20

reaction mixture was basified by 200 mL of 10% potassium carbonate water solution. The aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was triturated with hexane and filtered to give 4.3 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxitrile (90%) as a pale yellow solid, mp: 238-239°C.

5


10

Step 3: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide:

To a solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxitrile from step 2 (0.45 g, 0.0017 mol) in 10 mL of DMSO was added hydrogen peroxide (0.24 mL of 30% aqueous solution, 1.7 mmol) and potassium carbonate (0.04 g, 0.4 mmol) at 0°C. The mixture was stirred for 1 hour while allowing it to warm to room temperature. Water was added and the precipitate was collected by filtration and air-dried to give 0.32 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide as a white solid (67% yield), mp: 230-231 °C. Anal. Calc'd for $C_{15}H_{11}FN_3O$: C, 63.83; H, 3.93; N, 19.85. Found C, 63.42; H, 3.66; N, 19.58.

20

25


Example A-224

197

Methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate

To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxamide prepared as set forth in Example A-223 (2.9 g, 0.01 mol) in 50 mL of methanol was added N,N-dimethylformamide dimethyl acetal (3.67 g, 0.03 mol) dropwise. The reaction mixture was stirred at room temperature overnight and heated at reflux for 4 hours.

After cooling, the precipitate was collected by filtration and air-dried to give 2.0 g of methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate as a white solid (69% yield), mp: 239-241°C. Anal. Calc'd for $C_{14}H_{12}FN_3O_2$: C, 64.64; H, 4.07; N, 14.13. Found: C, 64.36; H, 4.10; N, 14.27.

Example A-225


4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide

A mixture of methyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate prepared as set forth in Example A-224 (0.45 g, 1.5 mmol) and 20 mL of methylamine (40% aqueous solution) was heated at 120°C in a sealed tube for 16 hours. After cooling, water was

SUBSTITUTE SHEET (RULE 26)

198

added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated to afford 0.4 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyridinecarboxamide as a white solid, mp: 88-89°C. Anal. Calc'd for $C_{14}H_{12}FN_3O$ + 0.4 H_2O : C, 63.32; H, 4.58; N, 18.46. Found C, 63.10; H, 4.62; N, 18.35.

Example A-226

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic acid

To a solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylate prepared as set forth in Example A-224 (0.90 g, 0.003 mol) in 10 mL of ethanol was added a solution of sodium hydroxide (0.24 g, 0.006 mol) in 5 mL of water. The reaction mixture was heated at reflux for 10 hours. After the removal of solvent, the residue was dissolved in water and acidified with citric acid solution to pH 5. Then the aqueous phase was extracted with ethyl acetate and the organic phase was dried over magnesium sulfate and concentrated. The crude was purified by treating with ether to give 0.62 g of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarboxylic

SUBSTITUTE SHEET (RULE 26)

acid as a white solid (73% yield), mp: 245°C(dec). Anal
Calc'd for $C_{15}H_{10}FN_3O + 0.2 H_2O$: C, 62.80; H, 3.65; N,
14.65. Found: C, 62.77; H, 3.42; N, 14.58.

- 5 Additional compounds of the present invention which
were prepared according to one or more of above reaction
schemes (particularly Schemes IX through XVII) are
disclosed in Table 3. The specific synthesis scheme or
schemes as well as the mass spectroscopy and elemental
analysis results for each compound also are disclosed in
Table 3.

Microanalyses										MS		General		Procedure		M+1		C calc		C found		H calc		H found		N calc		N found		water added		RtOAc added	
A-227	IX	240	69	69	4.3	4.6	17.2	16.8	0.25																								
A-228	IX	266	65.69	65.69	4.41	4.33	15.32	14.98																									
A-229	XI	254	70.6	70.6	4.8	4.5	16.5	16.3	0.1																								
A-230	IX	256	65.76	65.48	3.94	3.78	16.43	16.52																									
A-231	XI	280	64.18	63.95	4.39	4.31	13.86	13.90																									
A-232	XI	271	66.79	66.79	4.48	4.24	15.58	15.32																									
A-233	XI	284	66.9	66.8	5	5	14.6	14.9	0.2																								
A-234	XI	270	65.9	65.6	4.6	4.6	15.4	15.7	0.1																								
A-235	XI	264	77	76.7	6.5	6.5	15.8	15.7	0.1																								
A-236	IX	221	75.38	75.44	5.06	5.1	18.84	19	0.1																								
A-237	IX	290	61.52	61.67	3.58	3.51	14.35	14.32																									
A-238	XI	304	63.36	63.28	3.99	3.91	13.85	13.83																									
A-239	IX	258	65.37	65.39	3.53	3.52	16.33	16.31																									
A-240	IX	274	61.44	61.14	3.31	3.01	15.35	14.95																									
A-241	IX	300	56.02	55.99	3.36	3.26	14.00	14.01																									
A-242	XI	272	66.42	66.41	4.09	4.04	15.49	15.32																									
A-243	XI	314	57.34	57.22	3.85	3.68	13.37	13.27																									
A-244	IX	342	76.39	76.16	4.81	4.51	12.31	12.05	0.25																								
A-245	XI	341	64.89	64.65	6.36	6.17	15.93	15.82	0.6																								
A-246	XI	391	66.08	66.18	5.04	5.56	14.01	12.26	0.5																								
A-247	XI	362	64.46	64.16	4.65	4.34	18.79	18.65	0.6																								
A-249	XII	258	64.91	64.84	3.58	3.63	16.22	15.98	0.1																								

SUBSTITUTE SHEET (RULE 26)

A-250	IX	348	48.44	48.07	2.9	2.82	12.1	12.01		
A-251	XI	362	49.88	49.89	3.35	3.51	11.63	11.54		
A-252	XI	304	63.36	63.34	3.99	3.96	13.85	13.81		
A-253	XII	377	68.24	68.17	5	4.71	14.47	14.34	0.6	
A-254	XII	363	66.31	66.12	4.77	4.31	14.73	14.6	1	
A-215	XIV	265	67.3	67.4	3.5	3.4	20.9	20.7	0.2	
A-255	XII	298	64.63	64.64	5.42	5.41	23.55	23.32		
A-256	XI	272	66.42	66.58	4.09	4.26	15.49	14.78		
A-257	IX	276	60.11	60.4	3.06	3.18	15.02	14.73	0.25	
A-258	IX	254								
A-259	XI	268	71.89	71.63	5.28	5.24	15.72	15.84		
A-260	X	290	62.28	62.41	3.48	3.48	14.53	14.51		
A-261	X, XV	311	69.26	69.2	6.2	6.25	17.95	17.89	0.1	
A-262	XI	376	72.71	72.5	5.17	4.98	11.06	10.99	0.25	
A-263	XII	428	70.81	70.59	6.28	6.45	15.88	15.08	0.75	
A-264	XII	326	63.79	63.76	6.39	6.09	20.66	20.45	0.75	
A-265	IX	400	66.18	66.77	4.1	4.23	16.78	15.83	1	
A-266	XII	368	62.32	62.38	6.28	6.5	18.17	17.56	1	
A-267	XI	302	62.66	62.85	4.47	4.34	13.7	13.53	0.4	
A-268	XII	349	62.9	63.2	5.2	4.8	22.7	22.5	0.75	0.1
A-269	XI, XV	371	61.85	61.84	5.71	5.24	14.42	14.17	1	
A-270	XI, XV	404	70.66	70.7	4.82	4.61	10.3	10.15	0.25	
A-271	XI, XV	329	65.8	65.3	5.5	5.6	17.1	16.8		
A-272	XI	406	69.95	70.13	5.35	5.28	10.14	9.89	0.5	
A-273	XI	354	66.9	67.2	6.9	6.6	19.1	18.7	0.2	0.1
A-274	XI, XII, XV	434	63.6	63.1	6.3	5.8	14.4	14	2	0.2

WO 98/52940

201

PCT/US98/10436


SUBSTITUTE SHEET (RULE 26)

A-275	XI, XV	433	70.44	70.74	6.18	6.3	12.64	12.05	0.6	
A-276	XI, XII, XV	476	65.9	66.2	6.1	6.1	13.3	13.6	0.5	0.5
A-277	XII	338	61.11	63.02	6.48	6.39	18.75	16.61		
A-278	XI, XV	357	64.2	63.8	6.5	6	15	14.8	1	
A-279	XI, XII, XV	462	67.4	67.1	6.7	6.2	13.6	13.7	0.6	0.5
A-280	XII	299	61.27	61.47	5.37	5.11	17.86	17.21	0.9	
A-281	XII	313	64.63	64.94	5.55	5.63	17.73	17.48	0.2	
A-282	XII	313	64.63	64.81	5.55	5.43	17.73	17.38	0.3	
A-283	XI, XII	407	67.2	67	5	5.2	13.6	13.2	0.25	
A-284	XI, XV	339	70	70.3	6.9	6.9	16.3	16.2	0.25	
A-285	XI, XII, XV	476	68.2	68.5	5.7	6.2	14.7	13.6		
A-286	XVII	382	59.77	59.69	6.81	6.56	16.6	16.65	2.25	
A-287	XVII	340	56.07	56.26	7.31	7.1	17.21	17.27	3.75	
A-288	XVII	293	69.42	69.4	4.52	4.6	19.05	19.09	0.1	
A-289	XI, XII	407	68	67.5	5	4.5	13.8	13.5		
A-290	XI, XII	407	64	64.5	5.3	4.9	13	12.4	1.4	
A-291	IX	290	74.7	74.9	4.2	4.2	14.5	14.5		
A-292	XVII	326	61.22	61.46	4.77	4.53	16.8	16.97	0.4	
A-293	XVII	313	55.75	55.98	4.85	4.02	16.25	16.37	1.8	
A-294	XI	278	73.6	73.2	4.4	4.2	15.2	15		
A-295	XI	278	67.9	67.7	4.9	4.3	14	13.7	1.3	
A-296	IX		70.3	70.4	4.5	4.7	25.2	25.4		
A-297	IX		57.9	57.7	3.1	2.9	14.5	14.5		

WO 98/52940


202

PCT/US98/10436

Example A-227


4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine

5


Example A-228

4-[3-(1,3-benzodioxol-5-yl)-1H-pyrazol-4-yl]pyridine


10

Example A-229


4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

Example A-230

5 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine


Example A-231

4-[3-(1,3-benzodioxol-5-yl)-1-methyl-1H-pyrazol-4-yl]pyridine

Example A-232


205

4 - [3 - (4-chlorophenyl) -1-methyl-1H-pyrazol-4-yl]pyridine

Example A-233

5 4 - [3 - (3-chlorophenyl) -1-methyl-1H-pyrazol-4-yl] -2-methylpyridine and 4 - [5 - (3-chlorophenyl) -1-methyl-1H-pyrazol-4-yl] -2-methylpyridine


10

Example A-234


4 - [3 - (3-chlorophenyl) -1-methyl-1H-pyrazol-4-yl]pyridine and 4 - [5 - (3-chlorophenyl) -1-methyl-1H-pyrazol-4-yl]pyridine

SUBSTITUTE SHEET (RULE 26)


206

Example A-235

5 2-methyl-4 - [1-methyl-3 (or 5) - (3-methylphenyl) -1H-pyrazol-4-yl]pyridine

Example A-236


4 - (3-phenyl-1H-pyrazol-4-yl)pyridine

Example A-237

10 4 - [3 - [3 - (3-(trifluoromethyl)phenyl) -1H-pyrazol-4-yl]pyridine


SUBSTITUTE SHEET (RULE 26)

207

Example A-238


4-[1-methyl-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine

5

Example A-239


4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]pyridine

208


Example A-240

4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine

5

Example A-241

4-[3-(4-bromophenyl)-1H-pyrazol-4-yl]pyridine

Example A-242


10

4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine


SUBSTITUTE SHEET (RULE 26)**SUBSTITUTE SHEET (RULE 26)**

209

ne

Example A-243


5 4-[3-(4-bromophenyl)-1H-pyrazol-4-yl]pyridine

Example A-244

10 (E)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-(2-phenylethynyl)pyridine


SUBSTITUTE SHEET (RULE 26)

210

Example A-245

S


5 (S)-4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-methylbutyl)-2-pyridinamine

Example A-246

4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyridinamine


SUBSTITUTE SHEET (RULE 26)

211

Example A-247

N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-
2-pyridinemethanamine

5


Example A-248

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-
2-pyridinemethanamine

10


Anal Calc'd: C, 41.12; H, 3.58; N, 9.22. Found: C,
41.74; H, 5.05; N, 11.11.

212


Example A-249

2-fluoro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine

5

Example A-250

4-[3-(4-iodophenyl)-1H-pyrazol-4-yl]pyridine

Example A-251


10

4-[3-(4-iodophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

SUBSTITUTE SHEET (RULE 26)


SUBSTITUTE SHEET (RULE 26)

213

Example A-252

4-[1-methyl-3-[(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl]
]pyridine


5

Example A-253

N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine


SUBSTITUTE SHEET (RULE 26)

214

Example A-254

N-[3-(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinamine

5


Example A-255

4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-(1-methylhydrazino)pyridine

SUBSTITUTE SHEET (RULE 26)

215


Example A-256



2-fluoro-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]p
yridine

5

Example A-257




4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]-2-fluoro-
pyridine

SUBSTITUTE SHEET (RULE 26)

216


Example A-258



4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methylpyridine

5


Example A-259



4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-methylp
yridine

10


Example A-260



SUBSTITUTE SHEET (RULE 26)


217

4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-fluoropyridine

Example A-261

5


3-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazole-1-ethanamine

Example A-262

10


2-[2-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine

218

Example A-263

5


4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]-2-pyridinamine

Example A-264


N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl-1,2-ethanediamine

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)


Example A-265

2,4-bis[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine


Example A-266

N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-morpholineethanamine

SUBSTITUTESHEET (RULE 26)

Example A-267


3-(4-(4-fluorophenyl)-1H-pyrazol-4-yl)-2-(2-fluoro-4-pyridinyl)-1H-pyrazole-1-ethanol

Example A-268


4-[3-(4-(4-fluorophenyl)-1H-pyrazol-4-yl)-1-yl]ethyl-2-pyridinamine

SUBSTITUTESHEET (RULE 26)

221

Example A-269


5 4-[2-[3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-1-yl]ethyl]morpholine

Example A-270


10 (E)-3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethenyl]-4-pyridinyl]-1H-pyrazole-1-ethanol

SUBSTITUTE SHEET (RULE 26)

222

Example A-271


5 3-(4-fluorophenyl)-4-[2-(2-fluoro-4-pyridinyl)-N,N-dimethyl-1H-pyrazole-1-ethanamine]

Example A-272

3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-1H-pyrazole-1-ethanol


SUBSTITUTE SHEET (RULE 26)

223

Example A-273

4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyridinamine


5

Example A-274

4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine


10

224

Example A-275

3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-pyridinyl]-N,N-dimethyl-1H-pyrazole-1-ethanamine

5


Example A-276

N-[(4-fluorophenyl)methyl]-4-[3-(or 5)-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine

SUBSTITUTE SHEET (RULE 86)


SUBSTITUTE SHEET (RULE 26)

225

Example A-277

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl-2-pyridinamine


5

Example A-278

N,N-diethyl-3-(4-(2-fluoro-4-pyridinyl)-1H-pyrazol-1-yl)ethanamine

SUBSTITUTESHEET (RULE 26)

226


Example A-279

4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine

SUBSTITUTESHEET (RULE 26)

227


Example A-280



2-[[4-[3-(4-(4-fluorophenyl)-1H-pyrazol-4-yl)]-2-
pyridinyl]amino]ethanol

5

Example A-281




2-[[4-[3-(4-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)]-2-
pyridinyl]amino]ethanol

10

228


Example A-282



3-[[4-[3-(4-(4-fluorophenyl)-1H-pyrazol-4-yl)]-2-
pyridinyl]amino]-1-propanol


5

Example A-283




3 (or 5)-(4-(4-fluorophenyl)-4-[2-[[4-(
4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-
ethanol


229

Example A-284

5 **N,N-diethyl-3-(4-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-ethanamine**

Example A-285


10 **N-[(4-(4-fluorophenyl)methyl)-4-[3-(4-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine**

Example A-286


15 **N-[5-(4-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-morpholinepropanamine**

SUBSTITUTESHEET (FILE 89)


230

Example A-287

5 **N'-[5-(4-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-N,N-dimethyl-1,3-propanediamine**

Example A-288


10 **5-(4-(4-fluorophenyl)-N-2-propyl-4-(4-pyridinyl)-1H-pyrazol-3-amine**

Example A-289**SUBSTITUTESHEET (FILE 88)**

231

3-(4-fluorophenyl)-4-[2-[[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]-1H-pyrazole-1-ethanol


Example A-290



5


232

Example A-292



N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine methyl ester


Example A-293



N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]glycine

10

Example A-294




4-[3-[(4-fluorophenyl)-1H-pyrazol-4-yl]quinoline

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)


233

4 - [3 - (4 - fluorophenyl) - 1 - (2 - propynyl) - 1H - pyrazol - 4 - yl]pyridine

Example A-295


5

4 - [5 - (4 - fluorophenyl) - 1 - (2 - propynyl) - 1H - pyrazol - 4 - yl]pyridine

Example A-296

10

4, 4' - (1H - pyrazol - 3, 4 - diyl) bis [pyridine]


Example A-297

15

SUBSTITUTE SHEET (RULE 26)

234

4 - [3 - (3, 4 - dichlorophenyl) - 1H - pyrazol - 4 - yl]pyridine


Example A-298

N - [5 - (4 - chlorophenyl) - 4 - (4 - pyridinyl) - 1H - pyrazol - 3 - yl] - 4 - piperidine

5

The pyrimidine-substituted compounds of Examples A-299 through A-312 were synthesized in accordance with the chemistry described in Schemes I-XVIII by selection of the corresponding starting reagents:


10

Example A-299

2-Chloro-4 - [3 - (4 - fluorophenyl) - 1H - pyrazol - 4 - yl]pyrimidine


15 Step 1:

SUBSTITUTE SHEET (RULE 26)



- A mixture of 2,6-dichloro-4-methylpyrimidine (5.0 g, 0.031 mol), triethylamine (6.23 g, 0.062 mol) and catalytic amount of 5% Pd/C in 100 mL of THF was hydrogenated on a Parr apparatus under 40 psi at room temperature. After 0.5 hour, the catalyst was filtered and the filtrate was concentrated. The crude was purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 2.36 g of product as a pale yellow crystal (50% yield); mp: 47-49 °C.

Step 2: Preparation of 2-(2-chloro-4-pyrimidinyl)-1-(4-fluorophenyl)ethanone




2-(2-chloro-4-pyrimidinyl)-1-(4-fluorophenyl)ethanone

- To a solution of lithium diisopropylamide (generated from BuLi (0.045 mol) and diisopropylamine (0.048 mol) in THF) at -78 °C was added a solution of the compound prepared in step 1 (5.5 g, 0.037 mol) in THF slowly over 30 minutes. After 1 hour, a solution of ethyl 4-fluorobenzoate (7.62 g, 0.045 mol) in THF was added and

SUBSTITUTE SHEET (RULE 26)

the reaction mixture was stirred overnight and allowed to warm up to room temperature. Water was added and the aqueous phase was extracted with ethyl acetate. Organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product purified by chromatography on silica gel (ethyl acetate/hexane, 3:7) to give 4.78 g of a yellow solid (51% yield), mp: 112-113 °C.

Step 3: Preparation of (E)-2-(2-chloro-4-pyrimidinyl)-3-(dimethylamino)-1-(4-fluorophenyl)-2-propen-1-one



(E)-2-(2-chloro-4-pyrimidinyl)-3-(dimethylamino)-1-(4-fluorophenyl)-2-propen-1-one

- A mixture of the compound prepared in step 2 (4.7 g, 0.017 mol) in 100 mL of dimethylformamide dimethyl acetal was stirred at room temperature overnight. Excess dimethylformamide dimethyl acetal was removed under vacuum to give 4.5 g of crude product as a thick brown oil, which was used without further purification.


Step 4: Preparation of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine

- A solution of the compound prepared in step 3 (4.4 g) and hydrazine hydrate (0.82 g, 0.014 mol) was stirred at room temperature for 6 hours. The yellow precipitate was collected by filtration and air-dried to give 1.85 g of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-

SUBSTITUTE SHEET (RULE 26)

237

yl]pyrimidine as a yellow solid, mp: 204-205 °C; Anal. Calc'd for $C_{19}H_{10}ClFN_4$: C, 56.84; H, 2.94; N, 20.40; Cl, 12.91. Found: C, 56.43; H, 2.76; N, 20.02; Cl, 12.97.


Example A-300

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone hydrazone


A solution of the compound prepared in step 3 of Example A-299 (1.5 g) and hydrazine hydrate (5ml) in ethanol was heated at reflux overnight. After the reaction mixture was cooled, the solvent was removed. The residue was partitioned between ethyl acetate and water. The organic phase was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was purified by recrystallization from ethyl acetate and hexane to give 0.5 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone hydrazone, as a pale yellow solid (38% yield), mp: 149-150 °C; Anal. Calc'd for $C_{19}H_{11}FN_4$: C, 57.77; H, 4.10; N, 31.10. Found: C, 57.70; H, 4.31; N, 30.73.

SUBSTITUTE SHEET (RULE 28)

238

Example A-301

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine

Step 1: Preparation of

A solution of the compound prepared in step 2 of Example A-299 (3.0 g, 0.02 mol) and *tert*-butylbis(dimethylamino)methane (10.45 g, 0.06 mol) in 40 ml of DMF was stirred at 110 °C overnight. After the solvent was removed under vacuum, water was added and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by recrystallization from ethyl acetate and hexane to give 1.23 g of a yellow solid product (32% yield), mp: 76-77 °C; Anal. Calc'd for $C_{20}H_{20}N_6$: C, 62.47; H, 8.39; N, 29.14. Found: C, 62.19; H, 8.58; N, 29.02.


SUBSTITUTE SHEET (RULE 28)

239

Step 2: Preparation of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine

To a solution of the compound prepared in step 1 of the present Example (1.2 g, 0.0064 mol) and triethylamine (0.65 g, 0.0064 mol) in 10 mL of toluene was added 4-fluorobenzoyl chloride dropwise. The mixture was heated at reflux for 10 hours and the solvent was removed. The residue was partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude (1.6 g) was then dissolved in 50 mL of ethanol. The solution was treated with hydrazine hydrate (0.36 g, 0.006 mol) and the mixture was heated at reflux for 2 hours. After ethanol was removed, the residue was partitioned between water and ethyl acetate. The organic phase was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was purified by chromatography on silica gel (ethyl acetate/hexane, 1:1) to give 0.6 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine, as a yellow solid (33% yield), mp: 155-156 °C; Anal. Calc'd for $C_{15}H_{14}FN_5$: C, 63.59; H, 4.98; N, 24.72. Found: C, 63.32; H, 4.92; N, 24.31.

Example A-302



25


SUBSTITUTE SHEET (RULE 26)

240

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine

A suspension of 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 (0.3 g, 0.0011 mol) in 10 mL of methylamine (40% water solution) was heated in a sealed tube at 100 °C overnight. The mixture was then cooled to room temperature and the precipitate was filtered, air-dried to give 0.2 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-methyl-2-pyrimidinamine, as a white solid (68% yield), mp: 217-218 °C; Anal. Calc'd for $C_{15}H_{13}FN_5$: C, 62.45; H, 4.49; N, 26.01. Found: C, 62.58; H, 4.36; N, 25.90.

Example A-303



15

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine

20


This compound was synthesized by refluxing 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 in benzylamine overnight. The product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine, was obtained as a white solid in 95% yield; mp: 216-217 °C;

25

SUBSTITUTE SHEET (RULE 26)

241

Anal. Calc'd for $C_{20}H_{16}FN_3$: C, 69.55; H, 4.67; N, 20.28.
Found: C, 69.73; H, 4.69; N, 19.90.

Example A-304


5

N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine

This compound was synthesized by stirring 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 with excess cyclopropylamine in methanol at 50 °C for 12 hours. The product, N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine, was obtained as a white solid in 26% yield, mp: 203-204 °C; Anal. Calc'd for $C_{20}H_{16}FN_3$: C, 69.07; H, 4.78; N, 23.71. Found: C, 64.42; H, 4.82; N, 23.58.

SUBSTITUTE SHEET (RULE 26)

242


Example A-305

5

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine

This compound was synthesized by refluxing 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine prepared in accordance with Example A-299 in 4-methoxybenzylamine overnight. The product, 4-[3-(4-fluorophenyl)-2-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine, was obtained as a off-white solid in 80% yield, mp: 183-185 °C; Anal. Calc'd for $C_{21}H_{18}FN_4O$: C, 67.19; H, 4.83; N, 18.66. Found: C, 67.01; H, 5.11; N, 18.93.


15

Example A-306**SUBSTITUTE SHEET (RULE 26)**

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine

- 5 A solution of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine prepared in accordance with Example A-305 (0.35 g, 0.00093 mol) in 15 mL of trifluoroacetic acid was heated at reflux for 16 hours. Solvent was removed and the residue was partitioned between ethyl acetate and 1 N ammonia hydroxide. Organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and purified by chromatography on silica gel (ethyl acetate) to give 0.14 g of product, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine, as a pale yellow solid (59% yield), mp: 273-274 °C; Anal. Calc'd for $C_{13}H_{10}FN_4$, 0.25 H_2O : C, 60.11; H, 4.07; N, 26.96. Found: C, 60.15; H, 3.82; N, 26.38.

Example A-307




- 20 N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide

- 25 To a mixture of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine prepared in accordance with Example A-303 (0.15 g, 0.00043 mol), DMAP

- (0.027 g, 0.00022 mol) and acetic anhydride (0.066 g, 0.00066 mol) in 10 mL of THF was added triethylamine (0.053 g, 0.00052 mol). The solution was stirred at room temperature overnight. After the removal of solvent, the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated $NaHCO_3$, washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude product was triturated with ether to give 0.1 g of product, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide, as a white solid (60% yield), mp: 176-178 °C; Anal. Calc'd for $C_{22}H_{18}FN_4$: C, 68.21; H, 4.68; N, 18.08. Found: C, 67.67; H, 4.85; N, 17.79.

Example A-308




Ethyl [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]carbamate

- 20 To a suspension of 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine prepared in accordance with Example A-306 (0.26 g, 0.001 mol) in 5 mL of pyridine was added ethyl chloroformate dropwise. After the addition, the clear solution was stirred at room temperature for 6

245

hours. Water was added and the aqueous phase was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and filtered. The filtrate was concentrated and the crude was triturated with ether to give 0.15 g of product, ethyl [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]carbamate, as a white solid (46% yield), mp: 153-165 °C; Anal. Calc'd for $C_{18}H_{16}FNO_3$: C, 58.71; H, 4.31; N, 21.04. Found: C, 59.22; H, 4.51; N, 21.66.

Example A-309


4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared by the same procedure as described for Example A-208 except that 1-methyl-3-(4'-pyrimidinyl)acetyl benzene (prepared as set forth in Step 1 of Example A-19 from 4-methyl-pyrimidine and methyl 3-methylbenzoate) was used in place of 4-fluorobenzoyl-4-pyridinyl methane.

Anal. Calc'd for $C_{18}H_{16}N_4$ (236.27): C, 71.17; H, 5.12; N, 23.71. Found C, 70.67; H, 5.26; N, 23.53. m.p. (DSC): 151.67 °C.

SUBSTITUTE SHEET (RULE 26)


246

Example A-310

4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyrimidine

This compound was prepared according to the chemistry described in Schemes VI and IX by selection of the corresponding pyrimidine starting material in place of the pyridine starting material.

Anal. Calc'd for $C_{17}H_{12}ClN_4 \cdot 0.25H_2O$: C, 59.78; H, 3.67; N, 21.45. Found: C, 59.89; H, 3.32; N, 21.56. m.p. (DSC): 218.17 °C.

Example A-311

4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine


This compound was prepared according to the chemistry described in Schemes VI and IX by selection of

SUBSTITUTE SHEET (RULE 26)

247

the corresponding pyrimidine starting material in place of the pyridine starting material.

Anal. Calc'd for $C_{13}H_9N_4F$ (240.24): C, 64.99; H, 3.78; N, 23.22. Found: C, 64.78; H, 3.75; N, 23.31. m.p. (DSC): 168.58 °C.

Example A-312

10 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine


This compound was prepared according to the chemistry described in Schemes VI and IX by selection of the corresponding pyrimidine starting material in place of the pyridine starting material.

Anal. Calc'd for $C_{13}H_9N_4F$ (240.24): C, 64.99; H, 3.78; N, 23.32. Found: C, 64.94; H, 3.56; N, 23.44. m.p. (DSC): 191.47 °C.


20

Additional compounds of the present invention which could be prepared using one or more of the reaction schemes set forth in this application include, but are not limited to, the following:

248




4-[3-(4-chlorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine







1-[5-(4-bromophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine

249




250




SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

251




N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine




3-(4-fluorophenyl)-5-(4-piperazinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

252




3-(4-chlorophenyl)-5-(4-piperazinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol




4-[2-aminoethyl]-2-(4-fluorophenyl)-4,5,6,7-tetrahydro-3-(4-pyridinyl)pyrazolo[1,5-e]pyrimidin-8-ol

253




4-(2-aminoethyl)-2-(4-chlorophenyl)-4,5,6,7-tetrahydro-3-(4-pyridinyl)pyrazolo[1,5-e]pyrimidin-6-ol




3-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol

SUBSTITUTESHEET (RULE 26)


254



5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-ethanamine




5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-ethanamine




4-[3-(4-fluorophenyl)-5-(4-piperidinyl)-1H-pyrazol-4-yl]pyrimidine

SUBSTITUTESHEET (RULE 28)


255



4-[3-(4-chlorophenyl)-5-(4-piperidinyl)-1H-pyrazol-4-yl]pyrimidine




N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]acetamide




N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]acetamide

SUBSTITUTE SHEET (RULE 86)


256



N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]propanamide




N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]propanamide




6-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-1H-purine

SUBSTITUTE SHEET (RULE 86)

257



258





BIOLOGICAL EVALUATION

p38 Kinase Assay

Cloning of human p38a:

The coding region of the human p38a cDNA was obtained by PCR-amplification from RNA isolated from the human monocyte cell line THP.1. First strand cDNA was synthesized from total RNA as follows: 2 µg of RNA was annealed to 100 ng of random hexamer primers in a 10 µl reaction by heating to 70 °C for 10 minutes followed by 2 minutes on ice. cDNA was then synthesized by adding 1 µl of RNasin (Promega, Madison WI), 2 µl of 50 mM dNTP's, 4 µl of 5X buffer, 2 µl of 100 mM DTT and 1 µl (200 U) of Superscript II™ AMV reverse transcriptase. Random primer, dNTP's and Superscript™ reagents were all purchased from Life-Technologies, Gaithersburg, MD. The reaction was incubated at 42 °C for 1 hour.

Amplification of p38 cDNA was performed by aliquoting 5 µl of the reverse transcriptase reaction into a 100 µl PCR reaction containing the following: 80 µl dH₂O, 2 µl 50 mM dNTP's, 1 µl each of forward and reverse primers



SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

(50 pmol/ μ l), 10 μ l of 10X buffer and 1 μ l Expand TM polymerase (Boehringer Mannheim). The PCR primers incorporated Bam HI sites onto the 5' and 3' end of the amplified fragment, and were purchased from Genosys. The sequences of the forward and reverse primers were 5'-GATCAGGATTCATGTCCTCAGGAGGCCA-3' and 5'-GATCAGGATTCAGGACTCCATCTTTC-3' respectively. The PCR amplification was carried out in a DNA Thermal Cycler (Perkin Elmer) by repeating 30 cycles of 94 °C for 1 minute, 60 °C for 1 minute and 68 °C for 2 minutes. After amplification, excess primers and unincorporated dNTP's were removed from the amplified fragment with a Wizard TM PCR prep (Promega) and digested with Bam HI (New England Biolabs). The Bam HI digested fragment was ligated into BamHI digested pGEX 2T plasmid DNA (PharmaciaBiotech) using T-4 DNA ligase (New England Biolabs) as described by T. Maniatis, Molecular Cloning: A Laboratory Manual, 2nd ed. (1989). The ligation reaction was transformed into chemically competent *E. coli* DH10B cells purchased from Life-Technologies following the manufacturer's instructions. Plasmid DNA was isolated from the resulting bacterial colonies using a Promega WizardTM miniprep kit. Plasmids containing the appropriate Bam HI fragment were sequenced in a DNA Thermal Cycler (Perkin Elmer) with PrismTM (Applied Biosystems Inc.). cDNA clones were identified that coded for both human p38a isoforms (Lee et al. Nature 372, 739). One of the clones which contained the cDNA for p38a-2 (CSBP-2) inserted in the cloning site of pGEX 2T, 3' of the GST coding region was designated pMON 35802. The sequence obtained for this clone is an exact match of the cDNA clone reported by Lee et al. This expression plasmid allows for the production of a GST-p38a fusion protein.

SUBSTITUTESHEET (RULE 26)

Expression of human p38a:

GST/p38a fusion protein was expressed from the plasmid pMON 35802 in *E. coli*, strain DH10B (Life Technologies, Gibco-BRL). Overnight cultures were grown in Luria Broth (LB) containing 100 mg/ml ampicillin. The next day, 500 ml of fresh LB was inoculated with 10 ml of overnight culture, and grown in a 2 liter flask at 37 °C with constant shaking until the culture reached an absorbance of 0.8 at 600 nm. Expression of the fusion protein was induced by addition of isopropyl b-D-thiogalactoside (IPTG) to a final concentration of 0.05 mM. The cultures were shaken for three hours at room temperature, and the cells were harvested by centrifugation. The cell pellets were stored frozen until protein purification.

Purification of p38 Kinase- α :

All chemicals were from Sigma Chemical Co. unless noted. Twenty grams of *E. coli* cell pellet collected from five 1 L shake flask fermentations was resuspended in a volume of PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄, pH 7.3) up to 200 ml. The cell suspension was adjusted to 5 mM DTT with 2 M DTT and then split equally into five 50 ml Falcon conical tubes. The cells were sonicated (Ultrasonics model W375) with a 1 cm probe for 3 X 1 minutes (pulsed) on ice. Lysed cell material was removed by centrifugation (12,000 x g, 15 minutes) and the clarified supernatant applied to glutathione-sepharose resin (Pharmacia).

Glutathione-Sepharose Affinity Chromatography:

Twelve ml of a 50% glutathione sepharose-PBS suspension was added to 200 ml clarified supernatant and incubated batchwise for 30 minutes at room temperature. The resin was collected by centrifugation (600 x g, 5 min) and washed with 2 x 150 ml PBS/1% Triton X-100,

SUBSTITUTESHEET (RULE 26)

261

followed by 4 x 40 ml PBS. To cleave the p38 kinase from the GST-p38 fusion protein, the glutathione-sepharose resin was resuspended in 6 ml PBS containing 250 units thrombin protease (Pharmacia, specific activity > 7500 units/mg) and mixed gently for 4 hours at room temperature. The glutathione-sepharose resin was removed by centrifugation (600 x g, 5 min) and washed 2 x 6 ml with PBS. The PBS wash fractions and digest supernatant containing p38 kinase protein were pooled and adjusted to 0.3 mM PMSF.

Mono Q Anion Exchange Chromatography:

The thrombin-cleaved p38 kinase was further purified by FPLC-anion exchange chromatography. Thrombin-cleaved sample was diluted 2-fold with Buffer A (25 mM HEPES, pH 7.5, 25 mM beta-glycerophosphate, 2 mM DTT, 5% glycerol) and injected onto a Mono Q HR 10/10 (Pharmacia) anion exchange column equilibrated with Buffer A. The column was eluted with a 160 ml 0.1 M-0.6 M NaCl/Buffer A gradient (2 ml/minute flowrate). The p38 kinase peak eluting at 200 mM NaCl was collected and concentrated to 3-4 ml with a Filtron 10 concentrator (Filtron Corp.).

Sephacryl S100 Gel Filtration Chromatography:

The concentrated Mono Q- p38 kinase purified sample was purified by gel filtration chromatography (Pharmacia HiPrep 26/60 Sephacryl S100 column equilibrated with Buffer B (50 mM HEPES, pH 7.5, 50 mM NaCl, 2 mM DTT, 5% glycerol)). Protein was eluted from the column with Buffer B at a 0.5 ml/minute flowrate and protein was detected by absorbance at 280 nm. Fractions containing p38 kinase (detected by SDS-polyacrylamide gel electrophoresis) were pooled and frozen at -80 °C. Typical purified protein yields from 5 l *E. coli* shake flasks fermentations were 35 mg p38 kinase.

SUBSTITUTE SHEET (RULE 26)

262

In Vitro Assay

The ability of compounds to inhibit human p38 kinase alpha was evaluated using two in vitro assay methods. In the first method, activated human p38 kinase alpha phosphorylates a biotinylated substrate, PHAS-I (phosphorylated heat and acid stable protein-insulin inducible), in the presence of gamma ³²P-ATP (³²P-ATP). PHAS-I was biotinylated prior to the assay and provides a means of capturing the substrate which is phosphorylated during the assay. p38 Kinase was activated by MKK6. Compounds were tested in 10 fold serial dilutions over the range of 100 μ M to 0.001 μ M using 1% DMSO. Each concentration of inhibitor was tested in triplicate.

All reactions were carried out in 96 well

polypropylene plates. Each reaction well contained 25 mM HEPES pH 7.5, 10 mM magnesium acetate and 50 μ M unlabeled ATP. Activation of p38 was required to achieve sufficient signal in the assay. Biotinylated PHAS-I was used at 1-2 μ g per 50 μ l reaction volume, with a final concentration of 1.5 μ M. Activated human p38 kinase alpha was used at 1 μ g per 50 μ l reaction volume representing a final concentration of 0.3 μ M. Gamma 32P-ATP was used to follow the phosphorylation of PHAS-I. 32P-ATP has a specific activity of 3000 Ci/mmol and was used at 1.2 μ Ci per 50 μ l reaction volume. The reaction proceeded either for one hour or overnight at 30 °C.

Following incubation, 20 μ l of reaction mixture was transferred to a high capacity streptavidin coated filter plate (SAM-streptavidin-matrix, Promega) prewetted with phosphate buffered saline. The transferred reaction mix was allowed to contact the streptavidin membrane of the Promega plate for 1-2 minutes. Following capture of biotinylated PHAS-I with 32P incorporated, each well was washed to remove unincorporated 32P-ATP three times with 2M NaCl, three washes of 2M NaCl with 1% phosphoric, three washes of distilled water and finally a single wash

SUBSTITUTE SHEET (RULE 26)

of 95% ethanol. Filter plates were air dried and 20 μ l of scintillant was added. The plates were sealed and counted. Results are shown in Table 4.

- A second assay format was also employed that is based on p38 kinase alpha induced phosphorylation of EGFRP (epidermal growth factor receptor peptide, a 21 mer) in the presence of γ -P-ATP. Compounds were tested in 10 fold serial dilutions over the range of 100 μ M to 0.001 μ M in 1% DMSO. Each concentration of inhibitor was tested in triplicate. Compounds were evaluated in 50 μ l reaction volumes in the presence of 25 mM Hepes pH 7.5, 10 mM magnesium acetate, 4% glycerol, 0.4% bovine serum albumin, 0.4mM DTT, 50 μ M unlabeled ATP, 25 μ g EGFRP (200 μ M), and 0.05 uCi gamma γ -P-ATP. Reactions were initiated by addition of 0.09 μ g of activated, purified human GST-p38 kinase alpha. Activation was carried out using GST-MKK6 (5:1,p38:MKK6) for one hour at 30 °C in the presence of 50 μ M ATP. Following incubation for 60 minutes at room temperature, the reaction was stopped by addition of 150 μ l of AG 1X8 resin in 900 mM sodium formate buffer, pH 3.0 (1 volume resin to 2 volumes buffer). The mixture was mixed three times with pipetting and the resin was allowed to settle. A total of 50 μ l of clarified solution head volume was transferred from the reaction wells to Microlite-2 plates. 150 μ l of Microscint 40 was then added to each well of the Microlite plate, and the plate was sealed, mixed, and counted.

TABLE 4

Example	p38 kinase IC50 (μ M)
1	4.6
2	1.5
5	<0.1
8	3.8
16	1.5
23	2.6
25	0.7
10	0.3
26	2.5
28	8.0
33	12.1
34	0.8
36	1.1
15	1.3
38	0.3
39	<0.1
40	<0.1
42	<0.1
43	<0.1
20	<0.1
44	<0.1
45	<0.1
46	<0.1
47	3.2
48	1.8
50	2.3
25	<0.1
51	0.1
52	0.9
53	0.7
54	6.4
30	<0.1
55	
143	

TNF Cell Assays

- 35 Method of Isolation of Human Peripheral Blood Mononuclear Cells:

Human whole blood was collected in Vacutainer tubes containing EDTA as an anticoagulant. A blood sample (7 ml) was carefully layered over 5 ml PMN Cell Isolation Medium (Robbins Scientific) in a 15 ml round-bottom centrifuge tube. The sample was centrifuged at 450-500 x g for 30-35 minutes in a swing out rotor at room temperature. After centrifugation, the top band of cells were removed and washed 3 times with PBS w/o calcium or magnesium. The cells were centrifuged at 400 x g for 10 minutes at room temperature. The cells were resuspended

265

in Macrophage Serum Free Medium (Gibco BRL) at a concentration of 2 million cells/ml.

LPS Stimulation of Human PBMs:

5 PBM cells (0.1 ml, 2 million/ml) were co-incubated with 0.1 ml compound (10-0.41 μ M, final concentration) for 1 hour in flat bottom 96 well microtiter plates. Compounds were dissolved in DMSO initially and diluted in TCM for a final concentration of 0.1% DMSO. LPS (Calbiochem, 20 ng/ml, final concentration) was then added at a volume of 0.010 ml. Cultures were incubated overnight at 37 °C. Supernatants were then removed and tested by ELISA for TNF- α and IL1- β . Viability was analyzed using MTS. After 0.1 ml supernatant was collected, 0.020 ml MTS was added to remaining 0.1 ml cells. The cells were incubated at 37 °C for 2-4 hours, then the O.D. was measured at 490-650 nm.

20 Maintenance and Differentiation of the U937 Human Histiocytic Lymphoma Cell Line:

U937 cells (ATCC) were propagated in RPMI 1640 containing 10% fetal bovine serum, 100 IU/ml penicillin, 100 μ g/ml streptomycin, and 2 mM glutamine (Gibco). Fifty million cells in 100 ml media were induced to terminal monocytic differentiation by 24 hour incubation with 20 ng/ml phorbol 12-myristate 13-acetate (Sigma). The cells were washed by centrifugation (200 x g for 5 min) and resuspended in 100 ml fresh medium. After 24-48 hours, the cells were harvested, centrifuged, and resuspended in culture medium at 2 million cells/ml.

LPS Stimulation of TNF Production by U937 Cells:

U937 cells (0.1 ml, 2 million/ml) were incubated with 0.1 ml compound (0.004-50 μ M, final concentration) for 1 hour in 96 well microtiter plates. Compounds were prepared as 10 mM stock solutions in DMSO and diluted in

266

culture medium to yield a final DMSO concentration of 0.1% in the cell assay. LPS (E coli, 100 ng/ml final concentration) was then added at a volume of 0.02 ml. After 4 hour incubation at 37°C, the amount of TNF- α released in the culture medium was quantitated by ELISA. Inhibitory potency is expressed as IC50 (μ M). Results of these TNF Cell Assays are shown in Table 5.

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

267

268

Example.	TABLE 5	
	Human PBM Assay IC50 (μ M)	U937 Cell Assay IC50 (μ M)

1	0.5	
2	1.6	0.578
4	0.1	0.222
5		0.274
7	0.2	0.201
8	<0.1	
9	0.4	
10	0.7	1.687
12	8.5	
13	4.8	
14	1.2	
15	1.1	0.484
17	0.3	1.089
19		0.077
20		
21	3.2	
22	8.2	
24	2.7	0.029
26	<0.1	
27	0.1	
28	2.2	
29	2.6	
30	0.8	1.053
31		2.696
32		
33	0.4	
34	0.5	
35	0.7	
36	1.4	
37	1.5	0.099
38	0.2	0.208
39	0.7	0.244
40	0.4	
41	1.0	
42	0.7	
43	<0.1	0.243
44	0.4	0.477
45	<0.1	0.04
46		0.329
47		2.359
48	2.2	0.522
49	6.8	
50	0.9	
51		0.074
54	0.2	0.13
55	<0.1	0.228
143		0.301

Rat Assay

The efficacy of the novel compounds in blocking the production of TNF also was evaluated using a model based on rats challenged with LPS. Male Harlen Lewis rats [Sprague Dawley Co.] were used in this model. Each rat weighed approximately 300 g and was fasted overnight prior to testing. Compound administration was typically by oral gavage (although intraperitoneal, subcutaneous and intravenous administration were also used in a few instances) 1 to 24 hours prior to the LPS challenge. Rats were administered 30 μ g/kg LPS [salmonella typhosa, Sigma Co.] intravenously via the tail vein. Blood was collected via heart puncture 1 hour after the LPS challenge. Serum samples were stored at -20 °C until quantitative analysis of TNF- α by Enzyme Linked-Immuno-Sorbent Assay ("ELISA") [Biosource]. Additional details of the assay are set forth in Perretti, M., et al., Br. J. Pharmacol. (1993), 110, 868-874, which is incorporated by reference in this application.

Mouse Assay**Mouse Model Of LPS-Induced TNF Alpha Production:**

TNF alpha was induced in 10-12 week old BALB/c female mice by tail vein injection with 100 ng lipopolysaccharide (from S. Typhosa) in 0.2 ml saline. One hour later mice were bled from the retroorbital sinus and TNF concentrations in serum from clotted blood were quantified by ELISA. Typically, peak levels of serum TNF ranged from 2-6 ng/ml one hour after LPS injection. The compounds tested were administered to fasted mice by oral gavage as a suspension in 0.2 ml of 0.5% methylcellulose and 0.025% Tween 20 in water at 1 hour or 6 hours prior to LPS injection. The 1 hour protocol allowed evaluation of compound potency at Cmax plasma levels whereas the 6 hour protocol allowed estimation of

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

269

compound duration of action. Efficacy was determined at each time point as percent inhibition of serum TNF levels relative to LPS injected mice that received vehicle only.

- 5 Additional results obtained using the above-described assays are set forth in Table 6 below. p38 assay and U937 cell assay results are expressed as IC₅₀ (μm). Mouse-LPS assay results are expressed as percent inhibition.

TABLE 6

Example	p38 ¹	p38 ²	U937	mLPS 8h	mLPS 6h dose	mLPS 1h, 30mg/kg
A-212	0.49	0.74	0.0967	20	10	93
A-208	0.104	0.049	0.1896	98	30	97
A-227		0.06				96
A-228	0.76	0.339	0.4173	32	30	92
A-229		1.4	0.4622	76		91
A-230	0.42	0.178				96
A-231		0.174	0.3225	86	30	94
A-232		0.048				96
A-233		0.044				53
A-234		0.103				
A-235		0.104				56
A-236		0.237				94
A-237		0.093	0.087			60
A-238		0.177	0.4016			
A-239		0.034		51	30	87
A-240		0.961		78	30	85
A-241		0.338		79	30	87
A-242		0.047		95	30	87
A-243		0.729				82
A-244		0.099				
A-245		<.001	0.0337			
A-246	0.403	0.592	0.4952			65
A-247		<0.01	0.166			
A-249		0.432		73	30	86
A-250		2.873				
A-251		0.637		32		87
A-252		0.774	1.197	48	30	75
A-253		<.001	0.0044			61
A-254		0.081	0.1411			
A-215		2.34	0.2976	38	30	80
A-256		0.813	0.4562			
A-257	1.081	<.01	0.5167			57
A-213		0.22				68
A-258		0.48	1.2083			62
A-259		0.17	0.7574			93
A-210	0.16		0.1983	85	30	79
A-260			0.23	1.2821	47	30
A-214			0.06	1.4006		70
A-261			0.008	0.2542	48	30
A-216			0.018	1.8287	27	30
A-262		<0.1	0.3267			45
A-263	<0.01	<0.1	0.5434			49

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

271

Example	p38 ¹	p38 ²	U937	mLPS	mLPS	mLPS
			8h	6h dose	1h, 30mpk	
A-264			0.2594			61
A-265		<0.1	0.6016			32
A-266			0.5393			0
A-267		0.43	2.6681			80
A-268		<0.01	0.0074			11
A-217	0.697		0.3486			9
A-269			>10	UM		51
A-270		0.015	0.3466			53
A-271		0.216	4.2144			68
A-272	0.073		0.563			-8
A-273	6.98		>10			43
A-274	<0.1		0.92	21	30	
A-275	10.14		>10			
A-276	0.176		0.45	-24	30	
A-277	0.026			33	30	
A-278	0.285		2.3	62	30	
A-279	0.005		0.7	64	30	
A-280	0.134			15	30	
A-281	0.053			22	30	
A-218	0.044			18	30	
A-282	0.045		0.0973	30	30	
A-283	<0.1		0.7998	-20	30	
A-284	0.98		0.5088	-1		
A-285	<0.1		0.1795	11	30	
A-286	0.057		0.09	29	30	
A-287	0.041		0.27	-24	30	
A-288	0.017		0.3	40	30	
A-289	<0.1		0.14	44	30	
A-290			6.0191	4	30	
A-291	0.388		1.1309	36	30	
A-292	1.15		>10			
A-293	0.73					
A-294	0.015		0.5	61	30	
A-295	7.66		>10	94	30	
A-296	26					
A-297	0.52		0.17	89	30	

¹ p38α in vitro assay results based on PHAS-I assay procedure

² p38α in vitro assay results based on EGFRP assay procedure

272

Induction And Assessment Of Collagen-Induced Arthritis In Mice

Arthritis was induced in mice according to the procedure set forth in J.M. Stuart, Collagen Autoimmune Arthritis, Annual Rev. Immunol. 2:199 (1984), which is incorporated herein by reference. Specifically,

arthritis was induced in 8-12 week old DBA/1 male mice by injection of 50 μg of chick type II collagen (CII) (provided by Dr. Marie Griffiths, Univ. of Utah, Salt Lake City, UT) in complete Freund's adjuvant (Sigma) on

day 0 at the base of the tail. Injection volume was 100 μl. Animals were boosted on day 21 with 50 μg of CII in incomplete Freund's adjuvant (100 μl volume). Animals were evaluated several times each week for signs of

arthritis. Any animal with paw redness or swelling was counted as arthritic. Scoring of arthritic paws was conducted in accordance with the procedure set forth in Wooley et al., Genetic Control of Type II Collagen Induced Arthritis in Mice: Factors Influencing Disease Susceptibility and Evidence for Multiple MHC Associated

Gene Control., Trans. Proc., 15:180 (1983). Scoring of severity was carried out using a score of 1-3 for each paw (maximal score of 12/mouse). Animals displaying any redness or swelling of digits or the paw were scored as

scored as 2. Ankylosis of joints was scored as 3. Animals were evaluated for 8 weeks. 8-10 animals per group were used.

1. Gross swelling of the whole paw or deformity was scored as 2. Ankylosis of joints was scored as 3. Animals were evaluated for 8 weeks. 8-10 animals per group were used.

Preparation And Administration Of Compounds:

The compounds tested on mice having collagen-induced arthritis were prepared as a suspension in 0.5% methylcellulose (Sigma, St. Louis, MO), 0.025% Tween 20 (Sigma).

The compound suspensions were administered by oral gavage in a volume of 0.1 ml b.i.d. Administration began on day 20 post collagen injection and continued

273

daily until final evaluation on day 56. Scoring of arthritic paws was conducted as set forth above. Assay results are set forth in Table 7.

TABLE 7

Compound	Inhibition of Arthritis
A-210	58.5 @ 15 mpk
A-172	49.3 @ 100 mpk
A-189	51.6 @ 30 mpk
A-208	97.5 @ 60 mpk
A-208	75.0 @ 60 mpk

Also embraced within this invention is a class of pharmaceutical compositions comprising the active compounds of this invention in association with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and composition may, for example, be administered orally, intravascularly (IV), intraperitoneally, subcutaneously, intramuscularly (IM) or topically. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, hard or soft capsule, lozenges, dispersible powders, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. The active ingredient may also be administered by injection (IV, IM, subcutaneous or jet) as a composition wherein, for example, saline, dextrose, or water may be used as a suitable carrier. The pH of

SUBSTITUTE SHEET (RULE 26)

274

the composition may be adjusted, if necessary, with suitable acid, base, or buffer. Suitable bulking, dispersing, wetting or suspending agents, including mannitol and PEG 400, may also be included in the composition. A suitable parenteral composition can also include a compound formulated as a sterile solid substance, including lyophilized powder, in injection vials. Aqueous solution can be added to dissolve the compound prior to injection. The amount of therapeutically active compounds that are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the inflammation or inflammation related disorder, the route and frequency of administration, and the particular compound employed, and thus may vary widely. The pharmaceutical compositions may contain active ingredients in the range of about 0.1 to 1000 mg, preferably in the range of about 7.0 to 350 mg. A daily dose of about 0.01 to 100 mg/kg body weight, preferably between about 0.1 and about 50 mg/kg body weight and most preferably between about 0.5 to 30 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day. In the case of skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day. For disorders of the eye or other external tissues, e.g., mouth and skin, the formulations are preferably applied as a topical gel, spray, ointment or cream, or as a suppository, containing the active ingredients in a total amount of, for example, 0.075 to 30% w/w, preferably 0.2 to 20% w/w and most preferably 0.4 to 15% w/w. When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base.

SUBSTITUTE SHEET (RULE 26)

Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas.

- 10 Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of this invention can also be administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane. The transdermal patch may include the compound in a suitable solvent system with an adhesive system, such as an acrylic emulsion, and a polyester patch. The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and

the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the

- 5 formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other
- 10 containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used. Formulations suitable for
- 20 topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The anti-inflammatory active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w. For therapeutic purposes, the active compounds of this combination invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of
- 35 administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder,

277

cellulose esters of alkanolic acids, cellulose alkyl
esters, talc, stearic acid, magnesium stearate, magnesium
oxide, sodium and calcium salts of phosphoric and
sulfuric acids, gelatin, acacia gum, sodium alginate,
polyvinylpyrrolidone, and/or polyvinyl alcohol, and then
tableted or encapsulated for convenient administration.
Such capsules or tablets may contain a controlled-release
formulation as may be provided in a dispersion of active
compound in hydroxypropylmethyl cellulose. Formulations
for parenteral administration may be in the form of
aqueous or non-aqueous isotonic sterile injection
solutions or suspensions. These solutions and
suspensions may be prepared from sterile powders or
granules having one or more of the carriers or diluents
mentioned for use in the formulations for oral
administration. The compounds may be dissolved in water,
polyethylene glycol, propylene glycol, ethanol, corn oil,
cottonseed oil, peanut oil, sesame oil, benzyl alcohol,
sodium chloride, and/or various buffers. Other adjuvants
and modes of administration are well and widely known in
the pharmaceutical art.
All patent documents listed herein are incorporated
by reference.
Although this invention has been described with
respect to specific embodiments, the details of these
embodiments are not to be construed as limitations.

SUBSTITUTE SHEET (RULE 26)

278


**Description of parallel array synthesis methodology
utilized to prepare compounds of Examples B-1, B-11, and
B-111.**

Scheme B-1 describes the parallel array reaction blocks
that were utilized to prepare compounds of Examples B-
0001 through B-1574, and by analogy could also be used to
prepare compounds of Examples B-1575 through B-2269.
Parallel reactions were performed in multi-chamber
reaction blocks. A typical reaction block is capable of
performing 48 parallel reactions, wherein a unique
compound is optionally prepared in each reaction vessel
B1. Each reaction vessel B1 is made of either
polypropylene or pyrex glass and contains a frit B2
toward the base of the vessel. Each reaction vessel is
connected to the reaction block valve assembly plate B3
via leuc-lock attachment or through a threaded
connection. Each vessel valve B4 is either opened or
closed by controlling the leuc-lock position or by the
opening or closing of levers B5 within a valve assembly
plate row. Optionally, solutions can be either drained
or maintained above the vessel frits by leaving the
valves in the opened position and controlling the back
pressure beneath the valve assembly plate by control of
inert gas flow through the inert gas inlet valve B6. The
parallel reactions that are performed in these reaction
blocks are allowed to progress by incubation in a
jacketed, temperature controlled shaking station.
Temperature control of the reaction chambers is effected
by passing a heat-transfer liquid through jacketed
aluminum plates that make contact with the reaction block

SUBSTITUTE SHEET (RULE 26)

mantle **B7**. Mixing is effected at the shaking station by either vertical orbital shaking of the up-right reaction block or by lateral shaking of the reaction block tilted on its side.

Functionalized resins are optionally added to each reaction vessel **B1** during the course of reaction or at the conclusion of the reaction. These functionalized resins enable the rapid purification of each reaction vessel product. Vacuum filtration of the reaction block apparatus by opening of the vacuum valve **B8** allows purified products to be separated from resin-sequestered non-product species. Valve **B8** is located on the bottom reaction block chamber **B10** which houses the quadrant collection vial racks **B11**. The desired products are obtained as filtrates in unique collection vials **B9**. Removal of solvent from these collection vials affords desired products.



Scheme B-2 illustrates the various utilizations of functionalized resins to purify reaction vessel products

5 **B22** prior to filtration from the fritted vessels **B1** into collection vials **B9**. Said functionalized resins perform as 1) resin-bound reagents **B12**, which give rise to resin-bound reagent byproducts **B13**; 2) sequestrants **B14** or **B15** of excess solution-phase reactants **B16** or **B17**, respectively. Solution-phase reactants **B16** and **B17** contain inherent reactive functionality -rf₁ and -rf₂

10

281


which enable their chemoselective sequestration by the complementary reactive functionality -Cr₁ and -Cr₂ attached to resins B14 and B15; 3) sequestrants B18 of solution-phase byproducts B19. Byproduct B19 contains molecular recognition functionality -mr₂ which enables its chemoselective sequestration by the complementary functionality -Cmr₂ attached to resin B18; 4) reaction-quenching resins B20 which give rise to quenched resins B21. Resin B20 contains functionality -Q which mediates reaction quenching (for instance, proton transfer) of product B22 to form a desired isolable form of product B22. Upon performing reaction quench, the resin B20 is converted to resin B21 wherein -q represents the spent functionality on resin B21; 5) sequestrants B23 of chemically-tagged reagents B24 and their corresponding reagent byproducts B25. The soluble reagent B24 contains a bifunctional chemical group, -tag, which is inert to the reaction conditions but is used to enable the post-reaction sequestration of B24 by the complementary functionality -Ctag attached to resin B23. Additionally, the soluble reagent byproduct B25, formed during the course of reaction, contains the same chemical function -tag that also enables its sequestration by resin B23. Additionally, some reactants B16, particularly, sterically-hindered reactants and/or electron deficient nucleophiles, contain poorly sequesterable functionality (r₁ in this case is a poorly sequesterable functionality). These poorly sequesterable reactants B16 can be transformed in situ to more robustly sequesterable species B27 through their reaction with sequestration-enabling-reagents B26. B26 contain highly reactive, complementary functionality Cr₁, which reacts with B16 to form B27 in situ. The

SUBSTITUTE SHEET (RULE 26)

282

bifunctional molecular recognition functionality, mr, contained within B26 is also present on the in situ derivatized B27. Both B26 and B27 are sequestered by the complementary molecular recognition functionality attached to resin B28: By analogy, some reactions contain poorly sequesterable byproducts B19, wherein the molecular recognition functionality mr₂ in this case is not able to mediate the direct sequestration of B19 by the complementary functionality attached to resin B18. 10 Similar use of the bifunctional sequestration-enabling-reagent B29 transforms B19 into the more readily sequesterable species B30. The imparted molecular recognition functionality, mr, present in B30 is readily sequestered by the complementary functionality, Cmr, attached to resin B31. In some reactions, multiple 15 sequestration resins are utilized simultaneously to perform reaction purifications. Even resins containing incompatible (mutually reactive) functional groups can be used simultaneously because these resins scavenge complementary functionalized solution phase reactants, reagents, or byproducts from solution phase faster than resin cross-neutralization. Similarly, resins containing mutually reactive or neutralizing reaction-quenching functionality are able to quench solution phase 20 reactants, products, or byproducts faster than resin cross-neutralization. 25

SUBSTITUTE SHEET (RULE 26)



Scheme B3 describes the modular robotics laboratory environment that was utilized to prepare compounds of Examples B0001 through B000x. Chemicals that are utilized in the robotics laboratory are weighed and then dissolved or suspended into solvents at Station #1 (Automated Chemistry Prep Station). Thus, solutions or suspensions of known molarity are prepared for use at the other robotics workstations. Station #1 also optionally bar-code labels each chemical solution so that its identity can be read by bar-code scanning at this and other robotics workstations.

Reactions are initiated at the modular Stations #2 and #2 DUP. Station #2DUP is defined as a duplicate of Station #2 and is used to increase capacity within the robotics laboratory. A reaction block is mounted at Station #2 or #2 DUP. Also, racks containing reactants, reagents, solvents, and resin slurries are also mounted at Station #2 or #2 DUP. Under the control of a chemical

informatics mapping file, reactions are initiated by the transfer of reactant solutions, reagent solutions, solvents, and/or resin slurries into each mounted reaction block vessel. The transfer of known volumes of solutions, suspensions, or solvents is mediated by syringes which control a one-up septum piercing/argon purging cannula, a wide-bore resin slurry-depensing cannula, or by a six-up cannula which can simultaneously deliver volumes to a row of six reaction vessels. The reaction block and/or chemical solution racks may be optionally cooled below room temperature during the chemical solution transfer operations. After the transfer of chemical solutions and solvents has been performed by Station#2 or #2DUP, incubation of the reaction block may occur while the reaction block is mounted at the robot station. Preferably, however, the reaction block is removed after all volume transfers are complete and the reaction block is brought to ambient temperature. The reaction block is transferred off-line to either a vertical- or lateral shaking incubator Station #5.

The Automated weighing/archival Station #3 performs the functions of weighing empty collection vials (to obtain tare weights of collection vials) and also performs the functions of weighing collection vials containing filtered, purified products (to obtain gross weights of collection vials). After product-containing collection vials have been weighed (gross weight determinations) at workstation #3, the collection vial products are optionally redissolved into an organic solvent at workstation #3. Transfer of solvents is accomplished with syringes which control a mounted one-up septum-piercing/argon purging cannula. Each product-containing

285

collection vial is prepared as a solution of known molarity as directed and recorded by the chemical informatics system. These product solutions may be subsequently mounted at Station #2 or #7DUP for subsequent reaction steps or taken to Station #7 or #7DUP for analytical processing.

Rapid solvent evaporation of product-containing collection vials is accomplished by mounting the collection racks at Savant Automated Solvent Evaporation Stations #4, #4 DUP, or #4 TRIP, wherein #4DUP and #4TRIP are defined as a duplicate and a triplicate of Station #4 to increase the capacity for solvent removal within the robotics laboratory. Commercially available solvent removal stations were purchased from the Savant Company (model # SC210A speedvac unit equipped with model # RVT4104 vapor trap and model # VN100 vapornet cryopump).

Stations #7 and #7DUP perform analytical processing functions. Station #7DUP is defined as a duplicate of Station #7 to increase capacity within the robotics laboratory. Product-containing collection racks are mounted at either of these stations. Each product-containing collection vial is then prepared as a solution of known molarity as directed and recorded by the chemical informatics mapping file. Optionally, this dissolution function is performed by prior processing of the collection vial rack at Station #3 as described above. Station#7 or #7DUP, under the control of the chemical informatics mapping file, transfers aliquots of each product vial into unique and identifiable microtiter plate wells that are utilized to perform analytical determinations.

SUBSTITUTE SHEET (RULE 26)

286

One such microtiter plate is prepared at Station #7 or #7DUP for subsequent utilization at the Automated HPLC/Mass Spectrometer Station #8 or #8DUP. Station #8DUP is a duplicate of Station #8 to increase the analytical capacity of the robotics laboratory. Stations #8 and #8DUP are commercially available benchtop LC/Mass spec units purchased from Hewlett Packard (model HP1100 HPLC connected to HP1100 MSD (G1946A) mass spectrometer; this unit is also equipped with a model# G1322A solvent degasser, model# G1312A binary pump, a model# G1316A column heater, and a model# G1315A diode array detector. The HP unit has been interfaced with a commercially available autosampler rack (Gilson Company # 215 autosampler). Station #8 or #8DUP is utilized for the determination of product purity and identity by performing high performance liquid chromatography (HPLC) and companion atmospheric pressure chemical-ionization (APCI) or electrospray mass spectrometry for molecular weight determination.

Another microtiter plate is prepared at Station #7 or #7DUP for subsequent utilization at a commercially available flow-probe Varian NMR spectrometer Station #10 (Varian Instruments flow probe NMR, 300 MHz, interfaced with a commercially available Gilson 215 autosampler). Proton, 13 -Carbon, and/or 19 -Fluorine NMR spectra are determined at this Station #10. Other microtiter plates are optionally mounted at Station #7 or #7DUP for the purpose of preparing product-containing plates for biological assays. Aliquots of product-containing collection vials are transferred to these biological assay microtiter plates under the control of the chemical informatics mapping file. Identity and amount of each transferred product is


SUBSTITUTE SHEET (RULE 26)

recorded by the chemical informatics system for retrieval by biologists who perform the biological assaying of products.

5 The Fourier Transform Infrared (FT-IR) Spectrometer Station #11 is utilized to analyze resins for the identity of organic functional groups chemically attached to these resins. The resins, as mentioned above, contain chemical functionality utilized as reagents, chemoselective sequestrants, or reaction quenching media for the workup and purification of the crude product mixtures contained within reaction block vessels. The robotics laboratory utilizes a commercially available FT-IR spectrometer purchased from Nicolet Instruments (model # MagnaIR 560 interfaced with an InspectIR microscope for resin mounting and positioning).

Scheme B-3

The lines interconnecting the modular Stations denote the transfer of chemical racks, reaction blocks, and/or collection vial racks from one modular Station to another.



The ChemLib IT system is a composite of software running on the client's desktop and software running on a remote server.

The ChemLib IT system is a client/server software application developed to support and document the data handling flow in the robotics laboratory described above. This IT system integrates the chemist with the robotics synthesis laboratory and manages the data generated by this processes.

The software running on the server warehouses all the electronic data for the robotics chemistry unit. This

289

server, a Silicon Graphics IRIX station v6.2, runs the database software, Oracle 7 v7.3.3.5.0, that warehouses the data. Connection from the client's desktop to the server is provided by Oracle's TCP/IP Adapter v2.2.2.1.0 and SQL*Net v2.2.2.1.0A. SQL*Net is Oracle's network interface that allows applications running on the client's desktop to access data in Oracle's database.

The client's desktop is Microsoft Windows 95. The Chemlib IT system client software is composed of Omnis7 v3.5 and Microsoft Visual C++ v5.0. This composition on the client side is what is herein referred to as Chemlib. Chemlib communicates with the server for its data via Oracle's PL/SQL v2.3.3.4.0. These PL/SQL calls within Chemlib creates a network socket connection to Oracle's SQL*Net driver and the TCP/IP Adapter thereby allowing access to the data on the server.

A "library" is defined as a composite number of wells, where each well defines a single compound. Chemlib defines a library in a module called the *Electronic Spreadsheet*. The *Electronic Spreadsheet* is then a composite of n-number of wells containing the components that are required to synthesize the compound that exist in each these well(s).

The chemist begins by populating the *Electronic Spreadsheet* with those components required for the compound synthesis. The identity and the availability of these components are defined in the *Building Block Catalog* module of Chemlib. The *Building Block Catalog* is a catalog of a listing of all reagents, solvents, peripherals available in the robotics laboratory. Upon selecting the components for each compound we also

SUBSTITUTE SHEET (RULE 26)

290

declare the quantity of each component to be utilized. The quantity of each component can be identified by its molarity and volumetric amounts (ul) or by its solid state form (mg). Therefore a well in the *Electronic Spreadsheet* defines a compound that is identified by its components and the quantity of each of these components.

The assembly or the synthesis of these components for each compound in the *Electronic Spreadsheet* is defined in the *WS Sequence* module of Chemlib. The *Define WS Sequence* module identifies the synthesis steps to be performed at the robotics workstations and any activities to be performed manually or off-line from the robotics workstation. With this module we identify which components from the *Electronic Spreadsheet* and the activity that should be performed with this component in the robotics laboratory. In the *Define WS Sequence* module the chemist chooses from a list of activities to be performed in the robotics laboratory and assembles them in the order in which they are to occur. The Chemlib system takes these set of activities identified, and with the component data in the *Electronic Spreadsheet* assembles and reformats these instructions into terminology for the robotics workstation use. This robotics terminology is stored in a 'sequence' file on a common server that is accessible by the robotics workstation.

The robotics workstation performs the synthesis in a reaction block apparatus as described. Each well in the *Electronic Spreadsheet* is tracked and mapped to a unique location in the reaction block apparatus on the robotics workstation. The compound or product synthesized at the

SUBSTITUTE SHEET (RULE 26)

robotics workstation in the reaction block is then captured into collection vials.

The collection vials are first tarred then grossed on the robotics workstation after collecting their products from the reaction block. These weights (tare and gross) are recorded into the ChemLib system with the Tare/Gross Session module. The Tare/Gross Session module then calculates the product or compound yields and its final mass.

10

Preparation of the compound for analytical analysis and screening is defined by the Analytical WS Setup module in ChemLib. The Analytical WS Setup module identifies the dilution factor for each well in the Electronic Spreadsheet, based on the compound's product yield and the desired molar concentration. This identifies the quantity, in μL , to be transferred at the robotics workstation, to a specific location on the MTP (microtiter plate) to be sent for analysis and/or biological assaying. The mass spectrometric and HPLC results for each well are recorded and scored into the ChemLib system.

The Dilute/Archive WS module further identifies each compound by mapping the compound's well from the Electronic Spreadsheet to a specific MX block location for long term storage and archival as part of the registration process.

20

All communications between ChemLib and the robotics workstations are by ASCII files. These files are placed on a server by the ChemLib system that is accessible by

SUBSTITUTESHEET (RULE 28)

the robotics workstations. Reports generated by the robotics workstations are also placed on the server where the ChemLib system can read these files to record the data generated. Each robotics workstation consists of robotics hardware by Bohdan Automation, Inc. Mundelein, Illinois, and a PC currently running Microsoft Windows for Workgroup v3.11 and Ethernet software. The robotics workstation PC is logged into the network for one-way communication that allows the workstation to access the server for file access only.

10


General Scheme B4

Scaffold C-1 with a primary amine functionality contained within the R^4 substituent is reacted in spatially addressed, parallel array reaction block vessels with excess of electrophiles R^3-Q wherein Q is chloro, bromo, or an acid activating group including but not limited to N-hydroxysuccinimide. R^3-Q includes acid chlorides, alkyl chloroformates, sulfonyl chlorides, activated esters of carboxylic acids, activated carbamates, and isocyanates. Reaction of scaffold C-1 with R^3-Q is effected in the presence of a tertiary amine base at room temperature in a mixture of a polar aprotic solvent and/or a halogenated solvent. As illustrated in Scheme B-4 the products of the general formulae B-1 are isolated in purified form by addition of a carbonyl-functionalized resin B32 which covalently sequesters any unreacted primary amine scaffold C-1 as resin-bound adduct B35, and also by the addition of a primary amine-functionalized resin B33 which covalently sequesters any remaining electrophile R^3-Q from each reaction mixture as

SUBSTITUTESHEET (RULE 28)

293

resin-bound adduct **B34**. Resin **B33** also sequesters the HQ byproduct from the reaction mixture by proton transfer from solution-phase **Base-HQ**. Incubation at room temperature, filtration, rinsing of the resin cake, and concentration of the filtrates affords purified products **B-1** filtered away from resin-bound adducts **B32**, **B33**, **B34**, **B35**, and **B36**.




Scheme B-5 specifically illustrates the derivatization of the primary amine-containing scaffold **C1** to afford the desired products **B-1** in a parallel array synthesis format. In a parallel array synthesis reaction block, individual reaction products are prepared in each of multiple reaction block vessels in a spatially

SUBSTITUTE SHEET (RULE 26)

294

addressed format. A solution of the desired primary amine-containing scaffold **C1** (limiting amount,) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0 fold stoichiometric excess solution of N-methylmorpholine in DMF. To each reaction vessel is then added the electrophiles: either a 2.0 fold stoichiometric excess when $R'-Q$ is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when $R'-Q$ is a sulfonyl chloride, or a 1.25 fold stoichiometric excess when $R'-Q$ is an isocyanate. Excess electrophiles and N-methylmorpholine were used to effect more rapid and/or more complete conversion of scaffold **C1** to products **B-0001-B-0048** compared to reactions that do not utilize stoichiometric excesses of electrophiles and N-methylmorpholine. The reaction mixtures are incubated at ambient temperature for 2-3 h. Each reaction vessel is then charged with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin **B33** and the aldehyde-functionalized resin **B32**. The resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. The excess electrophiles $R'-Q$ and any unreacted scaffold amine **C1** are removed from the reaction medium as insoluble adducts **B34** and **B37** respectively. In addition the N-methylmorpholine hydrochloride salt formed during the course of the reaction is also neutralized to its free base form by proton transfer reaction to the amine-functionalized resin **B33**. Simple filtration of the insoluble resin-adducts **B32**, **B33**, **B34**, **B36**, and **B37**, rinsing of the resin cake with dichloroethane, and evaporation of the filtrates affords the desired products **B-1** in purified form.


SUBSTITUTE SHEET (RULE 26)



Scheme B-6 illustrates a general synthetic method involving the parallel array reaction of a scaffold C-11 containing a secondary amine functionality within the definition of the R' substituent. Each reaction vessel is charged with the secondary amine-containing scaffold C-11, followed by the introduction of a stoichiometric excess of an optionally unique electrophile R¹-Q into each vessel, wherein Q is chloro, bromo, or an acid activating group including but not limited to N-hydroxysuccinimide. R¹-Q includes acid chlorides, alkyl chloroformates,

sulfonyl chlorides, activated esters of carboxylic acids, activated carbamates, and isocyanates. Reaction of scaffold C-11 with R¹-Q is effected in the presence of tertiary amine base at room temperature or elevated temperature in a mixture of a polar aprotic solvent and/or a halogenated solvent. After solution-phase reactions have progressed to afford crude product mixtures in each vessel, the products B-11 are isolated in purified form by the addition of the isocyanate-functionalized resin B38 which covalently sequesters remaining secondary amine scaffold C-11 as resin-bound adduct B39, and also by the addition of the primary amine-functionalized resin B33 which covalently sequesters remaining electrophile R¹-Q from each reaction vessel as resin-bound adducts B40. Resin B33 also sequesters the HQ byproduct in each vessel as B36, formed by proton transfer from solution-phase Base-HQ. Incubation with these resins, either simultaneously or sequentially, followed by filtration, rinsing, and concentration of the filtrates affords purified products B-11 filtered away from resin-adducts B33, B36, B38, B39, and B40.

297



Scheme B-7 illustrates the conversion of the secondary-amine containing scaffold C-2 to the desired products B-11. In a parallel array synthesis reaction block, individual reaction products are prepared in each of 48 multiple reaction block vessels. A solution of the scaffold C-2 (limiting amount) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0-fold stoichiometric excess solution of N-methylmorpholine in DMF. To each reaction vessel is then added an electrophilic R¹-Q as a dichloroethane (DCE) solution: either a 2.0 fold stoichiometric excess is used when R¹-Q is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when R¹-Q is a sulfonyl chloride, or a 1.25 fold stoichiometric excess when R¹-Q is an isocyanate. The reaction mixtures are incubated at


SUBSTITUTE SHEET (RULE 26)

298

ambient temperature for 2-6 h. Each reaction vessel is then charged with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B-33 and the isocyanate-functionalized resin B-32. The resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. The excess electrophiles R¹-Q and unreacted scaffold amine C-2 are removed from the reaction medium as insoluble adducts B-40 and B-39, respectively. Resin B-33 also sequesters the HQ byproduct in each vessel as B-36, formed by proton transfer from solution-phase Base-HQ. Incubation with these resins, followed by filtration and rinsing with solvent mixtures of DMF and/or DCE, affords purified product solutions in collection vials filtered away from resin-adducts B-33, B-36, B-38, B-39, and B-40. Concentration of filtrates affords purified products B-11.

20


SUBSTITUTE SHEET (RULE 26)



5 Scheme B-8 illustrates another general synthetic method involving the parallel array reaction of a scaffold C-11 containing a secondary amine functionality within the definition of the R' substituent. Each reaction vessel is charged with the secondary amine-containing scaffold C-11, followed by the introduction of a stoichiometric excess of an optionally unique electrophile R^b-Q into each vessel. Reaction of scaffold C-11 with R^b-Q is effected in the presence of tertiary amine base at room temperature or elevated temperature in a mixture of a polar aprotic solvent and/or a halogenated solvent.

Excess electrophiles and N-methylmorpholine are used to effect more rapid and/or more complete conversion of scaffold C-11 to products B-11 compared to reactions that do not utilize stoichiometric excesses of electrophiles and N-methylmorpholine. The reaction mixtures are incubated at ambient temperature for 2-8 h. Each reaction vessel is then charged with the sequestration-enabling reagent phenylsulfonfylisocyanate B41. This reagent B41 reacts with remaining secondary amine scaffold C-11, converting C-11 to the in situ-derivatized compound B42. Subsequent incubation of these vessel mixtures with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin B33 sequesters the solution-phase species R^b-Q, HQ, B41, and B42 as the resin-bound adducts B40, B36, B44, and B43, respectively. The resin-charged reaction block is shaken vertically for 14-20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin- adducts B33, B36, B40, B43 and B44 and subsequent rinsing of the vessel resin-bed with DMF and/or DCE affords filtrates containing the purified products B-11. Concentration of the filtrates affords the purified products B-11.

301



5


Scheme B-9 illustrates the method of Scheme B-8 using scaffold C-2. A solution of the scaffold C-2 (limiting

SUBSTITUTE SHEET (RULE 26)

302

amount) in dimethylformamide (DMF) is added to the reaction vessels followed by a 4.0-fold stoichiometric excess solution of N-methylmorpholine in DMF. To each reaction vessel is then added an electrophile $\text{R}^1\text{-Q}$ as a dichloroethane (DCE) solution: either a 2.0 fold stoichiometric excess is used when $\text{R}^1\text{-Q}$ is an acid chloride or alkyl chloroformate, or a 1.5 fold stoichiometric excess when $\text{R}^1\text{-Q}$ is a sulfonyl chloride, or a 1.25 fold stoichiometric excess when $\text{R}^1\text{-Q}$ is an isocyanate. The reaction mixtures are incubated at ambient temperature for 2-6 h. After solution-phase reactions have progressed to afford crude product mixtures, each reaction vessel is then charged with a dichloroethane solution of the sequestration-enabling reagent phenylsulfonylisocyanate **B41**. This reagent **B41** reacts with remaining secondary amine scaffold C-2, converting C-2 to the *in situ*-derivatized compound **B45**. Subsequent incubation of these vessel mixtures with a large excess (15-20 fold stoichiometric excess) of the amine-functionalized resin **B33** sequesters the solution-phase species $\text{R}^1\text{-Q}$, **HQ**, **B41**, and **B45** as the resin-bound adducts **B40**, **B36**, **B44**, and **B46**, respectively. The resin-charged reaction block is shaken vertically for 20 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin-adducts **B33**, **B36**, **B40**, **B44**, and **B46** and subsequent rinsing of the vessel resin-bed with DCE affords filtrates containing the purified products **B-41**. Concentration of the filtrates affords the purified products **B-41**.

SUBSTITUTE SHEET (RULE 26)




5

Another general method for the parallel array reaction block synthesis is illustrated in Scheme B-10 for the derivatization of the carboxylic acid-containing scaffold

C-111. Scaffold **C-111** with a free carboxylic acid functionality is reacted in spatially addressed, parallel array reaction block vessels with excesses of optionally different primary or secondary amines **B47** in the presence of the polymer-bound carbodiimide reagent **B48** and a tertiary amine base in a mixture of a polar aprotic solvent and/or a halogenated solvent. After filtration of each crude vessel product mixture away from resins **B48** and **B49**, each reaction mixture is purified by treatment with the sequestration-enabling-reagent **B50** (tetrafluorophthalic anhydride). The reagent **B50** reacts with remaining excess amine **B47** to afford the *in situ*-derivatized intermediates **B51** which contain carboxylic acid molecular recognition functionality. Subsequent incubation of each reaction mixture with a 15-20-fold stoichiometric excess of the primary amine-functionalized resin **B33** sequestrers **B51**, **B50**, and any remaining acid scaffold **C-111** as resin-bound adducts **B52**, **B53**, and **B54**, respectively. Filtration of solution-phase products **B-111** away from these resin-bound adducts and rinsing of the resin beds with a polar aprotic solvent and/or halogenated solvent affords filtrates containing purified products **B-111**. Concentration of the filtrates affords purified **B-111**.

25

305



306


Scheme B-11 illustrates the conversion of the acid containing scaffold C-49 to the desired amide products B-411 in a parallel synthesis format. A limiting amount of the scaffold C-49 is added as a solution in dimethylformamide to each reaction vessel containing the polymer bound carbodimide reagent B-48 (5 fold stoichiometric excess). A solution of pyridine (4 fold stoichiometric excess) in dichloromethane is added to this slurry, followed by addition of an excess amount of a dimethylformamide solution of a unique amine B-47 (1.5 fold stoichiometric excess) to each vessel. The parallel reaction block is then agitated vertically on an orbital shaker for 16-18 h at ambient temperature and filtered to separate the solution phase product mixture away from resin-bound reagent B-48 and resin-bound reagent byproduct B-49. The resulting solutions (filtrates) containing a mixture of the desired amide products B-411, excess amines B-47 and any unreacted acid containing scaffold C-49, are treated with tetrafluorophthalic anhydride B-50. B-50 converts the excess amines B-47 in each filtrate vessel to its respective sequestrable half acid form B-51. After two h incubation time, an excess of the amine-functionalized resin B-33 and dichloromethane solvent are added to each reaction vessel. The amine-containing resin B-33 converts B-51, any remaining B-50, and any remaining C-49 to their resin-bound adducts B-52, B-53, and B-55, respectively. The resin-charged reaction block is shaken vertically for 16 h on an orbital shaker at ambient temperature to allow optimum agitation of the resin-containing vessel mixtures. Filtration of the insoluble resin-adducts B-53, B-52, B-53, and B-55 and subsequent rinsing of the vessel resin-bed with

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

dimethylformamide affords filtrates containing the purified products B-iii. Concentration of the filtrates affords the purified products B-iii.

Scheme B-11



309

Although Schemes B-1 through B-11 describe the use of parallel array chemical library technology to prepare compounds of general formulae B-1, B-11, and B-111, it is noted that one with ordinary skill in the art of classical synthetic organic chemistry would be able to prepare B-1, B-11, and B-111 by conventional means (one compound prepared at a time in conventional glassware and purified by conventional means such as chromatography and/or crystallization).

A general synthesis of pyridylpyrazole scaffolds C-1, C-11, and C-111 is depicted in Scheme C-1.

Step A: Picoline is treated with a base chosen from but not limited to n-butyllithium (n-BuLi), lithium di-isopropylamide (LDA), lithium hexamethyldisilazide (LHMDS), potassium t-butoxide (tBuOK), or sodium hydride (NaH) in an organic solvent such as tetrahydrofuran (THF), diethyl ether, t-butyl methyl ether, t-BuOH or dioxane from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. The metallated picoline solution is then added to a solution of ester B56. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from -20 °C to 120 °C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone B57 is isolated as a crude solid which can be purified by crystallization and/or chromatography.

SUBSTITUTE SHEET (RULE 26)

310

Step B: A solution of the pyridyl monoketone B57 in ether, THF, tBuOH, or dioxane is added to a base chosen from but not limited to n-BuLi, LDA, LHMDS, tBuOK, or NaH contained in hexane, THF, diethyl ether, t-butyl methyl ether, or t-BuOH from -78 °C to 50 °C for a period of time from ranging from 10 minutes to 3 hours. An appropriately substituted activated ester or acid halide derived from R'-CO₂H is then added as a solution in THF, ether, or dioxane to the monoketone anion of B57 while the temperature is maintained between -50 °C and 50 °C. The resulting mixture is allowed to stir at the specified temperature for a period of time from 5 minutes to three hours. The resulting pyridyl diketone intermediate B58 is utilized without purification in Step C.


Step C: The solution containing the pyridyl diketone B58 is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HCl, or HNO₃. The temperature during this step is maintained between -20 °C and room temperature. Hydrazine or hydrazine hydrate was then added to the mixture while maintaining the temperature between -20 °C and 40 °C for a period of 30 minutes to three hours. The mixture is then poured into water and extracted with an organic solvent. The pyridyl pyrazole C-1 or C-11 is obtained as a crude solid which is purified by chromatography or crystallization.

Step D In some cases the pyridyl pyrazole C-1 or C-11 is alkylated with Q-C(R¹)-(CH₂)_n-CO₂alkyl wherein Q is halogen. C-1 or C-11 is treated with a base chosen from NaH, NaOEt, KOtBu, or NEt₃ in an organic solvent such as THF, methylene chloride, dioxane, or DMF at temperatures

SUBSTITUTE SHEET (RULE 26)

between -20 °C and 150 °C and reaction times between 30 minutes and 12 hours. The resulting alkylated pyridyl pyrazole ester is then hydrolyzed to the acid by treatment with NaOH or LiOH in aqueous/alcohol solvent mixtures or in THF/water solvent mixtures. Alternatively, the ester function is removed by treatment with an organic or inorganic acid if the alkyl residue is *t*-butyl. Acidification, followed by extraction with an organic solvent affords **C-iii** which may be purified by chromatography or crystallization. In some cases, regioisomeric alkylated products **C-iv** are also formed. The desired **C-iii** can be separated away from **C-iv** by chromatographic purification or by fractional crystallization.

15



5 A synthesis of pyridylpyrazole scaffold **C-1** is depicted in Scheme C-2.

Step A:

313

Picoline is added to a solution of LiHMDS in THF at room temperature over a time period ranging from 30 minutes to 1 hour. The resulting solution is stirred for an additional 30 minutes to 1 hour at room temperature. This solution is then added to neat ethyl p-fluorobenzoate **B60** at room temperature over 1-2 h. The mixture is then allowed to stir at room temperature for 16-24 h. Equal portions of water and ethyl acetate are then added to the reaction and the mixture is partitioned in an extraction funnel. The organic layer is dried, filtered, and evaporated to give an oily solid. Hexanes are then added and the solid is filtered and washed with cold hexanes leaving the pyridyl monoketone **B61** for use in Step B.

15

Step B:

The pyridyl monoketone **B61** is added as a solution in THF to a flask maintained at room temperature which contains t-BuOK in a THF/ t-BuOH cosolvent. A yellow precipitate forms and stirring at room temperature is continued for 1-3 h. After this time, N-Cbz-protected glycine N-hydroxy succinimide **B62** is added dropwise at room temperature as a solution in THF over 1-3 h. This solution, containing crude diketone **B63**, is used directly in Step C.

25

Step C: The solution from step C is treated with water and the pH is adjusted to between 6 and 7 with acetic acid. Hydrazine hydrate is then added dropwise to the mixture as a solution in water over 30 minutes to 1h at room temperature. Water and ethyl acetate are then added to the flask and the mixture is then partitioned in a separatory funnel. The organic layer is dried, filtered, and evaporated to give a crude oil which is purified by

30

314

silica gel chromatography, giving rise to purified C-1Cbz.


Step: D

The Cbz protecting group contained in compound C-1Cbz is cleaved using hydrogen gas under pressure and Pd-C in methanol solvent. The resulting amine C-1 is obtained by filtration and concentration.

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

Scheme C-2



A number of pyridyl pyrazole scaffolds of type C-v are prepared as shown in Scheme C-3.

Step A: Picoline is treated with a base chosen from but not limited to *n*-BuLi, LDA, LiHMDS, tBuOK, or NaH in an organic solvent such as THF, ether, *t*-BuOH or dioxane from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. The metallated picoline solution is then added to a solution of an appropriately activated ester analog of a carboxylic acid CbzNH^R-(CH₂)_nCR^R(R⁶)-CO₂H or BocNH^R-(CH₂)_nCR^R(R⁶)-CO₂H, preferably but not limited to the N-hydroxysuccinimide B64. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from -20 °C to 120 °C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone B65 is isolated as a crude solid which can be purified by crystallization and/or chromatography.


Step B: A solution of the pyridyl monoketone B65 in ether, THF, tBuOH, or dioxane is added to a base chosen from but not limited to *n*-BuLi, LDA, LiHMDS, tBuOK, or NaH contained in hexane, THF, ether, dioxane, or tBuOH from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. The anion sometimes precipitates as a yellow solid. An appropriately substituted activated ester such as the N-hydroxysuccinimide B66 is then added as a solution in THF, ether, or dioxane to the monoketone anion while the temperature is maintained between -50 °C and 50 °C. The resulting mixture is allowed to stir at the specified temperature for a period of time from ranging from 5 minutes to 3 hours. The resulting pyridyl diketone intermediate B67 is utilized without further purification in Step C.

Step C: The solution containing the pyridyl diketone **B67** is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HCl, or HNO₃. The temperature during this step is maintained between -20 °C and room temperature. Hydrazine or hydrazine hydrate is then added to the mixture while maintaining the temperature between -20 °C and 40 °C for a period of 30 minutes to three hours. The mixture is then poured into water and extracted with an organic solvent. The pyridyl pyrazole **C-vBoc** or **C-vCbz** is obtained as a crude solid which is purified by chromatography or crystallization.

Step: D
The carbamate protecting groups from **C-vBoc** or **C-vCbz** are removed to afford the scaffolds **C-v** containing either a free primary amine (R⁴ is hydrogen) or a free secondary amine (R⁴ not equal to hydrogen). The Boc protecting carbamate groups are cleaved utilizing 1:1 trifluoroacetic acid (TFA)/methylene chloride at room temperature for several hours. The CBZ carbamate protecting groups are cleaved using hydrogen gas under pressure and Pd-C in an alcoholic solvent. The resulting amines **C-v** are then optionally crystallized or purified by chromatography.

SUBSTITUTE SHEET (RULE 26)

Scheme C-3



SUBSTITUTE SHEET (RULE 26)

The synthesis of scaffolds C-vi is accomplished as shown in Scheme C-4.


Step A:

A Boc protected pyridylpyrazole **B68** is treated with benzaldehyde in methylene chloride at room temperature in the presence of a drying agent for a period of time ranging from 1-24 h. Solvent is then evaporated and the resulting imine **B69** is used in step B without further purification.

Step B:

The pyridylpyrazole imine **B69** is dissolved in THF and stirred under nitrogen at temperatures ranging from -78 to -20 °C. A base such as LDA, *n*-BuLi, or LiHMDS is added dropwise to the mixture which is then stirred for an additional 10 minutes to 3 h. Two-five equivalents of an alkylating agent R²-Q are then added to the mixture and stirring is continued for several hours. The mixture is then quenched with acid and allowed to warm to room temperature and stirred several hours until cleavage of the Boc and the imine functions is complete. The pH is adjusted to 12 and then the mixture is extracted with an organic solvent, which is dried and evaporated. The crude pyridylpyrazole is then crystallized and/or chromatographed to give C-vi.

30




3

The synthesis of maleimide-containing scaffolds C-vii is accomplished as shown in Scheme C-5.

The maleimide pyrazole scaffolds C-vii are synthesized as depicted in scheme C-5. Condensation reaction of a primary amine H₂N-R with a maleic anhydride **B70** that is substituted at position 3 with either a bromo, chloro, or triflate group generates compound **B71**. The formed maleimide derivative **B71** then reacts with an acetophenone derivative **B72** in the presence of a Pd(0)

321

catalyst and base to afford compound **B73**. The methylene position of **B73** is then acylated with an acid anhydride **B74** or an activated acid ester **B75**, forming the di-ketone derivative **B76**. The di-ketone **B76** condenses with hydrazine to afford the desired maleimide pyrazole scaffold **C-vii**.




Scheme C-6 illustrates the synthesis of the maleimide pyrazole scaffold **C-63** wherein R^4 is hydrogen. The synthesis starts with the condensation reaction of bromomaleic anhydride **B77** with 2,4-dimethoxybenzylamine in acetic acid and acetic anhydride, giving rise to intermediate **B79**. The maleimide **B79** is then treated with 4'-fluoroacetophenone in the presence of catalytic amount

SUBSTITUTE SHEET (RULE 26)

322


$Pd_2(dba)_3$ and sodium *t*-butoxide to form the fluoroacetophenone substituted maleimide **B79**. The **B79** is treated with *tert*-butoxybis(dimethylamino)methane to yield the α -ketoenamine **B80**. The α -ketoenamine **B80** is condensed with hydrazine to form the maleimide pyrazole skeleton **B81**. The 2,4-dimethoxybenzyl group protecting group is optionally removed with ceric ammonium nitrate (CAN) to give compound **C-63**.



Scheme C-7 illustrates the synthesis of maleimide-containing scaffolds **C-64** and **C-65**. These scaffolds **C-49** and **C-50** are synthesized according to the general methods

SUBSTITUTE SHEET (RULE 26)


illustrated in Scheme C-5 and exemplified with the utilization of N-hydroxysuccinimides **B82** and **B83** to afford the maleimide-containing pyrazoles **B86** and **B87**, respectively. Optional removal of the 2,4-dimethoxybenzyl groups with CAN and subsequent removal of the Boc-protecting groups with trifluoroacetic acid (TFA) affords the scaffolds **C-64** and **C-65**.



The various functionalized resins and sequestration-enabling-reagents utilized to prepare and purify parallel reaction mixtures are more fully described below, including their commercial source or literature reference to their preparation.




4-benzyloxybenzaldehyde functionalized polystyrene.
Novabiochem cat. #01-64-0182




Prepared as reported in D. L. Flynn *et al.*,
J. American Chemical Society (1997) 119, 4874-4881.




Methylisocyanate functionalized polystyrene.
Novabiochem cat. # 01-64-0169



Polymer bound EDC, prepared as reported
by M. C. Desai *et al.*, *Tetrahedron Letters*
(1993) 34, 7685.



Benzenesulfonylisocyanate, purchased from
Aldrich Chemical Company, Cat# 23,225-7



Tetra-fluorophthalic anhydride, purchased
from Aldrich Chemical Company, Cat # 33,901-6

325

Experimental procedure for the parallel synthesis of a series of amides, carbamates, ureas and sulfonamides B-0001 through B-0048 from scaffold C-1.

Examples B-0001 through B-0048


To each reaction vessel (polypropylene syringe tubes fitted with a porous frit, closed at the bottom) of a parallel reaction apparatus was added 200 μ L of dimethylformamide. A stock solution of the scaffold amine C-1 in dimethylformamide (0.1 M, 500 μ L) was added to each reaction vessel followed by the addition of a stock solution of N-methylmorpholine in dimethylformamide (1.0 M, 200 μ L). A stock solution of each of the electrophiles was then added to the appropriate reaction vessels: a) 500 μ L of a 0.2 M solution of the acid chlorides in dichloroethane or b) 500 μ L of a 0.2 M solution of the chloroformates in dichloroethane or c) 313 μ L of a 0.2 M solution of the isocyanates in dichloroethane or d) 375 μ L of a 0.2 M solution of the sulfonyl chlorides in dichloroethane. The parallel reaction apparatus was then orbitally shaken (labline Benchtop orbital shaker) at 200 RPM at ambient

SUBSTITUTE SHEET (RULE 26)

326

temperature (23-30 °C) for a period of 2-3 h, under a gentle flow of nitrogen. At this time each reaction vessel was treated with approximately 250 mg of polyamine resin B33 (4.0 meq N/g resin) and approximately 100 mg of polyaldehyde resin B32 (2.9 mmol/g resin). Each reaction vessel was diluted with 1 mL dimethylformamide and 1 mL dichloroethane and the orbital shaking was continued at 200 RPM for a period of 14-20 h at ambient temperature. Each reaction vessel was then opened and the desired solution phase products separated from the insoluble quenched byproducts by filtration and collected in individual conical vials. Each vessel was rinsed twice with dichloroethane (1 mL) and the rinsings were also collected. The solutions obtained were then evaporated to dryness in a Savant apparatus (an ultracentrifuge equipped with high vacuum, scalable temperature settings and a solvent trap to condense the volatile solvent vapors). The resulting amide, carbamate, urea and sulfonamide products were then weighed and characterized. The yields and analytical data for the products obtained using this method are shown below.

SUBSTITUTE SHEET (RULE 26)



Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0001			85	397	398
B-0002			94	412	413
B-0003			91	340	341
B-0004			79	368	369
B-0005			92	498	499
B-0006			92	416	417
B-0007			86	450	451

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0008			86	448	449
B-0009			83	368	369
B-0010			86	338	339
B-0011			92	402	403
B-0012			74	442	443
B-0013			91	446	447
B-0014			84	352	353
B-0015			94	380	381
B-0016			89	440	441
B-0017			83	498	499





















SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0018			24	439	440
B-0019			89	474	475
B-0020			90	440	441
B-0021			85	386	387
B-0022			35	417	418
B-0023			94	397	398
B-0024			87	417	418
B-0025			5	354	-
B-0026			87	426	427
B-0027			89	350	351



SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0028			92	456	457
B-0029			89	428	429
B-0030			37	498	499
B-0031			18	407	408
B-0032			86	462	463
B-0033			3	352	-
B-0034			82	446	447
B-0035			28	569	570
B-0036			93	416	417
B-0037			91	422	423


SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0038			84	390	393
B-0039			87	402	403
B-0040			92	416	417
B-0041			75	444	445
B-0042			54	390	391
B-0043			80	396	397
B-0044			81	310	311
B-0045			91	408	409
B-0046			25	464	465
B-0047			88	430	431

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0048			95	414	415

SUBSTITUTE SHEET (RULE 26)



Example





















R¹ R² % Yield Calcd. Mass Spec Observed Mass Spec (M+H)

B-0049			85	414	415
B-0050			9	458	459
B-0051			91	426	427
B-0052			79	407	408
B-0053			92	407	408
B-0054			92	363	364
B-0055			88	505	506

By analogy to the procedure identified above for the preparation of Examples B0001-B0048, the following examples B-0049 through B-1573 were prepared.

335





















Example#

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0056			86	487	488
B-0057			83	384	395
B-0058			86	462	463
B-0059			92	466	467
B-0060			74	456	457
B-0061			35	458	459
B-0062			94	458	459
B-0063			87	372	373
B-0064			5	394	395
B-0065			87	420	395

SUBSTITUTE SHEET (RULE 26)

336

Example#

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0066			89	350	351
B-0067			92	386	387
B-0068			89	432	433
B-0069			37	390	391
B-0070			18	432	433
B-0071			86	440	441
B-0072			3	432	433
B-0073			92	450	451
B-0074			28	390	391
B-0075			93	402	403

SUBSTITUTE SHEET (RULE 26)

337

Example#

R²R¹

%Yield

Calcd. Mass Spec
Observed Mass Spec (M+H)

B-0076			91	400	401
B-0077			84	382	383
B-0078			87	396	397
B-0079			92	364	365
B-0080			75	447	448
B-0081			54	370	371
B-0082			80	430	431
B-0083			81	382	383
B-0084			91	464	465
B-0085			25	462	463

SUBSTITUTE SHEET (RULE 26)

338

Example#

R²R¹

%Yield

Calcd. Mass Spec
Observed Mass Spec (M+H)

B-0086			88	432	433
B-0087			95	416	417
B-0088				438	439
B-0089				336	337
B-0090				444	445
B-0091				368	369
B-0092				506	507
B-0093				436	437
B-0094				461	462
B-0095				408	409



SUBSTITUTE SHEET (RULE 26)

339

340















Example#

R¹ R² %Yield Calcd. Mass Spec Observed Mass Spec (M+H)

B-0096				410	411
--------	---	---	--	-----	-----

Example#

R¹ R² %Yield Calcd. Mass Spec Observed Mass Spec (M+H)

B-0087			14	486	487
B-0088			8	465	
B-0099			75	464	465
B-0100			72	388	389
B-0101			23	408	409
B-0102			37	487	488
B-0103			11	492	493

34.1

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0104			59	426	427
B-0105			79	360	361
B-0106			56	374	375
B-0107			33	346	347
B-0108			12	466	467
B-0109			65	450	451
B-0110			55	458	459
B-0111			41	458	459
B-0112			19	467	468
B-0113			78	453	454





















SUBSTITUTESHEET (RULE 26)

34.2

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0114			14	453	454
B-0115			33	453	-
B-0116			11	459	467
B-0117			77	438	439
B-0118			52	422	423
B-0119			82	434	435
B-0120			49	422	423
B-0121			64	414	415
B-0122			87	501	502
B-0123			100	450	451





















SUBSTITUTESHEET (RULE 28)

Example#

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0124			87	456	457
B-0125			45	472	473
B-0126			100	476	477
B-0127			100	433	434
B-0128			100	482	-
B-0129			96	480	481
B-0130			93	468	469
B-0131			90	468	469
B-0132			78	436	437
B-0133			76	426	427



SUBSTITUTE SHEET (RULE 26)

Example#















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0134			87	444	445
B-0135			67	476	477
B-0136			100	570	-
B-0137			35	480	481
B-0138			60	500	-
B-0139			73	585	586
B-0140			62	434	459
B-0141			100	483	484
B-0142			90	444	445
B-0143			61	492	493





















SUBSTITUTE SHEET (RULE 26)

345





















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0144			49	448	449

346

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0145			48	433	434
B-0146			32	415	416
B-0147			67	471	472
B-0148			79	465	-
B-0149			65	353	354
B-0150			53	465	466
B-0151			68	401	402

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0152			39	383	-
B-0153			96	427	428
B-0154			44	459	460
B-0155			74	479	480
B-0156			44	459	460
B-0157			72	415	416
B-0158			96	445	446
B-0159			97	411	412
B-0160			49	417	418
B-0161			93	459	460

SUBSTITUTESHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0162			91	405	406
B-0163			94	455	456
B-0164			84	455	456
B-0165			52	411	412
B-0166			72	417	418
B-0167			66	447	448
B-0168			27	415	416
B-0169			91	415	416
B-0170			8	351	352
B-0171			10	437	438



SUBSTITUTESHEET (RULE 26)















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0172			62	471	472
B-0173			40	455	456
B-0174			92	405	406
B-0175			96	387	388
B-0176			25	415	416
B-0177			100	397	398
B-0178			34	429	430
B-0179			72	429	430
B-0180			91	463	464
B-0181			100	463	464

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0182			50	447	448
B-0183			22	455	456
B-0184			63	465	466
B-0185			65	471	472
B-0186			42	429	430
B-0187			62	481	482
B-0188			98	439	440
B-0189			21	453	454
B-0190			57	417	418
B-0191			24	477	478

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0192			35	455	456

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0183			42	378	379
B-0194			65	365	366
B-0195			93	587	588
B-0196			82	365	366
B-0197			100	587	588
B-0198			86	373	374
B-0199			81	373	374

353





Example#	R ¹	R ²	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0200			78	373	374
B-0201			95	352	353
B-0202			100	416	417
B-0203			69	354	355
B-0204			93	340	341
B-0205			94	354	355
B-0206			79	424	425
B-0207			82	326	327
B-0208			88	378	379
B-0209			83	362	363















SUBSTITUTE SHEET (RULE 28)

354

Example#	R ¹	R ²	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0210			100	364	365
B-0211			60	325	326
B-0212			79	339	340
B-0213			71	353	354
B-0214			77	311	312
B-0215			24	353	354
B-0216				339	340
B-0217				381	382
B-0218				365	366
B-0219				401	402

SUBSTITUTE SHEET (RULE 28)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0220				415	416
B-0221				367	368

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0222			96	486	487
B-0223			100	465	466
B-0224			75	486	509a
B-0225			100	442	443
B-0226			88	482	483
B-0227			73	482	483
B-0228			37	452	

357





















Example	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0229			100	476	477
B-0230			94	476	477
B-0231			100	460	461
B-0232			90	440	441
B-0233			99	476	477
B-0234			100	486	487, 489
B-0235			89	486	487, 489
B-0236			100	476	477
B-0237			100	476	477
B-0238			92	438	-

SUBSTITUTE SHEET (RULE 26)

















358

Example	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0239			100	442	443
B-0240			100	442	443
B-0241			100	476	477
B-0242			100	460	461
B-0243			87	456	457
B-0244			100	436	437
B-0245			100	422	423
B-0246			100	452	453
B-0247			100	476	477
B-0248			79	468	-

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0249			100	516	517.519
B-0250			72	458	
B-0251			100	427	428
B-0252			100	450	451
B-0253			100	472	473
B-0254			100	433	434
B-0255			84	547	548
B-0256			100	484	507a
B-0257			85	534	535
B-0258			100	481	482

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0259			100	554	555
B-0260			91	500	501
B-0261			100	486	487
B-0262			100	481	482
B-0263			100	554	555
B-0264			75	375	376
B-0265			71	459	460
B-0266			100	412	413

SUBSTITUTE SHEET (RULE 26)

361





















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0267			100	386	387
B-0268			89	406	407
B-0269			84	386	387
B-0270			92	440	441
B-0271			98	428	429
B-0272			57	488	489
B-0273			100	440	441

SUBSTITUTE SHEET (RULE 26)





















362

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0274			94	397	398
B-0275			90	422	423
B-0276			100	408	409
B-0277			88	408	409
B-0278			100	426	427
B-0279			54	440	441
B-0280			79	414	415
B-0281			82	458	459
B-0282			89	426	427
B-0283			90	456	459

SUBSTITUTE SHEET (RULE 26)



Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0284			100	458	459
B-0285			94	458	459
B-0286			100	458	459
B-0287			96	458	459
B-0288			100	458	459
B-0289			96	406	407
B-0290			96	386	387
B-0291			95	440	441
B-0292			94	390	391
B-0293			100	408	409

SUBSTITUTE SHEET (RULE 86)















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0294			100	440	441
B-0295			91	408	409
B-0296			96	426	427
B-0297			88	390	391
B-0298			95	408	409
B-0299			90	408	409
B-0300			95	406	407
B-0301			99	450	451,453
B-0302			94	440	441
B-0303			100	378	379

SUBSTITUTE SHEET (RULE 86)

365

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0304			100	391	392

366

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0305			70	326	327
B-0306			59	340	341
B-0307			59	354	355
B-0308			60	368	369
B-0309			61	352	353
B-0310			61	366	367
B-0311			65	356	357

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0312			75	342	343
B-0313			68	356	357
B-0314			31	370	371
B-0315			61	384	385
B-0316			75	368	369
B-0317			62	366	367
B-0318			52	388	389
B-0319			53	424	425
B-0320			50	424	425
B-0321			54	442	443

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0322			64	474	475
B-0323			58	474	475
B-0324			60	422	423
B-0325			64	422	423
B-0326			58	422	423
B-0327			63	378	379
B-0328			68	389	390
B-0329			63	362	363
B-0330			48	376	377
B-0331			66	424	425

SUBSTITUTE SHEET (RULE 26)

369



Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0332			61	442	443
B-0333			60	458	459
B-0334			55	502	503
B-0335			60	454	455
B-0336			100	500	501
B-0337			65	458	-
B-0338			69	502	503
B-0339			69	454	-
B-0340			77	482	483
B-0341			64	458	459


SUBSTITUTE SHEET (RULE 29)















370

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0342			41	438	-
B-0343			63	430	431
B-0344			96	464	465
B-0345			62	507	508
B-0346			56	497	498
B-0347			61	341	342
B-0348			3	367	-
B-0349			57	403	404
B-0350			57	481	482
B-0351			31	355	356

SUBSTITUTE SHEET (RULE 29)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0352			51	397	398



Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0353			71	382	383
B-0354			35	512	513
B-0355			37	352	353
B-0356			57	404	405
B-0357			88	366	367
B-0358			88	410	411
B-0359			100	324	325

373











Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0360			56	364	365
B-0361			70	350	351
B-0362			100	464	465
B-0363			73	512	513
B-0364			88	377	378
B-0365			70	396	397
B-0366			100	354	355
B-0367			71	416	417
B-0368			86	454	455
B-0369			40	440	441















SUBSTITUTE SHEET (RULE 28)





















374

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0370			94	364	365
B-0371			88	460	461
B-0372			69	430	431
B-0373			100	430	431
B-0374			75	400	401
B-0375			74	366	367
B-0376			53	378	379
B-0377			71	387	388
B-0378			69	387	388
B-0379			66	387	388





















SUBSTITUTE SHEET (RULE 28)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0380			85	416	417
B-0381			93	430	431
B-0382			84	382	383
B-0383			74	583	584
B-0384			63	438	439

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0385			83	440	441
B-0386			99	422	423
B-0387			47	388	389
B-0388			100	448	449
B-0389			71	436	437
B-0390			100	458	459
B-0391			45	414	415

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0392			100	440	441
B-0393			75	388	389
B-0394			92	402	403
B-0395			87	374	375
B-0396			86	360	361
B-0397			81	452	453
B-0398			88	428	429
B-0399			99	436	437
B-0400			82	482	483
B-0401			94	367	368

SUBSTITUTE SHEET (RULE 28)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0402			73	325	326
B-0403			91	415	416
B-0404			41	378	380
B-0405			88	385	386
B-0406			100	419	420
B-0407			52	353	354
B-0408			83	339	340
B-0409			74	415	416
B-0410			100	419	420
B-0411			94	429	430

SUBSTITUTE SHEET (RULE 28)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0412			91	365	366
B-0413			79	367	368
B-0414			85	429	430
B-0415			82	401	402
B-0416			93	429	430
B-0417			97	429	430
B-0418			100	419	420
B-0419			100	431	432
B-0420			36	381	382
B-0421			96	353	354

SUBSTITUTE SHEET (RULE 26)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0422			100	461	462
B-0423			100	406	407
B-0424			76	366	367
B-0425			21	368	369
B-0426			100	354	355
B-0427			100	379	380
B-0428			100	379	380
B-0429			86	368	369

SUBSTITUTE SHEET (RULE 26)

381





















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0430			51	500	501
B-0431			76	479	480
B-0432			90	500	501
B-0433			96	456	457
B-0434			75	496	497
B-0435			52	496	497
B-0436			73	506	

SUBSTITUTE SHEET (RULE 28)







382

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0437			19	466	
B-0438			100	490	491
B-0439			67	464	465
B-0440			96	472	473
B-0441			87	472	473
B-0442			72	481	482
B-0443			66	473	474
B-0444			80	515	516
B-0445			94	490	491
B-0446			84	464	465

SUBSTITUTE SHEET (RULE 28)

Examples	R ¹	R ²	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0447			89	470	471
B-0448			100	490	491
B-0449			100	474	475
B-0450			100	447	448
B-0451			100	454	455
B-0452			95	496	497
B-0453			100	490	491
B-0454			100	500	501
B-0455			96	500	501
B-0456			89	494	495

SUBSTITUTE SHEET (RULE 26)

Examples	R ¹	R ²	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0457			93	482	483
B-0458			100	490	491
B-0459			100	490	491





















SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0460			93	450	451
B-0461			84	452	453
B-0462			96	456	457
B-0463			66	456	457
B-0464			69	490	491
B-0465			86	490	491
B-0466			78	474	475











SUBSTITUTE SHEET (RULE 86)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0467			78	470	471
B-0468			91	450	451
B-0469			85	436	437
B-0470			99	466	467
B-0471			100	490	491
B-0472			37	482	483
B-0473			92	462	463
B-0474			99	530	532
B-0475			55	472	473
B-0476			89	441	442















SUBSTITUTE SHEET (RULE 86)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0477			79	484	465
B-0478			92	486	487
B-0479			97	447	448
B-0480			75	561	562
B-0481			74	498	499
B-0482			57	548	549
B-0483			83	505	506
B-0484			100	568	569
B-0485			100	495	496
B-0486			100	426	427





















SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0487			32	389	390
B-0488			100	568	569
B-0489			91	500	501
B-0490			40	473	474
B-0491			73	514	515





















SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0482			89	400	401
B-0483			100	420	421
B-0484			100	400	401
B-0495			100	454	455
B-0496			100	442	443
B-0487			50	512	513
B-0498			100	454	455





















SUBSTITUTE SHEET (RULE 89)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0489			98	411	412
B-0500			100	438	437
B-0501			100	422	423
B-0502			100	422	423
B-0503			92	440	441
B-0504			67	454	455
B-0505			68	428	429
B-0506			98	472	473
B-0507			82	440	441
B-0508			99	472	473



SUBSTITUTE SHEET (RULE 89)

Example#	R ¹	R ²	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0509			100	472	473
B-0510			96	472	473
B-0511			100	472	473
B-0512			100	472	473
B-0513			100	472	473
B-0514			100	420	421
B-0515			100	400	401
B-0516			100	454	455
B-0517			100	404	405
B-0518			89	422	423


SUBSTITUTE SHEET (RULE 86)















Example#	R ¹	R ²	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0519			100	454	455
B-0520			98	422	423
B-0521			99	440	441
B-0522			88	404	405
B-0523			100	422	423
B-0524			100	422	423
B-0525			100	420	421
B-0526			100	464	465
B-0527			100	454	455
B-0528			100	392	393

SUBSTITUTE SHEET (RULE 86)





















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0529			94	405	406

SUBSTITUTE SHEET (RULE 26)























Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0530			67	382	383
B-0531			66	512	513
B-0532			37	352	353
B-0533			56	404	405
B-0534			100	366	367
B-0535			100	410	411
B-0536			41	324	325

SUBSTITUTE SHEET (RULE 26)











Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0537			100	364	365
B-0538			29	350	351
B-0539			70	464	465
B-0540			50	512	513
B-0541			61	377	378
B-0542			61	396	397
B-0543			59	354	355
B-0544			45	416	417
B-0545			100	454	455
B-0546			44	440	441

SUBSTITUTE SHEET (RULE 86)















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0547			64	364	365
B-0548			89	460	461
B-0549			100	430	431
B-0550			100	430	431
B-0551			81	400	401
B-0552			38	386	387
B-0553			31	378	379
B-0554			100	387	388
B-0555			66	387	388
B-0556			32	387	388

SUBSTITUTE SHEET (RULE 86)

397





















Example	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0557			70	416	417
B-0558			57	430	431
B-0559			74	382	383
B-0560			36	583	584
B-0561			51	438	439

398





















Example	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0562			88	440	441
B-0563			68	422	423
B-0564			47	388	389
B-0565			100	448	449
B-0566			76	436	437
B-0567			99	458	459
B-0568			45	414	415

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)





















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0569			88	440	441
B-0570			61	388	389
B-0571			58	402	403
B-0572			75	374	375
B-0573			72	360	361
B-0574			97	452	453
B-0575			71	428	429
B-0576			88	436	437
B-0577			72	482	483
B-0578			89	367	368

SUBSTITUTE SHEET (RULE 86)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0579			100	325	326
B-0580			75	415	416
B-0581			44	379	380
B-0582			75	395	396
B-0583			80	419	420
B-0584			57	353	354
B-0585			83	339	340
B-0586			71	415	416
B-0587			100	419	420
B-0588			94	428	430

















SUBSTITUTE SHEET (RULE 86)

401















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0588			78	365	366
B-0590			82	367	368
B-0591			72	429	430
B-0592			82	401	402
B-0593			88	429	430
B-0594			100	429	430
B-0595			99	419	420
B-0596			93	431	432
B-0597			40	381	382
B-0598			93	359	364

SUBSTITUTE SHEET (RULE 66)





















402

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0600			100	461	462
B-0601			98	406	407
B-0602			66	366	367
B-0603			25	368	369
B-0604			90	354	355
B-0605			86	379	380
B-0606			87	379	380
B-0607			72	368	369

SUBSTITUTE SHEET (RULE 66)





















Examples	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0607			34	500	501
B-0608			100	479	480
B-0609			82	500	501
B-0610			100	456	457
B-0611			76	496	497
B-0612			69	496	497
B-0613			61	506	

SUBSTITUTE SHEET (RULE 86)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0614			18	466	
B-0615			100	490	491
B-0616			77	484	485
B-0617			93	472	473
B-0618			84	472	473
B-0619			71	481	482
B-0620			89	473	474
B-0621			68	515	516
B-0622			70	490	491
B-0623			92	464	465







SUBSTITUTE SHEET (RULE 86)

405

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0624			98	470	471
B-0625			96	480	491
B-0626			100	474	475
B-0627			100	447	448
B-0628			64	454	455
B-0629			100	496	497
B-0630			85	490	491
B-0631			75	500	501
B-0632			83	500	501
B-0633			58	494	495

SUBSTITUTE SHEET (RULE 86)

406

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0634			63	482	483
B-0635			95	490	491
B-0636			100	490	491





















SUBSTITUTE SHEET (RULE 86)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0637			91	450	451
B-0638			96	436	437
B-0639			100	456	457
B-0640			100	456	457
B-0641			88	480	491
B-0642			99	480	491
B-0643			92	474	475











SUBSTITUTE SHEET (RULE 86)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0644			100	470	471
B-0645			92	450	451
B-0646			100	436	437
B-0647			90	468	467
B-0648			94	490	491
B-0649			57	482	
B-0650			82	462	463
B-0651			100	530	531
B-0652			53	472	
B-0653			84	441	442

SUBSTITUTE SHEET (RULE 86)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0654			92	464	465
B-0655			100	486	487
B-0656			98	447	448
B-0657			85	561	562
B-0658			92	498	499
B-0659			46	548	549
B-0660			80	505	506
B-0661			100	568	569
B-0662			98	495	496
B-0663			74	426	427

SUBSTITUTESHEET (RULE B6)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0664			30	389	390
B-0665			100	568	569
B-0666			93	500	501
B-0667			54	473	474
B-0668			66	514	515

SUBSTITUTESHEET (RULE B6)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0676			34	411	412
B-0677			46	436	437
B-0678			37	422	423
B-0679			34	422	423
B-0680			60	440	441
B-0681			31	454	455
B-0682			37	428	429
B-0683			46	472	473
B-0684			50	440	441
B-0685			44	472	473

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0669			65	400	401
B-0670			45	420	421
B-0671			43	400	401
B-0672			45	454	455
B-0673			41	442	443
B-0674			16	512	513
B-0675			39	454	455

413



Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0686			66	472	473
B-0687			57	472	473
B-0688			52	472	473
B-0689			42	472	473
B-0690			34	472	473
B-0691			52	420	421
B-0692			41	400	401
B-0693			56	454	455
B-0694			38	404	405
B-0695			43	422	423


SUBSTITUTE SHEET (RULE 26)















414

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0686			57	454	455
B-0687			51	422	423
B-0688			59	440	441
B-0689			46	404	405
B-0700			47	422	423
B-0701			46	422	423
B-0702			43	420	421
B-0703			57	464	465
B-0704			44	454	455
B-0705			33	392	393

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0706			35	405	405



Example#	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0707			76	516	517
B-0708			61	498	499
B-0709			37	464	465
B-0710			76	524	525
B-0711			75	512	513
B-0712			91	534	535
B-0713			42	480	481

417





















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0714			87	516	517
B-0715			60	464	465
B-0716			59	478	479
B-0717			61	450	451
B-0718			65	436	437
B-0719			84	528	529
B-0720			69	504	505
B-0721			63	512	513
B-0722			88	558	559
B-0723			68	443	444

SUBSTITUTESHEET (RULE 26)

















418

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0724			75	401	402
B-0725			83	491	492
B-0726			24	455	456
B-0727			67	471	472
B-0728			89	495	496
B-0729			38	429	430
B-0730			76	415	416
B-0731			60	491	492
B-0732			86	495	496
B-0733			81	505	506

SUBSTITUTESHEET (RULE 26)


Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0734			87	441	442
B-0735			83	443	444
B-0736			91	505	506
B-0737			9	477	-
B-0738			87	505	506
B-0739			82	505	506
B-0740			85	495	496
B-0741			68	507	508
B-0742			14	457	-
B-0743			77	429	430

SUBSTITUTE SHEET (RULE 26)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0744			86	537	538
B-0745			82	482	483
B-0746			74	442	443
B-0747			83	444	445
B-0748			94	430	431
B-0749			100	455	456
B-0750			100	455	456
B-0751			48	444	445

SUBSTITUTE SHEET (RULE 26)

4.21



Examples	R ¹	R ²	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0752			84	516	517
B-0753			67	498	499
B-0754			31	464	465
B-0755			85	524	525
B-0756			77	512	513
B-0757			57	534	535
B-0758			36	490	491

SUBSTITUTESHEET (RULE 26)

4.22

Examples	R ¹	R ²	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0759			79	516	517
B-0760			53	464	465
B-0761			50	478	479
B-0762			60	450	451
B-0763			75	436	437
B-0764			43	528	529
B-0765			75	504	505
B-0766			67	512	513
B-0767			43	558	559
B-0768			76	443	444

SUBSTITUTESHEET (RULE 26)

















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0769			78	401	402
B-0770			57	491	492
B-0771			14	455	456
B-0772			72	471	472
B-0773			100	495	496
B-0774			41	429	430
B-0775			91	415	416
B-0776			64	491	492
B-0777			90	495	496
B-0778			19	505	506

SUBSTITUTESHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0779			79	441	442
B-0780			40	443	444
B-0781			93	505	506
B-0782			57	477	478
B-0783			99	505	506
B-0784			100	505	506
B-0785			92	495	496
B-0786			91	507	508
B-0787			15	457	458
B-0788			48	429	430















SUBSTITUTESHEET (RULE 26)

4.25





















Examples	R ¹	R ²	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0789			91	537	538
B-0790			93	482	483
B-0791			76	442	443
B-0792			96	444	445
B-0793			54	430	431
B-0794			100	455	456
B-0795			100	455	456
B-0796			94	444	445

SUBSTITUTE SHEET (RULE 29)





















4.26

Examples	R ¹	R ²	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0787			90	458	459
B-0788			90	588	589
B-0799			82	428	429
B-0800			92	480	481
B-0801			82	442	443
B-0802			85	486	487
B-0803			89	400	401

SUBSTITUTE SHEET (RULE 29)











Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0804			87	440	441
B-0805			100	426	427
B-0806			99	540	541
B-0807			96	588	589
B-0808			82	453	454
B-0809			92	472	473
B-0810			98	430	431
B-0811			88	492	493
B-0812			81	530	531
B-0813			98	516	517

SUBSTITUTE SHEET (RULE 86)















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0814			100	440	441
B-0815			100	536	537
B-0816			99	506	507
B-0817			98	506	507
B-0818			86	476	477
B-0819			90	462	463
B-0820			91	454	455
B-0821			69	463	464
B-0822			79	463	464
B-0823			79	463	464





















SUBSTITUTE SHEET (RULE 86)

4.29





















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0824			82	492	493
B-0825			100	506	507
B-0826			97	458	459
B-0827			100	659	660
B-0828			97	514	515

4.30

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0829			63	458	459
B-830			70	588	589
B-0831			100	428	429
B-0832			81	480	481
B-0833			73	442	443
B-0834			79	486	487
B-0835			5	400	401

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0836			28	440	441
B-0837			81	426	427
B-0838			84	540	541
B-0839			80	588	589
B-0840			71	453	454
B-0841			55	472	473
B-0842			71	430	431
B-0843			68	492	493
B-0844			61	530	531
B-0845			84	516	517

SUBSTITUTESHEET (RULE 26)


Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0846			87	440	441
B-0847			86	536	537
B-0848			79	506	507
B-0849			81	506	507
B-0850			69	476	477
B-0851			83	462	463
B-0852			77	454	455
B-0853			87	463	464
B-0854			73	463	464
B-0855			92	463	464

SUBSTITUTESHEET (RULE 26)

4.33

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0856			75	492	493
B-0857			86	506	507
B-0858			84	458	459
B-0859			80	659	660
B-0860			94	514	515





















4.34

















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0861			84	583	584
B-0862			96	475	476
B-0863			69	423	424
B-0864			86	437	438
B-0865			62	395	-
B-0866			81	421	422
B-0867			100	535	536

SUBSTITUTE SHEET (RULE 28)

SUBSTITUTE SHEET (RULE 28)


Examples	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0868			89	583	584
B-0869			100	448	449
B-0870			100	425	426
B-0871			100	487	488
B-0872			78	501	502
B-0873			78	471	472
B-0874			92	475	476
B-0875			37	458	459
B-0876			69	507	508
B-0877			70	445	446

SUBSTITUTE SHEET (RULE 26)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-0878			91	431	432
B-0879			92	511	512
B-0880			89	410	411
B-0881			84	490	491
B-0882			85	500	501
B-0883			85	424	425
B-0884			86	532	533

SUBSTITUTE SHEET (RULE 26)

4.37



Example#	R ²	R ¹	% Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0885			51	583	-
B-0886			97	475	-
B-0887			29	423	424
B-0888			82	437	438
B-0889			93	395	396
B-0890			91	421	422
B-0891			43	535	536

SUBSTITUTE SHEET (RULE 26)


4.38

Example#	R ²	R ¹	% Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0892			62	583	584
B-0893			95	448	449
B-0894			100	425	426
B-0895			76	487	488
B-0896			62	501	502
B-0897			80	471	472
B-0898			79	475	476
B-0899			70	458	459
B-0900			82	507	508
B-0901			43	445	446

SUBSTITUTE SHEET (RULE 26)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0902			93	431	432
B-0903			100	511	512
B-0904			95	410	411
B-0905			89	480	491
B-0906			69	500	501
B-0907			28	424	425
B-0908			64	532	533

SUBSTITUTE SHEET (RULE 26)



Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0909			83	542	543
B-0910			80	434	435
B-0911			91	382	383
B-0912			100	396	397
B-0913			94	354	355
B-0914			95	380	381
B-0915			98	484	495

SUBSTITUTE SHEET (RULE 26)

44.1


Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0916			84	542	543
B-0917			79	407	408
B-0918			89	384	385
B-0919			91	446	447
B-0920			89	460	461
B-0921			84	430	431
B-0922			81	434	435
B-0923			76	417	418
B-0924			70	466	467
B-0925			64	404	405

SUBSTITUTE SHEET (RULE 26)

44.2

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0926			47	390	391
B-0927			89	470	471
B-0928			53	369	370
B-0929			100	449	450
B-0930			14	459	460
B-0931			41	383	384
B-0932			94	491	492

SUBSTITUTE SHEET (RULE 26)



Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0933			48	447	448
B-0934			44	429	430
B-0935			33	485	486
B-0936			30	479	
B-0937			68	367	368
B-0938			72	479	480
B-0939			76	415	416

SUBSTITUTESHEET (RULE 28)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0940			36	397	398
B-0941			41	441	442
B-0942			27	473	474
B-0943			55	483	484
B-0944			53	473	474
B-0945			82	429	430
B-0946			100	459	460
B-0947			60	425	426
B-0948			100	431	432
B-0949			98	473	474

SUBSTITUTESHEET (RULE 28)

44.5





















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0950			64	419	420
B-0951			100	469	470
B-0952			61	469	470
B-0953			67	425	426
B-0954			62	431	432
B-0955			39	461	462
B-0956			66	429	430
B-0957			93	429	430
B-0958			86	365	366
B-0959			73	451	452

SUBSTITUTESHEET (RULE 26)



44.6

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0960			98	485	486
B-0961			100	489	470
B-0962			100	419	420
B-0963			83	401	402
B-0964			38	429	430
B-0965			90	411	412
B-0966			76	443	444
B-0967			100	443	444
B-0968			100	477	478
B-0969			77	477	478















SUBSTITUTESHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0970			38	461	462
B-0971			95	469	470
B-0972			98	479	480
B-0973			96	485	486
B-0974			74	443	444
B-0975			100	495	496
B-0976			70	453	454
B-0977			100	467	468
B-0978			91	431	432
B-0979			54	491	492



















SUBSTITUTESHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0980			65	469	470



















SUBSTITUTESHEET (RULE 26)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0981			78	382	383
B-0982			82	512	513
B-0983			94	352	353
B-0984			81	404	405
B-0985			84	366	367
B-0986			80	410	411
B-0987			85	324	325















SUBSTITUTE SHEET (FILE 86)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0988			91	364	365
B-0989			88	350	351
B-0990			68	464	465
B-0991			86	512	513
B-0992			79	377	378
B-0993			81	396	397
B-0994			100	354	355
B-0995			75	416	417
B-0996			65	454	455

SUBSTITUTE SHEET (FILE 86)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-0997			64	440	441
B-0998			81	364	365
B-0999			79	460	461
B-1000			84	430	431
B-1001			78	430	431
B-1002			85	400	401
B-1003			83	386	387
B-1004			87	378	379
B-1005			57	387	388

SUBSTITUTE SHEET (RULE 86)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1006			80	387	388
B-1007			54	387	388
B-1008			64	416	417
B-1009			81	430	431
B-1010			81	382	383
B-1011			66	583	584
B-1012			69	438	439

SUBSTITUTE SHEET (RULE 86)

4.53

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1013			53	440	441
B-1014			61	422	423
B-1015			47	388	389
B-1016			74	448	449
B-1017			63	436	437
B-1018			82	458	459
B-1019			41	414	415

SUBSTITUTE SHEET (RULE 86)

4.54

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1020			100	440	441
B-1021			100	388	389
B-1022			74	402	403
B-1023			76	374	375
B-1024			73	360	361
B-1025			100	452	453
B-1026			95	428	429
B-1027			98	436	437
B-1028			100	482	483
B-1029			98	367	368

SUBSTITUTE SHEET (RULE 86)

















Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1030			88	325	326
B-1031			97	415	416
B-1032			64	379	380
B-1033			83	385	386
B-1034			67	419	420
B-1035			73	353	354
B-1036			79	339	340
B-1037			78	415	416
B-1038			100	419	420
B-1039			85	428	430

SUBSTITUTE SHEET (RULE 26)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1040			91	365	366
B-1041			88	367	368
B-1042			78	429	430
B-1043			79	401	402
B-1044			93	429	430
B-1045			100	429	430
B-1046			94	419	420
B-1047			100	431	432
B-1048			58	381	382
B-1049			97	353	354















SUBSTITUTE SHEET (RULE 26)

4.57





















Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1050			100	461	462
B-1051			88	406	407
B-1052			82	366	367
B-1053			21	368	
B-1054			98	354	355
B-1055			100	379	380
B-1056			85	379	380
B-1057			30	368	369

SUBSTITUTESHEET (RULE26)





















4.58

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1058			35	500	501
B-1059			77	479	480
B-1060			37	500	501
B-1061			86	456	457
B-1062			58	496	497
B-1063			59	496	497
B-1064			58	506	

SUBSTITUTESHEET (RULE26)







Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1065			24	466	-
B-1066			100	490	491
B-1067			74	464	465
B-1068			79	472	473
B-1069			97	472	473
B-1070			54	481	482
B-1071			67	473	474
B-1072			35	515	516
B-1073			100	490	491
B-1074			100	464	465

SUBSTITUTE SHEET (RULE 26)















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1075			100	470	471
B-1076			93	490	491
B-1077			100	474	475
B-1078			80	447	448
B-1079			85	454	455
B-1080			100	496	497
B-1081			100	490	491
B-1082			100	500	501
B-1083			93	500	501
B-1084			81	494	495

SUBSTITUTE SHEET (RULE 26)

461

Example#	R ²	R ³	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1085			83	482	483
B-1086			92	490	491
B-1087			100	490	491

462

Example#	R ²	R ³	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1088			97	450	451
B-1089			100	436	437
B-1090			100	456	457
B-1091			100	456	457
B-1092			96	490	491
B-1093			100	490	491
B-1094			100	474	475

SUBSTITUTESHEET (RULE 26)











SUBSTITUTESHEET (RULE 26)















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1095			81	470	471
B-1096			77	450	451
B-1097			100	436	437
B-1098			93	466	467
B-1099			100	490	491
B-1100			47	482	-
B-1101			64	462	463
B-1102			98	530	531
B-1103			65	472	-
B-1104			88	441	442

SUBSTITUTESHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1105			100	464	465
B-1106			91	486	487
B-1107			96	447	448
B-1108			55	561	562
B-1109			100	498	499
B-1110			73	548	549
B-1111			94	505	506
B-1112			100	568	569
B-1113			100	485	486
B-1114			73	426	427

SUBSTITUTESHEET (RULE 26)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1115			30	389	390
B-1116			100	568	569
B-1117			83	500	501
B-1118			55	473	-
B-1119			70	514	515





















Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1120			84	400	401
B-1121			86	420	421
B-1122			90	400	401
B-1123			100	454	455
B-1124			91	442	443
B-1125			50	512	513
B-1126			85	454	455

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1127			93	411	412
B-1128			87	436	437
B-1129			78	422	423
B-1130			96	422	423
B-1131			84	440	441
B-1132			77	454	455
B-1133			62	428	429
B-1134			91	472	473
B-1135			85	440	441
B-1136			82	472	473



SUBSTITUTE SHEET (RULE 86)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1137			95	472	473
B-1138			100	472	473
B-1139			100	472	473
B-1140			92	472	473
B-1141			100	472	473
B-1142			88	420	421
B-1143			90	400	401
B-1144			87	454	455
B-1145			93	404	405
B-1146			90	422	423

SUBSTITUTE SHEET (RULE 86)


Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1147			100	454	455
B-1148			87	422	423
B-1149			87	440	441
B-1150			90	404	405
B-1151			82	422	423
B-1152			85	422	423
B-1153			90	420	421
B-1154			78	464	465
B-1155			79	454	455
B-1156			95	392	393

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1157			81	405	406

SUBSTITUTE SHEET (RULE 26)

471



Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1158			54	396	397
B-1159			42	526	527
B-1160			27	366	367
B-1161			58	418	419
B-1162			62	380	381
B-1163			58	424	425
B-1164			67	338	339

SUBSTITUTE SHEET (RULE 26)

472

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1165			66	378	379
B-1166			65	364	365
B-1167			64	478	479
B-1168			76	526	527
B-1169			70	391	392
B-1170			76	410	411
B-1171			82	368	369
B-1172			73	430	431
B-1173			74	468	469
B-1174			83	454	455

SUBSTITUTE SHEET (RULE 26)

4/73

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1175			76	378	379
B-1176			96	474	475
B-1177			94	444	445
B-1178			90	444	445
B-1179			57	414	415
B-1180			75	400	401
B-1181			66	392	393
B-1182			74	401	402
B-1183			62	401	402
B-1184			51	401	402

SUBSTITUTE SHEET (RULE 26)

4/74

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1185			80	430	431
B-1186			86	444	445
B-1187			74	396	397
B-1188			76	587	588
B-1189			60	452	453

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1190			44	454	455
B-1191			47	436	437
B-1192			50	402	403
B-1193			62	462	463
B-1194			49	450	451
B-1195			61	472	473
B-1196			52	428	429

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1197			54	454	455
B-1198			44	402	403
B-1199			67	416	417
B-1200			45	388	389
B-1201			52	374	375
B-1202			100	466	467
B-1203			91	442	443
B-1204			100	450	451
B-1205			83	496	497
B-1206			97	381	382

SUBSTITUTE SHEET (RULE 26)

4.77

















Example#	R ¹	R ²	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-1207			100	339	340
B-1208			80	429	430
B-1209			69	393	394
B-1210			35	409	410
B-1211			100	433	434
B-1212			83	367	368
B-1213			78	353	354
B-1214			68	429	430
B-1215			65	433	434
B-1216			91	443	444

SUBSTITUTESHEET (RULE 28)















4.78

Example#	R ¹	R ²	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-1217			99	379	380
B-1218			92	381	382
B-1219			74	443	444
B-1220			67	415	416
B-1221			14	443	444
B-1222			19	443	444
B-1223			71	433	434
B-1224			100	445	446
B-1225			76	395	396
B-1226			58	367	368

SUBSTITUTESHEET (RULE 28)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1227			98	475	476
B-1228			71	420	421
B-1229			85	380	381
B-1230			10	382	-
B-1231			66	368	369
B-1232			100	393	394
B-1233			96	393	394
B-1234			66	382	383

SUBSTITUTE SHEET (RULE 86)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1235			50	514	515
B-1236			100	493	494
B-1237			91	514	515
B-1238			100	470	471
B-1239			71	510	511
B-1240			27	510	511
B-1241			73	520	-

SUBSTITUTE SHEET (RULE 86)

481







Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1242			26	480	481
B-1243			100	504	
B-1244			52	478	479
B-1245			100	486	487
B-1246			56	486	487
B-1247			43	495	496
B-1248			61	487	488
B-1249			32	529	530
B-1250			56	504	505
B-1251			58	478	479















SUBSTITUTE SHEET (RULE 26)

482

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1252			98	484	485
B-1253			59	504	505
B-1254			100	488	488
B-1255			96	461	
B-1256			79	468	469
B-1257			63	510	511
B-1258			100	504	505
B-1259			95	514	515
B-1260			92	514	515
B-1261			98	508	509

SUBSTITUTE SHEET (RULE 26)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-1262			97	496	497
B-1263			100	504	505
B-1264			100	504	505

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec (M+H)	Observed Mass Spec (M+H)
B-1265			100	464	465
B-1266			79	466	451
B-1267			100	470	471
B-1268			87	470	471
B-1269			100	504	505
B-1270			100	504	505
B-1271			56	488	489

485

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1272			98	484	485
B-1273			90	464	465
B-1274			87	450	451
B-1275			94	480	481
B-1276			100	504	505
B-1277			60	496	511
B-1278			68	476	477
B-1279			100	544	545
B-1280			68	486	-
B-1281			98	455	456

SUBSTITUTE SHEET (RULE 26)

486

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1282			100	478	479
B-1283			58	500	501
B-1284			58	461	462
B-1285			65	575	576
B-1286			87	512	513
B-1287			79	562	563
B-1288			100	519	520
B-1289			77	582	583
B-1290			100	509	510
B-1291			91	440	441

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1282			35	403	404
B-1293			73	582	583
B-1294			49	514	515
B-1295			48	487	-
B-1296			76	528	529

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1297			62	447	448
B-1298			66	452	453
B-1299			65	479	431
B-1300			71	444	445
B-1301			100	472	473
B-1302			75	410	411
B-1303			74	424	425

489

Example#	R ¹	R ²	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1304			11	430	431
B-1305			2	424	-
B-1306			30	433	434
B-1307			100	522	523
B-1308			100	508	509
B-1308			100	446	449
B-1310			26	430	431
B-1311			45	397	398
B-1312			14	507	508
B-1313			67	450	451

SUBSTITUTE SHEET (RULE 26)

490

Example#	R ¹	R ²	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1314			69	444	445
B-1315			57	450	451
B-1316			75	383	394
B-1317			100	461	462
B-1318			31	450	451
B-1319			23	464	465
B-1320			59	512	513

SUBSTITUTE SHEET (RULE 26)

Example# R² R¹ %Yield Calcd. Mass Spec (M+H) Observed Mass Spec (M+H)

B-1328			29	425	426
B-1329			67	450	451
B-1330			59	436	437
B-1331			45	436	437
B-1332			81	454	455
B-1333			23	468	469
B-1334			53	442	443
B-1335			81	486	487
B-1336			69	454	455
B-1337			67	486	487

SUBSTITUTE SHEET (RULE 86)

SUBSTITUTE SHEET (RULE 86)

493



Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1338			39	486	487
B-1339			61	486	487
B-1340			49	486	487
B-1341			55	486	487
B-1342			51	486	487
B-1343			72	434	435
B-1344			52	414	415
B-1345			43	468	469
B-1346			40	418	419
B-1347			67	436	437


SUBSTITUTE SHEET (RULE 26)















494





















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1348			39	488	489
B-1349			68	436	437
B-1350			73	454	455
B-1351			54	418	419
B-1352			77	436	437
B-1353			66	436	437
B-1354			58	434	435
B-1355			77	478	479
B-1356			50	468	469
B-1357			36	406	407

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1358			39	419	420



Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1359			95	552	553
B-1360			77	444	445
B-1361			100	392	393
B-1362			85	406	407
B-1363			100	364	365
B-1364			99	390	391
B-1365			92	504	505

Exemplar	R ³	R ¹	% yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1366			100	552	553
B-1367			100	417	418
B-1368			86	384	395
B-1369			100	456	457
B-1370			100	470	471
B-1371			77	440	441
B-1372			100	444	445
B-1373			42	427	428
B-1374			60	476	477
B-1375			84	414	415

SUBSTITUTE SHEET (RULE 26)

Example	R ¹	R ²	% Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1376			87	400	401
B-1377			100	480	481
B-1378			95	379	380
B-1379			83	459	460
B-1380			88	469	470
B-1381			84	383	384
B-1382			85	501	502

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1390			44	494	495
B-1391			50	456	457
B-1392			47	451	452
B-1393			44	444	445
B-1394			52	460	461
B-1395			77	440	441
B-1396			58	451	452
B-1397			64	460	461
B-1398			65	504	505
B-1399			50	494	495

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1383			46	416	417
B-1384			56	432	433
B-1385			59	426	427
B-1386			50	427	428
B-1387			12	427	428
B-1388			66	504	505
B-1389			48	460	461

501

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1400			74	440	441
B-1401			76	462	463
B-1402			65	462	463
B-1403			64	445	446
B-1404			70	512	513
B-1405			57	512	513
B-1406			73	512	513
B-1407			80	512	513
B-1408			2	512	513
B-1409			62	512	513

SUBSTITUTE SHEET (RULE 26)

502

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1410			42	512	513
B-1411			19	462	463
B-1412			74	462	463
B-1413			75	494	495
B-1414			68	462	463
B-1415			48	462	463
B-1416			48	494	495
B-1417			57	494	495
B-1418			49	494	495
B-1419			39	494	495

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1420			72	378	379
B-1421			74	406	407
B-1422			68	394	395
B-1423			57	408	409
B-1424			77	422	423
B-1425			26	408	409
B-1426			41	406	407
B-1427			37	404	405
B-1428			60	456	457
B-1429			2	418	419

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1430			61	442	443
B-1431			64	428	429
B-1432			71	429	430
B-1433			74	462	463
B-1434			88	466	467
B-1435			75	481	482
B-1436			71	504	505

SUBSTITUTE SHEET (RULE 26)

505

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1437			63	468	469
B-1438			76	502	503
B-1439			70	545	546
B-1440			62	535	536
B-1441			82	608	
B-1442			79	555	556
B-1443			28	513	514
B-1444			75	522	523
B-1445			74	526	527
B-1446			70	570	571

SUBSTITUTE SHEET (RULE 26)

506

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1447			73	506	507
B-1448			76	530	531
B-1449			82	530	531
B-1450			83	530	531
B-1451			74	530	531
B-1452			76	530	531
B-1453			73	530	531
B-1454			81	498	499
B-1455			83	498	499
B-1456			79	498	499



SUBSTITUTE SHEET (RULE 26)















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1457			74	496	497
B-1458			82	540	541
B-1459			80	476	477
B-1460			78	530	531
B-1461			82	487	488
B-1462			71	540	541
B-1463			78	546	547
B-1464			83	480	481
B-1465			84	496	497
B-1466			80	540	541





















SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1467			79	476	477
B-1468			79	530	531
B-1469			75	487	488
B-1470			80	480	481
B-1471			74	486	497
B-1472			75	540	541
B-1473			77	476	477
B-1474			81	530	531
B-1475			70	487	488
B-1476			54	540	541





















SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1477			79	646	647

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1478			87	394	395
B-1479			41	504	505
B-1480			87	451	452
B-1481			18	416	417
B-1482			77	427	428
B-1483			74	406	407
B-1484			82	422	423





















Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1485			85	460	461
B-1486			84	406	407
B-1487			71	392	393
B-1488			82	427	428
B-1489			87	444	445
B-1490			81	462	463
B-1491			87	462	463
B-1492			69	364	365
B-1493			53	417	418
B-1494			17	426	427

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1495			79	460	461
B-1496			80	444	445
B-1497			82	460	461
B-1498			72	378	379
B-1499			70	432	433
B-1500			68	390	391
B-1501			63	394	395
B-1502			78	408	409
B-1503			55	404	405
B-1504			39	418	419





















SUBSTITUTE SHEET (RULE 26)

513



Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1505			68	540	541
B-1506			69	462	463
B-1507			70	496	497
B-1508			65	480	481
B-1509			56	414	415
B-1510			62	400	401
B-1511			30	468	469
B-1512			50	476	477
B-1513			44	540	541
B-1514			42	530	531















SUBSTITUTESHEET (RULE 26)

514





















Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1515			68	486	487
B-1516			27	429	430
B-1517			92	466	467
B-1518			33	379	380
B-1519			50	393	394
B-1520			82	435	436
B-1521			86	509	510
B-1522			12	405	406
B-1523			59	459	460
B-1524			81	459	460

SUBSTITUTESHEET (RULE 26)

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1525			57	419	420





















Examples#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1526			73	410	411
B-1527			66	520	521
B-1528			91	467	468
B-1529			73	432	433
B-1530			91	443	444
B-1531			74	422	423
B-1532			68	438	439

517

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1533			84	476	477
B-1534			72	422	423
B-1535			78	408	409
B-1536			77	443	444
B-1537			86	460	461
B-1538			74	478	479
B-1539			85	478	479
B-1540			71	380	381
B-1541			71	433	434
B-1542			89	442	443

SUBSTITUTE SHEET (RULE 28)

518

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1543			82	476	477
B-1544			76	460	461
B-1545			77	476	477
B-1546			76	394	395
B-1547			58	448	449
B-1548			83	406	407
B-1549			67	410	411
B-1550			37	424	425
B-1551			55	420	421
B-1552			23	434	435

SUBSTITUTE SHEET (RULE 28)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1553			83	566	557
B-1554			84	478	479
B-1555			93	512	513
B-1556			83	496	497
B-1557			62	430	431
B-1558			45	416	417
B-1559			67	484	485
B-1560			16	492	493
B-1561			84	556	557
B-1562			74	546	547

SUBSTITUTE SHEET (RULE 26)

Examples	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1563			72	512	513
B-1564			57	445	446
B-1565			64	482	483
B-1566			71	395	396
B-1567			54	409	410
B-1568			76	451	452
B-1569			70	525	526
B-1570			79	421	422
B-1571			60	475	476
B-1572			77	475	476

SUBSTITUTE SHEET (RULE 26)

WO 98/52940



PCT/US98/10436

521

WO 98/52940

522

PCT/US98/10436

Example#	R ²	R ¹	%Yield	Calcd. Mass Spec	Observed Mass Spec (M+H)
B-1573			66	435	436

5

10

Proton NMR data for selected members from Examples B-0001 through B-1573 are shown in the following table.

15

20

25

30

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

Plate ID	¹ H NMR(solvent), δ ppm
B-0120	(DMF-d7) d 8.53(bd, J = 4.99Hz, 2H), 7.44-7.24(m, 11H), 4.41(s, 2H), 4.31(br, 2H)
B-0224	(DMF-d7) d 8.56(bd, J = 4.99Hz, 2H), 7.78-7.69(m, 4H), 7.39-7.19(m, 6H), 4.23(br, 2H)
B-0235	(DMF-d7) d 8.47(br, 2H), 7.91-7.75(m, 3H), 7.57-7.53(m, 1H), 7.38-7.34(m, 2H), 7.21-7.13(m, 4H), 4.20(br, 2H)
B-0244	(CDCl ₃ /CD ₃ OD) d 8.38(d, J = 5.38 Hz, 1H), 7.62-7.32(m, 9H), 7.04-6.95(m, 4H), 6.86-6.80(m, 2H), 4.52(d, J = 6.96 Hz, 1H), 1.40(d, J = 6.88 Hz, 3H)
B-0256	(DMF-d7) d 8.45(bd, J = 2.85, 2H), 7.87(br s, 4H), 7.76-7.75(m, 2H), 7.53-7.33(m, 5H), 7.18-7.13(br, 4H)
B-0426	(DMF-d7), 1.32(br, 3H), 1.67(br, 3H), 4.17(br, 2H), 5.12(br, 1H), 7.50(m, 6H), 8.77(m, 2H), 13.54(br, 1H)
B-0438	(DMSO), 1.14(t, J = 6.9 Hz, 3H), 4.54(m, 1H), 6.89(br, 2H), 7.21(br, 4H), 7.45(s, 1H), 7.61(q, J = 8.7 Hz, 2H), 8.52(d, J = 5.2 Hz, 2H)
B-0466	(DMF-d7), 1.67(bnd, J = 30.6 Hz, 3H), 4.61 (br, 1H), 7.25(m, 6H), 7.65(m, 3H), 8.59(br, 2H), 13.34(bnd, J = 34.8 Hz, 1H)
B-0473	(CD ₃ OD), 1.53(d, J = 7.2 Hz, 3H), 4.59(q, J = 7.2 Hz, 1H), 6.88(d, J = 4 Hz, 1H), 7.09(m, 3H), 7.15(dd, J = 4.4, 1.6 Hz, 2H), 7.26(m, 2H), 8.46(d, J = 6.0 Hz, 2H)
B-0477	(DMF), 1.80(br, 3H), 2.35(s, 1H), 4.98(br, 1H), 7.38(m, 6H), 7.85(m, 2H), 8.45(br, 1H), 8.75(d, J = 6.0 Hz, 2H)
B-0479	(Methanol-d4), 1.57(d, J = 5.6 Hz, 3H), 4.74(br, 1H), 7.23(m, 4H), 7.60(m, 2H), 7.81(m, 4H), 8.67(br, 2H)
B-0487	(DMF), 1.78(s, 3H), 2.76(br, 6H), 4.85(br, 1H), 7.42(br, 2H), 7.54(br, 2H), 7.66(br, 3H), 8.82(s, 2H)
B-0566	(CD ₃ OD), 1.38(d, J = 7.2 Hz, 3H), 4.15(br, 2H), 4.50(br, 1H), 7.04(br, 2H), 7.18(br, 2H), 7.30(m, 7H), 8.45(m, 2H)
B-0569	(CD ₃ OD), 1.56(br, 3H), 4.66(q, J = 6.7 Hz, 1H), 7.17(m, 8H), 7.56(m, 2H), 8.47(s, 2H)
B-0574	(Methanol-d4), 1.49(br, 3H), 3.86(br, 3H), 4.60(br, 1H), 6.92(br, 2H), 7.19(br, 2H), 7.31(br, 2H), 7.76(m, 4H), 8.60(br, 2H)
B-0639	(DMF-d7), 1.58(bnd, J = 30.0 Hz, 3H), 4.62(br, 1H), 7.25(m, 6H), 7.60(m, 4H), 8.59(br, 2H), 13.30(bnd, J = 12.3 Hz)
B-0643	7.18(m, 2H), 7.32(dd, J = 6.0, 4.4 Hz, 1H), 7.70(dd, J = 9.0, 5.8 Hz, 1H), 8.43(dd, J = 4.8, 3.2 Hz, 2H)
B-0650	(CD ₃ OD), 1.58(br, 3H), 4.62(q, J = 6.6 Hz, 1H), 6.93(br, 1H), 7.17(m, 5H), 7.31(br, 2H), 8.51(br, 2H)
B-0656	(CDCl ₃ /CD ₃ OD) d 8.48 (d, J = 5.30 Hz, 2H), 7.72-7.59(m, 4H), 7.14-7.10(m, 2H), 7.03-6.97(m, 4H), 4.80(q, J = 7.57Hz, 1H), 1.43(d, J = 7.26Hz, 3H)
B-0663	(CD ₃ OD), 1.52(d, J = 6.8 Hz, 3H), 3.75(s, 3H), 7.21(m, 2H), 7.42(m, 2H), 7.57(s, 1H), 7.76(s, 1H), 7.98(br, 2H), 8.76(br, 2H)
B-1165	H ₂ , 2H), 3.06(m, 1H), 3.43(q, J = 6.1 Hz, 2H), 7.02(m, 2H), 7.14(m, 2H), 7.41(m, 2H), 8.59(d, J = 5.6 Hz, 2H)
B-1169	= 1.8 Hz, 1H), 7.04(t, J = 6.6 Hz, 2H), 7.14(m, 2H), 7.36(m, 2H), 8.39(d, J = 1.8 Hz, 1H), 8.60(m, 2H)
B-1171	6.83(br, 1H), 7.02(t, J = 8.7 Hz, 2H), 7.15(d, J = 5.6 Hz, 2H), 7.40(m, 2H), 8.59(d, J = 5.0 Hz, 2H)


SUBSTITUTE SHEET (RULE 86)

Plate ID	¹ H NMR(solvent), δ ppm
B-1179	(CDCl ₃), 1.94(br, 2H), 2.53(s, 3H), 2.85(t, J = 6.2 Hz, 2H), 3.65(br, 2H), 6.15(br, 1H), 7.04(m, 3H), 7.22(m, 3H), 7.41(br, 4H), 8.60(br, 2H)
B-1183	(CDCl ₃), 2.00(br, 2H), 2.85(br, 2H), 3.64(br, 2H), 7.03(br, 3H), 7.17(br, 2H), 7.36(br, 2H), 7.66(br, 2H), 8.60(br, 2H), 8.77(br, 2H)
B-1194	(DMSO), 1.76(br, 2H), 2.66(br, 2H), 2.91(br, 2H), 4.30(s, 2H), 7.18(br, 5H), 7.35(m, 6H), 8.54(d, J = 5.8 Hz, 2H)
B-1200	(DMSO), 1.17(br, 3H), 1.76(br, 2H), 2.71(br, 2H), 2.97(br, 4H), 7.18(br, 4H), 7.36(br, 2H), 8.54(br, 2H)
B-1206	(DMSO), 1.03(s, 6H), 1.68(br, 2H), 2.63(br, 2H), 3.00(br, 2H), 3.65(br, 1H), 5.69(m, 2H), 7.16(br, 4H), 7.35(br, 2H), 8.54(br, 2H)
B-1216	(DMSO), 1.75(m, 2H), 2.14(s, 6H), 2.86(br, 2H), 3.10(br, 2H), 7.04(br, 3H), 7.18(br, 4H), 7.35(m, 2H), 7.47(br, 1H), 8.54(d, J = 4.8 Hz, 2H)
B-1226	(DMF), 1.25(br, 3H), 2.01(br, 2H), 3.35(br, 4H), 6.20(s, 1H), 6.30(s, 1H), 7.42(br, 4H), 7.65(br, 2H), 8.77(s, 2H)
B-1360	(DMSO-d6), 1.80(br, 4H), 2.82(br, 1H), 2.94(br, 1H), 3.10(br, 1H), 3.60(br, 1H), 4.54(br, 1H), 7.18(m, 4H), 7.30(m, 4H), 7.46(m, 2H), 8.54(br, 2H)
B-1361	(DMSO-d6), 0.99(br, 6H), 1.73(br, 4H), 2.89(br, 2H), 3.03(m, 1H), 4.04(br, 2H), 4.44(m, 1H), 7.18(m, 4H), 7.30(m, 2H), 8.57(d, J = 4.84 Hz, 2H)
B-1363	(DMSO-d6), 1.78(br, 4H), 2.01(s, 3H), 2.89(br, 1H), 3.05(br, 1H), 3.34(br, 1H), 3.85(br, 1H), 4.48(br, 1H), 7.12(br, 2H), 7.21(br, 2H), 7.30(br, 2H), 8.69(br, 2H)
B-1364	(CDCl ₃), 0.78(bnd, J = 3.0, 2.9 Hz, 2H), 1.00(s, 2H), 1.76(m, 1H), 1.86(b, 4H), 2.84(m, 1H), 2.99(m, 1H), 3.16(m, 1H), 4.33(br, 1H), 4.70(br, 1H), 6.99(m, 2H), 7.14(s, 2H), 7.29(m, 2H), 8.64(s, 2H)
B-1368	(CDCl ₃), 1.89(s, 4H), 2.65(m, 1H), 2.86(m, 1H), 3.06(m, 1H), 3.43(s, 3H), 3.93(d, J = 13.2 Hz, 1H), 4.08(d, J = 13.5 Hz, 1H), 4.18(d, J = 13.5 Hz, 1H), 4.68(d, J = 12.4 Hz, 1H), 7.60(m, 2H), 7.12(s, 2H), 7.26(m, 2H), 8.63(s, 2H)

SUBSTITUTE SHEET (RULE 86)

525

5



Examples B-1574 through B-1597 are prepared from Scaffold C-27

Example# R² R¹

B-1574					
B-1575					
B-1576					
B-1577					
B-1578					
B-1579					
B-1580					

526


By analogy to the procedure identified above for the preparation of Examples B0001-B0048, the following examples B-1574 through B-2269 are prepared.

B-1581											
B-1582											
B-1583											
B-1584											
B-1585											
B-1586											
B-1587											
B-1588											
B-1589											
B-1590											
B-1591											

SUBSTITUTE SHEET (RULE 26)

B-1592							
B-1593							
B-1594							
B-1595							
B-1596							
B-1597							

SUBSTITUTE SHEET (RULE 26)



Examples B-1598 through B-1621 are prepared from Scaffold C-28


Example#	R ²	R ¹			
B-1598					
B-1599					
B-1600					
B-1601					
B-1602					
B-1603					
B-1604					

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹			
B-1605					
B-1606					
B-1607					
B-1608					
B-1609					
B-1610					
B-1611					
B-1612					
B-1613					
B-1614					

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	
B-1615			
B-1616			
B-1617			
B-1618			
B-1619			
B-1620			
B-1621			



Examples B-1622 through B-1645 are prepared from Scaffold C-38


Example#	R ²	R ¹	
B-1622			
B-1623			
B-1624			
B-1625			
B-1626			
B-1627			
B-1628			

Example#	R ¹	R ²
B-1628		
B-1630		
B-1631		
B-1632		
B-1633		
B-1634		
B-1635		
B-1636		
B-1637		
B-1638		

SUBSTITUTE SHEET (RULE 26)

Example	R ²	R ¹
B-1638		
B-1640		
B-1641		
B-1642		
B-1643		
B-1644		
B-1645		

SUBSTITUTE SHEET (RULE 26)



Examples B-1646 through B-1669 are prepared from Scaffold C-39

Example#	R ²	R ¹			
B-1646					
B-1647					
B-1648					
B-1649					
B-1650					
B-1651					
B-1652					


SUBSTITUTESHEET (RULE 26)

Example#	R ²	R ¹			
B-1653					
B-1654					
B-1655					
B-1656					
B-1657					
B-1658					
B-1659					
B-1660					
B-1661					
B-1662					

SUBSTITUTESHEET (RULE 26)

Examples	R ²	R ¹			
B-1663					
B-1664					
B-1665					
B-1666					
B-1667					
B-1668					
B-1669					

SUBSTITUTE SHEET (RULE 26)



Examples B-1670 through B-1693 are prepared from Scaffold C-65

Examples	R ²	R ¹			
B-1670					
B-1671					
B-1672					
B-1673					
B-1674					
B-1675					
B-1676					

SUBSTITUTE SHEET (RULE 26)


Example#	R ²	R ¹	
B-1677			
B-1678			
B-1679			
B-1680			
B-1681			
B-1682			
B-1683			
B-1684			
B-1685			
B-1686			

SUBSTITUTESHEET (RULE 26)

Example#	R ²	R ¹	
B-1687			
B-1688			
B-1689			
B-1690			
B-1691			
B-1692			
B-1693			

SUBSTITUTESHEET (RULE 26)

541



Examples B-1694 through B-1717 are prepared from Scaffold C-66

Example#	R ²	R ¹			
B-1694					
B-1695					
B-1696					
B-1697					
B-1698					
B-1699					
B-1700					


SUBSTITUTE SHEET (RULE 26)

542

Example#	R ²	R ¹			
B-1701					
B-1702					
B-1703					
B-1704					
B-1705					
B-1706					
B-1707					
B-1708					
B-1709					
B-1710					





















SUBSTITUTE SHEET (RULE 26)

Examples	R ²	R ¹				
B-1711						
B-1712						
B-1713						
B-1714						
B-1715						
B-1716						
B-1717						

















Examples B-1718 through B-1741 are prepared from Scaffold C-69

Examples	R ²	R ¹				
B-1718						
B-1719						
B-1720						
B-1721						
B-1722						
B-1723						
B-1724						


Example#	R ²	R ¹			
B-1725					
B-1726					
B-1727					
B-1728					
B-1729					
B-1730					
B-1731					
B-1732					
B-1733					
B-1734					

SUBSTITUTE SHEET (RULE 86)

Example#	R ²	R ¹			
B-1735					
B-1736					
B-1737					
B-1738					
B-1739					
B-1740					
B-1741					

SUBSTITUTE SHEET (RULE 86)

547



Examples B-1742 through B-1765 are prepared from Scaffold C-70

Example#	R ²	R ¹
B-1742		
B-1743		
B-1744		
B-1745		
B-1746		
B-1747		
B-1748		

SUBSTITUTE SHEET (RULE 26)

548

Example#	R ²	R ¹
B-1749		
B-1750		
B-1751		
B-1752		
B-1753		
B-1754		
B-1755		
B-1756		
B-1757		
B-1758		


SUBSTITUTE SHEET (RULE 26)

549

Example#	R ²	R ¹			
B-1759					
B-1760					
B-1761					
B-1762					
B-1763					
B-1764					
B-1765					

SUBSTITUTE SHEET (RULE 29)

550



Examples B-1766 through B-1769 are prepared from Scaffold C-71

Example	R ²	R ¹			
B-1766					
B-1767					
B-1768					
B-1769					
B-1770					
B-1771					
B-1772					

SUBSTITUTE SHEET (RULE 29)


Examples	R ²	R ¹	
B-1773			
B-1774			
B-1775			
B-1776			
B-1777			
B-1778			
B-1779			
B-1780			
B-1781			
B-1782			

SUBSTITUTE SHEET (RULE 26)

Examples	R ²	R ¹	
B-1783			
B-1784			
B-1785			
B-1786			
B-1787			
B-1788			
B-1789			

SUBSTITUTE SHEET (RULE 26)

553



Examples B-1790 through B-1813 are prepared from Scaffold C-72

Example#	R ²	R ¹			
B-1790					
B-1791					
B-1792					
B-1793					
B-1794					
B-1795					
B-1796					


SUBSTITUTE SHEET (RULE 26)

554

Example#	R ²	R ¹			
B-1797					
B-1798					
B-1799					
B-1800					
B-1801					
B-1802					
B-1803					
B-1804					
B-1805					
B-1806					

SUBSTITUTE SHEET (RULE 26)





















Examples	R ²	R ¹	
B-1807			
B-1808			
B-1809			
B-1810			
B-1811			
B-1812			
B-1813			



Examples B-1814 through B-1837 are prepared from Scaffold C-73















Examples	R ²	R ¹	
B-1814			
B-1815			
B-1816			
B-1817			
B-1818			
B-1819			
B-1820			

557

Example#	R ²	R ¹			
B-1821					
B-1822					
B-1823					
B-1824					
B-1825					
B-1826					
B-1827					
B-1828					
B-1829					
B-1830					


SUBSTITUTESHEET (RULE 28)

558

Example#	R ²	R ¹			
B-1831					
B-1832					
B-1833					
B-1834					
B-1835					
B-1836					
B-1837					

SUBSTITUTESHEET (RULE 28)

559



Examples B-1838 through B-1861 are prepared from Scaffold C-33

Example#	R ²	R ¹	
B-1838			
B-1839			
B-1840			
B-1841			
B-1842			
B-1843			
B-1844			

SUBSTITUTE SHEET (RULE 26)

560

Example#	R ²	R ¹	
B-1845			
B-1846			
B-1847			
B-1848			
B-1849			
B-1850			
B-1851			
B-1852			
B-1853			
B-1854			


SUBSTITUTE SHEET (RULE 26)

561

Example#	R ²	R ¹			
B-1855					
B-1856					
B-1857					
B-1858					
B-1859					
B-1860					
B-1861					

SUBSTITUTE SHEET (RULE 26)

562



Examples B-1862 through B-1885 are prepared from Scaffold C-45

Example#	R ²	R ¹			
B-1862					
B-1863					
B-1864					
B-1865					
B-1866					
B-1867					
B-1868					

SUBSTITUTE SHEET (RULE 26)


Example#	R ²	R ¹			
B-1869					
B-1870					
B-1871					
B-1872					
B-1873					
B-1874					
B-1875					
B-1876					
B-1877					
B-1878					

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹			
B-1879					
B-1880					
B-1881					
B-1882					
B-1883					
B-1884					
B-1885					

SUBSTITUTE SHEET (RULE 26)

565



Examples B-1886 through B-1909 prepared from Scaffold C-42

Example#	R ²	R ¹			
B-1886					
B-1887					
B-1888					
B-1889					
B-1890					
B-1891					
B-1892					


SUBSTITUTE SHEET (RULE 26)

566

Example#	R ²	R ¹			
B-1893					
B-1894					
B-1895					
B-1896					
B-1897					
B-1898					
B-1899					
B-1900					
B-1901					
B-1902					




















SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹	
B-1903			
B-1904			
B-1905			
B-1906			
B-1907			
B-1908			
B-1909			

















Examples B-1910 through B-1933 are prepared from Scaffold C-44


Example#	R ²	R ¹	
B-1910			
B-1911			
B-1912			
B-1913			
B-1914			
B-1915			
B-1916			

Example#	R ²	R ¹			
B-1917					
B-1918					
B-1919					
B-1920					
B-1921					
B-1922					
B-1923					
B-1924					
B-1925					
B-1926					

SUBSTITUTE SHEET (RULE 86)

Example#	R ²	R ¹			
B-1927					
B-1928					
B-1929					
B-1930					
B-1931					
B-1932					
B-1933					

SUBSTITUTE SHEET (RULE 86)



Examples B-1834 through B-1957 are prepared from Scaffold C-41

Example#	R ²	R ¹			
B-1834					
B-1835					
B-1836					
B-1837					
B-1838					
B-1839					
B-1940					


SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹			
B-1841					
B-1842					
B-1843					
B-1844					
B-1845					
B-1846					
B-1847					
B-1848					
B-1849					
B-1850					

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹			
B-1951					
B-1952					
B-1953					
B-1954					
B-1955					
B-1956					
B-1957					

SUBSTITUTESHEET (RULE B9)



Examples B-1958 through B-1981 are prepared from Scaffold C-43

Example#	R ²	R ¹			
B-1958					
B-1959					
B-1960					
B-1961					
B-1962					
B-1963					
B-1964					

SUBSTITUTESHEET (RULE B9)


Example#	R ²	R ¹	
B-1965			
B-1966			
B-1967			
B-1968			
B-1969			
B-1970			
B-1971			
B-1972			
B-1973			
B-1974			

SUBSTITUTESHEET (RULE 96)

Example#	R ²	R ¹	
B-1975			
B-1976			
B-1977			
B-1978			
B-1979			
B-1980			
B-1981			

SUBSTITUTESHEET (RULE 96)

577



Examples B-1982 through B-2005 are prepared from Scaffold C-30

Examples#	R ¹	R ²		
B-1982				
B-1983				
B-1984				
B-1985				
B-1986				
B-1987				
B-1988				

SUBSTITUTE SHEET (RULE 26)


578

Examples#	R ¹	R ²		
B-1989				
B-1990				
B-1991				
B-1992				
B-1993				
B-1994				
B-1995				
B-1996				
B-1997				
B-1998				

SUBSTITUTE SHEET (RULE 26)

Example#	R ¹	R ²	R ³
B-1999			
B-2000			
B-2001			
B-2002			
B-2003			
B-2004			
B-2005			





















SUBSTITUTESHEET (RULE 28)

















Examples B-2008 through B-2029 are prepared from Scaffold C-60

Example#	R ²	R ³
B-2006		
B-2007		
B-2008		
B-2009		
B-2010		
B-2011		
B-2012		


SUBSTITUTESHEET (RULE 28)

Example#	R ²	R ¹			
B-2013					
B-2014					
B-2015					
B-2016					
B-2017					
B-2018					
B-2019					
B-2020					
B-2021					
B-2022					

SUBSTITUTESHEET (RULE 26)

Example#	R ²	R ¹			
B-2023					
B-2024					
B-2025					
B-2026					
B-2027					
B-2028					
B-2029					

SUBSTITUTESHEET (RULE 26)



Examples B-2030 through B-2053 are prepared from Scaffold C-36

Example#	R ²	R ¹					
B-2030							
B-2031							
B-2032							
B-2033							
B-2034							
B-2035							
B-2036							


SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹							
B-2037									
B-2038									
B-2039									
B-2040									
B-2041									
B-2042									
B-2043									
B-2044									
B-2045									
B-2046									

SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹			
B-2047					
B-2048					
B-2049					
B-2050					
B-2051					
B-2052					
B-2053					

SUBSTITUTE SHEET (RULE 26)



Examples B-2054 through B-2077 are prepared from Scaffold C-34

Example#	R ²	R ¹			
B-2054					
B-2055					
B-2056					
B-2057					
B-2058					
B-2059					
B-2060					


SUBSTITUTE SHEET (RULE 26)

Examples	R ²	R ¹				
B-2061						
B-2062						
B-2063						
B-2064						
B-2065						
B-2066						
B-2067						
B-2068						
B-2069						
B-2070						

SUBSTITUTESHEET (RULE 206)

Examples	R ²	R ¹				
B-2071						
B-2072						
B-2073						
B-2074						
B-2075						
B-2076						
B-2077						

SUBSTITUTESHEET (RULE 206)



















Examples B-2078 through B-2101 are prepared from Scaffold C-57

Example#	R ²	R ¹			
B-2076					
B-2079					
B-2080					
B-2081					
B-2082					
B-2083					
B-2084					


SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹			
B-2085					
B-2086					
B-2087					
B-2088					
B-2089					
B-2090					
B-2091					
B-2092					
B-2093					















SUBSTITUTE SHEET (RULE 26)

Example#	R ²	R ¹			
B-2094					
B-2095					
B-2096					
B-2097					
B-2098					
B-2099					
B-2100					
B-2101					





















SUBSTITUTE SHEET (RULE 69)

















Examples B-2102 through B-2125 are prepared from Scaffold C-52

Example#	R ²	R ¹					
B-2102							
B-2103							
B-2104							
B-2105							
B-2106							
B-2107							
B-2108							


SUBSTITUTE SHEET (RULE 28)

Example#	R ²	R ¹			
B-2109					
B-2110					
B-2111					
B-2112					
B-2113					
B-2114					
B-2115					
B-2116					
B-2117					
B-2118					

SUBSTITUTESHEET (RULE 28)

Example#	R ²	R ¹			
B-2119					
B-2120					
B-2121					
B-2122					
B-2123					
B-2124					
B-2125					















SUBSTITUTESHEET (RULE 28)




Examples B-2126 through B-2149 are prepared from Scaffold C-58

Example#	R^2	R^J				
B-2126						
B-2127						
B-2128						
B-2129						
B-2130						
B-2131						
B-2132						















Example#	R^2	R^J				
B-2133						
B-2134						
B-2135						
B-2136						
B-2137						
B-2138						
B-2139						
B-2140						
B-2141						
B-2142						

Example#	R ²	R ¹			
B-2143					
B-2144					
B-2145					
B-2146					
B-2147					
B-2148					
B-2149					





















SUBSTITUTE SHEET (RULE 26)

















Examples B-2150 through B-2173 are prepared from Scaffold C-32

Example#	R ²	R ¹			
B-2150					
B-2151					
B-2152					
B-2153					
B-2154					
B-2155					
B-2156					

SUBSTITUTE SHEET (RULE 26)


Example#	R ²	R ¹			
B-2157					
B-2158					
B-2159					
B-2160					
B-2161					
B-2162					
B-2163					
B-2164					
B-2165					
B-2166					

SUBSTITUTESHEET (RULE 26)

Example#	R ²	R ¹			
B-2167					
B-2168					
B-2169					
B-2170					
B-2171					
B-2172					
B-2173					

SUBSTITUTESHEET (RULE 26)

601



Examples 2174 through B-2197 are prepared from Scaffold C-64

Example#	R ²	R ¹			
B-2174					
B-2175					
B-2176					
B-2177					
B-2178					
B-2179					
B-2180					


SUBSTITUTE SHEET (RULE 89)

602

Example#	R ²	R ¹			
B-2181					
B-2182					
B-2183					
B-2184					
B-2185					
B-2186					
B-2187					
B-2188					
B-2189					
B-2190					

SUBSTITUTE SHEET (RULE 89)





















Example#	R ²	R ¹				
B-2191						
B-2192						
B-2193						
B-2194						
B-2195						
B-2196						
B-2197						



Examples B-2198 through B-2221 re prepared from Scaffold C-22















Example#	R ²	R ¹				
B-2198						
B-2199						
B-2200						
B-2201						
B-2202						
B-2203						
B-2204						

605


Example#	R ²	R ¹			
B-2205					
B-2206					
B-2207					
B-2208					
B-2209					
B-2210					
B-2211					
B-2212					
B-2213					
B-2214					

SUBSTITUTE SHEET (RULE 26)

606

Example#	R ²	R ¹			
B-2215					
B-2216					
B-2217					
B-2218					
B-2219					
B-2220					
B-2221					

SUBSTITUTE SHEET (RULE 26)




Examples B-2222 through B-2245 are prepared from Scaffold C-29

Example#	R ²	R ¹						
B-2222								
B-2223								
B-2224								
B-2225								
B-2226								
B-2227								
B-2228								

Example#	R ²	R ¹						
B-2229								
B-2230								
B-2231								
B-2232								
B-2233								
B-2234								
B-2235								
B-2236								
B-2237								

Example#	R ²	R ¹			
B-2238					
B-2239					
B-2240					
B-2241					
B-2242					
B-2243					
B-2244					
B-2245					

SUBSTITUTESHEET (RULE 26)



Examples B-2246 through B-2288 are prepared from Scaffold C-35

Example#	R ²	R ¹			
B-2246					
B-2247					
B-2248					
B-2249					
B-2250					
B-2251					
B-2252					

SUBSTITUTESHEET (RULE 26)

Example#	R ²	R ¹			
B-2253					
B-2254					
B-2255					
B-2256					
B-2257					
B-2258					
B-2259					
B-2260					
B-2261					
B-2262					

Example#	R ²	R ¹			
B-2263					
B-2264					
B-2265					
B-2266					
B-2267					
B-2268					
B-2269					

613

Examples B-2270 through B-2317

15 In a parallel array reaction block containing 48
fritted vessels, each reaction vessel was charged with
250 mg of polymer bound carbodiimide **B48** (1.0 mmol/g
resin) and a solution of the acid-containing scaffold **C-**
20 **49** in dimethylformamide (0.1 M, 500 μ L). To each slurry
was added a solution of pyridine in dichloromethane (0.2
M, 1000 μ L) followed by a solution of a unique amine **B47**
(0.2 M, 375 μ L) in dimethylformamide. The reaction
mixtures were agitated on a labline benchtop orbital
25 shaker at 250 RPM for 16-20 h at ambient temperature.
The reaction mixtures were filtered into conical vials
and the polymer was washed with 1.5 mL of
dimethylformamide and 2.0 mL of dichloromethane. The
filtrates were evaporated to dryness in a Savant
30 apparatus and dimethylformamide (350 μ L) was added to
each conical vial to dissolve the residue. A solution of
tetrafluorophthalic anhydride (1.0 M, 150 μ L) in


SUBSTITUTE SHEET (RULE 26)

614

dimethylformamide was added to the reconstituted conical
vials and the mixture incubated for 2 hours at ambient
temperature. Polyamine polymer **B33** (4.0 meq N/g resin,
250 mg) and 1.0 mL dichloromethane was then added to the
5 reaction mixture in each conical vial. After agitating
the reaction mixtures for 16 h at 250 RPM on an orbital
shaker at ambient temperature, the mixtures were filtered
through a polypropylene syringe tube fitted with a porous
frit. The polymers were washed twice with
10 dimethylformamide (1.0 mL each) and the filtrates and
washings collected in conical vials. The filtrates were
evaporated to dryness and weighed to afford the desired
amide products **B-2270 through B-2317** as oils or solids.
The analytical data and yields for the products prepared
15 in this manner are listed below.

SUBSTITUTE SHEET (RULE 26)


615



	R ²	Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2270		12	352	353
B-2271		39	432	433
B-2272		26	400	-
B-2273		14	396	397
B-2274		30	434	435
B-2275		43	443	-
B-2276		35	364	365

SUBSTITUTE SHEET (RULE 26)

616



	R ²	Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2277		33	490	-
B-2278		53	460	461
B-2279		10	420	-
B-2280		7	435	436
B-2281		18	401	402
B-2282		22	390	413 ^a *M+Na
B-2283		10	394	417 ^a *M+Na
B-2284		7	423	-
B-2285		23	450	-
B-2286		4	506	-

SUBSTITUTE SHEET (RULE 26)

617

	R ³	Yield	Calcd. Mass Spec.	Observed Mass Spec. M+H	
B-2287		5	437	438	
B-2288		8	435	436	
B-2289		4	450	451	
B-2290		9	456	457	
B-2291		9	415	416	
B-2292		5	366	369	
B-2293		5	366	367	
B-2294		5	381	382	
B-2295		16	410	411	
B-2296		4	483	-	























SUBSTITUTESHEET (RULE26)

618

	R ³	Yield	Calcd. Mass Spec.	Observed Mass Spec. M+H	
B-2297		7	490	-	
B-2298		4	537	-	
B-2299		4	507	508	
B-2300		7	442	-	
B-2301		20	396	397	
B-2302		30	459	-	
B-2303		6	482		
B-2304		5	395	396	
B-2305		10	460	-	
B-2306		11	466	467	





SUBSTITUTESHEET (RULE26)

619

R ²			Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2307			5	421	422
B-2308			26	470	-
B-2309			24	424	425
B-2310			9	348	-
B-2311			21	338	339
B-2312			28	398	399
B-2313			6	410	-
B-2314			15	363	364
B-2315			11	444	-
B-2316			11	418	-

SUBSTITUTESHEET (RULE 26)


620

R ²			Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2317			36	428	-

SUBSTITUTESHEET (RULE 26)

621




















622



By analogy to the procedure identified above for the preparation of Examples B-2270 through B-2317, the following examples B-2318 through B-2461 were prepared.




















	R ²	R ¹ R ³	Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2318			23	426	427
B-2319			23	394	-
B-2320			50	490	491
B-2321			49	426	427
B-2322			40	366	367
B-2323			68	410	411
B-2324			57	456	457

623

	R ²		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2325			41	382	383
B-2326			71	440	441
B-2327			36	464	465
B-2328			32	467	468
B-2329			34	465	466
B-2330			26	364	365
B-2331			38	464	465
B-2332			33	483	484
B-2333			36	378	379

SUBSTITUTESHEET (RULE 26)

624

	R ²		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2334			44	428	429
B-2335			27	406	407
B-2336			41	428	429
B-2337			27	423	424
B-2338			33	469	470
B-2339			52	518	519
B-2340			64	442	443
B-2341			41	350	351
B-2342			34	414	415

SUBSTITUTESHEET (RULE 26)

6/25

	R ²		Yield	Calcd Mass Spec.	Observed Mass Spec M+H
B-2343			29	424	425
B-2344			33	492	493
B-2345			30	420	421
B-2346			35	474	475
B-2347			34	392	393
B-2348			51	458	459
B-2349			73	517	518
B-2350			22	448	449
B-2351			64	486	487

SUBSTITUTE SHEET (RULE 26)

6/26

	R ²		Yield	Calcd Mass Spec.	Observed Mass Spec M+H
B-2352			41	482	483
B-2353			57	438	439
B-2354			63	484	485
B-2355			28	536	537
B-2356			29	408	409
B-2357			41	436	437
B-2358			41	451	452
B-2359			57	502	503
B-2360			46	496	497


SUBSTITUTE SHEET (RULE 26)

627

	R ²		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2361			13	476	477
B-2362			46	493	494
B-2363			57	396	397
B-2364			61	438	439
B-2365			72	424	425

SUBSTITUTE SHEET (RULE 26)

628



	R ²		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2366			34	380	381
B-2367			52	480	481
B-2368			35	407	407
B-2369			31	435	436
B-2370			33	414	415
B-2371			28	366	367
B-2372			37	422	423

SUBSTITUTE SHEET (RULE 26)

629

	R^2	R^B 	Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2373			50	432	433
B-2374			29	382	383
B-2375			35	395	396
B-2376			36	428	429
B-2377			68	438	439
B-2378			55	446	447
B-2379			33	364	365
B-2380			51	421	422
B-2381			52	429	430


SUBSTITUTESHEET (FILE 06)

630

	R^2	R^B 	Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2382			48	407	408
B-2383			63	382	383
B-2384			38	447	448
B-2385			59	498	450
B-2386			45	429	430
B-2387			74	558	-
B-2388			53	475	-
B-2389			33	493	494
B-2390			53	487	488

SUBSTITUTESHEET (FILE 06)


631



B-2391			Yield	Calcd. Mass Spec.	Observed Mass Spec. M+H
B-2392			57	464	465
B-2393			50	418	419
B-2394			65	488	489
B-2395			59	437	438
B-2396			34	534	535
B-2397			32	516	517
B-2398			81	533	534
B-2399			55	502	-

SUBSTITUTE SHEET (RULE 26)


632



B-2400			Yield	Calcd. Mass Spec.	Observed Mass Spec. M+H
B-2401			32	378	379
B-2402			71	519	520
B-2403			68	527	528
B-2404			62	447	448
B-2405			71	536	537
B-2406			47	394	395
B-2407			65	508	509
B-2408			34	485	486

SUBSTITUTE SHEET (RULE 26)


6.33



	R ²		Yield	Calcd. Mass Spec.	Observed Mass Spec. M+H
B-2409			47	448	449
B-2410			73	542	543
B-2411			81	489	490
B-2412			54	409	410
B-2413			37	493	494

SUBSTITUTESHEET (RULE 86)



















6.34



	R ²		Yield	Calcd. Mass Spec.	Observed Mass Spec. M+H
B-2414			14	473	474
B-2415			19	421	422
B-2416			13	386	387
B-2417			29	414	415
B-2418			6	420	421
B-2419			10	464	-
B-2420			5	442	443



















SUBSTITUTESHEET (RULE 86)

635

	R ²	R ^B N—R ^C	Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2421			28	454	455
B-2422			47	420	421
B-2423			53	400	401
B-2424			15	400	401
B-2425			18	522	523
B-2426			38	464	465
B-2427			26	468	469
B-2428			22	432	433
B-2429			41	404	405




















SUBSTITUTE SHEET (RULE 86)

636

	R ²	R ^B N—R ^C	Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2430			15	476	477
B-2431			6	446	447
B-2432			37	404	405
B-2433			8	428	429
B-2434			13	476	477
B-2435			23	442	443
B-2436			5	486	487
B-2437			4	492	493
B-2438			58	422	423




















SUBSTITUTE SHEET (RULE 86)

637

	R ²		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2449			12	454	455
B-2440			8	521	522
B-2441			6	443	444
B-2442			37	514	515
B-2443			15	518	-
B-2444			52	520	-
B-2445			33	517	518
B-2446			70	500	501
B-2447			56	488	489

SUBSTITUTESHEET (RULE 26)












638

	R ²		Yield	Calcd. Mass Spec.	Observed Mass Spec M+H
B-2448			51	522	523
B-2449			19	512	513
B-2450			16	538	539
B-2451			71	511	512
B-2452			71	500	501
B-2453			61	470	-
B-2454			15	472	473
B-2455			39	520	-
B-2456			51	533	534

SUBSTITUTESHEET (RULE 26)


639

640

	R ²		Yield	Calcd. Mass Spec.	Observed Mass Spec. M+H
B-2457			55	540	-
B-2458			22	488	489
B-2459			8	486	487
B-2460			13	534	535
B-2461			13	542	-

Example C-1

5-AMINOETHYL-4-(4-PYRIDYL)-3-(4-FLUOROPHENYL) PYRAZOLE



20 1-(4-fluorophenyl)-2-(4-pyridyl)-1-ethanone. 4-picoline (40 g, 0.43 mol) was added to a LiHMDS solution (0.45 mol, 450 mL of a 1.0 M solution in THF) over 30 minutes at room temperature (a slight exotherm was observed). The resulting solution was stirred for 1 h.

25 This solution was added to ethyl 4-fluorobenzoate (75.8 g, 0.45 mol, neat) over 1 h. The mixture was stirred overnight (16 h). Water (200 mL) was added and the mixture was extracted with EtOAc (2x200 mL). The organic layer was washed with brine (1x200 mL) and dried over

Na₂SO₄. The organic layer was filtered and the solvent was removed to leave oily solid. Hexane was added to the oil and the resulting solid was filtered and washed with hexane (cold). A yellow solid was isolated (50 g, 54%):

¹H NMR (CDCl₃) δ 8.58 (d, J = 5.7 Hz, 2H), 8.02 (dd, J = 5.5, 8.0, 2H), 7.12-7.21 (m, 4H), 4.23 (s, 2H); ¹⁹F NMR (CDCl₃) δ -104.38 (m); LC/MS, t_r = 2.14 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50°C), M+H = 216; High Resolution MS Calcd for C₂₃H₂₀N₄O₂F (M+H): 216.0825. Found: 216.0830 (Δ mmu = 0.5).

N-benzoyloxycarbonyl-5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole.

A 3L round bottom flask fitted with a mechanical stirrer, N₂ inlet and an addition funnel was charged with 557 mL (0.56 mol) of 1 M t-BuOK in THF and 53 mL (0.56 mol) of t-BuOH. The ketone, 1 (60 g, 0.28 mol) was dissolved in 600 mL of THF and added to the stirred mixture at room temperature. A yellow precipitate formed and the mixture was stirred for 1 h. N-benzoyloxycarbonyl-glycineyl N-hydroxysuccinimide (128.6 g, 0.42 mol) was dissolved in 600 mL of THF and added dropwise at r.t. over 1h. The mixture was stirred for another 5 minutes and 150 mL of water was added. the pH was adjusted to 6.7 with 70 mL of AcOH. Hydrazine monohydrate (41 mL in 100 mL of water) was added via an addition funnel. The mixture was stirred for 1 h and was diluted with 500 mL of water and 500 mL of ethyl acetate. The biphasic mixture was transferred to a sep funnel and the layers were separated. The aqueous layer was extracted with EtOAc (3x300 mL). The organic layer was

SUBSTITUTESHEET (RULE 26)

dried (Na₂SO₄), filtered and evaporated to leave 157 g of a crude reddish oil.

The oil was suspended in CH₂Cl₂ and filtered to remove any insoluble material (DCU, hydrazone of the monoketone). The solution was split into two portions and each portion was chromatographed (Biologage 75L, 3% EtOH/CH₂Cl₂ then 6% EtOH/CH₂Cl₂). The appropriate fractions were concentrated (some contamination from the monoketone and the hydrazone) from each portion to leave a yellow solid. The solid was suspended in ethyl acetate and heated to boiling for 10 minutes. The solution was allowed to cool to R.T. overnight. The precipitate was filtered to give 30 g of a white solid (27% yield of 2):

¹H NMR (DMF-d₃) δ 13.36 (s, 1H), 8.57 (d, J = 5.8 Hz, 2H), 7.16-7.52 (m, 1H), 5.11 (s, 2H), 4.48 (d, J = 5.4 Hz, 2H); ¹⁹F NMR (DMF-d₃) δ -114.9 (m), -116.8 (m) (split fluorine signal is due to the pyrazole tautomers); LC/MS, t_r = 3.52 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50°C), M+H = 403; High Resolution MS Calcd for C₂₃H₂₀N₄O₂F (M+H): 403.1570. Found: 403.1581 (Δ mmu = 1.1).

5-aminomethyl-4-(4-pyridyl)-3-(4-fluorophenyl) pyrazole.

To a 1L Parr bottle was added 7 g (17.4 mmol) of 2 and 180 mL of MeOH and 90 mL of THF to give a clear solution. The bottle was purged with nitrogen and 1.5 g of 10% Pd/C (wet Degussa type E101) was added. The Parr bottle was pressured to 40 psi (H₂) and was agitated. Hydrogen uptake was 5 psi after 5 h. The bottle was repressured to 42 psi and was agitated overnight. The bottle was purged with N₂ and was filtered through Celite. The Celite was washed with MeOH (3x50 mL) and

SUBSTITUTESHEET (RULE 26)


the filtrate was concentrated to give 4.5 g of an off-white solid (94%). ¹H NMR (DMSO-d₆) δ 8.52 (d, J = 4.63 Hz, 2H), 7.36 (dd, J = 5.64, 8.1 Hz, 2H), 7.16-7.30 (m, 4H), 3.79 (s, 2H); ¹⁹F NMR (DMSO-d₆) δ -114.56 (m); LC/MS, t_r = 1.21 minutes (5 to 95% acetonitrile/water over 15 minutes at 1 mL/min, at 254 nm at 50°C), M+H = 269 m/z; High Resolution MS Calcd for C₁₉H₁₄N₄F (M+H): 269.1202. Found: 269.1229 (Δ mmu = 2.7).

10







The following pyridylpyrazoles (C-2 through C-21, Table C-1) were prepared according to the experimental procedure described above for example C-1.

15






Table C-1.

Exempl e No.	Structure	MW, M + H Calculated Found	¹ H NMR (solvent), ppm
C-2		323.1672 323.1670	(DMF-d ₇): 8.77 (t, J = 4.4 Hz, 2H), 7.60 (m, 2H), 7.44 (t, J = 4.4 Hz, 2H), 7.35 (m, 2H), 3.22 (bd, 2H), 3.01 (septet, J = 5.3 Hz, 1H), 2.74 (m, 2H), 1.95 (m, 4H)







SUBSTITUTE SHEET (RULE 26)

C-3		282.127 (M) 282.1245 (M, EI)	(DMF-d ₇): 8.77 (br s, 2H), 7.64-7.62 (m, 2H), 7.50 (br s, 2H), 7.38-7.34 (m, 2H), 4.40-4.37 (m, 1H), 1.56 (br s, 3H)
C-4		282.127 (M) 282.1147 (M, EI)	(DMF-d ₇): 8.77 (br s, 2H), 7.64-7.62 (m, 2H), 7.50 (br s, 2H), 7.38-7.35 (m, 2H), 4.40-4.37 (m, 1H), 1.57 (br s, 3H)
C-5		323.1672 323.1687	(DMSO-d ₆): 8.56 (br, 2H), 7.32 (m, 2H), 7.18 (m, 4H), 2.91 (m, 2H), 2.71 (m, 2H) 1.88 (m, 1H), 1.65 (m, 2H), 1.40 (m, 2H)
C-6		359 359	(DMSO-d ₆): 8.46 (d, J = 4.6 Hz, 2H), 7.32-7.13 (m, 7H), 6.98-6.96 (m, 4H), 4.06 (t, J = 7.0 Hz, 1H), 2.98-2.95 (m, 2H)
C-7		359 359	(DMSO-d ₆): 8.46 (d, J = 5.4 Hz, 2H), 7.32-7.28 (m, 2H), 7.20-7.12 (m, 5H), 6.98-6.96 (m, 4H), 4.06 (t, J = 7.0 Hz, 1H), 2.98-2.94 (m, 2H)
C-8		313.1465 313.1492	(DMSO-d ₆): 13.83 (bs, 1H), 8.61 (d, J = 5.7 Hz, 2H), 8.33 (bs, 1H), 7.33 (m, 6H), 4.44 (m, 1H), 3.63 (m, 2H), 3.27 (s, 3H)

SUBSTITUTE SHEET (RULE 26)










C-9		313.1465 313.1457	(DMSO-d ₆): 8.55 (dd, J = 1.5, 4.4 Hz, 2H), 7.37-7.32 (m, 2H), 7.26 (dd, J = 1.6, 4.4 Hz, 2H), 7.22-7.16 (m, 2H), 4.06 (t, J = 6.5 Hz, 1H), 3.49 (d, J = 6.6 Hz, 2H), 3.20 (s, 3H)
C-10		354 354	(DMSO-d ₆): 13.03 (bs, 1H), 8.50 (dd, J=1.6, 2.7 Hz, 2H), 7.58 (bq, J=4.3 Hz, 1H), 7.3 (m, 2H), 7.12-7.21 (m, 4H), 3.77 (t, J=6.3 Hz, 1H), 2.45 (d, J=4.5 Hz, 3H), 1.97 (t, J=7.4 Hz, 2H), 1.85 (dt, J=7.3, 7.1 Hz, 2H)
C-11		354 354	(DMSO-d ₆): 13.03 (bs, 1H), 8.50 (dd, J=1.6, 2.7 Hz, 2H), 7.58 (bq, J=4.3 Hz, 1H), 7.3 (m, 2H), 7.12-7.21 (m, 4H), 3.77 (t, J=6.3 Hz, 1H), 2.45 (d, J=4.5 Hz, 3H), 1.97 (t, J=7.4 Hz, 2H), 1.85 (dt, J=7.3, 7.1 Hz, 2H)
C-12		283.1359 283.1363	(DMSO-d ₆): 8.53 (d, J = 5.0 Hz, 2H), 7.37-7.32 (m, 2H), 7.21-7.17 (m, 4H), 2.83 (d, J = 6.0 Hz, 2H), 2.77 (d, J = 6.0 Hz, 2H)
C-13		297.1515 297.1515	(DMSO-d ₆): 8.53 (d, J = 5.4 Hz, 2H), 7.34 (dd, J = 5.8, 8.2 Hz, 2H), 7.18

SUBSTITUTE SHEET (RULE 26)

C-14		284.0829 284.0806	(dd, J = 5.8, 9.8 Hz, 4H), 2.68 (t, J = 7.3 Hz, 2H), 2.52 (m, 2H), 1.64 (m, 2H) (CD ₃ OD): 8.74 (br, 2H), 7.77 (br, 2H), 7.45-7.58 (m, 3H), 7.30-7.40 (m, 1H), 4.43 (s, 2H)
C-15		285 285	(DMSO-d ₆): 8.53 (br, 2H), 7.56 (br, 2H), 7.26 (m, 4H), 3.75 (br, 2H)
C-16		329, 331 329, 331	(DMSO-d ₆): 8.53 (d, J = 4.4 Hz, 2H), 7.42 (d, J = 7.9 Hz, 2H), 7.34 (d, J = 8.5 Hz, 2H), 7.24 (d, J = 4.6 Hz, 2H), 3.76 (bs, 2H)
C-17		339 339	(DMSO-d ₆): 8.53 (t, J = 4.3 Hz, 2H), 7.33 (m, 3H), 7.19 (t, J = 4.6 Hz, 2H), 7.14 (d, J = 7.3 Hz, 1H), 3.23 (m, 2H), 2.88 (m, 3H), 1.92 (m, 3H), 1.70 (m, 1H)
C-18		339 339	(DMSO-d ₆): 8.57 (d, J = 4.6 Hz, 2H), 7.41 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.5 Hz, 2H), 7.20 (d, J = 4.8 Hz, 2H), 3.18 (bd, 2H), 2.88 (m, 1H), 2.76 (m, 2H), 1.82 (br, 4H)
C-19		383, 385 383, 385	(DMSO-d ₆): 8.56 (br, 2H), 7.52 (br, 2H), 7.14-7.29 (m, 4H), 2.99 (br, 2H),




SUBSTITUTE SHEET (RULE 26)

		2.71 (br, 1H), 2.51 (br, 2H), 1.68 (br, 4H)
--	--	---

C-25	
C-26	
C-27	
C-28	
C-29	
C-30	
C-31	
C-32	
C-33	

The following pyridylpyrazoles (C-22 through C-40, Table C-2) are prepared utilizing the general schemes C-1 and C-2 and the experimental procedure described for example C-1 above.

Table C-2

Compd. No.	Structure
C-22	
C-23	
C-24	

649

C-34	
C-35	
C-36	
C-37	
C-38	
C-39	
C-40	
C-41	
C-42	
C-43	
C-44	

SUBSTITUTE SHEET (RULE 26)


650

C-45	
C-46	
C-47	
C-48	

5

10

Example C-49



15

Step A

The pyrazole (2.60 g, 10.3 mmol) from **example 4** was suspended in 52 mL of dichloroethane and 52 mL of 2.5 M

SUBSTITUTE SHEET (RULE 26)


NaOH. Tetrabutylammonium hydroxide (0.5 mL of a 1 M aqueous solution) was added to the stirred mixture. To this mixture was added t-butyl bromoacetate (2.10 g, 10.8 mmol). The reaction mixture was stirred at room temperature for 4 h. The mixture was poured onto 200 mL of CH₂Cl₂ and 200 mL of H₂O. The phases were separated and the organic phase was washed with water (1x100 mL) and brine (1x100 mL). The organic layer was dried over Na₂SO₄ and was filtered. The solvent was removed to leave an off-white solid. This solid was triturated with hexane and the resulting solid isolated by filtration. The solid was washed with hexane to leave 3.4 g of a white solid (90%).

Step B

The alkylated pyrazole (3.7 g, 10.1 mmol) from Step A was treated with 57 mL of 4 N HCL in dioxane. The solution was stirred at room temperature for 4 h. The solvent was removed under reduced pressure and the residue was dissolved in THF. The solution was treated with propylene oxide (10.3 mmol) and was stirred for 1 h at room temperature. The solvent was removed to leave an oil. The residual solvent was chased with several portions of EtOH. The resulting solid was triturated with Et₂O and the title compound Example C-49 was isolated by filtration to afford 3.0 g of an off-white solid (95%). Mass spec: M+H calcd: 312; found 312. ¹H NMR (DMSO-d₆): 8.81 (d, J = 6.4 Hz, 2H), 7.73 (d, J =


5.8 Hz, 2H), 7.40 (m, 2H), 7.23 (t, J = 8.5 Hz, 1H), 5.16 (s, 2H), 2.40 (s, 3H).

Example C-50




According to the procedure described above in Example C-49, Example C-50 was also prepared starting from 4-(3-(4-fluorophenyl)-1H-pyrazole-4-yl)pyridine. Mass spec: M+H calcd: 298; found 298. ¹H NMR (DMSO-d₆): 8.75 (d, J = 6.4 Hz, 2H), 8.68 (s, 1H), 7.78 (d, J = 6.6 Hz, 2H), 7.52 (dd, J = 5.4, 8.5 Hz, 2H), 7.31 (t, J = 8.9 Hz, 2H), 5.16 (s, 2H).

Example C-51




Starting with the N-Boc-piperidinyl analog of Example C-2, Example C-51 is also prepared according to the methods described in Scheme C-1.

653

Example C-52

Step A: Picoline is treated with a base chosen from but not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH in an organic solvent such as THF, ether, t-BuOH or dioxane from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. The picoline solution is then added to a solution of N-Cbz-(L)-phenylalaninyl N-hydroxysuccinimide. The reaction is allowed to stir from 30 minutes to 48 hours during which time the temperature may range from -20 °C to 120 °C. The mixture is then poured into water and extracted with an organic solvent. After drying and removal of solvent the pyridyl monoketone is isolated as a crude solid which could be purified by crystallization and/or chromatography.




Step B: A solution of the pyridyl monoketone in ether, THF, tBuOH, or dioxane is added to a base chosen from but

SUBSTITUTE SHEET (RULE 26)

654


not limited to n-BuLi, LDA, LiHMDS, tBuOK, or NaH contained in hexane, THF, ether, dioxane, or tBuOH from -78 °C to 50 °C for a period of time from 10 minutes to 3 hours. Formyl acetic anhydride is then added as a solution in THF, ether, or dioxane to the monoketone anion while the temperature is maintained between -50 °C and 50 °C. The resulting mixture is allowed to stir at the specified temperature for a period of time from 5 minutes to several hours. The resulting pyridyl diketone intermediate is utilized without purification in Step C.



Step C: The solution containing the pyridyl diketone is quenched with water and the pH is adjusted to between 4 and 8 utilizing an inorganic or organic acid chosen from HOAc, H₂SO₄, HCl, or HNO₃. The temperature during this step is maintained between -20 °C and room temperature. Hydrazine or hydrazine hydrate is then added to the mixture while maintaining the temperature between -20 °C and 40 °C for a period of 30 minutes to several hours. The mixture is then poured into water and extracted with an organic solvent. The N-Cbz-protected pyridyl pyrazole is obtained as a crude solid which is purified by chromatography or crystallization.


SUBSTITUTE SHEET (RULE 26)

655



5 Step: D

The CBZ protecting group is cleaved using hydrogen gas under pressure and Pd-C in an alcohol solvent, affording scaffold C-52 after filtration and concentration.



10

15 The following compounds C-53 through C-59 in Table C-3 are prepared according to the general procedure described above for the preparation of C-52.

Table C-3

Example No.	Structure
C-53	

SUBSTITUTE SHEET (RULE 26)

656

C-54	
C-55	
C-56	
C-57	
C-58	
C-59	


Example C-60

5 Step A:

A Boc protected pyridylpyrazole is treated with benzaldehyde in methylene chloride at room temperature in

657

the presence of a drying agent for a period of time ranging from 1-24 h. Solvent is then evaporated and the resulting imine is used in step B without further purification.



Step B:



The pyridylpyrazole imine is dissolved in THF and stirred under nitrogen at temperatures ranging from -78 to -20 °C. A base such as LDA, n-BuLi, or LiHMDS is added dropwise to the mixture which is then stirred for an additional 10 minutes to 3 h. Two equivalents of a methyl iodide are then added to the mixture and stirring is continued for several hours. The mixture is then quenched with acid and allowed to warm to room temperature and stirred several hours until cleavage of the Boc and the imine functions is complete. The pH is adjusted to 12 and then the mixture is extracted with an organic solvent, which is dried and evaporated. The crude pyridylpyrazole is then crystallized and/or chromatographed to give purified C-60.

10
15
20

SUBSTITUTE SHEET (RULE 26)

658

Step B

**Example C-61**


Example C-61 is prepared according to the method described in example C-60, substituting 1,4-dibromobutane for methyl iodide.

10
15

20

Example C-62

SUBSTITUTE SHEET (RULE 26)




Example C-62 is prepared according to the method described in example C-60, substituting 1,3-dibromoethane for methyl iodide.

Example C-63


The synthesis of compound C-63 starts with the condensation reaction of bromomaleic anhydride **B77** with 2, 4-dimethoxybenzylamine in acetic acid and acetic anhydride. The maleimide **B78** is then treated with 4'-fluoroacetophenone in the presence of catalytic amount $\text{Pd}(\text{dba})_3$ and sodium t-butoxide to form the fluoroacetophenone substituted maleimide **B79**. **B79** is then treated with tert-butoxybis(dimethylamino)methane to yield the α -ketoenamine **B80**. The α -ketoenamine **B80** is condensed with hydrazine to form the N-protected maleimide pyrazole **B81**. The 2,4-dimethoxybenzyl group is cleaved with ceric ammonium nitrate (CAN) to give the title compound C-63.

Example C-64




Using the method described in Schemes C-6 and C-7, Example 64 is prepared.

661

Example C-65

Using the method described in Schemes C-6 and C-7, Example 65 is prepared.


Example C-66

Using the method described in Schemes C-6 and C-7, Example C-66 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for **B78**.


25

SUBSTITUTE SHEET (RULE 26)

662

Example C-67

Using the method described in Schemes C-6 and C-7, Example C-67 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for **B78**, and substituting N-Boc-glycyl N-hydroxysuccinimide for **B82**.


Example C-68

Using the method described in Schemes C-6 and C-7, Example C-68 is synthesized, substituting N-2,4-dimethoxybenzyl-4-bromopyridone for **B78**.


25

SUBSTITUTE SHEET (RULE 26)



663

Example C-69


Using the method described in Schemes C-6 and C-7, Example 69 is prepared, substituting N-Boc-nipecotyl N-hydroxysuccinimide for **B83**.

Example C-70

Using the method described in Schemes C-6 and C-7, Example 70 is prepared, substituting N-Boc-nipecotyl N-hydroxysuccinimide for **B83**.

Example C-71**Example C-72**

Using the method described in Schemes C-6 and C-7, Example 72 is prepared, substituting N-methyl-3-bromomaleimide for **B78**, and substituting N-Boc-nipecotyl N-hydroxysuccinimide for **B83**.

Example C-73

Using the method described in Schemes C-6 and C-7, Example 73 is prepared, substituting N-methyl-3-bromomaleimide for **B78** and substituting N-Boc-nipecotyl N-hydroxysuccinimide for **B83**.

Biological data from compounds of Examples B-0001 through B-1573 and of Examples B-2270 through B-2462 are shown in the following tables.

In vitro P38-alpha kinase inhibitory data are shown in the column identified as:

"P38 alpha kinase IC₅₀, uM or % inhib @ conc. (uM)"

10

In vitro whole cell assay for measuring the ability of the compounds to inhibit TNF production in human U937 cells stimulated with LPS are shown in the column identified as:

"U937 Cell IC₅₀, uM or % inhib @ conc., (uM)"

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the mouse is shown in the column identified as:

"Mouse LPS Model, % TNF inhib @ dose @ predose time"

wherein in the dose is milligram per kilogram (mpk) administered by oral gavage and the predose time indicates the number of hours before LPS challenge when the compound is administered.

In vivo assessment of the ability of the compounds to inhibit LPS-stimulated TNF release in the rat is shown in the column identified as:

"Rat LPS Model, % TNF inhib @ dose @ predose time"

wherein in the dose is milligram per kilogram (mpk) administered by oral gavage and the predose time

indicates the number of hours before LPS challenge when the compound is administered.

	P38 alpha kinase IC50, uM or % inhib @ conc. (uM)	U937 Cell IC50, uM or % inhib @ conc. (uM)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
Examples				
B-0001	53.0% @ 1.0uM	40.0% @ 1.0uM		
B-0002	71.0% @ 1.0uM	28.0% @ 10.0uM		
B-0003	70.0% @ 1.0uM	76.0% @ 10.0uM		
B-0004	80.0% @ 1.0uM	4.81uM		
B-0005	95.0% @ 1.0uM	2.97uM		
B-0006	82.0% @ 1.0uM	80% @ 10.0uM		
B-0007	74.0% @ 1.0uM	85.0% @ 10.0uM		
B-0008	42.0% @ 1.0uM	65.0% @ 10.0uM		
B-0009	0.04 uM	0.72uM		
B-0010	0.52 uM	0.65uM		
B-0011	0.03 uM	4.47uM		
B-0012	30.0% @ 1.0uM	44.0% @ 1.0uM		
B-0013	70.0% @ 1.0uM	84.0% @ 10.0uM		
B-0014	78.0% @ 1.0uM	80.0% @ 10.0uM		
B-0015	82.0% @ 1.0uM	80.0% @ 10.0uM		
B-0016	94.0% @ 1.0uM	3.98uM		
B-0017	58.0% @ 1.0uM	78.0% @ 10.0uM		
B-0018	60.0% @ 1.0uM	59.0% @ 10.0uM		
B-0019	84.0% @ 1.0uM	100.0% @ 10.0uM		
B-0020	73.0% @ 1.0uM	81.0% @ 10.0uM		
B-0021	68.0% @ 1.0uM	76.0% @ 10.0uM		
B-0022	69.0% @ 1.0uM	44.0% @ 1.0uM		
B-0023	90.0% @ 1.0uM	77.0% @ 10.0uM		
B-0024	94.0% @ 1.0uM	52.0% @ 1.0uM		
B-0025	88.0% @ 1.0uM	79.0% @ 10.0uM		
B-0026	96.0% @ 1.0uM	3.27uM		
B-0027	94.0% @ 1.0uM	11.0uM		
B-0028	69.0% @ 1.0uM	45.0% @ 10.0uM		
B-0029	91.0% @ 1.0uM	58.0% @ 10.0uM		
B-0030	92.0% @ 1.0uM	75.0% @ 10.0uM		
B-0031	94.0% @ 1.0uM	100.0% @ 10.0uM		
B-0032	94.0% @ 1.0uM	78.0% @ 10.0uM		
B-0033	97.0% @ 1.0uM	10.0uM		
B-0034	95.0% @ 1.0uM	10.0uM		
B-0035	94.0% @ 1.0uM	10.0uM		
B-0036	92.0% @ 1.0uM	8.24uM		
B-0037	91.0% @ 1.0uM	86.0% @ 10.0uM		
B-0038	71.0% @ 1.0uM	84.0% @ 10.0uM		
B-0039	89.0% @ 1.0uM	72.0% @ 10.0uM		
B-0040	93.0% @ 1.0uM	2.3uM		
B-0041	85.0% @ 1.0uM	66.0% @ 10.0uM		
B-0042	94.0% @ 1.0uM	2.76uM		

SUBSTITUTE SHEET (RULE 26)

	P38 alpha kinase IC50, uM or % inhib @ conc. (uM)	U937 Cell IC50, uM or % inhib @ conc. (uM)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
Examples				
B-0043	0.22 uM	0.54uM		
B-0044	0.14 uM	0.19uM		
B-0045	94.0% @ 1.0uM	1.01uM		
B-0046	96.0% @ 1.0uM	54.0% @ 1.0uM		
B-0047	94.0% @ 1.0uM	74.0% @ 10.0uM		
B-0048	94.0% @ 1.0uM	76.0% @ 10.0uM		
B-0049	88% @ 1.0uM	33.0% @ 1.0uM		
B-0050	73% @ 1.0uM	34.0% @ 1.0uM		
B-0051	3.3uM	2.15uM	47% @ 100mpk @ 6h	79% @ 3mpk @ 4h
B-0052	92% @ 1.0uM	15.0% @ 1.0uM		
B-0053	95% @ 1.0uM	34.0% @ 1.0uM		
B-0054	90% @ 1.0uM	30.0% @ 1.0uM		
B-0055	93% @ 1.0uM	>1.0uM		
B-0056	96% @ 1.0uM	21.0% @ 1.0uM		
B-0057	96% @ 1.0uM	29.0% @ 1.0uM		
B-0058	79% @ 1.0uM	18.0% @ 1.0uM		
B-0059	83% @ 1.0uM	35.0% @ 1.0uM		
B-0060	73% @ 1.0uM	22.0% @ 1.0uM		
B-0061	62% @ 1.0uM	27.0% @ 1.0uM		
B-0062	84% @ 1.0uM	36.0% @ 1.0uM		
B-0063	86% @ 1.0uM	40.0% @ 1.0uM		
B-0064	80% @ 1.0uM	4.0% @ 1.0uM		
B-0065	83% @ 1.0uM	21.0% @ 1.0uM		
B-0066	94% @ 1.0uM	28.0% @ 1.0uM		
B-0067	91% @ 1.0uM	1.0% @ 1.0uM		
B-0068	72% @ 1.0uM	22.0% @ 1.0uM		
B-0069	96% @ 1.0uM	37.0% @ 1.0uM		
B-0070	82% @ 1.0uM	30.0% @ 1.0uM		
B-0071	86% @ 1.0uM	31.0% @ 1.0uM		
B-0072	77% @ 1.0uM	32.0% @ 1.0uM		
B-0073	91% @ 1.0uM	24.0% @ 1.0uM		
B-0074	92% @ 1.0uM	42.0% @ 1.0uM		
B-0075	91% @ 1.0uM	35.0% @ 1.0uM		
B-0076	58% @ 1.0uM	21.0% @ 1.0uM		
B-0077	0.8uM	10.0uM		
B-0078	80% @ 1.0uM	20.0% @ 1.0uM		
B-0079	93% @ 1.0uM	13.0% @ 1.0uM		
B-0080	73% @ 1.0uM	73.0% @ 1.0uM		
B-0081	92% @ 1.0uM	13.0% @ 1.0uM		
B-0082	47% @ 1.0uM	27.0% @ 1.0uM		
B-0083	0.22uM	6.51uM		
B-0084	56% @ 1.0uM	30.0% @ 1.0uM		

SUBSTITUTE SHEET (RULE 26)

Examples	P38 alpha Kinase IC50, μ M or % inhib@conc. (μ M)	U937 Cell IC50, μ M or % inhib@conc. (μ M)	Mouse LPS Model % TNF - Inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0085	83% @ 1.0 μ M	21.0% @ 1.0 μ M		
B-0086	81% @ 1.0 μ M	37.0% @ 1.0 μ M		
B-0087	0.55 μ M	2.26 μ M	38% @ 30mpk @ -6h	
B-0088	96% @ 1.0 μ M	8.0% @ 1.0 μ M		
B-0089	0.04 μ M	3.39 μ M		
B-0090	98% @ 1.0 μ M	62.0% @ 1.0 μ M		
B-0091	96% @ 1.0 μ M	40.0% @ 1.0 μ M		
B-0092	97% @ 1.0 μ M	34.0% @ 1.0 μ M		
B-0093	3.18 μ M	1.25 μ M	30% @ 30mpk @ -6h	
B-0094	86% @ 1.0 μ M	62.0% @ 1.0 μ M		
B-0095	98% @ 1.0 μ M	38.0% @ 1.0 μ M		
B-0096	91% @ 1.0 μ M	22.0% @ 1.0 μ M		
B-0097	72.0% @ 10.0 μ M	36.0% @ 1.0 μ M		
B-0098	66.0% @ 10.0 μ M	12.0% @ 1.0 μ M		
B-0099	43.0% @ 1.0 μ M	>1.0 μ M		
B-0100	75.0% @ 1.0 μ M	5.0 μ M		
B-0101	71.0% @ 1.0 μ M	2.11 μ M		
B-0102	81.0% @ 1.0 μ M	15.0% @ 1.0 μ M		
B-0103	71.0% @ 1.0 μ M	6.0% @ 1.0 μ M		
B-0104	66.0% @ 1.0 μ M	5.0 μ M		
B-0105	78.0% @ 1.0 μ M	5.0 μ M		
B-0106	62.0% @ 1.0 μ M	5.0 μ M		
B-0107	0.27 μ M	4.85 μ M		
B-0108	61.0% @ 1.0 μ M	4.85 μ M		
B-0109	45.0% @ 1.0 μ M	18.0% @ 1.0 μ M		
B-0110	66.0% @ 1.0 μ M	13.0% @ 1.0 μ M		
B-0111	57.0% @ 1.0 μ M	>1.0 μ M		
B-0112	97.0% @ 1.0 μ M	1.12 μ M		
B-0113	75.0% @ 1.0 μ M	43.0% @ 1.0 μ M		
B-0114	45.0% @ 1.0 μ M	3.92 μ M		
B-0115	47.0% @ 1.0 μ M	2.0% @ 1.0 μ M		
B-0116	73.0% @ 1.0 μ M	35.0% @ 1.0 μ M		
B-0117	0.46 μ M	1.78 μ M	30% @ 30mpk @ -6h	
B-0118	1.18 μ M	1.29 μ M		
B-0119	89.0% @ 10.0 μ M	2.78 μ M		
B-0120	0.008 μ M	0.21 μ M	77% @ 100mpk @ -6h	70% @ 3mpk @ -4h
B-0121	79.0% @ 1.0 μ M	1.22 μ M		
B-0122	79.0% @ 10.0 μ M	2.0% @ 1.0 μ M		
B-0123	69.0% @ 1.0 μ M	>1.0 μ M		
B-0124	73.0% @ 1.0 μ M	16.0% @ 1.0 μ M		
B-0125	70.0% @ 10.0 μ M	17.0% @ 1.0 μ M		
B-0126	66.0% @ 1.0 μ M	1.57 μ M		

SUBSTITUTE SHEET (RULE 26)

Examples	P38 alpha Kinase IC50, μ M or % inhib@conc. (μ M)	U937 Cell IC50, μ M or % inhib@conc. (μ M)	Mouse LPS Model % TNF - Inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0127	82.0% @ 1.0 μ M	0.96 μ M		
B-0128	78.0% @ 1.0 μ M	1.81 μ M		
B-0129	51.0% @ 1.0 μ M	31.0% @ 1.0 μ M		
B-0130	69.0% @ 1.0 μ M	56.0% @ 1.0 μ M		
B-0131	43.0% @ 1.0 μ M	46.0% @ 1.0 μ M		
B-0132	78.0% @ 1.0 μ M	8.0% @ 1.0 μ M		
B-0133	51.0% @ 1.0 μ M	42.0% @ 1.0 μ M		
B-0134	60.0% @ 1.0 μ M	2.17 μ M		
B-0135	78.0% @ 1.0 μ M	58.0% @ 1.0 μ M		
B-0136	77.0% @ 1.0 μ M	44.0% @ 1.0 μ M		
B-0137	41.0% @ 1.0 μ M	37.0% @ 1.0 μ M		
B-0138	50.0% @ 1.0 μ M	32.0% @ 1.0 μ M		
B-0139	54.0% @ 10.0 μ M	17.0% @ 1.0 μ M		
B-0140	67% @ 10.0 μ M	9.0% @ 1.0 μ M		
B-0141	78.0% @ 1.0 μ M	10.0% @ 1.0 μ M		
B-0142	86.0% @ 1.0 μ M	12.0% @ 1.0 μ M		
B-0143	42.0% @ 1.0 μ M	3.63 μ M		
B-0144	98.0% @ 1.0 μ M	43.0% @ 1.0 μ M		
B-0145	54.0% @ 10.0 μ M	12.0% @ 1.0 μ M		
B-0146	77.0% @ 10.0 μ M	28.0% @ 1.0 μ M		
B-0147	44.0% @ 1.0 μ M	22.0% @ 1.0 μ M		
B-0148	51.0% @ 1.0 μ M	>1.0 μ M		
B-0149	1.15 μ M	10.0 μ M		
B-0150	27.0% @ 10.0 μ M	35.0% @ 1.0 μ M		
B-0151	43.0% @ 1.0 μ M	30.0% @ 1.0 μ M		
B-0152	51.0% @ 1.0 μ M	24.0% @ 1.0 μ M		
B-0153	57.0% @ 1.0 μ M	21.0% @ 1.0 μ M		
B-0154	65.0% @ 10.0 μ M	14.0% @ 1.0 μ M		
B-0155	40.0% @ 10.0 μ M	26.0% @ 1.0 μ M		
B-0156	42.0% @ 10.0 μ M	13.0% @ 1.0 μ M		
B-0157	48.0% @ 10.0 μ M	9.0% @ 1.0 μ M		
B-0158	58.0% @ 10.0 μ M	39.0% @ 1.0 μ M		
B-0159	54.0% @ 10.0 μ M	5.0% @ 1.0 μ M		
B-0160	59.0% @ 10.0 μ M	26.0% @ 1.0 μ M		
B-0161	72.0% @ 10.0 μ M	13.0% @ 1.0 μ M		
B-0162	23% @ 1.0 μ M	2.05 μ M		
B-0163	20.0% @ 10.0 μ M	10.0% @ 1.0 μ M		
B-0164	37.0% @ 10.0 μ M	20.0% @ 1.0 μ M		
B-0165	70.0% @ 10.0 μ M	18.0% @ 1.0 μ M		
B-0166	45.0% @ 10.0 μ M	37.0% @ 1.0 μ M		
B-0167	40.0% @ 1.0 μ M			
B-0168	44% @ 1.0 μ M	2.36 μ M		

SUBSTITUTE SHEET (RULE 26)

Examples	P38 alpha Kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-0169	43.0% @ 1.0 μ M	21.0% @ 1.0 μ M		
B-0170	43.0% @ 1.0 μ M	30.0% @ 1.0 μ M		
B-0171	61.0% @ 10.0 μ M	21.0% @ 1.0 μ M		
B-0172	16.0% @ 10.0 μ M	11.0% @ 1.0 μ M		
B-0173	33.0% @ 10.0 μ M	48.0% @ 1.0 μ M		
B-0174	54.0% @ 10.0 μ M	43.0% @ 1.0 μ M		
B-0175	41.0% @ 10.0 μ M	31.0% @ 1.0 μ M		
B-0176	50.0% @ 1.0 μ M	30.0% @ 1.0 μ M		
B-0177	70.0% @ 10.0 μ M	27.0% @ 1.0 μ M		
B-0178	12.0% @ 10.0 μ M	35.0% @ 1.0 μ M		
B-0179	27.0% @ 10.0 μ M	37.0% @ 1.0 μ M		
B-0180	34.0% @ 10.0 μ M	23.0% @ 1.0 μ M		
B-0181	5.0% @ 1.0 μ M	2.0% @ 1.0 μ M		
B-0182	39.0% @ 10.0 μ M	40.0% @ 1.0 μ M		
B-0183	12.0% @ 10.0 μ M	34.0% @ 1.0 μ M		
B-0184	66.0% @ 10.0 μ M	17.0% @ 1.0 μ M		
B-0185	65.0% @ 10.0 μ M	25.0% @ 1.0 μ M		
B-0186	40.0% @ 1.0 μ M	25.0% @ 1.0 μ M		
B-0187	4.0% @ 10.0 μ M	14.0% @ 1.0 μ M		
B-0188	70.0% @ 10.0 μ M	35.0% @ 1.0 μ M		
B-0189	42.0% @ 10.0 μ M	9.0% @ 1.0 μ M		
B-0190	59.0% @ 10.0 μ M	31.0% @ 1.0 μ M		
B-0191	40.0% @ 1.0 μ M	29.0% @ 1.0 μ M		
B-0192	12.0% @ 10.0 μ M	47.0% @ 1.0 μ M		
B-0193	0.54 μ M	6% @ 1.0 μ M		
B-0194	1.31 μ M	22% @ 1.0 μ M		
B-0195	1.03 μ M	55% @ 1.0 μ M		
B-0196	2.24 μ M	>1.0 μ M		
B-0197	2.0 μ M	14% @ 1.0 μ M		
B-0198	1.2 μ M	2% @ 1.0 μ M		
B-0199	1.34 μ M	3% @ 1.0 μ M		
B-0200	1.31 μ M	19% @ 1.0 μ M		
B-0201	0.29 μ M	59% @ 1.0 μ M		
B-0202	0.55 μ M	2.6 μ M		
B-0203	0.16 μ M	65% @ 1.0 μ M		
B-0204	0.21 μ M	48% @ 1.0 μ M		
B-0205	0.096 μ M	54% @ 1.0 μ M		
B-0206	5.76 μ M	14% @ 1.0 μ M		
B-0207	0.12 μ M	52% @ 1.0 μ M		
B-0208	0.067 μ M	>1.0 μ M		
B-0209	0.29 μ M	8% @ 1.0 μ M		
B-0210	0.057 μ M	67% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 86)

Examples	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-0211	0.25 μ M	30% @ 1.0 μ M		
B-0212	0.12 μ M	29% @ 1.0 μ M		
B-0213	0.31 μ M	39% @ 1.0 μ M		
B-0214	0.16 μ M	50% @ 1.0 μ M		
B-0215	0.11 μ M	51% @ 1.0 μ M		
B-0216	0.56 μ M	>1.0 μ M		
B-0217	0.55 μ M	>1.0 μ M		
B-0218	0.53 μ M	18% @ 1.0 μ M		
B-0219	0.91 μ M	40% @ 1.0 μ M		
B-0220	0.13 μ M	40% @ 1.0 μ M		
B-0221	2.4 μ M	>1.0 μ M		
B-0222	0.4 μ M	29.0% @ 1.0 μ M		
B-0223	0.2 μ M	1.0% @ 1.0 μ M		
B-0224	<0.1 μ M	93.0% @ 1.0 μ M		
B-0225	0.047 μ M	37.0% @ 1.0 μ M		
B-0226	0.074 μ M	20.0% @ 1.0 μ M		
B-0227	0.045 μ M	1.0% @ 1.0 μ M		
B-0228	0.15 μ M	44.0% @ 1.0 μ M		
B-0229	<0.1 μ M	61.0% @ 1.0 μ M		
B-0230	0.041 μ M	30.0% @ 1.0 μ M		
B-0231	0.055 μ M	40.0% @ 1.0 μ M		
B-0232	0.048 μ M	24.0% @ 1.0 μ M		
B-0233	0.095 μ M	43.0% @ 1.0 μ M		
B-0234	0.11 μ M	68.0% @ 1.0 μ M		
B-0235	1.31 μ M	90.0% @ 1.0 μ M		
B-0236	0.077 μ M	48.0% @ 1.0 μ M		
B-0237	0.13 μ M	60.0% @ 1.0 μ M		
B-0238	0.47 μ M	82.0% @ 1.0 μ M		
B-0239	5.73 μ M	84.0% @ 1.0 μ M		
B-0240	0.2 μ M	70.0% @ 1.0 μ M		
B-0241	0.1 μ M	45.0% @ 1.0 μ M		
B-0242	<0.1 μ M	78.0% @ 1.0 μ M		
B-0243	0.039 μ M	53.0% @ 1.0 μ M		
B-0244	0.02 μ M	57.0% @ 1.0 μ M		
B-0245	0.13 μ M	24.0% @ 1.0 μ M		
B-0246	<0.1 μ M	>1.0 μ M		
B-0247	0.082 μ M	75.0% @ 1.0 μ M		
B-0248	<0.1 μ M	11.0% @ 1.0 μ M		
B-0249	<0.1 μ M	75.0% @ 1.0 μ M		
B-0250	0.28 μ M	36.0% @ 1.0 μ M		
B-0251	0.31 μ M	1.0% @ 1.0 μ M		
B-0252	0.041 μ M	54.0% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 86)

Examples	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF Inhib @ dose @predose time	Rat LPS Model % Inhib @dose @predose time
B-0253	0.061 μ M	74.0% @ 1.0 μ M		
B-0254	0.13 μ M	59.0% @ 1.0 μ M		
B-0255	0.32 μ M	69.0% @ 1.0 μ M		
B-0256	<0.1 μ M	86.0% @ 1.0 μ M		
B-0257	1.71 μ M	11.0% @ 1.0 μ M		
B-0258	0.37 μ M	63.0% @ 1.0 μ M		
B-0259	0.35 μ M	58.0% @ 1.0 μ M		
B-0260	0.56 μ M	23.0% @ 1.0 μ M		
B-0261	0.49 μ M	23.0% @ 1.0 μ M		
B-0262	0.41 μ M	89.0% @ 1.0 μ M		
B-0263	0.62 μ M	64.0% @ 1.0 μ M		
B-0264	0.14 μ M	18.0% @ 1.0 μ M		
B-0265	0.92 μ M	24.0% @ 1.0 μ M		
B-0266	0.25 μ M	24.0% @ 1.0 μ M		
B-0267	0.48 μ M	11.0% @ 1.0 μ M		
B-0268	3.39 μ M	19.0% @ 1.0 μ M		
B-0269	9.81 μ M	18.0% @ 1.0 μ M		
B-0270	5.79 μ M	13.0% @ 1.0 μ M		
B-0271	7.55 μ M	12.0% @ 1.0 μ M		
B-0272	1.81 μ M	48.0% @ 1.0 μ M		
B-0273	5.03 μ M	13.0% @ 1.0 μ M		
B-0274	2.88 μ M	25.0% @ 1.0 μ M		
B-0275	2.67 μ M	33.0% @ 1.0 μ M		
B-0276	1.25 μ M	26.0% @ 1.0 μ M		
B-0277	0.86 μ M	34.0% @ 1.0 μ M		
B-0278	1.26 μ M	36.0% @ 1.0 μ M		
B-0279	1.39 μ M	33.0% @ 1.0 μ M		
B-0280	0.86 μ M	18.0% @ 1.0 μ M		
B-0281	7.37 μ M	24.0% @ 1.0 μ M		
B-0282	0.75 μ M	36.0% @ 1.0 μ M		
B-0283	6.66 μ M	29.0% @ 1.0 μ M		
B-0284	0.083 μ M	65.0% @ 1.0 μ M		
B-0285	4.57 μ M	29.0% @ 1.0 μ M		
B-0286	0.33 μ M	50.0% @ 1.0 μ M		
B-0287	4.0 μ M	22.0% @ 1.0 μ M		
B-0288	4.46 μ M	26.0% @ 1.0 μ M		
B-0289	0.16 μ M	55.0% @ 1.0 μ M		
B-0290	0.66 μ M	44.0% @ 1.0 μ M		
B-0291	1.33 μ M	20.0% @ 1.0 μ M		
B-0292	0.22 μ M	28.0% @ 1.0 μ M		
B-0293	0.66 μ M	53.0% @ 1.0 μ M		
B-0294	0.68 μ M	45.0% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 26)

Examples	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF Inhib @ dose @predose time	Rat LPS Model % Inhib @dose @predose time
B-0295	0.82 μ M	45.0% @ 1.0 μ M		
B-0296	8.03 μ M	36.0% @ 1.0 μ M		
B-0297	0.78 μ M	30.0% @ 1.0 μ M		
B-0298	0.58 μ M	48.0% @ 1.0 μ M		
B-0299	0.87 μ M	54.0% @ 1.0 μ M		
B-0300	0.78 μ M	32.0% @ 1.0 μ M		
B-0301	0.18 μ M	50.0% @ 1.0 μ M		
B-0302	4.02 μ M	24.0% @ 1.0 μ M		
B-0303	0.22 μ M	10.0% @ 1.0 μ M		
B-0304	0.56 μ M	28.0% @ 1.0 μ M		
B-0305				
B-0306				
B-0307				
B-0308				
B-0309				
B-0310				
B-0311				
B-0312				
B-0313				
B-0314				
B-0315				
B-0316				
B-0317				
B-0318				
B-0319				
B-0320				
B-0321				
B-0322				
B-0323				
B-0324				
B-0325				
B-0326				
B-0327				
B-0328				
B-0329				
B-0330				
B-0331				
B-0332				
B-0333				
B-0334				
B-0335				
B-0336				

SUBSTITUTE SHEET (RULE 26)

Examples	P38 alpha kinase IC50, μM or % inhib @ conc. (μM)	U937 Cell IC50, μM or % inhib @ conc. (μM)	Mouse LPS Model % TNF @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-0337				
B-0338				
B-0339				
B-0340				
B-0341				
B-0342				
B-0343				
B-0344				
B-0345				
B-0346				
B-0347				
B-0348				
B-0349				
B-0350				
B-0351				
B-0352				
B-0353	1.37 μM	55% @ 1.0 μM	51% @ 30mpk @ 6h	54% @ 3mpk @ 4h
B-0354	1.0 μM	40.0% @ 1.0 μM		
B-0355	0.75 μM	24.0% @ 1.0 μM		
B-0356	0.66 μM			
B-0357	1.46 μM	0.66 μM		
B-0358	0.37 μM	17.0% @ 1.0 μM		
B-0359	0.45 μM	47.0% @ 1.0 μM		
B-0360	1.6 μM	19.0% @ 1.0 μM		
B-0361	0.33 μM	46.0% @ 1.0 μM		
B-0362	0.52 μM	27.0% @ 1.0 μM		
B-0363	4.67 μM	25.0% @ 1.0 μM		
B-0364	1.44 μM	27.0% @ 1.0 μM		
B-0365	0.96 μM	27.0% @ 1.0 μM		
B-0366	0.7 μM	46.0% @ 1.0 μM		
B-0367	1.0 μM	23.0% @ 1.0 μM	37% @ 30mpk @ 6h	
B-0368	1.0 μM	0.64 μM		
B-0369	0.76 μM	57.0% @ 1.0 μM		
B-0370	0.65 μM	28.0% @ 1.0 μM		
B-0371	0.49 μM	28.0% @ 1.0 μM		
B-0372	0.35 μM	29.0% @ 1.0 μM		
B-0373	0.45 μM	18.0% @ 1.0 μM		
B-0374	1.38 μM	12.0% @ 1.0 μM		
B-0375	1.0 μM	19.0% @ 1.0 μM		
B-0376	2.89 μM	12.0% @ 1.0 μM		
B-0377	1.29 μM	36.0% @ 1.0 μM		
B-0378	1.1 μM	36.0% @ 1.0 μM		

SUBSTITUTE SHEET (RULE 26)

Examples	P38 alpha kinase IC50, μM or % inhib @ conc. (μM)	U937 Cell IC50, μM or % inhib @ conc. (μM)	Mouse LPS Model % TNF @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-0379	0.53 μM	24.0% @ 1.0 μM		
B-0380	1.41 μM	32.0% @ 1.0 μM		
B-0381	0.22 μM	47.0% @ 1.0 μM		
B-0382	0.41 μM	32.0% @ 1.0 μM		
B-0383	1.43 μM	10.0% @ 1.0 μM		
B-0384	4.02 μM	16.0% @ 1.0 μM		
B-0385	0.057 μM	0.9 μM	30% @ 30mpk @ 6h	0% @ 3mpk @ 4h
B-0386	0.13 μM	54.0% @ 1.0 μM		
B-0387	0.41 μM	52.0% @ 1.0 μM		
B-0388	<0.1 μM	36.0% @ 1.0 μM		
B-0389	0.07 μM	0.05 μM		
B-0390	0.089 μM	55.0% @ 1.0 μM		62% @ 3mpk @ 4h
B-0391	0.86 μM	18.0% @ 1.0 μM		
B-0392	0.13 μM	57.0% @ 1.0 μM		
B-0393	0.043 μM	66.0% @ 1.0 μM		
B-0394	0.13 μM	45.0% @ 1.0 μM		
B-0395	0.087 μM	48.0% @ 1.0 μM		
B-0396	0.087 μM	0.44 μM		
B-0397	0.17 μM	41.0% @ 1.0 μM		
B-0398	0.054 μM	66.0% @ 1.0 μM		
B-0399	0.14 μM	39.0% @ 1.0 μM		
B-0400	0.16 μM	25.0% @ 1.0 μM		
B-0401	0.46 μM	52.0% @ 1.0 μM		
B-0402	0.14 μM	1.51 μM		
B-0403	1.77 μM	2.42 μM		
B-0404	0.31 μM	48.0% @ 1.0 μM		
B-0405	0.79 μM	30.0% @ 1.0 μM		
B-0406	0.54 μM	35.0% @ 1.0 μM		
B-0407	0.76 μM	27.0% @ 1.0 μM		
B-0408	0.5 μM	50.0% @ 1.0 μM		
B-0409	0.53 μM	30.0% @ 1.0 μM		
B-0410	0.38 μM	44.0% @ 1.0 μM		
B-0411	0.62 μM	50.0% @ 1.0 μM		
B-0412	0.24 μM	48.0% @ 1.0 μM		
B-0413	0.18 μM	55.0% @ 1.0 μM		
B-0414	2.54 μM	25.0% @ 1.0 μM		
B-0415	0.42 μM	43.0% @ 1.0 μM		
B-0416	0.32 μM	34.0% @ 1.0 μM		
B-0417	0.91 μM	28.0% @ 1.0 μM		
B-0418	0.22 μM	27.0% @ 1.0 μM		
B-0419	0.85 μM	41.0% @ 1.0 μM		
B-0420	0.63 μM	48.0% @ 1.0 μM		

SUBSTITUTE SHEET (RULE 26)

Example#	P38 alpha kinase IC50,µM or % inhib@conc. (µM)	U937 Cell IC50,µM inhib@conc. (µM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0421	0.48µM	57.0% \pm 1.0µM		
B-0422	<0.1µM	40.0% \pm 1.0µM		
B-0423	0.18µM	33.0% \pm 1.0µM		
B-0424	0.083µM	32.0% \pm 1.0µM		
B-0425	0.28µM	54.0% \pm 1.0µM		
B-0426	0.055µM	0.74µM		41% \pm 3mpk \pm 4h
B-0427	0.53µM	39.0% \pm 1.0µM		
B-0428	0.99µM	27.0% \pm 1.0µM		
B-0429	0.27µM	45.0% \pm 1.0µM		
B-0430	0.29µM	75.0% \pm 1.0µM		
B-0431	0.21µM	88.0% \pm 1.0µM		
B-0432	<0.1µM	82.0% \pm 1.0µM		
B-0433	<0.1µM	85.0% \pm 1.0µM		
B-0434	0.12µM	61.0% \pm 1.0µM		
B-0435	0.3µM	71.0% \pm 1.0µM		
B-0436	1.11µM	59.0% \pm 1.0µM		
B-0437	0.58µM	91.0% \pm 1.0µM		
B-0438	<0.1µM	65.0% \pm 1.0µM		
B-0439	2.12µM	83.0% \pm 1.0µM		
B-0440	0.86µM	58.0% \pm 1.0µM		
B-0441	0.8µM	71.0% \pm 1.0µM		
B-0442	<0.1µM	61.0% \pm 1.0µM		
B-0443	2.01µM	83.0% \pm 1.0µM		
B-0444	1.01µM	83.0% \pm 1.0µM		
B-0445	<0.1µM	80.0% \pm 1.0µM		
B-0446	0.78µM	71.0% \pm 1.0µM		
B-0447	0.18µM	78.0% \pm 1.0µM		
B-0448	0.4µM	81.0% \pm 1.0µM		
B-0449	0.53µM	81.0% \pm 1.0µM		
B-0450	0.28µM	83.0% \pm 1.0µM		
B-0451	0.071µM	75.0% \pm 1.0µM	42% \pm 30mpk \pm 8h	
B-0452	0.7µM	75.0% \pm 1.0µM		
B-0453	0.47µM	75.0% \pm 1.0µM		
B-0454	0.11µM	80.0% \pm 1.0µM		
B-0455	<0.1µM	95.0% \pm 1.0µM		
B-0456	1.81µM	67.0% \pm 1.0µM		36% \pm 3mpk \pm 4h
B-0457	0.089µM	81.0% \pm 1.0µM		
B-0458	0.033µM	70.0% \pm 1.0µM		
B-0459	0.099µM	76.0% \pm 1.0µM		
B-0460	0.081µM	82.0% \pm 1.0µM		
B-0461	0.025µM	96.0% \pm 1.0µM		
B-0462	<0.1µM	97.0% \pm 1.0µM		

SUBSTITUTE SHEET (RULE 86)

Example#	P38 alpha kinase IC50,µM or % inhib@conc. (µM)	U937 Cell IC50,µM inhib@conc. (µM)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0463	0.052µM	95.0% \pm 1.0µM		
B-0464	<0.1µM	91.0% \pm 1.0µM		
B-0465	0.084µM	98.0% \pm 1.0µM		
B-0466	<0.1µM	98.0% \pm 1.0µM		0% \pm 3mpk \pm 4h
B-0467	<0.1µM	77.0% \pm 1.0µM		
B-0468	0.031µM	93.0% \pm 1.0µM		
B-0469	0.056µM	92.0% \pm 1.0µM		
B-0470	0.063µM	92.0% \pm 1.0µM		
B-0471	0.027µM	97.0% \pm 1.0µM		
B-0472	0.18µM	54.0% \pm 1.0µM		
B-0473	0.004µM	95.0% \pm 1.0µM		
B-0474	0.024µM	86.0% \pm 1.0µM		
B-0475	0.21µM	74.0% \pm 1.0µM		
B-0476	0.56µM	69.0% \pm 1.0µM		
B-0477	1.48µM	96.0% \pm 1.0µM		
B-0478	0.034µM	87.0% \pm 1.0µM		
B-0479	0.031µM	90.0% \pm 1.0µM		15% \pm 3mpk \pm 4h
B-0480	0.12µM	88.0% \pm 1.0µM		
B-0481	0.014µM	95.0% \pm 1.0µM		56% \pm 3mpk \pm 4h
B-0482	0.97µM	66.0% \pm 1.0µM		
B-0483	0.57µM	68.0% \pm 1.0µM		
B-0484	0.28µM	62.0% \pm 1.0µM		
B-0485	0.04µM	95.0% \pm 1.0µM		
B-0486	0.24µM	80.0% \pm 1.0µM		
B-0487	0.11µM	88.0% \pm 1.0µM		54% \pm 3mpk \pm 4h
B-0488	0.62µM	86.0% \pm 1.0µM		
B-0489	0.3µM	80.0% \pm 1.0µM		
B-0490	0.91µM	74.0% \pm 1.0µM		
B-0491	0.43µM	66.0% \pm 1.0µM		
B-0492	0.069µM	42.0% \pm 1.0µM		
B-0493	0.3µM	36.0% \pm 1.0µM		
B-0494	0.13µM	30.0% \pm 1.0µM		
B-0495	0.12µM	25.0% \pm 1.0µM		
B-0496	0.83µM	16.0% \pm 1.0µM		
B-0497	0.44µM	31.0% \pm 1.0µM		
B-0498	0.33µM	11.0% \pm 1.0µM		
B-0499	0.39µM	37.0% \pm 1.0µM		
B-0500	0.26µM	41.0% \pm 1.0µM		
B-0501	0.048µM	52.0% \pm 1.0µM		
B-0502	0.065µM	48.0% \pm 1.0µM		
B-0503	0.16µM	73.0% \pm 1.0µM		
B-0504	0.4µM	43.0% \pm 1.0µM		

SUBSTITUTE SHEET (RULE 86)

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-0505	0.28 μ M	44.0% @ 1.0 μ M		
B-0506	0.94 μ M	43.0% @ 1.0 μ M		
B-0507	0.18 μ M	75.0% @ 1.0 μ M		
B-0508	2.0 μ M	48.0% @ 1.0 μ M		
B-0509	0.1 μ M	86.0% @ 1.0 μ M		
B-0510	0.69 μ M	61.0% @ 1.0 μ M		
B-0511	0.007 μ M	90.0% @ 1.0 μ M		
B-0512	1.0 μ M	53.0% @ 1.0 μ M		
B-0513	0.72 μ M	52.0% @ 1.0 μ M		
B-0514	0.14 μ M	87.0% @ 1.0 μ M		
B-0515	0.42 μ M	61.0% @ 1.0 μ M		
B-0516	0.37 μ M	84.0% @ 1.0 μ M		
B-0517	0.094 μ M	52.0% @ 1.0 μ M		
B-0518	0.11 μ M	64.0% @ 1.0 μ M		
B-0519	0.043 μ M	87.0% @ 1.0 μ M		
B-0520	0.4 μ M	67.0% @ 1.0 μ M		
B-0521	1.37 μ M	52.0% @ 1.0 μ M		
B-0522	0.15 μ M	75.0% @ 1.0 μ M		
B-0523	0.19 μ M	83.0% @ 1.0 μ M		
B-0524	0.4 μ M	77.0% @ 1.0 μ M		
B-0525	0.16 μ M	76.0% @ 1.0 μ M		
B-0526	0.031 μ M	87.0% @ 1.0 μ M		
B-0527	1.09 μ M	83.0% @ 1.0 μ M		
B-0528	0.14 μ M	70.0% @ 1.0 μ M		
B-0529	0.11 μ M	73.0% @ 1.0 μ M		
B-0530	5.53 μ M	45.0% @ 1.0 μ M		
B-0531	0.50 μ M	48.0% @ 1.0 μ M		
B-0532	0.45 μ M	1.01 μ M	41% @ 30mpk @ 4h	
B-0533	1.23 μ M	87.0% @ 1.0 μ M		
B-0534	0.41 μ M	54.0% @ 1.0 μ M		
B-0535	0.44 μ M	0.87 μ M		
B-0536	0.46 μ M	0.15 μ M		
B-0537	3.44 μ M	51.0% @ 1.0 μ M		
B-0538	1.13 μ M	45.0% @ 1.0 μ M		
B-0539	2.84 μ M	21.0% @ 1.0 μ M		
B-0540	3.62 μ M	54.0% @ 1.0 μ M		
B-0541	3.24 μ M	28.0% @ 1.0 μ M		
B-0542	1.55 μ M	50.0% @ 1.0 μ M		
B-0543	1.56 μ M	43.0% @ 1.0 μ M		
B-0544	1.12 μ M	27.0% @ 1.0 μ M		
B-0545	1.06 μ M	41.0% @ 1.0 μ M		
B-0546	1.04 μ M	18.0% @ 1.0 μ M		
B-0547	1.24 μ M	21.0% @ 1.0 μ M		
B-0548	1.77 μ M	28.0% @ 1.0 μ M		
B-0549	2.22 μ M	22.0% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 26)

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-0550	2.41 μ M	14.0% @ 1.0 μ M		
B-0551	1.08 μ M	56.0% @ 1.0 μ M		
B-0552	0.13 μ M	46.0% @ 1.0 μ M		
B-0553	1.44 μ M	47.0% @ 1.0 μ M		
B-0554	2.58 μ M	20.0% @ 1.0 μ M		
B-0555	1.87 μ M	34.0% @ 1.0 μ M		
B-0556	0.49 μ M	39.0% @ 1.0 μ M		
B-0557	1.32 μ M	32.0% @ 1.0 μ M		
B-0558	0.85 μ M	33.0% @ 1.0 μ M		
B-0559	0.53 μ M	49.0% @ 1.0 μ M		
B-0560	2.57 μ M	31.0% @ 1.0 μ M		
B-0561	2.07 μ M	40.0% @ 1.0 μ M		
B-0562	0.22 μ M	0.3 μ M		5% @ 3mpk @ 4h
B-0563	0.18 μ M	0.13 μ M		
B-0564	0.82 μ M	58% @ 1.0 μ M		
B-0565	0.23 μ M	0.59 μ M		
B-0566	<0.1 μ M	0.17 μ M		0% @ 3mpk @ 4h
B-0567	0.14 μ M	0.26 μ M		
B-0568	1.22 μ M	46.0% @ 1.0 μ M		
B-0569	0.15 μ M	0.26 μ M		
B-0570	0.27 μ M	46.0% @ 1.0 μ M		
B-0571	0.38 μ M	44.0% @ 1.0 μ M		
B-0572	0.27 μ M	41.0% @ 1.0 μ M		
B-0573	0.36 μ M	1.7 μ M		
B-0574	0.13 μ M	0.66 μ M		37% @ 3mpk @ 4h
B-0575	0.032 μ M	0.17 μ M		
B-0576	0.068 μ M	0.39 μ M		
B-0577	0.091 μ M	66.0% @ 1.0 μ M		65% @ 3mpk @ 4h
B-0578	1.88 μ M	47.0% @ 1.0 μ M		
B-0579	0.11 μ M	79.0% @ 1.0 μ M		
B-0580	2.23 μ M	0.84 μ M		
B-0581	0.26 μ M	2.17 μ M		
B-0582	1.03 μ M	37.0% @ 1.0 μ M		
B-0583	3.93 μ M	26.0% @ 1.0 μ M		
B-0584	0.66 μ M	54.0% @ 1.0 μ M		
B-0585	0.83 μ M	79.0% @ 1.0 μ M	50% @ 30mpk @ 4h	
B-0586	0.81 μ M	51.0% @ 1.0 μ M		
B-0587	6.84 μ M	38% @ 1.0 μ M		
B-0588	12.8 μ M	42% @ 1.0 μ M		
B-0589	1.71 μ M	42% @ 1.0 μ M		
B-0590	1.57 μ M	38.0 μ M		
B-0591	3.59 μ M	28.0% @ 1.0 μ M		
B-0592	1.82 μ M	45.0% @ 1.0 μ M		
B-0593	1.22 μ M	36.0% @ 1.0 μ M		
B-0594	-	41.0% @ 1.0 μ M		
B-0595	2.42 μ M	22.0% @ 1.0 μ M		
B-0596	20.0 μ M	41.0% @ 1.0 μ M		
B-0597	1.68 μ M	63.0% @ 1.0 μ M		
B-0598	2.12 μ M	50.0% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 26)

Examples#	P38 alpha kinase IC50, μ M or % inhib@conc. (μ M)	U837 Cell IC50, μ M or % inhib@conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @ dose @predose time
B-0659	4.16 μ M	21.0% @ 1.0 μ M		
B-0660	0.002 μ M	28.0% @ 1.0 μ M		
B-0661	0.089 μ M	1.31 μ M		43% @ 3mpk @ 4h
B-0662	0.97 μ M	61.0% @ 1.0 μ M		
B-0663	0.09 μ M	51.0% @ 1.0 μ M		
B-0664	0.3 μ M	20.0% @ 1.0 μ M		
B-0665	0.18 μ M	47.0% @ 1.0 μ M		
B-0666	0.17 μ M	53.0% @ 1.0 μ M		
B-0667	2.19 μ M	70.0% @ 1.0 μ M		
B-0668	0.059 μ M	73.0% @ 1.0 μ M		
B-0669	<0.1 μ M	87.0% @ 1.0 μ M		
B-0670	0.55 μ M	88.0% @ 1.0 μ M		
B-0671	0.16 μ M	60.0% @ 1.0 μ M		
B-0672	0.17 μ M	78.0% @ 1.0 μ M		
B-0673	0.76 μ M	70.0% @ 1.0 μ M		0% @ 3mpk @ 4h
B-0674	0.08 μ M	83.0% @ 1.0 μ M		
B-0675	0.38 μ M	87.0% @ 1.0 μ M		
B-0676	0.045 μ M	82.0% @ 1.0 μ M		
B-0677	0.37 μ M	80.0% @ 1.0 μ M		
B-0678	<0.1 μ M	88.0% @ 1.0 μ M		
B-0679	1.59 μ M	58.0% @ 1.0 μ M		
B-0680	0.38 μ M	78.0% @ 1.0 μ M		
B-0681	0.12 μ M	54.0% @ 1.0 μ M		
B-0682	0.085 μ M	88.0% @ 1.0 μ M		
B-0683	0.023 μ M	85.0% @ 1.0 μ M		
B-0684	<0.1 μ M	85.0% @ 1.0 μ M		
B-0685	0.25 μ M	72.0% @ 1.0 μ M		
B-0686	0.2 μ M	77.0% @ 1.0 μ M		
B-0687	0.06 μ M	81.0% @ 1.0 μ M		
B-0688	<0.1 μ M	80.0% @ 1.0 μ M		
B-0689	0.6 μ M	40.0% @ 1.0 μ M		
B-0690	0.15 μ M	55.0% @ 1.0 μ M		
B-0691	<0.1 μ M	86.0% @ 1.0 μ M		
B-0692	0.11 μ M	82.0% @ 1.0 μ M		
B-0693	0.25 μ M	89.0% @ 1.0 μ M		
B-0694	0.051 μ M	93.0% @ 1.0 μ M		50% @ 3mpk @ 4h
B-0695	0.38 μ M	94.0% @ 1.0 μ M		
B-0696	0.58 μ M	65.0% @ 1.0 μ M		
B-0697	0.49 μ M	90.0% @ 1.0 μ M		
B-0698	0.069 μ M	85.0% @ 1.0 μ M		0% @ 3mpk @ 4h
B-0699	0.059 μ M	88.0% @ 1.0 μ M		
B-0700	0.26 μ M	94.0% @ 1.0 μ M		
B-0701	1.51 μ M	76.0% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 26)

Examples#	P38 alpha kinase IC50, μ M or % inhib@conc. (μ M)	U837 Cell IC50, μ M or % inhib@conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @ dose @predose time
B-0648	<0.1 μ M	83.0% @ 1.0 μ M		
B-0649	0.83 μ M	39.0% @ 1.0 μ M		
B-0650	0.006 μ M	95.0% @ 1.0 μ M		8% @ 3mpk @ 4h
B-0651	1.78 μ M	81.0% @ 1.0 μ M		
B-0652	0.19 μ M	83.0% @ 1.0 μ M		
B-0653	2.01 μ M	74.0% @ 1.0 μ M		
B-0654	5.97 μ M	78.0% @ 1.0 μ M		
B-0655	1.25 μ M	76.0% @ 1.0 μ M		
B-0656	0.007 μ M	95.0% @ 1.0 μ M		28% @ 3mpk @ 4h
B-0657	0.17 μ M	83.0% @ 1.0 μ M		
B-0658	1.14 μ M	91.0% @ 1.0 μ M		
B-0659	2.54 μ M	87.0% @ 1.0 μ M		
B-0660	0.086 μ M	92.0% @ 1.0 μ M		
B-0661	<0.1 μ M	90.0% @ 1.0 μ M		
B-0662	<0.1 μ M	95.0% @ 1.0 μ M		
B-0663	0.88 μ M	74.0% @ 1.0 μ M		
B-0664	0.39 μ M	80.0% @ 1.0 μ M		
B-0665	0.47 μ M	72.0% @ 1.0 μ M		
B-0666	0.17 μ M	73.0% @ 1.0 μ M		
B-0667	0.83 μ M	75.0% @ 1.0 μ M		
B-0668	0.27 μ M	78.0% @ 1.0 μ M		
B-0669	0.89 μ M	34.0% @ 1.0 μ M		
B-0670	3.15 μ M	32.0% @ 1.0 μ M		
B-0671	6.38 μ M	36.0% @ 1.0 μ M		
B-0672	6.59 μ M	32.0% @ 1.0 μ M		
B-0673	8.54 μ M	48.0% @ 1.0 μ M		
B-0674	2.81 μ M	42.0% @ 1.0 μ M		
B-0675	5.42 μ M	3.0% @ 1.0 μ M		
B-0676	2.09 μ M	22.0% @ 1.0 μ M		
B-0677	1.53 μ M	25.0% @ 1.0 μ M		
B-0678	0.38 μ M	52.0% @ 1.0 μ M		
B-0679	0.062 μ M	45.0% @ 1.0 μ M		
B-0680	0.42 μ M	67.0% @ 1.0 μ M		
B-0681	1.96 μ M	17.0% @ 1.0 μ M		
B-0682	0.76 μ M	39.0% @ 1.0 μ M		
B-0683	13.0 μ M	32.0% @ 1.0 μ M		
B-0684	0.54 μ M	68.0% @ 1.0 μ M		
B-0685	15.4 μ M	33.0% @ 1.0 μ M		
B-0686	0.42 μ M	59.0% @ 1.0 μ M		
B-0687	10.1 μ M	15.0% @ 1.0 μ M		
B-0688	0.56 μ M	58.0% @ 1.0 μ M		
B-0689	14.8 μ M	27.0% @ 1.0 μ M		
B-0690	27.1 μ M	36.0% @ 1.0 μ M		
B-0691	0.16 μ M	48.0% @ 1.0 μ M		
B-0692	0.39 μ M	29.0% @ 1.0 μ M		
B-0693	0.39 μ M	28.0% @ 1.0 μ M		
B-0694	0.62 μ M	21.0% @ 1.0 μ M		
B-0695	0.23 μ M	32.0% @ 1.0 μ M		
B-0696	0.065 μ M	35.0% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 26)

683

684

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-0697	0.45 μ M	44.0% @ 1.0 μ M		
B-0698	2.33 μ M	43.0% @ 1.0 μ M		
B-0699	0.34 μ M	31.0% @ 1.0 μ M		
B-0700	0.24 μ M	56.0% @ 1.0 μ M		
B-0701	0.39 μ M	45.0% @ 1.0 μ M		
B-0702	0.036 μ M	39.0% @ 1.0 μ M		
B-0703	0.12 μ M	38.0% @ 1.0 μ M		
B-0704	2.19 μ M	28.0% @ 1.0 μ M		
B-0705	0.44 μ M	21.0% @ 1.0 μ M		
B-0706	0.44 μ M	32.0% @ 1.0 μ M		
B-0707	1.7 μ M			
B-0708	2.1 μ M			
B-0709	0.84 μ M			
B-0710	1.99 μ M			
B-0711	1.99 μ M			
B-0712	2.9 μ M			
B-0713	4.3 μ M			
B-0714	3.7 μ M			
B-0715	3.2 μ M			
B-0716	4.6 μ M			
B-0717	4.3 μ M			
B-0718	1.4 μ M			
B-0719	3.4 μ M			
B-0720	1.3 μ M			
B-0721	3.8 μ M			
B-0722	0.071 μ M	>1.0 μ M		
B-0723	0.071 μ M			
B-0724	0.06 μ M	17.0% @ 1.0 μ M		
B-0725	9.7 μ M			
B-0726	1.4 μ M			
B-0727	0.51 μ M			
B-0728	20.0 μ M			
B-0729	0.87 μ M			
B-0730	0.25 μ M	11.0% @ 1.0 μ M		
B-0731	0.87 μ M	>1.0 μ M		
B-0732	14.0 μ M			
B-0733	32.0 μ M			
B-0734	0.92 μ M			
B-0735	1.0 μ M			
B-0736	26.0 μ M			
B-0737	2.6 μ M			
B-0738	2.7 μ M			
B-0739	4.1 μ M			
B-0740	4.4 μ M			
B-0741	26.0 μ M			
B-0742	2.2 μ M			
B-0743	1.2 μ M			
B-0744	23.0 μ M			
B-0745	6.0 μ M			

SUBSTITUTE SHEET (RULE 28)

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-0746	0.01 μ M	22.0% @ 1.0 μ M		
B-0747	1.1 μ M			
B-0748	1.2 μ M			
B-0749	4.4 μ M			
B-0750	0.92 μ M			
B-0751	1.6 μ M			
B-0752	0.33 μ M			
B-0753	0.37 μ M			
B-0754	0.55 μ M			
B-0755	2.3 μ M			
B-0756	0.94 μ M			
B-0757	0.54 μ M	16.0% @ 1.0 μ M		
B-0758	1.5 μ M			
B-0759	0.3 μ M			
B-0760	0.01 μ M	13.0% @ 1.0 μ M		
B-0761	<0.1 μ M			
B-0762	0.13 μ M	5.0% @ 1.0 μ M		
B-0763	0.015 μ M	17.0% @ 1.0 μ M		
B-0764	0.67 μ M	26.0% @ 1.0 μ M		
B-0765	0.3 μ M	29.0% @ 1.0 μ M		
B-0766	0.95 μ M			
B-0767	0.08 μ M			
B-0768	1.4 μ M			
B-0769	12.7 μ M			
B-0770	2.3 μ M			
B-0771	0.5 μ M			
B-0772	0.8 μ M			
B-0773	14.0 μ M			
B-0774	1.5 μ M			
B-0775	0.6 μ M	>1.0 μ M		
B-0776	0.9 μ M	>1.0 μ M		
B-0777	21.0 μ M			
B-0778	51.0 μ M			
B-0779	0.5 μ M			
B-0780	1.1 μ M			
B-0781	48.0 μ M			
B-0782	22.0 μ M			
B-0783	8.0 μ M			
B-0784	7.0 μ M			
B-0785	23.0 μ M			
B-0786	24.0 μ M			
B-0787	1.5 μ M			
B-0788	1.2 μ M			
B-0789	33.0 μ M			
B-0790	1.0 μ M	4.0% @ 1.0 μ M		
B-0791	0.3 μ M	>1.0 μ M		
B-0792	1.1 μ M			
B-0793	0.3 μ M			
B-0794	2.9 μ M	2.0% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 86)

Example#	P38 alpha Kinase IC50, μ M or % inhib@conc. (μ M)	U937 Cell IC50, μ M or % inhib@conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0785	1.9 μ M	11.0% @ 1.0 μ M		
B-0786	1.4 μ M	-		
B-0797	1.04 μ M	-		
B-0798	1.73 μ M	-		
B-0799	-	> 1.0 μ M		
B-0800	1.01 μ M	> 1.0 μ M		
B-0801	0.67 μ M	> 1.0 μ M		
B-0802	-	> 1.0 μ M		
B-0803	0.057 μ M	53.0% @ 1.0 μ M		
B-0804	0.3 μ M	32.0% @ 1.0 μ M		
B-0805	0.71 μ M	> 1.0 μ M		
B-0806	3.28 μ M	> 1.0 μ M		
B-0807	10.8 μ M	-		
B-0808	3.09 μ M	> 1.0 μ M		
B-0809	1.22 μ M	7.0% @ 1.0 μ M		
B-0810	1.11 μ M	> 1.0 μ M		
B-0811	2.78 μ M	2.0% @ 1.0 μ M		
B-0812	2.12 μ M	> 1.0 μ M		
B-0813	3.02 μ M	> 1.0 μ M		
B-0814	-	> 1.0 μ M		
B-0815	2.11 μ M	> 1.0 μ M		
B-0816	3.46 μ M	> 1.0 μ M		
B-0817	3.07 μ M	33.0% @ 1.0 μ M		
B-0818	4.87 μ M	> 1.0 μ M		
B-0819	1.08 μ M	> 1.0 μ M		
B-0820	1.64 μ M	3.0% @ 1.0 μ M		
B-0821	1.44 μ M	-		
B-0822	1.33 μ M	-		
B-0823	2.39 μ M	> 1.0 μ M		
B-0824	3.41 μ M	-		
B-0825	-	-		
B-0826	1.74 μ M	-		
B-0827	15.6 μ M	-		
B-0828	7.9 μ M	-		
B-0829	0.61 μ M	55.0% @ 1.0 μ M		
B-0830	0.54 μ M	34.0% @ 1.0 μ M		
B-0831	0.50 μ M	> 1.0 μ M		
B-0832	1.49 μ M	-		
B-0833	0.95 μ M	23.0% @ 1.0 μ M		
B-0834	1.25 μ M	-		
B-0835	-	-		
B-0836	1.24 μ M	-		
B-0837	1.96 μ M	> 1.0 μ M		
B-0838	3.1 μ M	-		
B-0839	4.3 μ M	-		
B-0840	0.63 μ M	47.0% @ 1.0 μ M		
B-0841	0.32 μ M	36.0% @ 1.0 μ M		
B-0842	0.72 μ M	63.0% @ 1.0 μ M		
B-0843	0.61 μ M	> 1.0 μ M		

SUBSTITUTE SHEET (RULE 86)

Example#	P38 alpha Kinase IC50, μ M or % inhib@conc. (μ M)	U937 Cell IC50, μ M or % inhib@conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @predose time	Rat LPS Model % inhib @dose @predose time
B-0844	0.4 μ M	25.0% @ 1.0 μ M		
B-0845	1.7 μ M	-		
B-0846	1.8 μ M	-		
B-0847	0.73 μ M	21.0% @ 1.0 μ M		
B-0848	1.56 μ M	-		
B-0849	1.25 μ M	-		
B-0850	1.81 μ M	-		
B-0851	0.91 μ M	39.0% @ 1.0 μ M		
B-0852	1.02 μ M	-		
B-0853	-	36.0% @ 1.0 μ M		
B-0854	-	25.0% @ 1.0 μ M		
B-0855	-	8.0% @ 1.0 μ M		
B-0856	-	38.0% @ 1.0 μ M		
B-0857	5.25 μ M	-		
B-0858	2.1 μ M	48.0% @ 1.0 μ M		
B-0859	39.5 μ M	-		
B-0860	38.1 μ M	-		
B-0861	1.32 μ M	12.0% @ 1.0 μ M		
B-0862	2.15 μ M	4.0% @ 1.0 μ M		
B-0863	0.81 μ M	26.0% @ 1.0 μ M		
B-0864	0.39 μ M	4.0% @ 1.0 μ M		
B-0865	0.66 μ M	46.0% @ 1.0 μ M		
B-0866	1.38 μ M	28.0% @ 1.0 μ M		
B-0867	0.62 μ M	> 1.0 μ M		
B-0868	3.29 μ M	8.0% @ 1.0 μ M		
B-0869	4.18 μ M	> 1.0 μ M		
B-0870	3.13 μ M	> 1.0 μ M		
B-0871	1.9 μ M	> 1.0 μ M		
B-0872	3.13 μ M	3.0% @ 1.0 μ M		
B-0873	6.92 μ M	> 1.0 μ M		
B-0874	1.82 μ M	> 1.0 μ M		
B-0875	2.13 μ M	8% @ 1.0 μ M		
B-0876	0.89 μ M	> 1.0 μ M		
B-0877	1.17 μ M	13.0% @ 1.0 μ M		
B-0878	0.65 μ M	19.0% @ 1.0 μ M		
B-0879	0.87 μ M	1.0% @ 1.0 μ M		
B-0880	0.16 μ M	40.0% @ 1.0 μ M		
B-0881	1.36 μ M	> 1.0 μ M		
B-0882	1.48 μ M	9% @ 1.0 μ M		
B-0883	1.06 μ M	> 1.0 μ M		
B-0884	1.89 μ M	-		
B-0885	-	-		
B-0886	-	-		
B-0887	-	-		
B-0888	-	-		
B-0889	-	-		
B-0890	-	-		
B-0891	-	-		
B-0892	-	-		

SUBSTITUTE SHEET (RULE 86)

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-0833				
B-0834				
B-0835				
B-0836				
B-0837				
B-0838				
B-0839				
B-0840				
B-0841				
B-0842				
B-0843				
B-0844				
B-0845				
B-0846				
B-0847				
B-0848				
B-0849				
B-0850				
B-0851				
B-0852				
B-0853				
B-0854				
B-0855				
B-0856				
B-0857				
B-0858				
B-0859				
B-0860				
B-0861				
B-0862				
B-0863				
B-0864				
B-0865				
B-0866				
B-0867				
B-0868				
B-0869				
B-0870				
B-0871				
B-0872				
B-0873				
B-0874				
B-0875				
B-0876				
B-0877				
B-0878				
B-0879				
B-0880				
B-0881				
B-0882				
B-0883				
B-0884				
B-0885				
B-0886				
B-0887				
B-0888				
B-0889				
B-0890				
B-0891				
B-0892				
B-0893				
B-0894				
B-0895				
B-0896				
B-0897				
B-0898				
B-0899				
B-0900				
B-0901				
B-0902				
B-0903				
B-0904				
B-0905				
B-0906				
B-0907				
B-0908				
B-0909				
B-0910				
B-0911				
B-0912				
B-0913				
B-0914				
B-0915				
B-0916				
B-0917				
B-0918				
B-0919				
B-0920				
B-0921				
B-0922				
B-0923				
B-0924				
B-0925				
B-0926				
B-0927				
B-0928				
B-0929				
B-0930				
B-0931				
B-0932				
B-0933	47.0% @ 1.0 μ M	37.0% @ 1.0 μ M		
B-0934	67.0% @ 1.0 μ M	36.0% @ 1.0 μ M		
B-0935	69.0% @ 1.0 μ M	54.0% @ 1.0 μ M		
B-0936	69.0% @ 1.0 μ M	> 1.0 μ M		
B-0937	64.0% @ 1.0 μ M	1.7 μ M		
B-0938	51.0% @ 1.0 μ M	29.0% @ 1.0 μ M		
B-0939	78.0% @ 1.0 μ M	14.0% @ 1.0 μ M		
B-0940	56.0% @ 1.0 μ M	22.0% @ 1.0 μ M		
B-0941	81.0% @ 1.0 μ M	25.0% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 26)

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-0942	82.0% @ 1.0 μ M	2.0% @ 1.0 μ M		
B-0943	63.0% @ 10.0 μ M	24.0% @ 1.0 μ M		
B-0944	45.0% @ 1.0 μ M	27.0% @ 1.0 μ M		
B-0945	96.0% @ 1.0 μ M	0.93 μ M		
B-0946	76.0% @ 1.0 μ M	31.0% @ 1.0 μ M		
B-0947	69.0% @ 1.0 μ M	34.0% @ 1.0 μ M		
B-0948	66.0% @ 1.0 μ M	1.81 μ M		
B-0949	90.0% @ 1.0 μ M	17.0% @ 1.0 μ M		
B-0950	81.0% @ 1.0 μ M	0.59 μ M		
B-0951	82.0% @ 1.0 μ M	29.0% @ 1.0 μ M		
B-0952	44.0% @ 1.0 μ M	21.0% @ 1.0 μ M		
B-0953	63.0% @ 1.0 μ M	25.0% @ 1.0 μ M		
B-0954	62.0% @ 1.0 μ M	0.52 μ M		
B-0955	49.0% @ 1.0 μ M	0.54 μ M		
B-0956	56.0% @ 1.0 μ M	1.33 μ M		
B-0957	79.0% @ 1.0 μ M	22.0% @ 1.0 μ M		
B-0958	74.0% @ 1.0 μ M	0.38 μ M		
B-0959	83.0% @ 1.0 μ M	39.0% @ 1.0 μ M		
B-0960	48.0% @ 1.0 μ M	4.0% @ 1.0 μ M		
B-0961	79.0% @ 1.0 μ M	23.0% @ 1.0 μ M		
B-0962	85.0% @ 1.0 μ M	2.71 μ M		
B-0963	76.0% @ 1.0 μ M	39.0% @ 1.0 μ M		
B-0964	94.0% @ 1.0 μ M	5.0 μ M		
B-0965	74.0% @ 1.0 μ M	1.1 μ M		
B-0966	50.0% @ 1.0 μ M	5.0% @ 1.0 μ M		
B-0967	80.0% @ 1.0 μ M	29.0% @ 1.0 μ M		
B-0968	35.0% @ 1.0 μ M	26.0% @ 1.0 μ M		
B-0969	63.0% @ 1.0 μ M	35.0% @ 1.0 μ M		
B-0970	76.0% @ 10.0 μ M	0.88 μ M		
B-0971	61.0% @ 1.0 μ M	39.0% @ 1.0 μ M		
B-0972	65.0% @ 1.0 μ M	2.0% @ 1.0 μ M		
B-0973	66.0% @ 10.0 μ M	48.0% @ 1.0 μ M		
B-0974	57.0% @ 1.0 μ M	47.0% @ 1.0 μ M		
B-0975	82.0% @ 1.0 μ M	32.0% @ 1.0 μ M		
B-0976	75.0% @ 1.0 μ M	36.0% @ 1.0 μ M		
B-0977	60.0% @ 1.0 μ M	26.0% @ 1.0 μ M		
B-0978	59.0% @ 1.0 μ M	36.0% @ 1.0 μ M		
B-0979	56.0% @ 10.0 μ M	23.0% @ 1.0 μ M		
B-0980	66.0% @ 1.0 μ M	31.0% @ 1.0 μ M		
B-0981	62.0% @ 1.0 μ M	57.0% @ 1.0 μ M		
B-0982	65.0% @ 1.0 μ M	23.0% @ 1.0 μ M		
B-0983	75.0% @ 1.0 μ M	0.8 μ M		
B-0984	60.0% @ 1.0 μ M	51.0% @ 1.0 μ M		
B-0985	86.0% @ 1.0 μ M	0.75 μ M		
B-0986	70.0% @ 1.0 μ M	71.0% @ 1.0 μ M		
B-0987	73.0% @ 1.0 μ M	79.0% @ 1.0 μ M		
B-0988	72.0% @ 1.0 μ M	65.0% @ 1.0 μ M		
B-0989	85.0% @ 1.0 μ M	0.85 μ M		
B-0990		26.0% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 26)

Examples	P38 alpha kinase IC50, μ M or % inhib@conc. (μ M)	U837 Cell IC50, μ M or % inhib@conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @pre-dose time	Ret LPS Model % inhib @dose @pre-dose time
B-0991	58.0% @ 1.0 μ M	33.0% @ 1.0 μ M		
B-0992	77.0% @ 1.0 μ M	45.0% @ 1.0 μ M		
B-0993	57.0% @ 1.0 μ M	73.0% @ 1.0 μ M		
B-0994	55.0% @ 1.0 μ M	43.0% @ 1.0 μ M		
B-0995	53.0% @ 1.0 μ M	14.0% @ 1.0 μ M		
B-0996	54.0% @ 1.0 μ M	27.0% @ 1.0 μ M		
B-0997	69.0% @ 1.0 μ M	22.0% @ 1.0 μ M		
B-0998	67.0% @ 1.0 μ M	25.0% @ 1.0 μ M		
B-0999	61.0% @ 1.0 μ M	24.0% @ 1.0 μ M		
B-1000	35.0% @ 1.0 μ M	42.0% @ 1.0 μ M		
B-1001	63.0% @ 1.0 μ M	31.0% @ 1.0 μ M		
B-1002	70.0% @ 1.0 μ M	41.0% @ 1.0 μ M		
B-1003	74.0% @ 1.0 μ M	28.0% @ 1.0 μ M		
B-1004	79.0% @ 1.0 μ M	45.0% @ 1.0 μ M		
B-1005	58.0% @ 1.0 μ M	23.0% @ 1.0 μ M		
B-1006	69.0% @ 1.0 μ M	38.0% @ 1.0 μ M		
B-1007	52.0% @ 1.0 μ M	34.0% @ 1.0 μ M		
B-1008	54.0% @ 1.0 μ M	23.0% @ 1.0 μ M		
B-1009	80.0% @ 1.0 μ M	55.0% @ 1.0 μ M		
B-1010	75.0% @ 1.0 μ M	1.0 μ M		
B-1011	72.0% @ 1.0 μ M	17.0% @ 1.0 μ M		
B-1012	-	20.0% @ 1.0 μ M		
B-1013	85.0% @ 1.0 μ M	7.0% @ 1.0 μ M		
B-1014	88.0% @ 1.0 μ M	20.0% @ 1.0 μ M		
B-1015	77.0% @ 1.0 μ M	34.0% @ 1.0 μ M		
B-1016	58.0% @ 1.0 μ M	10.0% @ 1.0 μ M		
B-1017	96.0% @ 1.0 μ M	58.0% @ 1.0 μ M		
B-1018	85.0% @ 1.0 μ M	34.0% @ 1.0 μ M		
B-1019	82.0% @ 1.0 μ M	66.0% @ 1.0 μ M		
B-1020	87.0% @ 1.0 μ M	36.0% @ 1.0 μ M		
B-1021	82.0% @ 1.0 μ M	35.0% @ 1.0 μ M		
B-1022	84.0% @ 1.0 μ M	53.0% @ 1.0 μ M		
B-1023	83.0% @ 1.0 μ M	57.0% @ 1.0 μ M		
B-1024	89.0% @ 1.0 μ M	23.0% @ 1.0 μ M		
B-1025	61.0% @ 1.0 μ M	53.0% @ 1.0 μ M		
B-1026	87.0% @ 1.0 μ M	18.0% @ 1.0 μ M		
B-1027	58.0% @ 1.0 μ M	17.0% @ 1.0 μ M		
B-1028	70.0% @ 1.0 μ M	64.0% @ 1.0 μ M		
B-1029	69.0% @ 1.0 μ M	60.0% @ 1.0 μ M		
B-1030	76.0% @ 1.0 μ M	42.0% @ 1.0 μ M		
B-1031	69.0% @ 1.0 μ M	37.0% @ 1.0 μ M		
B-1032	76.0% @ 1.0 μ M	34.0% @ 1.0 μ M		
B-1033	86.0% @ 1.0 μ M	39.0% @ 1.0 μ M		
B-1034	66.0% @ 1.0 μ M	52.0% @ 1.0 μ M		
B-1035	75.0% @ 1.0 μ M	68.0% @ 1.0 μ M		
B-1036	68.0% @ 1.0 μ M	41.0% @ 1.0 μ M		
B-1037	-	0.57 μ M		
B-1038	57.0% @ 1.0 μ M	1.33 μ M		
B-1039	-	1.33 μ M		

SUBSTITUTE SHEET (RULE 26)

Examples	P38 alpha kinase IC50, μ M or % inhib@conc. (μ M)	U837 Cell IC50, μ M or % inhib@conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @pre-dose time	Ret LPS Model % inhib @dose @pre-dose time
B-1040	72.0% @ 1.0 μ M	0.38 μ M		
B-1041	70.0% @ 1.0 μ M	73.0% @ 1.0 μ M		
B-1042	79.0% @ 1.0 μ M	12.0% @ 1.0 μ M		
B-1043	64.0% @ 1.0 μ M	53.0% @ 1.0 μ M		
B-1044	94.0% @ 1.0 μ M	0.83 μ M		
B-1045	78.0% @ 1.0 μ M	25.0% @ 1.0 μ M		
B-1046	72.0% @ 1.0 μ M	66.0% @ 1.0 μ M		
B-1047	72.0% @ 1.0 μ M	58.0% @ 1.0 μ M		
B-1048	67.0% @ 1.0 μ M	19.0% @ 1.0 μ M		
B-1049	67.0% @ 1.0 μ M	85.0% @ 1.0 μ M		
B-1050	-	0.54 μ M		
B-1051	68.0% @ 1.0 μ M	41% @ 1.0 μ M		
B-1052	69.0% @ 1.0 μ M	66% @ 1.0 μ M		
B-1053	78.0% @ 1.0 μ M	0.4 μ M		
B-1054	79.0% @ 1.0 μ M	55.0% @ 1.0 μ M		
B-1055	89.0% @ 1.0 μ M	63.0% @ 1.0 μ M		
B-1056	89.0% @ 1.0 μ M	0.78 μ M		
B-1057	85.0% @ 1.0 μ M	0.72 μ M		
B-1058	0.66 μ M	43.0% @ 1.0 μ M		
B-1059	0.18 μ M	24.0% @ 1.0 μ M		
B-1060	0.11 μ M	32.0% @ 1.0 μ M		
B-1061	0.03 μ M	18.0% @ 1.0 μ M		
B-1062	<0.1 μ M	26.0% @ 1.0 μ M		
B-1063	0.16 μ M	44.0% @ 1.0 μ M		
B-1064	0.39 μ M	50.0% @ 1.0 μ M		
B-1065	0.56 μ M	40.0% @ 1.0 μ M		
B-1066	<0.1 μ M	39.0% @ 1.0 μ M		
B-1067	1.6 μ M	32.0% @ 1.0 μ M		
B-1068	0.48 μ M	24.0% @ 1.0 μ M		
B-1069	0.22 μ M	27.0% @ 1.0 μ M		
B-1070	<0.1 μ M	44.0% @ 1.0 μ M		
B-1071	<0.1 μ M	48.0% @ 1.0 μ M		
B-1072	0.36 μ M	28.0% @ 1.0 μ M		
B-1073	<0.1 μ M	21.0% @ 1.0 μ M		
B-1074	0.23 μ M	33.0% @ 1.0 μ M		
B-1075	0.03 μ M	29.0% @ 1.0 μ M		
B-1076	0.06 μ M	31.0% @ 1.0 μ M		
B-1077	<0.1 μ M	38.0% @ 1.0 μ M		
B-1078	0.28 μ M	48.0% @ 1.0 μ M		
B-1079	<0.1 μ M	40.0% @ 1.0 μ M		
B-1080	0.19 μ M	28.0% @ 1.0 μ M		
B-1081	<0.1 μ M	37.0% @ 1.0 μ M		
B-1082	<0.1 μ M	54.0% @ 1.0 μ M		
B-1083	<0.1 μ M	23.0% @ 1.0 μ M		
B-1084	0.43 μ M	29.0% @ 1.0 μ M		
B-1085	<0.1 μ M	28.0% @ 1.0 μ M		
B-1086	<0.1 μ M	42.0% @ 1.0 μ M		
B-1087	0.05 μ M	32.0% @ 1.0 μ M		
B-1088	0.73 μ M	48.0% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 26)

Examples	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-1089	<0.1 μ M	39.0% @ 1.0 μ M		
B-1090	<0.1 μ M	90.0% @ 1.0 μ M		
B-1091	<0.1 μ M	73.0% @ 1.0 μ M		
B-1092	0.27 μ M	85.0% @ 1.0 μ M		
B-1093	0.33 μ M	36.0% @ 1.0 μ M		
B-1094	0.013 μ M	69.0% @ 1.0 μ M		
B-1095	<0.1 μ M	70.0% @ 1.0 μ M		
B-1096	<0.1 μ M	32.0% @ 1.0 μ M		
B-1097	<0.1 μ M	44.0% @ 1.07 μ M		
B-1098	<0.1 μ M	82.0% @ 1.0 μ M		
B-1099	0.26 μ M	74.0% @ 1.0 μ M		
B-1100	0.22 μ M	58.0% @ 1.0 μ M		
B-1101	0.028 μ M	82.0% @ 1.0 μ M		
B-1102	0.035 μ M	83.0% @ 1.0 μ M		
B-1103	0.064 μ M	90.0% @ 1.0 μ M		
B-1104	0.12 μ M	69.0% @ 1.0 μ M		
B-1105	<0.1 μ M	84.0% @ 1.0 μ M		
B-1106	<0.1 μ M	86.0% @ 1.0 μ M		
B-1107	0.057 μ M	81.0% @ 1.0 μ M		
B-1108	0.22 μ M	80.0% @ 1.0 μ M		
B-1109	0.054 μ M	64.0% @ 1.0 μ M		
B-1110	0.47 μ M	64.0% @ 1.0 μ M		
B-1111	0.19 μ M	64.0% @ 1.0 μ M		
B-1112	0.58 μ M	43.0% @ 1.0 μ M		
B-1113	<0.1 μ M	72.0% @ 1.0 μ M		
B-1114	0.069 μ M	51.0% @ 1.0 μ M		
B-1115	0.024 μ M	89.0% @ 1.0 μ M		
B-1116	0.41 μ M	91.0% @ 1.0 μ M		
B-1117	0.13 μ M	73.0% @ 1.0 μ M		
B-1118	0.33 μ M	91.0% @ 1.0 μ M		
B-1119	0.35 μ M	80.0% @ 1.0 μ M		
B-1120	0.47 μ M	9.0% @ 1.0 μ M		
B-1121	3.58 μ M	29.0% @ 1.0 μ M		
B-1122	1.84 μ M	32.0% @ 1.0 μ M		
B-1123	2.93 μ M	27.0% @ 1.0 μ M		
B-1124	1.49 μ M	52.0% @ 1.0 μ M		
B-1125	0.56 μ M	41.0% @ 1.0 μ M		
B-1126	1.50 μ M	>1.0 μ M		
B-1127	0.71 μ M	7.0% @ 1.0 μ M		
B-1128	2.55 μ M	26.0% @ 1.0 μ M		
B-1129	1.07 μ M	46.0% @ 1.0 μ M		
B-1130	0.50 μ M	29.0% @ 1.0 μ M		
B-1131	0.076 μ M	34.0% @ 1.0 μ M		
B-1132	0.72 μ M	11.0% @ 1.0 μ M		
B-1133	0.38 μ M	33.0% @ 1.0 μ M		
B-1134	1.71 μ M	33.0% @ 1.0 μ M		
B-1135	0.23 μ M	38.0% @ 1.0 μ M		
B-1136	1.17 μ M	40.0% @ 1.0 μ M		
B-1137	0.038 μ M	35.0% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 86)

Examples	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-1138	1.82 μ M	>1.0 μ M		
B-1139	0.041 μ M	29.0% @ 1.0 μ M		
B-1140	1.68 μ M	39.0% @ 1.0 μ M		
B-1141	2.47 μ M	32.0% @ 1.0 μ M		
B-1142	0.11 μ M	37.0% @ 1.0 μ M		
B-1143	0.17 μ M	40.0% @ 1.0 μ M		
B-1144	0.44 μ M	72.0% @ 1.0 μ M		
B-1145	1.07 μ M	71.0% @ 1.0 μ M		
B-1146	0.47 μ M	61.0% @ 1.0 μ M		
B-1147	0.095 μ M	53.0% @ 1.0 μ M		
B-1148	0.43 μ M	61.0% @ 1.0 μ M		
B-1149	1.55 μ M	48.0% @ 1.0 μ M		
B-1150	0.47 μ M	75.0% @ 1.0 μ M		
B-1151	0.32 μ M	72.0% @ 1.0 μ M		
B-1152	0.73 μ M	53.0% @ 1.0 μ M		
B-1153	2.22 μ M	52.0% @ 1.0 μ M		
B-1154	0.085 μ M	46.0% @ 1.0 μ M		
B-1155	3.22 μ M	30.0% @ 1.0 μ M		
B-1156	0.27 μ M	78.0% @ 1.0 μ M		
B-1157	0.26 μ M	66.0% @ 1.0 μ M		
B-1158	74% @ 1.0 μ M	74% @ 1.0 μ M	53% @ 30mpk @ 6h	
B-1159	66.0% @ 1.0 μ M	1.03 μ M	60% @ 30mpk @ 6h	
B-1160	79.0% @ 1.0 μ M	0.38 μ M	40% @ 30mpk @ 6h	
B-1161	64.0% @ 1.0 μ M	0.93 μ M	40% @ 30mpk @ 6h	
B-1162	79.0% @ 1.0 μ M	0.59 μ M	40% @ 30mpk @ 6h	
B-1163	74.0% @ 1.0 μ M	0.37 μ M		
B-1164	-	0.35 μ M		
B-1165	66.0% @ 1.0 μ M	0.99 μ M		
B-1166	77.0% @ 1.0 μ M	0.39 μ M	50% @ 30mpk @ 6h	
B-1167	70.0% @ 1.0 μ M	1.08 μ M		
B-1168	66.0% @ 1.0 μ M	0.63 μ M		
B-1169	80.0% @ 1.0 μ M	0.11 μ M		
B-1170	82.0% @ 1.0 μ M	0.57 μ M		
B-1171	78.0% @ 1.0 μ M	0.23 μ M		
B-1172	68.0% @ 1.0 μ M	1.95 μ M		
B-1173	65.0% @ 1.0 μ M	62% @ 1.0 μ M		
B-1174	80.0% @ 1.0 μ M	0.86 μ M		
B-1175	72.0% @ 1.0 μ M	1.53 μ M		
B-1176	67.0% @ 1.0 μ M	67.0% @ 1.0 μ M		
B-1177	70.0% @ 1.0 μ M	1.18 μ M		
B-1178	82.0% @ 1.0 μ M	1.61 μ M		
B-1179	86.0% @ 1.0 μ M	0.41 μ M		
B-1180	78.0% @ 1.0 μ M	0.53 μ M		
B-1181	78.0% @ 1.0 μ M	66% @ 1.0 μ M		
B-1182	72.0% @ 1.0 μ M	0.65 μ M		
B-1183	77.0% @ 1.0 μ M	0.20 μ M		
B-1184	69.0% @ 1.0 μ M	0.53 μ M		
B-1185	71.0% @ 1.0 μ M	0.79 μ M		
B-1186	83.0% @ 1.0 μ M	60% @ 1.0 μ M		

SUBSTITUTE SHEET (RULE 86)

Examples	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-1187	76.0% @ 1.0 μ M	1.80 μ M		
B-1188	-	36.0% @ 1.0 μ M		
B-1189	68.0% @ 1.0 μ M	0.83 μ M		
B-1190	78.0% @ 1.0 μ M	62.0% @ 1.0 μ M		
B-1191	74.0% @ 1.0 μ M	57.0% @ 1.0 μ M		
B-1192	84.0% @ 1.0 μ M	0.47 μ M		
B-1193	69.0% @ 1.0 μ M	65.0% @ 1.0 μ M		
B-1194	87.0% @ 1.0 μ M	0.58 μ M		
B-1195	52.0% @ 1.0 μ M	60.0% @ 1.0 μ M		
B-1196	74.0% @ 1.0 μ M	66.0% @ 1.0 μ M		
B-1197	77.0% @ 1.0 μ M	45.0% @ 1.0 μ M		
B-1198	82.0% @ 1.0 μ M	0.46 μ M		
B-1199	87.0% @ 1.0 μ M	49.0% @ 1.0 μ M		
B-1200	95.0% @ 1.0 μ M	0.64 μ M		
B-1201	84.0% @ 1.0 μ M	0.51 μ M		
B-1202	71.0% @ 1.0 μ M	58.0% @ 1.0 μ M		
B-1203	84.0% @ 1.0 μ M	59.0% @ 1.0 μ M		
B-1204	68.0% @ 1.0 μ M	59.0% @ 1.0 μ M		
B-1205	74.0% @ 1.0 μ M	46.0% @ 1.0 μ M		
B-1206	81.0% @ 1.0 μ M	0.34 μ M		
B-1207	90.0% @ 1.0 μ M	58.0% @ 1.0 μ M		
B-1208	82.0% @ 1.0 μ M	51.0% @ 1.0 μ M		
B-1209	86.0% @ 1.0 μ M	55.0% @ 1.0 μ M		
B-1210	82.0% @ 1.0 μ M	57.0% @ 1.0 μ M		
B-1211	88.0% @ 1.0 μ M	59.0% @ 1.0 μ M		
B-1212	90.0% @ 1.0 μ M	57.0% @ 1.0 μ M		
B-1213	84.0% @ 1.0 μ M	0.62 μ M		
B-1214	76.0% @ 1.0 μ M	58.0% @ 1.0 μ M		
B-1215	66.0% @ 1.0 μ M	0.23 μ M		
B-1216	88.0% @ 1.0 μ M	0.18 μ M		
B-1217	87.0% @ 1.0 μ M	0.46 μ M		
B-1218	88.0% @ 1.0 μ M	76.0% @ 1.0 μ M		
B-1219	85.0% @ 1.0 μ M	37.0% @ 1.0 μ M		
B-1220	81.0% @ 1.0 μ M	53.0% @ 1.0 μ M		
B-1221	82.0% @ 1.0 μ M	44.0% @ 1.0 μ M		
B-1222	65.0% @ 1.0 μ M	9.0% @ 1.0 μ M		
B-1223	80.0% @ 1.0 μ M	61.0% @ 1.0 μ M		
B-1224	82.0% @ 1.0 μ M	74.0% @ 1.0 μ M		
B-1225	89.0% @ 1.0 μ M	73.0% @ 1.0 μ M		
B-1226	89.0% @ 1.0 μ M	0.18 μ M		
B-1227	83.0% @ 1.0 μ M	0.22 μ M		
B-1228	90.0% @ 1.0 μ M	0.72 μ M		
B-1229	87.0% @ 1.0 μ M	0.65 μ M		
B-1230	90.0% @ 1.0 μ M	0.26 μ M		
B-1231	94.0% @ 1.0 μ M	0.58 μ M		
B-1232	81.0% @ 1.0 μ M	54.0% @ 1.0 μ M		
B-1233	85.0% @ 1.0 μ M	0.36 μ M		
B-1234	89.0% @ 1.0 μ M	0.49 μ M		
B-1235	0.04 μ M	76.0% @ 1.0 μ M		

SUBSTITUTESHEET (RULE 86)

Examples	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-1236	0.1 μ M	53.0% @ 1.0 μ M		
B-1237	0.22 μ M	39.0% @ 1.0 μ M		
B-1238	0.14 μ M	16.0% @ 1.0 μ M		
B-1239	<0.1 μ M	38.0% @ 1.0 μ M		
B-1240	<0.1 μ M	59.0% @ 1.0 μ M		
B-1241	0.04 μ M	81.0% @ 1.0 μ M		
B-1242	0.08 μ M	83.0% @ 1.0 μ M		
B-1243	0.04 μ M	47.0% @ 1.0 μ M		
B-1244	0.28 μ M	44.0% @ 1.0 μ M		
B-1245	0.49 μ M	42.0% @ 1.0 μ M		
B-1246	0.27 μ M	40.0% @ 1.0 μ M		
B-1247	<0.1 μ M	58.0% @ 1.0 μ M		
B-1248	<0.1 μ M	68.0% @ 1.0 μ M		
B-1249	0.24 μ M	60.0% @ 1.0 μ M		
B-1250	0.14 μ M	18.0% @ 1.0 μ M		
B-1251	0.41 μ M	38.0% @ 1.0 μ M		
B-1252	0.17 μ M	46.0% @ 1.0 μ M		
B-1253	0.18 μ M	57.0% @ 1.0 μ M		
B-1254	0.16 μ M	68.0% @ 1.0 μ M		
B-1255	12.9 μ M	75.0% @ 1.0 μ M		
B-1256	0.12 μ M	41.0% @ 1.0 μ M		
B-1257	1.48 μ M	40.0% @ 1.0 μ M		
B-1258	0.07 μ M	56.0% @ 1.0 μ M		
B-1259	<0.1 μ M	0.48 μ M		
B-1260	0.11 μ M	48.0% @ 1.0 μ M		
B-1261	0.74 μ M	44.0% @ 1.0 μ M		
B-1262	<0.1 μ M	63.0% @ 1.0 μ M		
B-1263	1.05 μ M	57.0% @ 1.0 μ M		
B-1264	0.32 μ M	47.0% @ 1.0 μ M		
B-1265	0.43 μ M	51.0% @ 1.0 μ M		
B-1266	<0.1 μ M	58.0% @ 1.0 μ M		
B-1267	<0.1 μ M	73.0% @ 1.0 μ M		
B-1268	<0.1 μ M	79.0% @ 1.0 μ M		
B-1269	0.46 μ M	84.0% @ 1.0 μ M		
B-1270	0.47 μ M	83.0% @ 1.0 μ M		
B-1271	0.13 μ M	74.0% @ 1.0 μ M		
B-1272	0.014 μ M	38.0% @ 1.0 μ M		
B-1273	<0.1 μ M	36.0% @ 1.0 μ M		
B-1274	<0.1 μ M	41.0% @ 1.0 μ M		
B-1275	<0.1 μ M	50.0% @ 1.0 μ M		
B-1276	0.062 μ M	11.0% @ 1.0 μ M		
B-1277	<0.1 μ M	47.0% @ 1.0 μ M		
B-1278	0.12 μ M	85.0% @ 1.0 μ M		
B-1279	<0.1 μ M	79.0% @ 1.0 μ M		
B-1280	0.039 μ M	83.0% @ 1.0 μ M		
B-1281	<0.1 μ M	85.0% @ 1.0 μ M		
B-1282	<0.1 μ M	75.0% @ 1.0 μ M		
B-1283	<0.1 μ M	64.0% @ 1.0 μ M		
B-1284	<0.1 μ M	75.0% @ 1.0 μ M		

SUBSTITUTESHEET (RULE 86)

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-1285	0.057 μ M	80.0% @ 1.0 μ M		
B-1286	0.15 μ M	78.0% @ 1.0 μ M		
B-1287	0.25 μ M	55.0% @ 1.0 μ M		
B-1288	0.15 μ M	74.0% @ 1.0 μ M		
B-1289	0.73 μ M	35.0% @ 1.0 μ M		
B-1290	0.26 μ M	75.0% @ 1.0 μ M		
B-1291	0.097 μ M	55.0% @ 1.0 μ M		
B-1292	0.07 μ M	74.0% @ 1.0 μ M		
B-1293	0.3 μ M	48.0% @ 1.0 μ M		
B-1294	0.013 μ M	54.0% @ 1.0 μ M		
B-1295	0.079 μ M	74.0% @ 1.0 μ M		
B-1296	0.038 μ M	48.0% @ 1.0 μ M		
B-1297	0.02 μ M	>1.0 μ M		
B-1298	0.055 μ M	20.0% @ 1.0 μ M		
B-1299	0.091 μ M	>1.0 μ M		
B-1300	0.071 μ M	18.0% @ 1.0 μ M		
B-1301	0.12 μ M	15.0% @ 1.0 μ M		
B-1302	0.023 μ M	11.0% @ 1.0 μ M		
B-1303	0.08 μ M	>1.0 μ M		
B-1304	0.11 μ M	10.0% @ 1.0 μ M		
B-1305	0.64 μ M	9.0% @ 1.0 μ M		
B-1306	0.11 μ M	>1.0 μ M		
B-1307	0.009 μ M	16.0% @ 1.0 μ M		
B-1308	<0.1 μ M	>1.0 μ M		
B-1309	0.045 μ M	>1.0 μ M		
B-1310	0.12 μ M	11.0% @ 1.0 μ M		
B-1311	0.05 μ M	57.0% @ 1.0 μ M		
B-1312	0.35 μ M	>1.0 μ M		
B-1313	0.035 μ M	37.0% @ 1.0 μ M		
B-1314	0.045 μ M	24.0% @ 1.0 μ M		
B-1315	0.055 μ M	12.0% @ 1.0 μ M		
B-1316	0.026 μ M	36.0% @ 1.0 μ M		
B-1317	0.019 μ M	9.0% @ 1.0 μ M		
B-1318	<0.1 μ M	1.0% @ 1.0 μ M		
B-1319	0.24 μ M	>1.0 μ M		
B-1320	0.047 μ M	43.0% @ 1.0 μ M		
B-1321	0.47 μ M	66.0% @ 1.0 μ M		
B-1322	0.12 μ M	87.0% @ 1.0 μ M		
B-1323	0.013 μ M	85.0% @ 1.0 μ M		
B-1324	0.16 μ M	83.0% @ 1.0 μ M		
B-1325	0.27 μ M	95.0% @ 1.0 μ M		
B-1326	0.092 μ M	84.0% @ 1.0 μ M		
B-1327	0.13 μ M	65.0% @ 1.0 μ M		
B-1328	0.032 μ M	86.0% @ 1.0 μ M		
B-1329	0.66 μ M	54.0% @ 1.0 μ M		
B-1330	0.053 μ M	85.0% @ 1.0 μ M		
B-1331	0.004 μ M	85.0% @ 1.0 μ M		
B-1332	0.007 μ M	81.0% @ 1.0 μ M		
B-1333	0.45 μ M	76.0% @ 1.0 μ M		

SUBSTITUTESHEET (RULE 86)

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-1334	0.13 μ M	73.0% @ 1.0 μ M		
B-1335	0.097 μ M	63.0% @ 1.0 μ M		
B-1336	0.072 μ M	83.0% @ 1.0 μ M		
B-1337	0.4 μ M	90.0% @ 1.0 μ M		
B-1338	0.18 μ M	73.0% @ 1.0 μ M		
B-1339	0.12 μ M	67.0% @ 1.0 μ M		
B-1340	0.043 μ M	63.0% @ 1.0 μ M		
B-1341	0.42 μ M	52.0% @ 1.0 μ M		
B-1342	0.25 μ M	59.0% @ 1.0 μ M		
B-1343	0.065 μ M	83.0% @ 1.0 μ M		
B-1344	0.014 μ M	86.0% @ 1.0 μ M		
B-1345	0.27 μ M	73.0% @ 1.0 μ M		
B-1346	0.043 μ M	86.0% @ 1.0 μ M		
B-1347	0.021 μ M	84.0% @ 1.0 μ M		
B-1348	0.009 μ M	69.0% @ 1.0 μ M		
B-1349	0.037 μ M	86.0% @ 1.0 μ M		
B-1350	0.019 μ M	78.0% @ 1.0 μ M		
B-1351	0.068 μ M	78.0% @ 1.0 μ M		
B-1352	0.013 μ M	76.0% @ 1.0 μ M		
B-1353	0.062 μ M	80.0% @ 1.0 μ M		
B-1354	0.013 μ M	83.0% @ 1.0 μ M		
B-1355	0.07 μ M	75.0% @ 1.0 μ M		
B-1356	0.059 μ M	91.0% @ 1.0 μ M		
B-1357	0.18 μ M	84.0% @ 1.0 μ M		
B-1358	0.18 μ M	76.0% @ 1.0 μ M		
B-1359	0.005	84.0% @ 1.0 μ M		
B-1360	0.11	0.15 μ M		
B-1361	0.03	0.29 μ M		
B-1362	0.003	0.29 μ M		
B-1363	0.009	0.28 μ M	51.0% @ 30 pmk @-6h	53% @ 3mpk @-4h
B-1364	0.009	0.27 μ M	53.0% @ 30 mpk @-6.0h	17% @ 3mpk @-4h
B-1365	0.17	88.0% @ 1.0 μ M		
B-1366	0.04	0.27 μ M		
B-1367	<0.1	0.22 μ M		
B-1368	0.031	0.33 μ M	44.0% @ 30 mpk @-	
B-1369	<0.1	0.29 μ M		
B-1370	<0.1	0.77 μ M		
B-1371	0.06	83.0% @ 1.0 μ M		
B-1372	<0.1	0.41 μ M	48.0% @ 30 mpk @-	
B-1373	0.016	0.17 μ M		
B-1374	<0.1	0.28 μ M		
B-1375	0.01	0.25 μ M		
B-1376	0.009	0.26 μ M	3.0% @ 30 mpk @-6h	
B-1377	0.12	5.0 μ M		
B-1378	0.02	1.04 μ M		
B-1379	<0.1	0.092 μ M		
B-1380	<0.1	0.28 μ M		

SUBSTITUTESHEET (RULE 86)

697

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF - Inhib @ dose @pre-dose time	Rat LPS Model % Inhib @ dose @pre-dose time
B-1381	0.055	0.73 μ M		
B-1382	<0.1	0.44 μ M		
B-1383	0.0012	0.15 μ M		
B-1384	0.57	0.37 μ M		
B-1385	<0.1	0.11 μ M		
B-1386	<0.1	0.25 μ M		
B-1387	<0.1	0.1 μ M		
B-1388	0.57	1.39 μ M		
B-1389	0.06	0.57 μ M		
B-1390	<0.1	71.0% @ 1.0 μ M		
B-1391	0.016 μ M	82.0% @ 1.0 μ M		
B-1392	0.059 μ M	82.0% @ 1.0 μ M		
B-1393	3.17 μ M	80.0% @ 1.0 μ M		
B-1394	0.32 μ M	76.0% @ 1.0 μ M		
B-1395	1.48	61.0% @ 1.0 μ M		
B-1396	1.55	73.0% @ 1.0 μ M		
B-1397	0.92	85.0% @ 1.0 μ M		
B-1398	0.67	83.0% @ 1.0 μ M		
B-1399	0.14	74.0% @ 1.0 μ M		
B-1400	0.024	83.0% @ 1.0 μ M		
B-1401	0.053	75.0% @ 1.0 μ M		
B-1402	0.12	76.0% @ 1.0 μ M		
B-1403	4.54	71% @ 1.0 μ M		
B-1404	0.6	70% @ 1.0 μ M		
B-1405	0.28	56.0% @ 1.0 μ M		
B-1406	1.39	71.0% @ 1.0 μ M		
B-1407	0.4	69.0% @ 1.0 μ M		
B-1408	0.27	72.0% @ 1.0 μ M		
B-1409	<0.1	69% @ 1.0 μ M		
B-1410	<0.1	81.0% @ 1.0 μ M		
B-1411	<0.1	80.0% @ 1.0 μ M		
B-1412	0.097	78.0% @ 1.0 μ M		
B-1413	0.016	83.0% @ 1.0 μ M		
B-1414	0.025	79.0% @ 1.0 μ M		
B-1415	1.41	81.0% @ 1.0 μ M		
B-1416	0.14	69.0% @ 1.0 μ M		
B-1417	0.069	82.0% @ 1.0 μ M		
B-1418	1.01	84.0% @ 1.0 μ M		
B-1419	0.3	82.0% @ 1.0 μ M		
B-1420	<0.1	75.0% @ 1.0 μ M		
B-1421	0.014	68.0% @ 1.0 μ M		
B-1422	0.58	84.0% @ 1.0 μ M		
B-1423	1.58	76.0% @ 1.0 μ M		
B-1424	0.96	83.0% @ 1.0 μ M		
B-1425	0.09	80.0% @ 1.0 μ M		
B-1426	0.18	84.0% @ 1.0 μ M		
B-1427	<0.1	86.0% @ 1.0 μ M		
B-1428	<0.1	87.0% @ 1.0 μ M		
B-1429	<0.1			

SUBSTITUTE SHEET (RULE 86)

698

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF - Inhib @ dose @pre-dose time	Rat LPS Model % Inhib @ dose @pre-dose time
B-1430	0.75 μ M	35.0% @ 1.0 μ M		
B-1431	0.38 μ M	59.0% @ 1.0 μ M		
B-1432	0.11 μ M	51.0% @ 1.0 μ M		
B-1433	0.26 μ M	21.0% @ 1.0 μ M		
B-1434	0.19 μ M	28.0% @ 1.0 μ M		
B-1435	1.8 μ M	45.0% @ 1.0 μ M		
B-1436	1.0 μ M	20.0% @ 1.0 μ M		
B-1437	0.3 μ M	23.0% @ 1.0 μ M		
B-1438	2.01 μ M	27.0% @ 1.0 μ M		
B-1439	1.7 μ M	17.0% @ 1.0 μ M		
B-1440	0.87 μ M	3.0% @ 1.0 μ M		
B-1441	1.95 μ M	56.0% @ 1.0 μ M		
B-1442	1.54 μ M	18.0% @ 1.0 μ M		
B-1443	0.014 μ M	83.0% @ 1.0 μ M		
B-1444	0.3 μ M	24.0% @ 1.0 μ M		
B-1445	0.43 μ M	27.0% @ 1.0 μ M		
B-1446	0.77 μ M	36.0% @ 1.0 μ M		
B-1447	0.5 μ M	34.0% @ 1.0 μ M		
B-1448	1.43 μ M	22.0% @ 1.0 μ M		
B-1449	1.61 μ M	50.0% @ 1.0 μ M		
B-1450	2.1 μ M	48.0% @ 1.0 μ M		
B-1451	2.68 μ M	50% @ 1.0 μ M		
B-1452	2.41 μ M	47.0% @ 1.0 μ M		
B-1453	2.53 μ M	49.0% @ 1.0 μ M		
B-1454	1.6 μ M	12.0% @ 1.0 μ M		
B-1455	1.21 μ M	8.0% @ 1.0 μ M		
B-1456	1.29 μ M	>1.0 μ M		
B-1457	0.43 μ M	43.0% @ 1.0 μ M		
B-1458	0.95 μ M	55.0% @ 1.0 μ M		
B-1459	0.67 μ M	46.0% @ 1.0 μ M		
B-1460	0.95 μ M	28.0% @ 1.0 μ M		
B-1461	0.4 μ M	39.0% @ 1.0 μ M		
B-1462	0.22 μ M	50.0% @ 1.0 μ M		
B-1463	2.34 μ M	26.0% @ 1.0 μ M		
B-1464	1.18 μ M	27.0% @ 1.0 μ M		
B-1465	3.23 μ M	31.0% @ 1.0 μ M		
B-1466	1.69 μ M	>1.0 μ M		
B-1467	1.22 μ M	1.0% @ 1.0 μ M		
B-1468	1.61 μ M	10.0% @ 1.0 μ M		
B-1469	0.37 μ M	14.0% @ 1.0 μ M		
B-1470	0.6 μ M	28.0% @ 1.0 μ M		
B-1471	0.85 μ M	25.0% @ 1.0 μ M		
B-1472	0.93 μ M	12.0% @ 1.0 μ M		
B-1473	1.24 μ M	14.0% @ 1.0 μ M		
B-1474	1.23 μ M	31.0% @ 1.0 μ M		
B-1475	2.1 μ M	24.0% @ 1.0 μ M		
B-1476	0.047 μ M	42.0% @ 1.0 μ M		
B-1477	2.5 μ M	34.0% @ 1.0 μ M		
B-1478				

SUBSTITUTE SHEET (RULE 86)

Examples	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U537 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-1479				

Examples	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U537 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-2270	0.72 μ M	31% @ 10.0 μ M		
B-2271	0.93 μ M	38% @ 10.0 μ M		
B-2272	0.26 μ M	53.0% @ 10.0 μ M		
B-2273	1.92 μ M	39.0% @ 10.0 μ M		
B-2274	0.26 μ M	59.0% @ 10.0 μ M		
B-2275	2.16 μ M	53.0% @ 10.0 μ M		
B-2276	11.5 μ M	37.0% @ 10.0 μ M		
B-2277	14.9 μ M	44.0% @ 10.0 μ M		
B-2278	0.8 μ M	51.0% @ 10.0 μ M		
B-2279	0.32 μ M	36.0% @ 10.0 μ M		
B-2280	0.4 μ M	57.0% @ 10.0 μ M		
B-2281	0.81 μ M	60.0% @ 10.0 μ M		
B-2282	0.91 μ M	41.0% @ 10.0 μ M		
B-2283	0.04 μ M	53.0% @ 10.0 μ M		
B-2284	4.61 μ M	62.0% @ 10.0 μ M		
B-2285	2.29 μ M	48.0% @ 10.0 μ M		
B-2286	0.017 μ M	0.78 μ M	25% @ 30mpk @ 1h	
B-2287	2.56 μ M	61.0% @ 10.0 μ M		
B-2288	6.51 μ M	46.0% @ 10.0 μ M		
B-2289	3.0 μ M	30.0% @ 10.0 μ M		
B-2290	2.37 μ M	59.0% @ 10.0 μ M		
B-2291	0.016 μ M	41% @ 10.0 μ M		
B-2292	8.82 μ M	57.0% @ 10.0 μ M		
B-2293	2.11 μ M	56.0% @ 10.0 μ M		
B-2294	1.68 μ M	50.0% @ 10.0 μ M		
B-2295	1.79 μ M	56.0% @ 10.0 μ M		
B-2296	17.3 μ M	63.0% @ 10.0 μ M		
B-2297	3.59 μ M	57.0% @ 10.0 μ M		
B-2298	0.29 μ M	4.22 μ M		
B-2299	1.97 μ M	62.0% @ 10.0 μ M		
B-2300	0.07 μ M	43.0% @ 10.0 μ M		
B-2301	0.18 μ M	44.0% @ 10.0 μ M		
B-2302	1.0 μ M	58.0% @ 10.0 μ M		
B-2303	0.011 μ M	54.0% @ 10.0 μ M		
B-2304	1.41 μ M	50.0% @ 10.0 μ M		
B-2305	0.54 μ M	60.0% @ 10.0 μ M		
B-2306	5.88 μ M	39.0% @ 10.0 μ M		
B-2307	2.29 μ M	59.0% @ 10.0 μ M		
B-2308	0.66 μ M	56.0% @ 10.0 μ M		
B-2309	0.29 μ M	47.0% @ 10.0 μ M		

701

Example#	P38 alpha kinase IC50, μ M or % Inhib @ conc. (μ M)	UB37 Cell IC50, μ M or % Inhib @ conc. (μ M)	Mouse LPS Model % TNF Inhib @ dose @ predose time	Rel LPS Model % Inhib @ dose @ predose time
B-2310	0.12 μ M	1.2 μ M	50% @ 30mpk @ 6h	
B-2311	7.18 μ M	60% @ 10.0 μ M		
B-2312	2.93 μ M	43.0% @ 10.0 μ M		
B-2313	42.3 μ M	58.0% @ 10.0 μ M		
B-2314	11.0 μ M	66.0% @ 10.0 μ M		
B-2315	0.48 μ M	36.0% @ 10.0 μ M		
B-2316	0.48 μ M	58.0% @ 10.0 μ M		
B-2317	1.0 μ M	60.0% @ 10.0 μ M		
B-2318	73.0% @ 10.0 μ M	25.0% @ 10.0 μ M		
B-2319	75.0% @ 10.0 μ M	40.0% @ 10.0 μ M		
B-2320	44.0% @ 10.0 μ M	35.0% @ 10.0 μ M		
B-2321	68.0% @ 10.0 μ M	27.0% @ 10.0 μ M		
B-2322	78.0% @ 10.0 μ M	38.0% @ 10.0 μ M		
B-2323	69.0% @ 10.0 μ M	46.0% @ 10.0 μ M		
B-2324	58.0% @ 10.0 μ M	36.0% @ 10.0 μ M		
B-2325	60.0% @ 10.0 μ M	51.0% @ 10.0 μ M		
B-2326	76.0% @ 10.0 μ M	33.0% @ 10.0 μ M		
B-2327	76.0% @ 10.0 μ M	23.0% @ 10.0 μ M		
B-2328	65.0% @ 10.0 μ M	28.0% @ 10.0 μ M		
B-2329	72.0% @ 10.0 μ M	37.0% @ 10.0 μ M		
B-2330	81.0% @ 10.0 μ M	44.0% @ 10.0 μ M		
B-2331	74.0% @ 10.0 μ M	47.0% @ 10.0 μ M		
B-2332	70.0% @ 10.0 μ M	36.0% @ 10.0 μ M		
B-2333	58.0% @ 10.0 μ M	50.0% @ 10.0 μ M		
B-2334	81.0% @ 10.0 μ M	45.0% @ 10.0 μ M		
B-2335	82.0% @ 10.0 μ M	50.0% @ 10.0 μ M		
B-2336	48.0% @ 10.0 μ M	35.0% @ 10.0 μ M		
B-2337	46.0% @ 10.0 μ M	59.0% @ 10.0 μ M		
B-2338	73.0% @ 10.0 μ M	50.0% @ 10.0 μ M		
B-2339	84.0% @ 10.0 μ M	>10.0 μ M		
B-2340	35.0% @ 10.0 μ M	12.0% @ 10.0 μ M		
B-2341	75.0% @ 10.0 μ M	50.0% @ 10.0 μ M		
B-2342	63.0% @ 10.0 μ M	46.0% @ 10.0 μ M		
B-2343	43.0% @ 10.0 μ M	27.0% @ 10.0 μ M		
B-2344	71.0% @ 10.0 μ M	50.0% @ 10.0 μ M		
B-2345	64.0% @ 10.0 μ M	38.0% @ 10.0 μ M		
B-2346	45.0% @ 10.0 μ M	48.0% @ 10.0 μ M		
B-2347	49.0% @ 10.0 μ M	50.0% @ 10.0 μ M		
B-2348	78.0% @ 10.0 μ M	48.0% @ 10.0 μ M		
B-2349	75.0% @ 10.0 μ M	27.0% @ 10.0 μ M		

SUBSTITUTE SHEET (RULE 89)

702

Example#	P38 alpha kinase IC50, μ M or % Inhib @ conc. (μ M)	UB37 Cell IC50, μ M or % Inhib @ conc. (μ M)	Mouse LPS Model % TNF Inhib @ dose @ predose time	Rel LPS Model % Inhib @ dose @ predose time
B-2350	38.0% @ 10.0 μ M	56.0% @ 10.0 μ M		
B-2351	77.0% @ 10.0 μ M	1.0% @ 10.0 μ M		
B-2352	37.0% @ 10.0 μ M	18.0% @ 10.0 μ M		
B-2353	38.0% @ 10.0 μ M	33.0% @ 10.0 μ M		
B-2354	65.0% @ 10.0 μ M	25.0% @ 10.0 μ M		
B-2355	84.0% @ 10.0 μ M	50.0% @ 10.0 μ M		
B-2356	77.0% @ 10.0 μ M	45.0% @ 10.0 μ M		
B-2357	47.0% @ 10.0 μ M	41.0% @ 10.0 μ M		
B-2358	17.0% @ 10.0 μ M	52.0% @ 10.0 μ M		
B-2359	76.0% @ 10.0 μ M	35.0% @ 10.0 μ M		
B-2360	45.0% @ 10.0 μ M	>10.0 μ M		
B-2361	19.0% @ 10.0 μ M	46.0% @ 10.0 μ M		
B-2362	60% @ 100.0 μ M	39.0% @ 10.0 μ M		
B-2363	44.0% @ 10.0 μ M	1.0% @ 10.0 μ M		
B-2364	47.0% @ 10.0 μ M	4.0% @ 10.0 μ M		
B-2365	82.0% @ 10.0 μ M	43.0% @ 10.0 μ M		
B-2366	70.0% @ 10.0 μ M	59.0% @ 10.0 μ M		
B-2367	46.0% @ 10.0 μ M	40.0% @ 10.0 μ M		
B-2368	65.0% @ 10.0 μ M	55.0% @ 10.0 μ M		
B-2369	32.0% @ 10.0 μ M	>10.0 μ M		
B-2370	73% @ 100.0 μ M	20.0% @ 10.0 μ M		
B-2371	54.0% @ 10.0 μ M	36.0% @ 10.0 μ M		
B-2372	55.0% @ 100.0 μ M	>10.0 μ M		
B-2373	50.0% @ 100.0 μ M	6% @ 10.0 μ M		
B-2374	35.0% @ 10.0 μ M	20.0% @ 10.0 μ M		
B-2375	62.0% @ 100.0 μ M	>10.0 μ M		
B-2376	32.0% @ 10.0 μ M	17.0% @ 10.0 μ M		
B-2377	34.0% @ 10.0 μ M	17.0% @ 10.0 μ M		
B-2378	48.0% @ 10.0 μ M	61.0% @ 10.0 μ M		
B-2379	73.0% @ 100.0 μ M	45.0% @ 10.0 μ M		
B-2380	81% @ 100.0 μ M	53.0% @ 10.0 μ M		
B-2381	68% @ 100.0 μ M	2.0% @ 10.0 μ M		
B-2382	51.0% @ 10.0 μ M	24.0% @ 10.0 μ M		
B-2383	63.0% @ 10.0 μ M	35.0% @ 10.0 μ M		
B-2384	48% @ 100.0 μ M	10.0% @ 10.0 μ M		
B-2385	79.0% @ 10.0 μ M	19.0% @ 10.0 μ M		
B-2386	38.0% @ 10.0 μ M	19.0% @ 10.0 μ M		
B-2387	50.0% @ 100.0 μ M	>10.0 μ M		
B-2388	42.0% @ 10.0 μ M	24.0% @ 10.0 μ M		
B-2389	39.0% @ 10.0 μ M	29.0% @ 10.0 μ M		

SUBSTITUTE SHEET (RULE 89)

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-2390	34.0% @ 10.0 μ M	27.0% @ 1.0 μ M		
B-2391	40.0% @ 10.0 μ M	59.0% @ 10.0 μ M		
B-2392	63.0% @ 10.0 μ M	46.0% @ 10.0 μ M		
B-2393	43.0% @ 10.0 μ M	> 10.0 μ M		
B-2394	37.0% @ 10.0 μ M	22.0% @ 10.0 μ M		
B-2395	32.0% @ 10.0 μ M	28.0% @ 10.0 μ M		
B-2396	75.0% @ 10.0 μ M	> 10.0 μ M		
B-2397	83.0% @ 10.0 μ M	22.0% @ 10.0 μ M		
B-2398	55% @ 100.0 μ M	10.0% @ 10.0 μ M		
B-2399	69.0% @ 10.0 μ M	18.0% @ 10.0 μ M		
B-2400	60.0% @ 10.0 μ M	40.0% @ 10.0 μ M		
B-2401	78.0% @ 10.0 μ M	44.0% @ 10.0 μ M		
B-2402	43.0% @ 10.0 μ M	52.0% @ 10.0 μ M		
B-2403	72% @ 100.0 μ M	52.0% @ 10.0 μ M		
B-2404	58% @ 100.0 μ M	52.0% @ 10.0 μ M		
B-2405	47% @ 100.0 μ M	> 10.0 μ M		
B-2406	45.0% @ 10.0 μ M	24.0% @ 10.0 μ M		
B-2407	47% @ 100.0 μ M	27.0% @ 10.0 μ M		
B-2408	39.0% @ 10.0 μ M	10.0% @ 10.0 μ M		
B-2409	76.0% @ 10.0 μ M	26.0% @ 10.0 μ M		
B-2410	33.0% @ 10.0 μ M	32.0% @ 10.0 μ M		
B-2411	26% @ 100.0 μ M	13.0% @ 10.0 μ M		
B-2412	40.0% @ 10.0 μ M	31.0% @ 10.0 μ M		
B-2413	75.0% @ 10.0 μ M	37.0% @ 10.0 μ M		
B-2414	86.0% @ 10.0 μ M	38.0% @ 10.0 μ M		
B-2415	84.0% @ 10.0 μ M	50.0% @ 10.0 μ M		
B-2416	85.0% @ 10.0 μ M	43.0% @ 1.0 μ M		
B-2417	83.0% @ 10.0 μ M	16.0% @ 10.0 μ M		
B-2418	86.0% @ 10.0 μ M	34.0% @ 10.0 μ M		
B-2419	86.0% @ 10.0 μ M	66.0% @ 10.0 μ M		
B-2420	70.0% @ 10.0 μ M	34.0% @ 10.0 μ M		
B-2421	89.0% @ 10.0 μ M	38.0% @ 10.0 μ M		
B-2422	90.0% @ 10.0 μ M	17.0% @ 10.0 μ M		
B-2423	85.0% @ 10.0 μ M	> 10.0 μ M		
B-2424	86.0% @ 10.0 μ M	43.0% @ 10.0 μ M		
B-2425	79.0% @ 10.0 μ M	42.0% @ 10.0 μ M		
B-2426	88.0% @ 10.0 μ M	53.0% @ 10.0 μ M		
B-2427	87.0% @ 10.0 μ M	59.0% @ 10.0 μ M		
B-2428	82.0% @ 10.0 μ M	50.0% @ 10.0 μ M		
B-2429	92.0% @ 10.0 μ M	32.0% @ 10.0 μ M		

SUBSTITUTE SHEET (RULE 26)

Example#	P38 alpha kinase IC50, μ M or % inhib @ conc. (μ M)	U937 Cell IC50, μ M or % inhib @ conc. (μ M)	Mouse LPS Model % TNF inhib @ dose @ predose time	Rat LPS Model % inhib @ dose @ predose time
B-2430	90.0% @ 10.0 μ M	61.0% @ 10.0 μ M		
B-2431	85.0% @ 10.0 μ M	58.0% @ 10.0 μ M		
B-2432	86.0% @ 10.0 μ M	40.0% @ 10.0 μ M		
B-2433	94.0% @ 10.0 μ M	84.0% @ 10.0 μ M		
B-2434	92.0% @ 10.0 μ M	63.0% @ 10.0 μ M		
B-2435	84.0% @ 10.0 μ M	4.0% @ 10.0 μ M		
B-2436	80.0% @ 10.0 μ M	54.0% @ 10.0 μ M		
B-2437	82.0% @ 10.0 μ M	41.0% @ 10.0 μ M		
B-2438	75.0% @ 10.0 μ M	40.0% @ 10.0 μ M		
B-2439	81.0% @ 10.0 μ M	44.0% @ 10.0 μ M		
B-2440	77.0% @ 10.0 μ M	78.0% @ 10.0 μ M		
B-2441	88.0% @ 10.0 μ M	46.0% @ 10.0 μ M		
B-2442	86.0% @ 10.0 μ M	> 10.0 μ M		
B-2443	84.0% @ 10.0 μ M	44.0% @ 10.0 μ M		
B-2444	88.0% @ 10.0 μ M	7.0% @ 10.0 μ M		
B-2445	94.0% @ 10.0 μ M	15.0% @ 10.0 μ M		
B-2446	90.0% @ 10.0 μ M	28.0% @ 10.0 μ M		
B-2447	94.0% @ 10.0 μ M	> 10.0 μ M		
B-2448	75.0% @ 10.0 μ M	30.0% @ 10.0 μ M		
B-2449	86.0% @ 10.0 μ M	42.0% @ 10.0 μ M		
B-2450	87.0% @ 10.0 μ M	46.0% @ 1.0 μ M		
B-2451	87.0% @ 10.0 μ M	45.0% @ 10.0 μ M		
B-2452	89.0% @ 10.0 μ M	33.0% @ 10.0 μ M		
B-2453	91.0% @ 10.0 μ M	> 10.0 μ M		
B-2454	89.0% @ 10.0 μ M	40.0% @ 10.0 μ M		
B-2455	87.0% @ 10.0 μ M	54.0% @ 10.0 μ M		
B-2456	86.0% @ 10.0 μ M	53.0% @ 10.0 μ M		
B-2457	90.0% @ 10.0 μ M	18.0% @ 10.0 μ M		
B-2458	83.0% @ 10.0 μ M	35.0% @ 10.0 μ M		
B-2459	82.0% @ 10.0 μ M	81.0% @ 10.0 μ M		
B-2460	80.0% @ 10.0 μ M	76.0% @ 10.0 μ M		
B-2461	67.0% @ 10.0 μ M	59.0% @ 10.0 μ M		

SUBSTITUTE SHEET (RULE 26)

alkoxycarbonylheterocyclylarylene,
alkoxycarbonylalkoxylarylene,
65 heterocyclcarbonylalkylarylene, alkylthioalkylene,
cycloalkylthioalkylene, alkylthioarylene,
aralkylthioarylene, heterocyclthioarylene,
arylthioalkylarylene, arylsulfonylaminoalkylene,
alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
70 said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
heterocyclylalkylene, alkylheterocyclylarylene,
alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
aryloxycarbonylarylene, arylcarbonylarylene,
alkylthioarylene, heterocyclthioarylene,
75 arylthioalkylarylene, and alkylsulfonylarylene groups
are optionally substituted with one or more radicals
independently selected from alkyl, halo, haloalkyl,
alkoxy, keto, amino, nitro, and cyano; or

80 R^{23} is $-\text{CHR}^{24}\text{R}^{25}$ wherein R^{24} is alkoxycarbonyl, and R^{25}
is selected from aralkyl, aralkoxyalkylene,

heterocyclalkylene, alkylheterocyclalkylene,
alkoxycarbonylalkylene, alkylthioalkylene, and
aralkylthioalkylene; wherein said aralkyl and

85 heterocyclyl groups are optionally substituted with one
or more radicals independently selected from alkyl and
nitro; or

R^{24} and R^{25} together with the nitrogen atom to which
they are attached form a heterocycle, wherein said
heterocycle is optionally substituted with one or more
90 radicals independently selected from alkyl, aryl,
heterocyclyl, heterocyclalkylene,


alkylheterocyclalkylene, aryloxyalkylene,
alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl,
alkoxycarbonyl, aralkoxycarbonyl, alkylamino and

95 alkoxycarbonylamino; wherein said aryl,
heterocyclalkylene and aryloxyalkylene radicals are
optionally substituted with one or more radicals
independently selected from halogen, alkyl and alkoxy;

and

100 R^2 is selected from hydrido, halogen, alkyl, alkenyl,
alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl,
aralkyl, alkylheterocyclyl, heterocyclylalkyl,
alkylamino, alkenylamino, alkynylamino, arylamino,
heterocyclylamino, heterocyclylalkylamino, aralkylamino,
105 aminoalkyl, aminoaryl, aminoalkylamino,
arylaminooalkylene, alkylaminooalkylene, arylaminooalkylene,
alkylaminooalkylene, alkylaminooalkylamino, cycloalkyl,
cycloalkenyl, alkoxy, heterocyclloxy, alkylthio,
arylthio, heterocyclylthio, carboxy, carboxyalkyl,
110 carboxycycloalkyl, carboxycycloalkenyl,
carboxyalkylamino, alkoxycarbonyl, heterocyclcarbonyl,
alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl,
alkoxycarbonylheterocyclcarbonyl, alkoxyalkylamino,
alkoxycarbonylaminoalkylamino, and heterocyclsulfonyl;
115 wherein the aryl, heterocyclyl, heterocyclalkyl,
cycloalkyl and cycloalkenyl groups are optionally
substituted with one or more radicals independently
selected from halo, keto, amino, alkyl, alkenyl, alkynyl,
aryl, heterocyclyl, aralkyl, heterocyclalkyl,
120 epoxylalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy,
aralkoxy, haloalkyl, alkylamino, alkynylamino,
alkylaminooalkylamino, heterocyclalkylamino,
alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl,
arylsulfonyl, and aralkylsulfonyl; or

125 R^2 has the formula:



wherein:


j is an integer from 0 to 8; and

m is 0 or 1; and

130 R^{30} and R^{31} are independently selected from hydrogen,

2. A compound of Claim 1 wherein

R¹ is selected from hydrido, lower alkyl, lower cycloalkyl, lower alkenyl, lower alkynyl, lower heterocyclyl, lower cycloalkylalkylene, lower haloalkyl, lower hydroxyalkyl, lower aralkyl, lower alkoxyalkyl, lower mercaptoalkyl, lower alkylthioalkylene, amino, lower alkylamino, lower arylamino, lower alkylaminoalkylene, and lower heterocyclylalkylene; or R¹ has the formula



wherein:

i is 0, 1 or 2; and

R²⁵ is selected from hydrogen, lower alkyl, lower phenylalkyl, lower heterocyclylalkyl, lower alkoxyalkylene, lower phenoxyalkylene, lower aminoalkyl, lower alkylaminoalkyl, lower phenoxyaminoalkyl, lower alkylcarbonylalkylene, lower phenoxycarbonylalkylene, and lower heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkylalkylene, lower phenylalkyl, lower alkoxycarbonylalkylene, and lower alkylaminoalkyl; and

R²⁷ is selected from lower alkyl, lower cycloalkyl, lower alkynyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower cycloalkylalkylene, lower cycloalkenylalkylene, lower cycloalkylarylene, lower cycloalkylcycloalkyl, lower heterocyclylalkylene, lower alkylphenylene, lower alkylphenylalkyl, lower phenylalkylphenylene, lower alkylheterocyclyl, lower alkylheterocyclylalkylene, lower alkylheterocyclylphenylene, lower

phenylalkylheterocyclyl, lower alkoxyalkylene, lower alkoxyphenylene, lower alkoxyphenylalkyl, lower alkoxyheterocyclyl, lower alkoxyalkoxyphenylene, lower phenoxyphenylene, lower phenylalkoxyphenylene, lower alkoxyheterocyclylalkylene, lower phenoxyalkoxyphenylene, lower alkoxycarbonylalkylene, lower alkoxycarbonylheterocyclyl, lower alkoxycarbonylheterocyclylcarbonylalkylene, lower aminoalkyl, lower alkylaminoalkylene, lower phenylaminocarbonylalkylene, lower alkoxyphenylaminocarbonylalkylene, lower aminocarbonylalkylene, arylaminocarbonylalkylene, lower alkylaminocarbonylalkylene, lower phenylcarbonylalkylene, lower alkoxycarbonylphenylene, lower phenylphenylcarbonylphenylene, lower alkylphenylcarbonylphenylene, lower alkoxycarbonylheterocyclylphenylene, lower alkoxycarbonylalkoxyphenylene, lower heterocyclylcarbonylalkylphenylene, lower alkylthioalkylene, cycloalkylthioalkylene, lower alkylthiophenylene, lower phenylalkylthiophenylene, lower heterocyclylthiophenylene, lower phenylthioalkylphenylene, lower phenylsulfonylaminoalkylene, lower alkylsulfonylphenylene, lower alkylaminoalkoxyphenylene; wherein said lower alkyl, lower cycloalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower heterocyclylalkylene, lower alkylheterocyclylphenylene, lower alkoxyphenylene, lower phenoxyphenylene, lower phenylaminocarbonylalkylene, lower phenoxycarbonylphenylene, lower phenylcarbonylphenylene, lower alkylthiophenylene, lower heterocyclylthiophenylene, lower

phenylthioalkylphenylene, and lower alkylsulfonylphenylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, lower haloalkyl, lower alkoxy, keto, amino, nitro, and cyano; or

R^{27} is -CHR²⁸R²⁹ wherein R²⁸ is lower alkoxycarbonyl, and R²⁹ is selected from lower phenylalkyl, lower phenylalkoxyalkylene, lower heterocyclylalkylene, lower alkylheterocyclylalkylene, lower alkoxycarbonylalkylene, lower alkylthioalkylene, and lower phenylalkylthioalkylene; wherein said phenylalkyl and heterocyclyl groups are optionally substituted with one or more radicals independently selected from lower alkyl and nitro; or

R⁴ and R³ together with the nitrogen atom to which they are attached form a 4-8 membered ring heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from lower alkyl, aryl selected from phenyl, biphenyl and naphthyl, heterocyclyl, heterocyclylalkylene, lower

alkylheterocyclylalkylene, lower phenoxyalkylene, lower alkoxyphenylene, lower alkylphenoxyalkylene, lower alkylcarbonyl, lower alkoxycarbonyl, lower phenylalkoxycarbonyl, lower alkylamino and lower alkoxyamino, wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclylalkylene and lower phenoxyalkylene radicals are optionally

R^1 is selected from hydrido, halogen, lower alkyl, lower haloalkyl, lower hydroxyalkyl, 5- or 6-membered heterocyclyl, lower alkylnheterocyclyl, lower heterocyclylalkyl, lower alkylnamino, lower phenylamino, lower heterocyclylamino, lower phenylalkylamino, lower heterocyclylalkylamino, lower phenylalkylamino, lower

SUBSTITUTE SHEET (RULE 26)

105 aminoalkyl, lower aminoalkylamino, lower alkylaminoalkylamino, lower cycloalkyl, lower alkenyl, lower alkoxy carbonylalkyl, lower cycloalkenyl, lower carboxyalkylamino, lower alkoxy carbonyl, lower heterocyclylcarbonyl, lower alkoxy carbonyl heterocyclylcarbonyl, lower alkoxy carbonyl heterocyclylcarbonyl, lower alkoxyalkylamino, lower alkoxy carbonyl aminoalkylamino, lower


110 heterocyclylsulfonyl, lower heterocyclyloxy, and lower heterocyclylthio; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl, and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, lower alkyl,

115 lower alkynyl, phenyl, 5- or 6-membered heterocyclyl, lower phenylalkyl, lower heterocyclylalkyl, lower epoxyalkyl, carboxy, lower alkoxy, lower aryloxy, lower epoxyalkoxy, lower haloalkyl, lower alkylamino, lower phenylaminoalkylamino, lower alkynylamino, lower amino (hydroxyalkyl), lower heterocyclylalkylamino, lower alkylcarbonyl, lower alkoxy carbonyl, lower alkylsulfonyl, lower phenylalkylsulfonyl, and phenylsulfonyl; or

120

125

R^1 has the formula:



wherein:

j is 0, 1 or 2; and

m is 0.2

130 R^0 and R^1 are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

135 R^2 is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,

SUBSTITUTE SHEET (RULE 26)

aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclalkylcarbonylaminoalkylene; and

R^{13} is selected from hydrogen, alkyl, -C(O) R^{14} ,

140 -C(O)OR¹⁵, -SO₂R¹⁶, -C(O)NR¹⁷R¹⁸, and -SO₂NR¹⁹R²⁰;

wherein R^{18} is selected from alkyl, cycloalkyl,

haloalkyl, alkenyl, aryl, heterocycl, aralkyl,

arylcycloalkyl, cycloalkenylalkylene,

heterocyclalkylene, alkylarylene, alkylheterocycl,

145 arylarylene, arylheterocycl, alkoxy, alkenoxy,

alkoxyalkylene, alkoxyaralkyl, alkoxyarylene,

aryloxyalkylene, aralkoxyalkylene, cycloalkyloxyalkylene,

alkoxycarbonyl, heterocyclcarbonyl,

150 alkoxycarbonylalkylene, alkylcarbonyloxyarylene,

aralkoxycarbonylheterocycl, alkylcarbonylheterocycl,

arylcarbonyloxyalkylarylene, and alkylthioalkylene;

wherein said aryl, heterocycl, aralkyl, alkylarylene,

arylheterocycl, alkoxyarylene, aryloxyalkylene,

155 cycloalkoxyalkylene, alkoxycarbonylalkylene, and

alkylcarbonylheterocycl groups are optionally

substituted with one or more radicals independently

selected from alkyl, halo, haloalkyl, alkoxy, haloalkoxy,

keto, amino, nitro, and cyano; or

160 R^{13} is CHR²¹R²² wherein R^{21} is arylsulfonylamino or

alkylarylsulfonylamino, and R^{22} is selected from aralkyl,

amino, alkylamino, and aralkylamino; or

R^{13} is -NR²³R²⁴ wherein R^{23} is alkyl, and R^{24} is aryl;

and

165 wherein R^{14} is selected from alkyl, haloalkyl, aryl,

heterocycl, cycloalkylalkylene, alkylarylene,

alkenylarylene, arylarylene, aralkyl, aralkenyl,

heterocyclheterocycl, carboxyarylene, alkoxyarylene,

alkoxycarbonylarylene, alkylcarbonylaminoarylene,

170 alkylcarbonylaminoheterocycl,

arylcarbonylaminoalkylheterocycl, alkylaminoarylene,

alkylamino, alkylaminoarylene, alkylsulfonylarylene, alkylsulfonylaralkyl, and arylsulfonylheterocycl;

175 wherein said aryl, heterocycl, cycloalkylalkylene, aralkyl, alkylcarbonylaminoheterocycl, and

alkylsulfonylarylene groups are optionally substituted

with one or more radicals independently selected from

alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy,

keto, amino, nitro, and cyano; and

180 wherein R^{17} is selected from hydrogen and alkyl; and

wherein R^{18} is selected from hydrogen, alkyl,

alkenyl, aryl, heterocycl, aralkyl, alkylarylene,

arylcycloalkyl, arylarylene, cycloalkylalkylene,

heterocyclalkylene, alkylheterocyclalkylene,

185 aralkylheterocycl, alkoxyalkylene, alkoxyarylene,

aryloxyarylene, arylcarbonyl, alkoxycarbonyl,

alkoxycarbonylalkylene, alkoxycarbonylarylene,

alkylcarbonylcarbonylalkylene, alkylaminoalkylene,

alkylaminoaralkyl, alkylcarbonylaminoalkylene,

190 alkylthioarylene, alkylsulfonylaralkyl, and

aminosulfonylaralkyl; wherein said aryl, heterocycl,

aralkyl, and heterocyclalkylene groups are optionally

substituted with one or more radicals independently

selected from alkyl, halo, hydroxy, haloalkyl, alkoxy,

haloalkoxy, keto, amino, nitro, and cyano; or

R^{19} is -CR²⁵R²⁶ wherein R^{25} is alkoxycarbonyl, and R^{26}

is alkylthioalkylene; or

R^{17} and R^{18} together with the nitrogen atom to which

they are attached form a heterocycle; and

200 R^{19} and R^{20} have the same definition as R^{14} and R^{17} in


claim 1; or

R^{21} is -CR²⁷R²⁸ wherein R^{27} is phenyl and R^{28} is hydroxy;

or

R^{22} is selected from the group consisting of

717



(VI)
wherein

k is an integer from 0 to 3; and
 R^{56} is hydrogen or lower alkyl; and
 R^{57} is hydrogen or lower alkyl; or

R⁶ and R⁷ form a lower alkylene bridge; and R⁸ is selected from hydrogen, alkyl, aralkyl, aryl, heterocyclyl, heterocyclylalkyl, alkoxyacetyl, alkylsulfonyl, aralkylsulfonyl, arylsulfonyl, -C(O)R⁹, -SO₂R¹⁰, and -C(O)NHR¹¹;

wherein R⁹ is selected from alkyl, haloalkyl, cycloalkyl, aryl, heterocyclyl, alkylarylene, aralkyl, alkyheterocyclyl, alkoxy, alkenoxy, aralkoxy, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl; wherein said aryl, heterocyclyl, and aralkyl groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and


wherein R⁶⁰ is selected from alkyl, aryl, heterocyclyl, alkylarylene, alkylheterocyclyl, aralkyl, heterocyclylheterocyclyl, alkoxyarylene, alkylamino, alkylaminoarylene, alkylsulfonylarylene, and arylsulfonylheterocyclyl; wherein said aryl, heterocyclyl, and aralkyl groups are optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

SUBSTITUTE SHEET (RULE 26)

718

wherein R⁶ is selected from alkyl, aryl, alkylarylene, and alkoxyarylene; wherein said aryl group is optionally substituted with one or more radicals independently selected from alkyl, halo, hydroxy, haloalkyl, alkoxy, haloalkoxy, keto, amino, nitro, and cyano; and

240 R³ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl, and



wherein R³ is selected from hydrogen, lower alkyl, lower aminoalkyl, lower alkoxyalkyl, lower alkenoxyalkyl, and lower arylalkoxyalkyl; and

wherein the R¹ pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from lower alkylthio, lower alkyldisulfenyl, aminoalkylthio, halo, lower alkyl, lower aralkyl, lower phenylalkenyl, lower phenylheterocyclyl, carboxy, lower alkyldisulfenyl, cyano, lower alkoxy, lower cycloalkylamino, lower alkenylamino, lower alkenylamino, lower alkenylamino, lower aminodialkyl, lower aryldiamino, lower aralkyldiamino, nitro, halosulfenyl, lower alkyldicarbonyl, lower alkoxydicarbonylamino, lower alkoxyphenylalkylamino, lower alkyldiaminodialkylamino, lower hydroxyalkylamino, lower heterocyclylamino, lower heterocyclylalkylamino, lower phenylalkylheterocyclylamino, lower alkyldiaminodicarbonyl, lower alkoxyphenylalkylamino, hydrazinyl, lower alkylhydrazinyl, or -NR²R³ wherein R² is lower alkyldicarbonyl or amino, and R³ is lower alkyl or lower

SUBSTITUTE SHEET (RULE 26)

265 phenylalkyl; and

R' is selected from hydrido, lower cycloalkyl, lower cycloalkenyl, aryl selected from phenyl, biphenyl, and naphthyl, and 5- or 6- membered heterocyclyl; wherein the lower cycloalkyl, lower cycloalkenyl, aryl and 5-10

270 membered heterocyclyl groups of R' are optionally substituted with one or more radicals independently

selected from lower alkylthio, lower alkylsulfonyl, lower alkylsulfinyl, halo, lower alkyl, lower alkynyl, lower alkoxy, lower aryloxy, lower aralkoxy, lower

275 heterocyclyl, lower haloalkyl, amino, cyano, nitro, lower alkylamino, and hydroxy; or
a pharmaceutically-acceptable salt or tautomer thereof.

3. A compound of Claim 2 wherein

R' is selected from hydrido, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,

5 dichloromethyl, trichloromethyl, pentafluoromethyl, heptafluoropropyl, difluoroethoxymethyl,

dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, ethenyl, propenyl,

10 ethynyl, propargyl, 1-propynyl, 2-propynyl, piperidinyl, piperazinyl, morpholinyl, benzyl, phenylethyl,

morpholinylethyl, morpholinylethyl, pyrrolidinylethyl, piperazinylethyl, piperidinylethyl, pyridinylethyl,

thienylethyl, methoxymethyl, ethoxymethyl, amino, methylamino, dimethylamino, phenylamino,

15 methylaminomethyl, dimethylaminomethyl, methylaminoethyl, dimethylaminoethyl, ethylaminomethyl, diethylaminoethyl, cyclopropyl, cyclopentyl, cyclohexyl, cyclohexylethyl, hydroxymethyl, hydroxyethyl, mercaptomethyl, and methylthiomethyl; and

20 R' is selected from hydrido, chloro, fluoro, bromo, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, phenyl, biphenyl, fluoromethyl, difluoromethyl,

trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, 25 difluoroethoxymethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxymethyl, hydroxyethyl, pyridinyl, isothiazolyl, isoxazolyl, thienyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isochinolinyl, imidazolyl,

30 benzimidazolyl, furyl, pyrazinyl, piperidinyl, piperazinyl, morpholinyl, N-methylpiperazinyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N,N-dimethylamino, N-methyl-N-phenylamino, 35 N-phenylamino, piperidinylamino, N-benzylamino, N-propargylamino, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, aminomethyl, aminoethyl, aminoethoxyamino, aminopropylamino, N,N-

40 dimethylaminoethoxyamino, N,N-dimethylaminopropylamino, morpholinylethylamino, morpholinylethylamino, carboxymethylamino, methoxymethylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, 1,1-

45 dimethylethoxycarbonyl, 1,1-dimethylethoxycarbonylaminoethoxyamino, 1,1-dimethylethoxycarbonylaminoethoxyamino, piperazinylethoxyamino, and 1,1-

dimethylethoxycarbonyl-piperazinylethoxyamino; wherein the aryl, heteroaryl, cycloalkyl and cycloalkenyl groups are

50 optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, isopropyl, tert-butyl, isobutyl, benzyl, carboxy, methoxy, ethoxy, phenoxy, benzyloxy,

trifluoromethyl, fluoromethyl, difluoromethyl, 55 trifluoroethyl, methoxycarbonyl, ethoxycarbonyl, and 1,1-dimethylethylcarboxyl; or

R² is -CR⁴R⁵ wherein R⁴ is phenyl and R⁵ is hydroxy; and

721

R¹ is selected from pyridinyl, pyrimidinyl, and purinyl; wherein R¹ is optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, amino, sulfonyl, methyl, ethyl, isopropyl, tert-butyl, isobutyl, cyano, methoxycarbonyl, ethoxycarbonyl, aminocarbonyl, methylcarbamoylamino, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, dichloromethyl, chloromethyl, hydroxy, fluorophenylmethyl, fluorophenylethyl, chlorophenylmethyl, chlorophenylethyl, fluorophenylethyl, chlorophenylethyl, fluorophenylpyrazolyl, chlorophenylpyrazolyl, carboxy, methoxy, ethoxy, propyloxy, n-butoxy, methylamino, ethylamino, dimethylamino, diethylamino, 2-methylbutylamino, propargylamino, aminomethyl, aminoethyl, N-methyl-N-phenylamino, phenylamino, diphenylamino, benzylamino, phenethylamino, cyclopropylamino, nitro, chlorosulfonyl, amino, methylcarbamoyl, methoxycarbonylamino, ethoxycarbonylamino, methoxycarbonylmethylamino, N,N-dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylethylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, phenylmethylamino, fluorophenylmethylamino, ethylaminocarbonyl, methylcarbamoyl, methoxycarbonyl, ethylaminocarbonyl, methoxycarbonyl, methoxyphenylmethylamino, hydrazinyl, 1-methylhydrazinyl, or -NR²R³ wherein R² is methylcarbamoyl or amino, and R³ is methyl, ethyl or phenylmethyl; and

R¹ is selected from hydrido, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, phenyl, biphenyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, pyridinyl, thienyl, isothiazolyl,

SUBSTITUTE SHEET (RULE 26)

722

isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isoguinolinyll, imidazolyl, benzimidazolyl, furyl, pyrazinyl, dihydropyranyl, dihydropyridinyl, dihydrofuryl, tetrahydropyranyl, tetrahydrofuryl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkenyl, cycloalkenyl, aryl and heterocyclyl groups of R¹ are optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, tert-butyl, isobutyl, ethynyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl, difluoromethyl, amino, cyano, nitro, dimethylamino, and hydroxy; or

a pharmaceutically-acceptable salt or tautomer thereof.

4. A compound of Claim 3 wherein

R¹ is hydrido, methyl, ethyl, propargyl, hydroxyethyl, dimethylaminoethyl, diethylaminoethyl or morpholinylethyl;

R² is selected from hydrido, methyl, ethyl, propyl, phenyl, trifluoromethyl, methoxycarbonylmethyl, N,N-dimethylamino, N-phenylamino, piperidinyl, piperazinyl, pyridinyl, N-methylpiperazinyl, and piperazinylamino; wherein the phenyl, piperidinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, methyl, ethyl, and trifluoromethyl;

R³ is selected from pyridinyl, pyrimidinyl or quinolinyl; wherein R³ is optionally substituted with one or more radicals independently selected from fluoro, bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl, benzyl, phenethyl, acetyl, hydroxyl, methoxy, dimethylamino, benzylamino, phenethylamino, aminomethyl, amino, hydroxy, and methylcarbamoyl;

R¹ is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl,

SUBSTITUTE SHEET (RULE 26)

5 dihydrobenzofuryl, and benzedioxolyl; wherein the
 cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of
 R' are optionally substituted with one or more radicals
 25 independently selected from methylthio, fluoro, chloro,
 bromo, methyl, ethyl, methoxy, ethoxy, phenoxy,
 benzyloxy, trifluoromethyl, nitro, dimethylamino, and
 hydroxy; or
 a pharmaceutically-acceptable salt or tautomer thereof.

5. A compound of Claim 4 wherein

R' is hydrido or methyl;

R² is selected from hydrido, methyl or ethyl;

R³ is selected from pyridinyl, pyrimidinyl or

5 quinolinyl; wherein R' is optionally substituted with one
 or more radicals independently selected from fluoro,
 bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl,
 benzyl, phenethyl, acetyl, hydroxyl, methoxy,
 10 dimethylamino, benzylamino, phenethylamino, aminomethyl,
 amino, hydroxy, and methylcarbonyl;

R⁴ is selected from phenyl which is optionally

substituted with one or more radicals independently

selected from methylthio, fluoro, chloro, bromo, methyl,

ethyl, methoxy, ethoxy, phenoxy, benzyloxy,

15 trifluoromethyl, nitro, dimethylamino, and hydroxy; or
 a pharmaceutically-acceptable salt or tautomer thereof.

6. A compound of Claim 2 wherein

R¹ is selected from hydrido, methyl, ethyl, propyl,

isopropyl, tert-butyl, isobutyl, fluoromethyl,

20 difluoromethyl, trifluoromethyl, chloromethyl,

dichloromethyl, trichloromethyl, pentafluoroethyl,

5 heptafluoropropyl, difluorochloromethyl,

dichlorofluoromethyl, difluoroethyl, difluoropropyl,

dichloroethyl, dichloropropyl, ethenyl, propenyl,


ethynyl, propargyl, 1-propynyl, 2-propynyl, piperidinyl,

10 piperazinyl, morpholinyl, benzyl, phenylethyl,

morpholinylmethyl, morpholinylethyl, pyrrolidinylmethyl,
 piperazinylmethyl, piperidinylmethyl, pyridinylmethyl,
 thienylmethyl, methoxymethyl, ethoxymethyl, amino,
 methylamino, dimethylamino, phenylamino,

15 methylaminomethyl, dimethylaminomethyl, methylaminoethyl,
 dimethylaminoethyl, ethylaminoethyl, diethylaminoethyl,
 cyclopropyl, cyclopentyl, cyclohexyl, cyclohexylmethyl,
 hydroxymethyl, hydroxyethyl, mercaptomethyl, and
 methylthiomethyl; and

R² has the formula:



wherein:

j is 0, 1 or 2; and

m is 0; and

25 R³⁰ and R³¹ are independently selected from hydrogen
 and lower alkyl;

R³² is selected from hydrogen, lower alkyl, lower

phenylalkyl, lower heterocyclylalkyl, lower

alkoxyalkylene, aryloxyalkylene, aminoalkyl, lower

30 alkylaminoalkyl, lower phenylaminoalkyl, lower

alkylcarbonylalkylene, lower phenylcarbonylalkylene, and

lower heterocyclylcarbonylaminoalkylene;

R³³ is selected from hydrogen, lower alkyl, -C(O)R³⁵,

-C(O)OR³⁵, -SO₂R³⁶, -C(O)NR³⁷R³⁸, and -SO₂NR³⁷R³⁸;

35 wherein R³⁵ is selected from lower alkyl, lower

cycloalkyl, lower haloalkyl, lower alkenyl, aryl selected

from phenyl, biphenyl and naphthyl, lower heterocyclyl,

lower phenylalkyl, lower phenylcycloalkyl, lower

cycloalkenylalkylene, lower heterocyclylalkylene, lower

40 alkylphenylene, lower alkylheterocyclyl, phenylphenylene,

lower phenylheterocyclyl, lower alkoxy, lower alkenoxy,

lower alkoxyalkylene, lower alkoxyphenylalkyl, lower

725

alkoxyphenylene, lower phenoxyalkylene, lower phenylalkoxyalkylene, lower cycloalkyloxyalkylene, lower alkoxycarbonyl, lower heterocyclylcarbonyl, lower alkylcarbonyloxyalkylene, lower alkylcarbonyloxyphenylene, lower alkoxycarbonylalkylene, lower alkoxycarbonylphenylene, lower alkylcarbonylphenylene, lower

phenylcarbonyloxyalkylphenylene, and lower alkylthioalkylene; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower alkylphenylene, lower phenylheterocyclyl, lower alkoxyphenylene, lower phenoxyalkylene, lower cycloalkoxyalkylene, lower alkoxycarbonylalkylene, and lower

alkylcarbonylheterocyclyl groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; or

R^5 is CHR^4R^6 wherein R^4 is phenylsulfonamino or lower alkylphenylsulfonamino, and R^6 is selected from lower phenylalkyl, amino, lower alkylamino, and lower phenylalkylamino; or

R^5 is $-NR^6R^7$ wherein R^6 is lower alkyl, and R^7 is aryl selected from phenyl, biphenyl and naphthyl; and wherein R^6 is selected from lower alkyl, lower

haloalkyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower cycloalkylalkylene, lower alkylphenylene, lower alkenylphenylene,

phenylphenylene, lower phenylalkyl, lower phenylalkenyl, lower heterocyclylheterocyclyl, carboxyphenylene, lower alkoxyphenylene, lower alkoxycarbonylphenylene, lower

alkylcarbonylaminoheterocyclyl, lower alkylcarbonylaminoheterocyclyl, lower phenylcarbonylaminoalkylheterocyclyl, lower

726

alkylaminophenylene, lower alkylamino, lower alkylaminophenylene, lower alkylsulfonophenylene, lower alkylsulfonophenylene, lower alkylsulfonophenylalkyl, and lower phenylsulfonophenylheterocyclyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower cycloalkylalkylene, lower phenylalkyl, lower alkoxyphenylaminoheterocyclyl, and lower

alkylsulfonophenylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R^2 is selected from hydrogen and lower alkyl; and

wherein R^3 is selected from hydrogen, lower alkyl, lower alkenyl, aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, lower alkylphenylene, lower phenylcycloalkyl, phenylphenylene, lower cycloalkylalkylene, lower heterocyclylalkylene, lower alkylheterocyclylalkylene, lower

phenylalkylheterocyclyl, lower alkoxyalkylene, lower alkoxyphenylene, lower phenoxyphenylene, phenylcarbonyl, lower alkoxycarbonyl, lower alkoxycarbonylalkylene, lower alkoxycarbonylphenylene, lower

alkylcarbonylcarbonylalkylene, lower alkylaminalkylene, lower alkylaminophenylalkyl, lower alkylthiophenylene, lower alkylcarbonylaminoalkylene, lower

alkylsulfonophenylalkyl, and lower aminoalkylphenylalkyl; wherein said aryl selected from phenyl, biphenyl and naphthyl, lower heterocyclyl, lower phenylalkyl, and lower heterocyclylalkylene groups are

optionally substituted with one or more radicals independently selected from lower alkyl, halo, hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; or


R^3 is $-CR^{12}R^{13}$ wherein R_{12} is lower alkoxycarbonyl,

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

- 115 and R₃ is lower alkylthioalkylene; or
 R³⁷ and R³⁸ together with the nitrogen atom to which
 they are attached form a 4-8 membered ring heterocycle;
 R³⁹ and R⁴⁰ have the same definition as R³⁶ and R³⁷ in
 claim 2; or

- 120 R² is selected from the group consisting of



(VI)

(VII)

(VIII)

wherein

k is an integer from 0 to 2; and

R³⁶ is hydrogen or lower alkyl; and

R³⁷ is hydrogen or lower alkyl; and

R³⁸ is selected from hydrogen, lower alkyl, lower

phenylalkyl, aryl selected from phenyl, biphenyl and

naphthyl, lower heterocyclyl, lower heterocyclylalkyl,

lower alkoxy, lower alkylsulfonyl, lower

phenylalkylsulfonyl, lower phenylsulfonyl, -C(O)R³⁹,

-SO₂R⁴⁰, and -C(O)NHR⁴¹;

wherein R³⁹ is selected from lower alkyl, lower

haloalkyl, lower cycloalkyl, aryl selected from phenyl,

biphenyl and naphthyl, lower heterocyclyl, lower

alkylphenylene, lower phenylalkyl, lower

alkylheterocyclyl, lower alkoxy, lower alkenoxy, lower

phenylalkoxy, lower alkoxyalkylene, lower

alkoxyphenylene, lower alkoxyphenylalkyl; wherein said

aryl selected from phenyl, biphenyl and naphthyl, lower

heterocyclyl, and lower phenylalkyl groups are optionally

substituted with one or more radicals independently

selected from lower alkyl, halo, hydroxy, lower

- haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino,
 145 nitro, and cyano; and

wherein R⁴⁰ is selected from lower alkyl, aryl
 selected from phenyl, biphenyl and naphthyl, lower
 heterocyclyl, lower alkylphenylene, lower

alkylheterocyclyl, lower phenylalkyl, lower

heterocyclylheterocyclyl, lower alkoxyphenylene, lower

alkylamino, lower alkylaminophenylene, lower

alkylsulfonylphenylene, and lower

phenylsulfonylheterocyclyl; wherein said aryl selected

from phenyl, biphenyl and naphthyl, lower heterocyclyl,

and lower phenylalkyl groups are optionally substituted

with one or more radicals independently selected from

lower alkyl, halo, hydroxy, lower haloalkyl, lower

alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano;

and

wherein R⁴¹ is selected from lower alkyl, aryl

selected from phenyl, biphenyl and naphthyl, lower

alkylphenylene, and lower alkoxyphenylene; wherein said

aryl group is optionally substituted with one or more

radicals independently selected from lower alkyl, halo,

hydroxy, lower haloalkyl, lower alkoxy, lower haloalkoxy,

keto, amino, nitro, and cyano; and

R³ is selected from pyridinyl, pyrimidinyl, and

purinyl; wherein R³ is optionally substituted with one or

more radicals independently selected from methylthio,

methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo,

aminosulfonyl, methyl, ethyl, isopropyl, tert-butyl,

isobutyl, cyano, methoxycarbonyl, ethoxycarbonyl,

aminocarbonyl, methylcarbamoylamino, trifluoromethyl,

difluoromethyl, fluoromethyl, trichloromethyl,

dichloromethyl, chloromethyl, hydroxy,

fluorophenylmethyl, fluorophenylethyl,

chlorophenylmethyl, chlorophenylethyl,

fluorophenylethyl, chlorophenylethyl,

fluorophenylpyrazolyl, chlorophenylpyrazolyl, carboxy,

729

- 180 methoxy, ethoxy, propyloxy, n-butoxy, methylamino, ethylamino, dimethylamino, diethylamino, 2-methylbutylamino, propargylamino, aminomethyl, aminoethyl, N-methyl-N-phenylamino, phenylamino, diphenylamino, benzylamino, phenethylamino, cyclopropylamino, nitro, chlorosulfonyl, amino, methylcarbonyl, methoxycarbonylamino, ethoxycarbonylamino, methoxyphenylmethylamino, N,N-dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylethylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino, phenylmethylpiperidinylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, ethylaminocarbonyl, methoxyphenylmethylamino, hydrazinyl, 1-methylhydrazinyl, or -NR³R³ wherein R³ is methylcarbonyl or amino, and R³ is methyl, ethyl or phenylmethyl; and R⁴ is selected from hydrido, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, phenyl, biphenyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, pyridinyl, thienyl, isochiazolyl, isoxazolyl, thiazolyl, oxazolyl, pyrimidinyl, quinolyl, isochinolyl, imidazolyl, benzimidazolyl, furyl, pyrazinyl, dihydropyranyl, dihydropyridinyl, dihydrofuryl, tetrahydropyranyl, tetrahydrofuryl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of R⁴ are optionally substituted with one or more radicals independently selected from methylthio, methylsulfinyl, methylsulfonyl, fluoro, chloro, bromo, methyl, ethyl, isopropyl, tert-butyl, isobutyl, ethynyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, fluoromethyl, difluoromethyl, amino, cyano, nitro, dimethylamino, and hydroxy; or

SUBSTITUTE SHEET (RULE 86)


730

a pharmaceutically-acceptable salt or tautomer thereof.

7. A compound of Claim 6 wherein

R¹ is hydrido, methyl, ethyl, propargyl, hydroxyethyl, dimethylaminoethyl, diethylaminoethyl or morpholinylethyl;

5 R² has the formula:



wherein:

j is 0, 1 or 2; and

m is 0; and

R³⁰ is hydrogen; and

10 R³¹ is selected from hydrogen and lower alkyl; and R³² is selected from hydrogen and lower alkyl; and

R³³ is selected from lower alkyl, -C(O)R³⁵, -C(O)OR³⁵, -SO₂R³⁵, -C(O)NR³⁵R³⁶, and -SO₂NR³⁵R³⁶;

15 wherein R³⁵ is selected from lower alkyl, lower cycloalkyl, phenyl, lower heterocyclyl, lower alkylphenylene, lower alkoxy, lower alkenoxy, lower alkoxyalkylene, lower phenoxyalkylene, and lower phenylalkoxyalkylene; wherein said phenyl and lower

20 phenoxyalkylene groups are optionally substituted with one or more radicals independently selected from lower alkyl, halo, and lower haloalkyl; and wherein R³⁶ is selected from lower alkyl, phenyl, lower heterocyclyl, lower alkylphenylene, phenylphenylene, lower phenylalkyl, lower alkylheterocyclyl, lower heterocyclylheterocyclyl, lower alkoxyphenylene, and lower alkylamino; wherein said phenyl and lower heterocyclyl groups are optionally substituted with one or more radicals independently

25 selected from lower alkyl, halo, hydroxy, lower

SUBSTITUTE SHEET (RULE 86)


haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino, nitro, and cyano; and

wherein R³⁷ is hydrogen; and

wherein R³⁸ is selected from lower alkyl, phenyl, and lower alkylphenylene;

wherein R³⁹ and R⁴⁰ have the same definition as R³⁸ and R³⁷ in claim 2; or

R² is selected from the group consisting of



40

wherein

(VI)

(VIII)

k is an integer from 0 or 1; and

R³⁶ is hydrogen; and

R³⁷ is hydrogen; and

R³⁸ is selected from -C(O)R⁴⁰ and -SO₂R⁴⁰;

wherein R³⁹ is selected from lower alkyl, lower

cycloalkyl, phenyl, lower alkylphenylene, and lower

alkoxyalkylene; wherein said phenyl group is optionally

substituted with one or more radicals independently

selected from lower alkyl, halo, hydroxy, lower

haloalkyl, lower alkoxy, lower haloalkoxy, keto, amino,

nitro, and cyano; and

wherein R⁴⁰ is selected from lower alkyl; and

R³ is selected from pyridinyl, pyrimidinyl or

quinolinyl; wherein R³ is optionally substituted with one

or more radicals independently selected from fluoro,

bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl,

benzyl, phenethyl, acetyl, hydroxyl, methoxy,

dimethylamino, benzylamino, phenethylamino, aminomethyl,

9. A compound of Claim 1 wherein R¹ is hydrido.

10. A compound of Claim 2 wherein R¹ is hydrido.

11. A compound of Claim 3 wherein R¹ is hydrido.

12. A compound of Claim 6 wherein R¹ is hydrido.

60 amino, hydroxy, and methylcarbonyl; and

R⁴ is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein the cycloalkyl, cycloalkenyl, aryl and heterocyclyl groups of

65 R⁴ are optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; or

70 a pharmaceutically-acceptable salt or tautomer thereof.

8. A compound of Claim 7 wherein

R¹ is hydrido or methyl; and

R³ is selected from pyridinyl, pyrimidinyl or

quinolinyl; wherein R³ is optionally substituted with one

5 or more radicals independently selected from fluoro,

bromo, methyl, cyano, methoxycarbonyl, aminocarbonyl,

benzyl, phenethyl, acetyl, hydroxyl, methoxy,

dimethylamino, benzylamino, phenethylamino, aminomethyl,

amino, hydroxy, and methylcarbonyl; and

10 R⁴ is selected from phenyl which is optionally

substituted with one or more radicals independently

selected from methylthio, fluoro, chloro, bromo, methyl,

ethyl, methoxy, ethoxy, phenoxy, benzyloxy,

trifluoromethyl, nitro, dimethylamino, and hydroxy; or

15 a pharmaceutically-acceptable salt or tautomer thereof.

733

13. A compound of Claim 3 wherein R¹ is methyl or ethyl.

14. A compound of Claim 6 wherein R¹ is methyl or ethyl.

15. A compound of Claim 2 wherein R² is hydrido.

16. A compound of Claim 3 wherein R² is hydrido.

17. A compound of Claim 2 wherein R⁴ is optionally substituted phenyl.

18. A compound of Claim 3 wherein R⁴ is optionally substituted phenyl.

19. A compound of Claim 6 wherein R⁴ is optionally substituted phenyl.

20. A compound of Claim 2 wherein R¹ and R² are selected independently from hydrido, methyl and ethyl.

21. A compound of Claim 3 wherein R¹ and R² are selected independently from hydrido, methyl and ethyl


22. A compound of Claim 2 wherein R¹ and R² are selected independently from hydrido, methyl and ethyl; and R⁴ is optionally substituted phenyl.

23. A compound of Claim 3 wherein R¹ and R² are selected independently from hydrido, methyl and ethyl; and R⁴ is optionally substituted phenyl.

24. A compound of Formula IX

SUBSTITUTE SHEET (RULE 26)

734



wherein

Z represents a carbon atom or a nitrogen atom; and

R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl, lower aminoalkyl, lower heterocyclyl, lower aralkyl, lower aminoalkyl and lower alkylaminoalkyl; and R² is selected from hydrido, lower alkyl, aryl

selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower

haloalkyl, lower hydroxyalkyl, lower alkoxyalkyl, lower aminoalkyl, lower alkylaminoalkyl, phenylamino, lower aralkyl, lower aralkylamino, lower

alkylaminoalkylamino, lower aminoalkyl, lower

aminoalkylamino, lower alkylamino, lower

heterocyclylamino, lower heterocyclylalkyl, lower

heterocyclylalkylamino, lower alkylheterocyclyl, lower

carboxycycloalkyl, lower carboxyalkylamino, lower

alkoxyalkylamino, lower alkoxyalkylaminoalkylamino, lower

heterocyclylcarbonyl, lower

alkoxyalkylheterocyclyl, and lower

alkoxyalkylheterocyclylcarbonyl, wherein the aryl and heteroaryl groups are optionally substituted with one or

more radicals independently selected from halo, lower

alkyl, keto, aralkyl, carboxy, lower alkylaminoalkylamino, lower alkynylamino, lower heterocyclalkylamino, lower alkylcarbonyl and lower alkoxy carbonyl; or

30 R^2 is $-CR^aR^b$ wherein R^a is phenyl and R^b is hydroxy; and

R^4 is selected from hydrido, lower cycloalkyl, lower cycloalkenyl, lower cycloalkyldienyl, 5- or 6-membered heterocyclyl, and aryl selected from phenyl, biphenyl, naphthyl; wherein R^4 is optionally substituted at a substitutable position with one or more radicals

35 independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and

40 R^5 is selected from halo, amino, cyano, aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxy carbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower

45 arylheterocyclyl, carboxy, lower cycloalkylamino, lower alkoxy carbonylamino, lower alkoxyaralkylamino, lower alkylaminoalkylamino, lower heterocyclamino, lower heterocyclalkylamino, lower aralkylheterocyclamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower

50 alkoxyaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or $-NR^aR^b$ wherein R^a is lower alkylcarbonyl or amino, and R^b is lower alkyl or lower phenylalkyl; or
a pharmaceutically-acceptable salt or tautomer thereof.

25. A compound of Claim 24 wherein R^1 is selected from hydrido, methyl, ethyl, hydroxyethyl and propargyl; and

5 R^2 is selected from hydrido, methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, N-methylamino,

N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino, dimethylaminopropylamino,

10 morpholinylpropylamino, morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-

15 dimethyl)ethylcarbonylaminopropylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, 1,1-dimethyl-ethylpiperazinylcarbonyl; wherein the phenyl,

20 piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl; and

25 R^1 is selected from cyclohexyl, cyclohexenyl, cyclohexadienyl, phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R^1 is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

35 R^2 is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy,

methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylamino,

40 morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, piperidinylamino, pyridinylmethylamino,

alkyl, keto, aralkyl, carboxy, lower

alkylaminoalkylamino, lower alkynylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxycarbonyl; or

30 R^2 is $-CR^4R^{55}$ wherein R^4 is phenyl and R^{55} is hydroxy; and

R^1 is selected from 5- or 6-membered heteroaryl, and aryl selected from phenyl, biphenyl, and naphthyl;

35 wherein R^1 is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, aryloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and R^3 is selected from halo, amino, cyano,

40 aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxyalkyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower arylheterocyclyl, carboxy, lower cycloalkylamino, lower

45 alkylaminoalkylamino, lower alkoxyaralkylamino, lower heterocyclylalkylamino, lower aralkylheterocyclylamino, lower alkylaminocarbonyl, lower alkylcarbonyl, lower alkoxyaralkylamino, hydrazinyl, and lower alkylhydrazinyl, or $-NR^4R^3$ wherein R^4 is lower

50 alkylcarbonyl or amino, and R^3 is lower alkyl or lower phenylalkyl; or a pharmaceutically-acceptable salt or tautomer thereof.

36. A compound of Claim 35 wherein

55 R^1 is selected from methyl, ethyl, hydroxyethyl and propargyl; and

R^2 is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, N-methylamino, N,N-dimethylamino, N-ethylamino, N,N-diethylamino, N-propylamino, N-phenylamino, aminomethyl, aminoethyl, aminoethylamino,

SUBSTITUTESHEET (RULE 28)

aminopropylamino, propargylamino, benzylamino, piperidinylamino, dimethylaminoethylamino, dimethylaminopropylamino, morpholinylpropylamino, 65 morpholinylethylamino, piperidinyl, piperazinyl, imidazolyl, morpholinyl, pyridinyl, N-methylpiperazinyl, carboxymethylamino, methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-

70 dimethyl)ethylcarbonylaminopropylamino, (1,1-dimethyl)ethylcarbonylaminoethylamino, piperazinylcarbonyl, and 1,1-dimethyl-

ethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or 75 more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl, methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl; and

R^1 is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R^1 is 80 optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R^2 is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl,

85 fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino,

ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, propargylamino, imidazolylamino, morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino, 95 piperidinylamino, pyridinylmethylamino,

phenylmethylpiperidinylamino, aminomethyl, cyclopropylamino, amino, hydroxy, methylcarbonyl,

SUBSTITUTESHEET (RULE 28)

741

ethoxycarbonylamino, methoxyphenylmethylamino, phenylmethylamino, fluorophenylmethylamino, fluorophenylethylamino, methylaminocarbonyl, methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or -NR⁴R⁵ wherein R⁴ is methylcarbonyl or amino, and R⁵ is methyl or benzyl; or a pharmaceutically-acceptable salt or tautomer thereof.

37. A compound of Claim 35 wherein R¹ is lower alkyl.

38. A compound of Claim 36 wherein R¹ is lower alkyl.

39. A compound of Claim 35 wherein R² is hydrido.


40. A compound of Claim 36 wherein R² is hydrido.

41. A compound of Claim 35 wherein R¹ is methyl or ethyl, and R² is selected from hydrido, methyl and ethyl.

42. A compound of Claim 36 wherein R¹ is methyl or ethyl, and R² is selected from hydrido, methyl and ethyl.

43. A compound of Claim 35 wherein Z represents a carbon atom.

44. A compound of Formula XI



SUBSTITUTE SHEET (RULE 86)

742

wherein
Z represents a carbon atom or a nitrogen atom; and
R¹ is selected from lower alkyl, lower hydroxyalkyl, lower aralkyl, lower aminoalkyl and lower alkylaminoalkyl; and

R² is selected from hydrido, lower alkyl, aryl selected from phenyl, biphenyl, and naphthyl, 5- or 6-membered heterocyclyl selected from piperidinyl, piperazinyl, imidazolyl, pyridinyl and morpholinyl, lower haloalkyl, lower hydroxyalkyl, lower alkoxyalkyl, lower aminoalkyl, lower aralkyl, lower aralkylamino, lower alkylaminoalkylamino, lower aminoalkyl, lower aminoalkylamino, lower alkylaminoalkyl, lower heterocyclylalkyl, lower heterocyclylalkylamino, lower alkylheterocyclyl, lower carboxycycloalkyl, lower carboxyalkylamino, lower alkoxyalkylamino, lower alkoxyalkylaminoalkylamino, lower heterocyclylcarbonyl, lower alkoxyalkylheterocyclyl, and lower alkoxyalkylheterocyclylcarbonyl; wherein the aryl and heteroaryl groups are optionally substituted with one or more radicals independently selected from halo, lower alkyl, keto, aralkyl, carboxy, lower

alkylaminoalkylamino, lower alkylamino, lower heterocyclylalkylamino, lower alkylcarbonyl and lower alkoxyalkylamino; or

R² is -CR⁴R⁵ wherein R⁴ is phenyl and R⁵ is hydroxy; and

R¹ is selected from 5- or 6-membered heteroaryl, and aryl selected from phenyl, biphenyl, and naphthyl; wherein R¹ is optionally substituted with one or more radicals independently selected from halo, lower alkyl, lower alkoxy, arloxy, lower aralkoxy, lower haloalkyl, lower alkylthio, lower alkylamino, nitro, hydroxy; and R⁵ is selected from halo, amino, cyano,

SUBSTITUTE SHEET (RULE 86)

aminocarbonyl, lower alkyl, lower alkoxy, hydroxy, lower aminoalkyl, lower aralkyl, lower aralkyloxy, lower aralkylamino, lower alkoxycarbonyl, lower alkylamino, lower alkylcarbonyl, lower aralkenyl, lower

50 alkylcarbonyl or amino, and R⁶ is lower alkyl or lower phenylalkyl; or a pharmaceutically-acceptable salt or tautomer thereof.

45. A compound of Claim 44 wherein

R¹ is selected from methyl, ethyl, hydroxyethyl and propargyl; and

R^2 is selected from methyl, ethyl, propyl, phenyl, trifluoromethyl, hydroxyethyl, methoxycarbonylethyl, ethoxycarbonylethyl, *N*-methylamino, *N,N*-dimethylamino, *N*-ethylamino, *N,N*-diethylamino, *N*-propylamino, *N*-phenylamino, aminomethyl, aminoethyl, aminoethylamino, aminopropylamino, propargylamino, benzylamino.

ethylpiperazinylcarbonyl; wherein the phenyl, piperidinyl, piperazinyl, imidazolyl, morpholinyl, and pyridinyl groups are optionally substituted with one or more radicals independently selected from fluoro, chloro, bromo, keto, methyl, ethyl, trifluoromethyl, benzyl,

methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-dimethyl)ethoxycarbonyl;

R' is selected from phenyl, quinolyl, biphenyl, pyridinyl, thienyl, furyl, dihydropyranlyl, benzofuryl, dihydrobenzofuryl, and benzodioxolyl; wherein R' is optionally substituted with one or more radicals independently selected from methylthio, fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, trifluoromethyl, nitro, dimethylamino, and hydroxy; and

R³ is selected from fluoro, chloro, bromo, methyl, fluorophenylethyl, fluorophenylethenyl, fluorophenylpyrazolyl, cyano, methoxycarbonyl, aminocarbonyl, acetyl, hydroxy, carboxy, methoxy, methylamino, dimethylamino, 2-methylbutylamino, ethylamino, dimethylaminoethylamino, hydroxypropylamino, hydroxyethylamino, imidazolylamino,

methoxy or benzyl, or a pharmaceutically-acceptable salt or tautomer thereof.

46. A compound of Claim 44 wherein R¹ is lower alkyl.

47. A compound of Claim 45 wherein R¹ is lower alkyl.

48. A compound of Claim 44 wherein R² is hydrido.

49. A compound of Claim 45 wherein R² is hydrido.

thereof.

54. A compound of Claim 53 wherein

R¹ is selected from hydrido, methyl, ethyl,

hydroxyethyl and propargyl;

R² is selected from methyl, ethyl, propyl, phenyl,

trifluoromethyl, hydroxyethyl, methoxycarbonylethyl,

ethoxycarbonylethyl, N-methylamino, N,N-dimethylamino, N-

ethylamino, N,N-diethylamino, N-propylamino, N-

phenylamino, aminomethyl, aminoethyl, aminoethylamino,

aminopropylamino, propargylamino, benzylamino,

dimethylaminopropylamino, morpholinylpropylamino,

morpholinylethylamino, piperidinyl, piperazinyl,

imidazolyl, morpholinyl, pyridinyl, carboxymethylamino,

methoxyethylamino, (1,1-dimethyl)ethylcarbonyl, (1,1-

dimethyl)ethylcarbonylamino, (1,1-

dimethyl)ethylcarbonylaminoethylamino,

piperazinylcarbonyl, 1,1-dimethyl-

ethylpiperazinylcarbonyl; wherein the phenyl,

piperidinyl, piperazinyl, imidazolyl, morpholinyl, and

pyridinyl groups are optionally substituted with one or

more radicals independently selected from fluoro, chloro,

bromo, keto, methyl, ethyl, trifluoromethyl, benzyl,

methoxy, methoxycarbonyl, ethoxycarbonyl and (1,1-

dimethyl)ethoxycarbonyl;

R⁴ is phenyl that is optionally substituted with one

or more radicals independently selected from methylthio,

fluoro, chloro, bromo, methyl, ethyl, methoxy, ethoxy,

phenoxy, benzyloxy, trifluoromethyl, nitro,

dimethylamino, and hydroxy; and

R⁵ is selected from fluoro, chloro, bromo, methyl,

fluorophenylethyl, fluorophenylethenyl,

fluorophenylpyrazolyl, cyano, methoxycarbonyl,

aminocarbonyl, acetyl, hydroxy, carboxy, methoxy,

methylamino, dimethylamino, 2-methylbutylamino,

ethylamino, dimethylaminoethylamino, hydroxypropylamino,

35 hydroxyethylamino, imidazolylamino,

morpholinylethylamino, (1-ethyl-2-hydroxy)ethylamino,

piperidinylamino, pyridinylmethylamino,

phenylmethylpiperidinylamino, aminomethyl,

cyclopropylamino, amino, hydroxy, methylcarbonyl,

ethoxycarbonylamino, methoxyphenylmethylamino,

phenylmethylamino, fluorophenylmethylamino,

fluorophenylethylamino, methylaminocarbonyl,

methylcarbonyl, hydrazinyl, and 1-methylhydrazinyl, or -

NR²R³ wherein R² is methylcarbonyl or amino, and R³ is

methyl or benzyl; or

a pharmaceutically-acceptable salt or tautomer

thereof.

55. A compound of Claim 53 wherein R¹ is hydrido or

lower alkyl.

56. A compound of Claim 54 wherein R¹ is hydrido or

lower alkyl.

57. A compound of Claim 53 wherein R¹ is hydrido.

58. A compound of Claim 54 wherein R¹ is hydrido.

59. A compound of Claim 53 wherein R² is hydrido.

60. A compound of Claim 54 wherein R² is hydrido.

61. A compound of Claim 53 wherein R⁴ is phenyl

substituted with one or more fluoro, chloro or bromo.

62. A compound of Claim 54 wherein R⁴ is phenyl

substituted with one or more fluoro, chloro or bromo.

63. A compound of Claim 53 wherein R¹ and R² are


selected independently from hydrido, methyl and ethyl.

749

64. A compound of Claim 54 wherein R¹ and R² are selected independently from hydrido, methyl and ethyl.

65. A compound of Claim 53 wherein Z represents a carbon atom.

66. A compound of Formula IX



wherein

Z represents a carbon atom or a nitrogen atom; and

5 R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl and lower alkynyl; and

10 R² is selected from hydrido and lower alkyl; and R³ is selected from phenyl and benzodioxolyl; wherein phenyl is optionally substituted with one or more halo radicals; and

R⁴ is selected from hydrido, halo and alkylhydrazinyl; or a pharmaceutically-acceptable salt or tautomer thereof.

67. A compound of Claim 66 wherein

Z represents a carbon atom; and

R¹ is selected from hydrido, methyl, hydroxyethyl, propargyl; and

SUBSTITUTE SHEET (RULE 26)

750

5 R² is hydrido; and R¹ is selected from phenyl and benzodioxolyl; wherein phenyl is optionally substituted with one or more radicals independently selected from chloro, fluoro and bromo; and

10 R³ is selected from hydrido, fluoro, and 1-methylhydrazinyl; or a pharmaceutically-acceptable salt or tautomer thereof.

68. A compound of Claim 67 wherein

Z represents a carbon atom; and

R¹ is selected from hydrido and methyl; and

R² is hydrido; and

5 R³ is selected from phenyl that is optionally substituted with one or more radicals independently selected from chloro, fluoro and bromo; and

R⁴ is selected from hydrido and fluoro; or a pharmaceutically-acceptable salt or tautomer thereof.

69. A compound of Claim 1 selected from compounds, their tautomers and their pharmaceutically acceptable salts, of the group consisting of

5 4-[5-(3-fluoro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;

4-(3-methyl-5-phenyl-1H-pyrazol-4-yl)pyridine;

4-[5-methyl-3-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine;

4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;

4-[5-methyl-3-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine;

10 4-[5-methyl-3-(4-(methylthio)phenyl)-1H-pyrazol-4-yl]pyridine;

4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;

4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;

4-[5-(2,5-dimethylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;

15 4-[5-(1,3-benzodioxol-5-yl)-3-methyl-1H-pyrazol-4-yl]pyridine;

SUBSTITUTE SHEET (RULE 26)

- yl]pyridine;
 4-[3-methyl-5-(4-phenoxyphenyl)-1H-pyrazol-4-yl]pyridine;
 4-[5-[(1,1'-biphenyl)-4-yl]-3-methyl-1H-pyrazol-4-yl]pyridine;
 20 4-[3-methyl-5-[3-(phenoxyphenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-methyl-5-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine;
 4-[3-methyl-5-[2-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]pyridine;
 25 2-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol;
 3-[3-methyl-4-(4-pyridinyl)-1H-pyrazol-4-yl]phenol;
 1-hydroxy-4-[3-methyl-5-phenyl-1H-pyrazol-4-yl]pyridinium;
 30 5-(4-fluorophenyl)-N, N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
 5-(4-fluorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
 4-[5-(4-fluorophenyl)-3-phenyl-1H-pyrazol-4-yl]pyridine;
 35 4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]pyridine;
 4-(5-cyclohexyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
 40 4-[5-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
 4-[5-(3-methylphenyl)-3-propyl-1H-pyrazol-4-yl]pyridine;
 4-[(3-methyl-5-phenyl-1H-pyrazol-4-yl)methyl]pyridine;
 4-[3,5-bis(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
 45 4-[4-methyl-2-(2-trifluorophenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(2-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
 4-[5-methyl-3-(2,4-dimethylphenyl)-1H-pyrazol-4-yl]pyridine;
 4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine;
 50 4-[3-(3-fluoro-2-methylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;

SUBSTITUTE SHEET (RULE 86)

- yl]pyridine;
 4-[3-(3,5-dimethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
 55 4-[3-(3,5-dimethoxyphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
 4-[5-methyl-3-(3-nitrophenyl)-1H-pyrazol-4-yl]pyridine;
 N,N-dimethyl-4-[5-methyl-4-(4-pyridinyl)-1H-pyrazol-3-yl]benzenamine;
 60 4-[3-(2,3-dihydrobenzofuran-5-yl)-5-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-bromophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(2-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(3-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
 65 4-[3-methyl-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine;
 4-(3-ethyl-4-phenyl-1H-pyrazol-4-yl]pyridine;
 4-[5-(3-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
 70 4-[3-ethyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
 4-[5-(3,4-difluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-ethoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]pyridine;
 75 4-[3-methyl-5-(3-thienyl)-1H-pyrazol-4-yl]pyridine;
 4-[5-(2,4-dichlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
 4-[5-(3-chloro-4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
 ethyl 3-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazole-5-propanoate;
 4-[3-(4-fluorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
 85 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
 5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;

SUBSTITUTE SHEET (RULE 86)

753

- 90 5-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
- 95 5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyrimidin-2-amine;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- 100 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- 105 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-amine;
- 110 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxy-5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
2-methoxy-5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
- 115 2-methoxy-5-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxy-5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
2-methoxy-4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
2-methoxy-4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxy-5-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;

SUBSTITUTE SHEET (RULE 26)

754

- 125 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2-methoxy-5-[3-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]pyridine;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
- 130 4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
- 135 4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
- 140 4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridin-2-ol;
5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
- 145 4-[5-(3-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(2-methylphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
- 150 4-[5-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
4-[5-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-methanamine;
- 155 5-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
4-[5-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]pyridine-2-carboxamide;
- 160

SUBSTITUTE SHEET (RULE 26)

4-(3-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole;
4-(5-isothiazolyl)-3-methyl-5-phenyl-1H-pyrazole;
4-(5-isoxazolyl)-3-methyl-5-phenyl-1H-pyrazole;
3-methyl-4-(5-thiazolyl)-1H-pyrazole;
3-methyl-4-(5-oxazolyl)-5-phenyl-1H-pyrazole;
4-(3-(4-fluorophenyl)-1H-pyrazol-4-yl)pyridine;
2-methyl-6-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
4-(1-methyl-3-phenyl-1H-pyrazol-4-yl)pyridine;
4-(3-phenyl-1H-pyrazol-4-yl)pyridine;

2-methyl-6-(3-phenyl-1H-pyrazol-4-yl)pyridine;
4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1-methyl-pyrazol-4-yl]pyridine;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-2-methylpyridine;
4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
4-[3-(3-chlorophenyl)-1-methyl-pyrazol-4-yl]-2-

255
260

methyipyridine;
5-(4-chlorophenyl)-N-phenyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
5-(4-chlorophenyl)-N-methyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
5-(4-chlorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
5-(4-chlorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine dihydrate;
5-(3-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazol-3-amine;
N,N-dimethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;

N-methyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;
N-ethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;
N,N-diethyl-5-(3-methylphenyl)-4-(4-pyridinyl)-1H-pyrazol-3-amine;
N,N-dichlorophenyl)-N,N-diethyl-4-(4-pyridinyl)-1H-

SUBSTITUTION SHEET (RULE 28)

pyrazol-3-, -amine;
270 4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-y]morpholine;
5-(4-chlorophenyl)-N-propyl-4-(4-pyridinyl)-1H-pyrazol-3-
amine;
5-(4-chlorophenyl)-N(phenylmethyl)-4-(4-pyridinyl)-1H-
pyrazol-3-, -amine hydrate (2:1);
5-(4-chlorophenyl)-N-(2-methoxyethyl)-4-(4-pyridinyl)-1H-
pyrazol-3-, -amine monohydrate;
1,1-dimethylethyl-4-[5-(4-chlorophenyl)-4-(4-pyridinyl)-
1H-pyrazol-3-yl]-1-piperazinecarboxylate;
280 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-
yl]piperazine trihydrochloride;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(4-
methypiperazine;

1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine trihydrochloride;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine;

290 N-[5-(4-chlorophenyl)-4-[2-(phenylmethylamino)-4-pyridinyl]-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride;
1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-(phenylmethyl) piperazine;
4-[3-(4-fluorophenyl)-5-(1-piperazinyl)-1H-pyrazol-4-yl]pyrimidine, dihydrochloride;

1,1-dimethylethylenyl [3-[[(5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)amino]propyl] carbamate; N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,3-propanediamine, trihydrochloride monohydrate; 1,1-dimethylethylenyl [2-{[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl] amino} ethyl] carbamate; 1,1-dimethylethylenyl 4-[5-(4-chlorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1-

SUBSTITUTE SHEET (RULE 26)

- 305 piperazinecarboxylate;
 1,1-dimethylethyl 4-[5-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazol-3-yl]-1-piperazinecarboxylate;
 1,1-dimethylethyl 3-[[5-(4-chlorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazol-3-yl]amino]propyl carbamate;
 310 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-ethylpiperazine;
 N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-1,2-ethanediamine;
 4-[3-(2,6-difluorophenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
 315 4-[3-(3-ethylphenyl)-5-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(3-chlorophenyl)-5-ethyl-1H-pyrazol-4-yl]pyridine;
 4-[3-ethyl-5-(3-ethylphenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-chlorophenyl)-5-(1-methylethyl)-1H-pyrazol-4-yl]pyridine;
 320 4-[3-cyclopropyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]pyridine;
 325 4-[5-(cyclopropyl-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 5-cyclopropyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
 3-[4-fluorophenyl]-5-(2-methoxy-4-pyridinyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
 330 4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone;
 1-acetyl-4-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]-2(1H)-pyridinone;
 335 Ethyl 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylate;
 2-[3-(4-fluorophenyl)-1-(2-hydroxyethyl)-4-(4-pyridinyl)-1H-pyrazol-5-yl]cyclopropanecarboxylic acid;
 3-(4-fluorophenyl)-5-(4-imidazolyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
 340

- 4-[3-(4-chloro-3-methylphenyl)-1H-pyrazol-4-yl]pyridine
 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-carboxylic acid;
 5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-3-methanol;
 345 1-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]piperazine;
 1,1-dimethylethyl 4-[[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]carbonyl]-1-piperazinecarboxylate;
 350 4-(1,5-dimethyl-3-phenyl-1H-pyrazol-4-yl)pyridine;
 4-(1,3-dimethyl-5-phenyl-1H-pyrazol-4-yl)pyridine;
 4-[3-(4-chlorophenyl)-1,5-dimethyl-1H-pyrazol-4-yl]pyridine;
 4-[5-(4-chlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]pyridine;
 355 4-[5-ethyl-1-methyl-3-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
 4-[3-ethyl-1-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]pyridine;
 360 4-[3-(4-chlorophenyl)-1-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-chlorophenyl)-2-ethyl-5-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
 365 4-[3-(2-chlorophenyl)-1H-pyrazol-4-yl]pyridine;
 3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol;
 3-(4-fluorophenyl)-4-(4-pyrimidinyl)-1H-pyrazole-1-ethanol;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 370 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-1-butanol;
 4-[5-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinecarbonitrile;
 375 4-[2-[3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-1-

yl] ethyl] morpholine;
3- (4- fluorophenyl) -1-methyl- α -phenyl-4- (4-pyridinyl) -1H-pyrazole-5-methanol;
N- (5- (4-fluorophenyl) -4- (4-pyridinyl) -1H-pyrazol-3-yl) -4-morpholinylethanamine;
4- [3- (3-chlorophenyl) -1H-pyrazol-4-yl] -2 (1H)-pyridinone hydrazone;
4- (3- (3-chlorophenyl) -1H-pyrazol-4-yl) -N- (phenylmethyl) -2-pyridinamine;
4- [3- (3-chlorophenyl) -1H-pyrazol-4-yl] -N- (phenylethyl) -2-pyridinamine;
4- [3- (3-chlorophenyl) -1H-pyrazol-4-yl] -N-ethyl-2-pyridinamine;
4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -2-pyridinecarboxamide;
Methyl 4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -2-pyridinecarboxylate;
4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -N-methyl-2-pyridinecarboxamide;
4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] -2-pyridinecarboxylic acid;
4- [3- (4-fluorophenyl) -1H-pyrazol-4-yl] pyridine;
4- [3- (3-fluorophenyl) -1H-pyrazol-4-yl] pyridine;
4- [3- (1,3-benzodioxol-5-yl) -1H-pyrazol-4-yl] pyridine;
4- [3- (3-fluorophenyl) -1-methyl-1H-pyrazol-4-yl] pyridine;
4- [3- (4-chlorophenyl) -1H-pyrazol-4-yl] pyridine;
4- [3- (1,3-benzodioxol-5-yl) -1-methyl-1H-pyrazol-4-yl] pyridine;
4- [3- (4-chlorophenyl) -1-methyl-1H-pyrazol-4-yl] pyridine;
4- [3- (3-chlorophenyl) -1-methyl-1H-pyrazol-4-yl] pyridine;
4- [3- (3-chlorophenyl) -1-methyl-1H-pyrazol-4-yl] -2-methylpyridine;
4- [5- (3-chlorophenyl) -1-methyl-1H-pyrazol-4-yl] pyridine;
4- [5- (3-chlorophenyl) -1-methyl-1H-pyrazol-4-yl] pyridine;
2-methyl-4- [1-methyl-3- (3-methylphenyl) -1H-pyrazol-4-yl] pyridine;
2-methyl-4- [1-methyl-5- (3-methylphenyl) -1H-pyrazol-4-

SUBSTITUTE SHEET (RULE 26)

[illegible]

SUBSTITUTE SHEET (RULE 26)

- pyridine;
 450 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-methylpyridine;
 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-methyl-
 pyridine;
 4-[3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-flu-
 oropyridine;
 455 3-(4-fluorophenyl)-N,N-dimethyl-4-(4-pyridinyl)-1H-pyrazo-
 le-1-ethanamine;
 2-[2-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1-
 methyl-1H-pyrazol-4-yl]pyridine;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-
 (phenylmethyl)-4-piperidinyl]-2-pyridinamine;
 460 N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-
 N,N-dimethyl-1,2-ethanediamine;
 2,4-bis[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
 465 N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-
 morpholineethanamine;
 3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-pyrazole-
 1-ethanol;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-
 1-yl)ethyl]-2-pyridinamine;
 470 4-[2-[3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-1H-
 pyrazol-1-yl]ethyl]morpholine;
 (E)-3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethenyl]-
 4-pyridinyl]-1H-pyrazole-1-ethanol;
 3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-N,N-dimethyl-
 475 1H-pyrazole-1-ethanamine;
 3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-
 pyridinyl]-1H-pyrazole-1-ethanol;
 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-
 pyrazol-4-yl]-N,N-dimethyl-2-pyridinamine;
 480 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-
 pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine;
 3-(4-fluorophenyl)-4-[2-[2-(4-fluorophenyl)ethyl]-4-
 pyridinyl]-N,N-dimethyl-1H-pyrazole-1-ethanamine;
 N-[(4-fluorophenyl)methyl]-4-[3(or 5)-(4-fluorophenyl)-1-

SUBSTITUTE SHEET (RULE 26)

- 485 [[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-
 pyridinamine;
 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl-2-
 pyridinamine;
 N,N-diethyl-3-(4-fluorophenyl)-4-(2-fluoro-4-pyridinyl)-
 490 1H-pyrazole-1-ethanamine;
 4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-
 pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]-2-pyridinamine;
 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-
 pyridinyl]amino]ethanol;
 495 2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-
 pyridinyl]amino]ethanol;
 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-
 pyridinyl]amino]-1-propanol;
 3-(4-fluorophenyl)-4-[2-[[4-(4-fluorophenyl)methyl]amino]-
 500 4-pyridinyl]-1H-pyrazole-1-ethanol;
 5-(4-fluorophenyl)-4-[2-[[4-(4-fluorophenyl)methyl]amino]-
 4-pyridinyl]-1H-pyrazole-1-ethanol;
 N,N-diethyl-3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-
 pyrazole-1-ethanamine;
 505 N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-
 morpholinyl)ethyl]-1H-pyrazol-4-yl]-2-pyridinamine;
 N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-
 morpholinepropanamine;
 N'-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-
 510 N,N-dimethyl-1,3-propanediamine;
 5-(4-fluorophenyl)-N-2-propynyl-4-(4-pyridinyl)-1H-
 pyrazol-3-amine;
 3-(4-fluorophenyl)-4-[2-[[4-(4-fluorophenyl)methyl]amino]-
 4-pyridinyl]-1H-pyrazole-1-ethanol;
 515 5-(4-fluorophenyl)-4-[2-[[4-(4-fluorophenyl)methyl]amino]-
 4-pyridinyl]-1H-pyrazole-1-ethanol;
 4-[3-[(4-fluorophenyl)-1H-pyrazol-4-yl]quinoline;
 N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-
 520 yl]glycine methyl ester;
 N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-

SUBSTITUTE SHEET (RULE 26)

765

yl] glycine;
 4-[3-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine;
 4-[5-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl]pyridine;
 4,4'-(1H-pyrazole-3,4-diyl)bis[pyridine];
 4-[3-(3,4-dichlorophenyl)-1H-pyrazol-4-yl]pyridine;
 N-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-piperidinamine;

530 2-chloro-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine;

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2(1H)-pyrimidinone hydrazone;

535 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N,N-dimethyl-2-pyrimidinamine;

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)-2-pyrimidinamine;

540 N-cyclopropyl-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine;

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]-2-pyrimidinamine;

545 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinamine; N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N-(phenylmethyl)acetamide;

ethyl 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl] carbamate;

550 4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]pyrimidine;




4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyrimidine;

4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine; and

4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyrimidine.

766




70. A compound of claim 1 selected from compounds, their tautomers and their pharmaceutically acceptable salts, of the group consisting of



SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)

767






SUBSTITUTE SHEET (RULE 26)

768






SUBSTITUTE SHEET (RULE 26)

769






SUBSTITUTESHEET (RULE 26)

770






SUBSTITUTESHEET (RULE 26)

771






SUBSTITUTESHEET (RULE 28)

772






SUBSTITUTESHEET (RULE 28)

773



SUBSTITUTE SHEET (RULE 28)

774



SUBSTITUTE SHEET (RULE 28)

71. A compound of claim 1 that is 4-(5-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl)pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

72. A compound of claim 1 that is 4-(3-(4-fluorophenyl)-1-(2-propynyl)-1H-pyrazol-4-yl)pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

73. A compound of claim 1 that is 3-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazole-1-ethanol or a pharmaceutically-acceptable salt or a tautomer thereof.

74. A compound of claim 1 that is 4-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-2-(1-methylhydrazino)pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

75. A compound of claim 1 that is 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]piperazine or a pharmaceutically-acceptable salt or a tautomer thereof.

76. A compound of claim 1 that is 4-[3-(cyclopropyl-5-(4-fluorophenyl)-1H-pyrazol-4-yl)pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

77. A compound of claim 1 that is 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

78. A compound of claim 1 that is 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine or a pharmaceutically-acceptable salt or a tautomer thereof.

79. A compound of claim 1 that is 4-(3-(4-fluorophenyl)-1H-pyrazol-4-yl)pyrimidine or a pharmaceutically-acceptable salt or a tautomer thereof.

80. A compound of claim 1 that is 2-fluoro-4-(3-(4-fluorophenyl)-1H-pyrazol-4-yl)pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

81. A compound of claim 1 that is 4-(3-(3,4-difluorophenyl)-1-methyl-1H-pyrazol-4-yl)pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

82. A compound of claim 1 that is 4-(3-(4-bromophenyl)-1H-pyrazol-4-yl)pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

83. A compound of claim 1 that is 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-fluoropyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

84. A compound of claim 1 that is 4-[3-(1,3-benzodioxol-5-yl)-1-methyl-1H-pyrazol-4-yl]pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

85. A compound of claim 1 that is 4-[3-(3-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.


86. A compound of claim 1 that is 4-(3-(3-fluorophenyl)-1-methyl-pyrazol-4-yl)pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

777

87. A compound of claim 1 that is 5-(4-fluorophenyl)-N-2-propynyl-4-(4-pyridinyl)-1H-pyrazol-3-amine or a pharmaceutically-acceptable salt or a tautomer thereof.

88. A substituted pyrazole that specifically binds to an ATP binding site of p38 kinase.

89. A compound of claim 88 having the formula:



wherein

5 R^1 is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units; and

10 R^2 is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical that binds with p38 kinase at said ATP binding site of p38 kinase; and

15 R^3 is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a hydrogen bond acceptor functionality; and

20 R^4 is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units;

provided R^3 is not 2-pyridinyl when R^4 is a phenyl ring containing a 2-hydroxy substituent and when R^3 is hydrido; further provided R^4 is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R^4 is hydrido; and further provided R^4 is not

SUBSTITUTESHEET (RULE 28)

778

methylsulfonylphenyl, or
a pharmaceutically-acceptable salt or tautomer thereof.

90. A compound of claim 89 wherein R^2 is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical that binds with lys_{82} , glu_{82} , leu_{82} , ile_{82} , leu_{84} , and thr_{10} sidechains at said ATP binding site of p38 kinase, said radical being substantially disposed within a hydrophobic cavity formed during said binding by p38 kinase at the ATP binding site.

91. A compound of claim 89 wherein R^3 is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a hydrogen bond acceptor functionality that hydrogen bonds with the N-H backbone of Met_{106} of p38 kinase.

92. A compound of claim 89 wherein R^4 is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 250 atomic mass units.

93. A compound of claim 89 wherein R^4 is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 250 atomic mass units.

94. A compound of claim 89 wherein
 R^1 is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units; and

R^2 is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical wherein said radical binds with lys_{82} , glu_{82} , leu_{82} , ile_{82} , leu_{84} , and thr_{10} sidechains

SUBSTITUTESHEET (RULE 28)

at said ATP binding site of p38 kinase, said radical being substantially disposed within a hydrophobic cavity formed during said binding by p38 kinase at the ATP binding site; and

R' is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a hydrogen bond acceptor functionality that hydrogen bonds with the N-H backbone of Met₁₀₄ of p38 kinase; and

R' is a hydrocarbyl, heterosubstituted hydrocarbyl or heterocyclyl radical having a molecular weight less than about 360 atomic mass units.

95. A compound of claim 94 wherein R' and R' are independently selected from hydrocarbyl, heterosubstituted hydrocarbyl and heterocyclyl radicals and have a combined molecular weight less than about 360 atomic mass units.

96. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from the compounds of Claims 1; or a pharmaceutically acceptable salt thereof.

97. A pharmaceutical composition of Claim 96 wherein said compound is selected from the compounds of Claim 3; or a pharmaceutically acceptable salt thereof.

98. A pharmaceutical composition of Claim 96 wherein said compound is selected from the compounds of Claim 4; or a pharmaceutically acceptable salt thereof.

99. A pharmaceutical composition of Claim 96 wherein said compound is selected from the compounds of Claim 5; or a pharmaceutically acceptable salt thereof.

100. A pharmaceutical composition of Claim 96

wherein said compound is selected from the compounds of Claim 6; or a pharmaceutically acceptable salt thereof.

101. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from the compounds of Claim 24; or a pharmaceutically acceptable salt thereof.

102. A pharmaceutical composition of Claim 101 wherein said compound is selected from the compounds of Claim 25; or a pharmaceutically acceptable salt thereof.

103. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from the compounds of Claim 25; or a pharmaceutically acceptable salt thereof.

104. A pharmaceutical composition of Claim 103 wherein said compound is selected from the compounds of Claim 36; or a pharmaceutically acceptable salt thereof.

105. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from the compounds of Claim 44; or a pharmaceutically acceptable salt thereof.

106. A pharmaceutical composition of Claim 105 wherein said compound is selected from the compounds of Claim 45; or a pharmaceutically acceptable salt thereof.

107. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from the compounds of Claim 53; or a pharmaceutically acceptable salt thereof.

108. A pharmaceutical composition of Claim 107

781


wherein said compound is selected from the compounds of Claim 54; or a pharmaceutically acceptable salt thereof

109. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from the of compounds of Claim 66; or a pharmaceutically acceptable salt thereof.

110. A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from the compounds of Claims 65; or a pharmaceutically salt thereof.

11.1. A pharmaceutical composition of Claim 11.0 wherein said compound is 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.

112. A method of treating a TNF mediated disorder, said method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of a compound of Formula I




wherein

R¹ is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylalkylene, haloalkyl, haloalkenyl, heterocyclylalkylene, haloalkyl, haloalkenyl,

SUBSTITUTION SHEET (RULE 28)

782

haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, arylalkyl, heterocyclyloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxy-carbonylalkylene, arylloxy-carbonylalkylene, heterocyclyl-carbonylalkylene, heterocyclyl-carbonylarylene, heterocyclyloxy-carbonylarylene, alkyl-carbonylalkylene, aryl-carbonylalkylene, heterocyclyl-carbonylalkylene, alkyl-carbonylarylene, aryl-carbonylarylene, heterocyclyl-carbonylarylene, heterocyclyl-carbonyloxyalkylene, alkyl-carbonyloxyalkylene, heterocyclyl-carbonyloxyalkylene, alkyl-carbonyloxyarylene, heterocyclyl-carbonyloxyarylene, or heterocyclyl-carbonyloxyarylene; and



R^1 has the formula

wherein:


i is an integer from 0 to 9;

40 ²⁴ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

SUBSTITUTE SHEET (RULE 26)

785

- 115 alkoxy, carbonylamino, alkylamino, and heterocyclylsulfonyl; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxylalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminocarbonylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxy, carbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or
- 120
- 125 R^3 has the formula:





wherein:

- 130 j is an integer from 0 to 8; and
 m is 0 or 1; and
 R^{30} and R^{31} are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminocarbonyl, alkylaminocarbonyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and
- 135 R^{32} is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;
- 140 R^{33} is selected from hydrogen, alkyl, $-C(O)R^{35}$, $-C(O)OR^{35}$, $-SO_2R^{36}$, $-C(O)NR^{37}R^{38}$, and $-SO_2NR^{39}R^{40}$, wherein R^{35} , R^{36} , R^{37} , R^{38} , R^{39} and R^{40} are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and
- 145 R^{34} is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

SUBSTITUTE SHEET (RULE 26)

786

R^2 is $-CR^{41}R^{42}$ wherein R^{41} is aryl, and R^{42} is hydroxy; and
 R^3 is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,



(IV)

(V)

wherein R^3 is selected from hydrogen, alkyl, aminocarbonyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; and


- 155 wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxy, carbonyl, aryloxy, carbonyl, heterocyclyloxy, carbonyl, alkoxy, carbonyl, alkoxy, aralkylamino, aminocarbonyl, aminocarbonyl, alkylaminocarbonyl, hydroxyalkylamino, aralkylamino, heterocyclylalkylamino, aralkylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, haloalkyl, aminocarbonyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or $-NR^{44}R^{45}$ wherein R^{44} is alkylcarbonyl or amino, and R^{45} is alkyl or aralkyl; and
- 160
- 165 R^4 is selected from hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R^4 is optionally substituted with one or more radicals
- 170
- 175

SUBSTITUTE SHEET (RULE 26)

- independently selected from halo, alkyl, alkenyl, alkenyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxy carbonyl, aryloxy carbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy; provided R³ is not 2-pyridinyl when R⁴ is a phenyl ring containing a 2-hydroxy substituent and when R⁴ is hydrido; further provided R³ is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴ is hydrido; and further provided R⁴ is not methylsulfonylphenyl; or a pharmaceutically-acceptable salt or tautomer thereof.

113. A method of treating a p38 kinase mediated disorder, said method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of a compound of


Formula I



wherein

R¹ is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl,

- 10 cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkenoxyalkenyl, aryloxyalkyl, heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkylthioalkylene, alkylthioalkenyl, amino, aminoalkyl, alkylamino, alkenylamino, alkylaminamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkylsulfonyl, alkylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxy carbonyl, alkoxy carbonylalkylene, aryloxy carbonylalkylene, heterocycliloxy carbonylalkylene, alkoxy carbonylalkylene, aryloxy carbonylalkylene, heterocycliloxy carbonylalkylene, heterocycliloxy carbonylalkylene, alkyl carbonylalkylene, heterocyclyl carbonylalkylene, alkyl carbonylalkylene, aryl carbonylalkylene, heterocyclyl carbonylalkylene, alkyl carbonylalkylene, heterocycliloxy carbonylalkylene, alkyl carbonylalkylene, aryl carbonylalkylene, heterocycliloxy carbonylalkylene, and aryl carbonylalkylene, and heterocycliloxy carbonylalkylene; or
- 35 R¹ has the formula



wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl,

789

alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

45 R^6 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxy, carbonylalkylene, and alkylaminoalkyl; and R^7 is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, arylloxyarylene, aralkoxyarylene,

50 alkoxyheterocyclylalkylene, arylloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkoxycarbonylalkylene, alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylloxycarbonylalkylene, alkoxycarbonylarylene, arylloxycarbonylarylene, alkylarylloxycarbonylarylene, alkylcarbonylheterocyclylarylene, alkoxycarbonylheterocyclylarylene,

55 alkoxycarbonylalkoxyarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, alkylthioalkyl, aralkylthioalkylene, heterocyclylthioalkylene, aralkylthioalkylene, heterocyclylthioalkylene, aralkylthioalkylarylene, arylsulfonylthioalkylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, arylloxyarylene, arylaminocarbonylalkylene, arylloxycarbonylarylene, arylcarbonylalkylene, heterocyclylthioalkylene, alkylthioalkylarylene, heterocyclylthioalkylene, arylthioalkylarylene, and alkylsulfonylarylene groups

790

are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

80 R^8 is $-\text{CHR}^9\text{R}^{10}$ wherein R^9 is alkoxy, carbonyl, and R^{10} is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocyclyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

90 R^8 and R^9 together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, arylloxyalkylene, alkoxyarylene, alkylarylloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclylalkylene and arylloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy;

95 R^8 is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, aminoalkyl, aminoaryl, aminoalkylamino, arylaminoalkylene, alkylaminoalkylene, arylaminoarylene, alkylaminoarylene, alkoxy, heterocyclyloxy, alkylthio, arylthio, heterocyclylthio, carboxy, carboxylalkyl, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl,

60 alkoxyheterocyclylalkylene, arylloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkylaminoalkylene, arylaminocarbonylalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkylaminocarbonylalkylene, arylloxycarbonylalkylene, alkoxycarbonylarylene, arylloxycarbonylarylene, alkylarylloxycarbonylarylene, alkylcarbonylheterocyclylarylene, alkoxycarbonylheterocyclylarylene,


65 alkoxycarbonylalkoxyarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioalkyl, aralkylthioalkylene, heterocyclylthioalkylene, aralkylthioalkylene, heterocyclylthioalkylene, aralkylthioalkylarylene, arylsulfonylthioalkylene, alkylaminosulfonylarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, arylloxyarylene, arylaminocarbonylalkylene, arylloxycarbonylarylene, arylcarbonylalkylene, alkylthioalkylarylene, heterocyclylthioalkylene, arylthioalkylarylene, and alkylsulfonylarylene groups

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

- alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylaminocarbonyl, and heterocyclylsulfonyl; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxycarbonyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylaminocarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or


R² has the formula:



wherein:

- 130 j is an integer from 0 to 8; and
m is 0 or 1; and
R²⁰ and R²¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxycarbonyl, and alkylcarbonyloxyalkyl; and
R²² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminocarbonyl;
140 R²³ is selected from hydrogen, alkyl, -C(O)R²⁴, -C(O)OR²⁵, -SO₂R²⁶, -C(O)NR²⁷R²⁸, and -SO₂NR²⁹R³⁰, wherein R²⁴, R²⁵, R²⁶, R²⁷, R²⁸ and R²⁹ are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and
145

- R⁴ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or
R⁵ is -CR⁴R⁴³ wherein R⁴ is aryl, and R⁴³ is hydroxy; and
R⁶ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,




(IV)

(V)

- wherein R³ is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl;
155 and
wherein the R³ pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxycarbonyl, aryloxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylaminocarbonyl, heterocyclylalkylaminocarbonyl, alkoxyaralkylamino, aminosulfinyl, aminosulfonyl, alkylaminocarbonylaminocarbonyl, hydroxyalkylamino, aralkylamino, heterocyclylalkylamino, aralkylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylaminocarbonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or -NR⁴⁴R⁴⁵ wherein R⁴⁴ is alkylcarbonyl or amino, and R⁴⁵ is alkyl or aralkyl; and
175 R⁴ is selected from hydrido, alkyl, alkenyl, alkynyl,

793

180 R' is optionally substituted with one or more radicals
cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein
independently selected from halo, alkyl, alkenyl,
alkynyl, aryl, heterocyclyl, alkylthio, arylthio,
alkylthioalkylene, arylthioalkylene, alkylsulfonyl,
alkylsulfonylalkylene, arylsulfonylalkylene,
alkylsulfonyl, arylsulfonylalkylene,
arylsulfonylalkylene, alkoxy, arylalkoxy, aralkoxy,
aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,
185 alkoxy carbonyl, arylalkoxy carbonyl, haloalkyl, amino, cyano,
nitro, alkylamino, arylamino, alkylaminoalkylene,
arylaminoalkylene, aminodialkylamino, and hydroxy;
provided R' is not 2-pyridinyl when R' is a phenyl ring
containing a 2-hydroxy substituent and when R' is hydrido,
190 further provided R' is selected from aryl, heterocyclyl,
unsubstituted cycloalkyl and cycloalkenyl when R' is
hydrido; and further provided R' is not
methylsulfonylphenyl, or
a pharmaceutically-acceptable salt or tautomer
thereof.




114. A method of treating inflammation, said method comprising treating the subject having or susceptible to inflammation with a therapeutically-effective amount of a compound of Formula I

wherein
R¹ is selected from hydrido, alkyl, cycloalkyl,

SUBSTITUTE SHEET (RULE 26)

794

- alkenyl, cycloalkenyl, alkynyl, aryl, heterocycli, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocycli, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heterocycliyoxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkylamino, alkynylamino, arylamino, heterocycliylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocycliylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocycliylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocycliyoxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocycliyoxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene, heterocycliycarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocycliycarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocycliycarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and heterocycliycarbonyloxyarylene; or
- R¹ has the formula



wherein:

R^{25} is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene,

SUBSTITUTE SHEET (RULE 26)

40 aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R³⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl,

45 alkoxycarbonylalkylene, and alkylaminoalkyl; and

R³⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene,

50 cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene,

aralkylheterocyclyl, alkoxylalkylene, alkoxylarylene, alkoxylaralkyl, alkoxylheterocyclyl, alkoxylalkoxyarylene, arylalkoxyarylene, aralkoxyarylene,

55 alkoxylheterocyclylalkylene, arylalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl,

alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene,

60 alkoxylaminocarbonylalkylene, aminocarbonylalkylene, arylaminocarbonylalkylene, alkoxycarbonylalkylene, alkoxycarbonylarylene,

arylalkoxyarylene, alkylaryloxyalkoxyarylene, arylcarbonylalkylene, alkylarylcabonylarylene, alkoxycarbonylheterocyclylarylene,

65 alkoxycarbonylalkoxyarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene,

aralkylthioarylene, heterocyclylthioarylene, arylthioalkylarylene, arylsulfonaminoalkylene,

70 alkylsulfonarylene, alkylaminosulfonarylene; wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene,

alkoxyarylene, arylalkoxyarylene, arylaminocarbonylalkylene, arylalkoxyarylene, arylcarbonylarylene,

75 alkylthioarylene, heterocyclylthioarylene,

arylthioalkylarylene, and alkylsulfonarylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

80 R³⁷ is -CHR³⁶R³⁸ wherein R³⁶ is alkoxycarbonyl, and R³⁸ is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and

85 heterocyclyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R³⁶ and R³⁷ together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene,

alkylheterocyclylalkylene, arylalkoxyalkylene,

95 alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and

alkoxycarbonylamino; wherein said aryl,

heterocyclylalkylene and arylalkoxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy;

100 and

R³ is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl,

alkylamino, alkenylamino, alkynylamino, arylamino,

105 heterocyclylamino, heterocyclylalkylamino, aralkylamino, aminoalkyl, aminoaryl, aminoalkylamino,

arylaminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl,

alkylaminocarbonyl, alkylaminocarbonyl, cycloalkyl,


cycloalkenyl, alkoxy, heterocyclyloxy, alkylthio,

110 arylthio, heterocyclylthio, carboxy, carboxylalkyl,

carboxycycloalkyl, carboxycycloalkenyl,

797

- 115 carboxyalkylamino, alkoxycarbonyl, heterocyclylcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylamino, and heterocyclylsulfonyl; wherein the aryl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or
- 120
- 125 R^3 has the formula:



wherein:

- 130 j is an integer from 0 to 8; and
- 135 m is 0 or 1; and

R^{30} and R^{31} are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and


- 140 R^{32} is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;

R^{33} is selected from hydrogen, alkyl, $-C(O)R^{35}$, $-C(O)OR^{35}$, $-SO_2R^{36}$, $-C(O)NR^{37}R^{38}$, and $-SO_2NR^{39}R^{40}$, wherein R^{35} , R^{36} , R^{37} , R^{38} and R^{40} are independently selected from hydrocarbon, heterosubstituted hydrocarbon and

SUBSTITUTESHEET (RULE 26)

798

- 145 heterocyclyl; and
- 150 R^4 is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or R^3 is $-CR^4R^5$ wherein R^4 is aryl, and R^5 is hydroxy; and R^3 is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,



(IV)


(V)

- 155 wherein R^4 is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; and

- 160 wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxycarbonyl, aryloxycarbonyl, heterocyclyloxy carbonyl, alkoxycarbonylamino, alkoxyaralkylamino, aminoalkyl, aminoalkyl, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, heterocyclylalkylamino, aralkylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, haloalkyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or $-NR^4R^5$ wherein R^4 is alkylcarbonyl or amino, and R^5 is alkyl or aralkyl; and
- 170


SUBSTITUTESHEET (RULE 26)

- 175 R' is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R' is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfonylalkylene, arylsulfinylalkylene, alkylsulfonylalkylene, arylsulfonylalkylene, alkylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxy carbonyl, aryloxy carbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy; provided R' is not 2-pyridinyl when R' is a phenyl ring containing a 2-hydroxy substituent and when R' is hydrido; further provided R' is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R' is hydrido; and further provided R' is not methylsulfonylphenyl; or
- 180 a pharmaceutically-acceptable salt or tautomer thereof.
- 185 115. A method of treating arthritis, said method comprising treating the subject having or susceptible to arthritis with a therapeutically-effective amount of a compound of Formula I



wherein

- R' is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene, heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene, alkylthioalkenyl, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene, alkylsulfonylalkylene, acyl, acyloxy carbonyl, alkoxy carbonylalkylene, aryloxy carbonylalkylene, heterocycliloxy carbonylalkylene, alkoxy carbonylarylene, aryloxy carbonylarylene, heterocycliloxy carbonylalkylene, alkyl carbonylalkylene, heterocyclyl carbonylalkylene, alkyl carbonylarylene, aryl carbonylarylene, heterocyclyl carbonylarylene, alkyl carbonyloxyalkylene, aryl carbonyloxyalkylene, heterocyclyl carbonyloxyalkylene, alkyl carbonyloxyarylene, aryl carbonyloxyarylene, and heterocyclyl carbonyloxyarylene; or
- 10 R' has the formula



wherein:

i is an integer from 0 to 9;

801

40 R^5 is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

45 R^6 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and R^7 is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene, cycloalkenylalkylene, cycloalkylarylene, cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylalkylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene, alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene,

50 alkoxyheterocyclylalkylene, aryloxyalkoxyarylene, alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclylalkylene, aminoalkyl, alkylaminoalkylene, arylaminoalkylene, alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, alkoxycarbonylalkylene, alkylaminocarbonylalkylene, arylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylarylcarbonylarylene, arylcarbonylheterocyclylarylene, alkoxycarbonylalkoxyarylene,

55 heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalkylarylene, arylsulfonylaminoalkylene, arylsulfonylarylene, alkylaminosulfonylarylene, wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, arylalkoxyarylene, arylaminocarbonylalkylene,

60 alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene, alkoxycarbonylalkylene, alkylaminocarbonylalkylene, arylaminocarbonylalkylene, arylcarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, alkylarylcarbonylarylene, arylcarbonylheterocyclylarylene, alkoxycarbonylalkoxyarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalkylarylene, arylsulfonylaminoalkylene, arylsulfonylarylene, alkylaminosulfonylarylene, wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, arylalkoxyarylene, arylaminocarbonylalkylene,

65 alkoxycarbonylalkoxyarylene, heterocyclylcarbonylalkylarylene, alkylthioalkylene, cycloalkylthioalkylene, alkylthioarylene, aralkylthioarylene, heterocyclylthioarylene, arylthioalkylarylene, arylsulfonylaminoalkylene, arylsulfonylarylene, alkylaminosulfonylarylene, wherein said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, alkylheterocyclylarylene, alkoxyarylene, arylalkoxyarylene, arylaminocarbonylalkylene,

802

75 aryloxycarbonylarylene, arylcarbonylarylene, arylthioarylene, heterocyclylthioarylene, arylthioalkylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or

80 R^7 is -CH R^8 - R^9 wherein R^8 is alkoxycarbonyl, and R^9 is selected from aralkyl, aralkoxyalkylene, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocyclyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

90 R^4 and R^9 together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclylalkylene, alkylheterocyclylalkylene, aryloxyalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl,


95 heterocyclylalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and R^2 is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, alkylamino, alkenylamino, alkylamino, arylamino, heterocyclylamino, heterocyclylalkylamino, aralkylamino, aminoalkyl, aminoaryl, aminoalkylamino, arylaminoalkylene, alkylaminoalkylene, arylaminoalkylene, cycloalkyl, cycloalkenyl, alkoxy, heterocyclyloxy, alkylthio,

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

- 110 arylthio, heterocyclylthio, carboxy, carboxyalkyl, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxy carbonyl, heterocyclyl carbonyl, alkoxy carbonylalkyl, alkoxy carbonyl heterocyclyl, alkoxy carbonyl heterocyclyl carbonyl, alkoxyalkylamino, alkoxy carbonyl aminoalkylamino, and heterocyclyl sulfonyl; wherein the aryl, heterocyclyl, and heterocyclylalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclylalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylamino, heterocyclylalkylamino, alkyl carbonyl, alkoxy carbonyl, alkylsulfonyl, arylsulfonyl, and aralkylsulfonyl; or

R² has the formula:



wherein:

- 130 j is an integer from 0 to 8; and
m is 0 or 1; and
R³⁰ and R³¹ are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and
135 R³² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;
140 R³³ is selected from hydrogen, alkyl, -C(O)R³⁵, -C(O)OR³⁵, -SO₂R³⁵, -C(O)NR³⁵R³⁶, and -SO₂NR³⁵R³⁶, wherein R³⁵,

R³⁶, R³⁷, R³⁸, R³⁹ and R⁴⁰ are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

- 145 R³⁸ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or
R³ is -CR⁴¹R⁴² wherein R⁴¹ is aryl, and R⁴² is hydroxy; and
R⁴ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,



(IV)

(V)

wherein R⁴³ is selected from hydrogen, alkyl, aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; and

- 155 wherein the R³ pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxy carbonyl, aryloxy carbonyl, heterocyclyl oxy carbonyl, alkoxy carbonyl amino, alkoxy aralkyl amino, aminosulfinyl, aminosulfonyl, alkylaminoalkyl amino, hydroxyalkyl amino, aralkyl amino, heterocyclylalkyl amino, aralkyl heterocyclyl amino, nitro, alkylaminocarbonyl, alkyl carbonyl amino, haloalkyl, aminoalkyl, haloalkyl, alkyl carbonyl, hydrazinyl, alkylhydrazinyl,

805

arylhydrazinyl, or -NR⁴R⁵ wherein R⁴ is alkylcarbonyl or amino, and R⁵ is alkyl or aralkyl; and

175 R¹ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R¹ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfinylalkylene, arylsulfinylalkylene, alkylsulfonyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy;


185 provided R³ is not 2-pyridinyl when R⁴ is a phenyl ring containing a 2-hydroxy substituent and when R¹ is hydrido; further provided R¹ is selected from aryl, heterocyclyl, unsubstituted cycloalkyl and cycloalkenyl when R⁴ is hydrido; and further provided R¹ is not methylsulfonylphenyl; or

190 a pharmaceutically-acceptable salt or tautomer thereof.

116. A method of treating a p38 kinase mediated disorder, said method comprising treating the subject having or susceptible to such disorder with a therapeutically-effective amount of a compound of Formula I

SUBSTITUTESHEET (RULE28)

806



wherein

Z represents a carbon atom or a nitrogen atom; and R¹ is selected from hydrido, lower alkyl, lower hydroxyalkyl and lower alkynyl; and

10 R² is selected from hydrido and lower alkyl; and R³ is selected from phenyl and benzodioxolyl; wherein phenyl is optionally substituted with one or more halo radicals; and

15 R⁴ is selected from hydrido, halo and alkylhydrazinyl; or a pharmaceutically-acceptable salt or tautomer thereof.


117. The method of Claim 112 wherein the TNF mediated disorder is selected from the group of disorders consisting of bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease state, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease and cachexia.

SUBSTITUTESHEET (RULE28)

118. The method of Claim 112 wherein the TNF mediated disorder is inflammation.
119. The method of Claim 112 wherein the TNF mediated disease is arthritis.
120. The method of Claim 112 wherein the TNF mediated disorder is asthma.
121. The method of claim 112 wherein the compound is 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine or a pharmaceutically-acceptable salt or a tautomer thereof.
122. The method of claim 112 wherein the compound is 1-[5-(4-chlorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-4-methylpiperazine or a pharmaceutically-acceptable salt or a tautomer thereof.
123. The method of Claim 113 wherein the disorder is a p38 α kinase mediated disorder.
124. The method of Claim 113 wherein the p38 kinase mediated disorder is selected from the group of disorders consisting of bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease state, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease and cachexia.
125. The method of Claim 113 wherein the p38 kinase mediated disorder is inflammation.
126. The method of Claim 113 wherein the p38 kinase

SUBSTITUTE SHEET (RULE 26)

- mediated disorder is arthritis.
127. The method of Claim 113 wherein the p38 kinase mediated disorder is asthma.
128. The method of Claim 116 wherein the disorder is a p38 α kinase mediated disorder.
129. The method of Claim 116 wherein the p38 kinase mediated disorder is selected from the group of disorders consisting of bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease state, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease and cachexia.
130. The method of Claim 116 wherein the p38 kinase mediated disorder is inflammation.
131. The method of Claim 116 wherein the p38 kinase mediated disorder is arthritis.
132. The method of Claim 116 wherein the p38 kinase mediated disorder is asthma.
133. A method of preparing pyrazoles of Formula I




SUBSTITUTE SHEET (RULE 26)

809

wherein

[illegible]

R^1 has the formula



wherein:

i is an integer from 0 to 9;

SUBSTITUTE SHEET (RULE 26)

810

35 R³ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

40 R²⁶ is selected from hydrogen, alkyl, alkenyl,

alkynyl, cycloalkylaryl, aralkyl, alkoxy carbonyl alkyl, and alkylaminoalkyl; and R² is selected from alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl, cycloalkylaryl, cycloalkenyl, cycloalkylarylene, cycloalkenylarylene, cycloalkylarylene,

50 cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene,
alkylarylalkyl, aralkylarylene, alkylheterocyclyl,
alkylheterocyclylalkylene, alkylheterocyclylarylene,
arylheterocyclyl, alkoxyalkylene, alkoxyarylene,
alkoxyarylalkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene,
aryloxyarylene, aralkoxyarylene,

alkoxyheterocyclylalkylene, arylloxyalkoxyarylene,
alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl,
alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl
alkylaminoalkylene, arylaminocarbonylalkylene,
alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene
arylaminocarbonylalkylene, alkylaminocarbonylalkylene,
arylcarbonylalkylene, alkoxycarbonylalkylene,
aryloxycarbonylarylene, alkylaryloxycarbonylarylene,
arylcarbonylarylene, alkylarylcarbonylarylene,
alkoxycarbonylheterocyclylarylene,

alkoxycarbonylalkoxyarylene,
heterocyclylcarbonylalkylarylene, alkylthioalkylene,
cycloalkylthioalkylene, alkylthioarylene,
aralkylthioarylene, heterocyclylthioarylene,
arylthioalkylarylene, arylsulfonylaminoalkylene,
alkylsulfonylarylene, alkylamnosulfonylarylene; wherein
said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
heterocyclylalkylene, alkylheterocyclylarylene,
alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,
alkoxyarylene, aryloxyarylene, arylaminocarbonylalkylene,


SUBSTITUTE SHEET (RULE 26)

aryloxycarbonylarylene, arylcarbonylarylene, alkylthioarylene, heterocyclithioarylene, arylthioalkylarylene, and alkylsulfonylarylene groups are optionally substituted with one or more radicals independently selected from alkyl, halo, haloalkyl, alkoxy, keto, amino, nitro, and cyano; or R^{27} is $-\text{CHR}^{28}\text{R}^{29}$ wherein R^{28} is alkoxycarbonyl, and R^{29} is selected from aralkyl, aralkoxyalkyl, heterocyclylalkylene, alkylheterocyclylalkylene, alkoxycarbonylalkylene, alkylthioalkylene, and aralkylthioalkylene; wherein said aralkyl and heterocyclyl groups are optionally substituted with one or more radicals independently selected from alkyl and nitro; or

R^{24} and R^{27} together with the nitrogen atom to which they are attached form a heterocycle, wherein said heterocycle is optionally substituted with one or more radicals independently selected from alkyl, aryl, heterocyclyl, heterocyclalkylene, alkylheterocyclalkylene, alkoxyarylene, alkylaryloxyalkylene, alkylcarbonyl, alkoxycarbonyl, aralkoxycarbonyl, alkylamino and alkoxycarbonylamino; wherein said aryl, heterocyclalkylene and aryloxyalkylene radicals are optionally substituted with one or more radicals independently selected from halogen, alkyl and alkoxy; and

R^2 is selected from hydrido, halogen, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl, aralkyl, alkylheterocyclyl, heterocyclalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, heterocyclalkylamino, aralkylamino, aminoalkyl, aminoaryl, aminoalkylamino, arylaminoarylene, alkylaminoarylene, alkylaminoalkylene, arylaminoalkylene, cycloalkenyl, alkoxy, heterocyclloxy, alkylthio,

arylthio, heterocyclylthio, carboxy, carboxyalkyl, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylheterocyclcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylene, and heterocyclsulfonyl; wherein the aryl, heterocyclyl, heterocyclalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylene, heterocyclalkylalkylene, alkoxyalkyl, alkoxycarbonyl, alkoxyalkylsulfonyl, or arylsulfonyl, and aralkylsulfonyl; or R^2 has the formula:



wherein:

j is an integer from 0 to 8; and


m is 0 or 1; and

R^{30} and R^{31} are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R^{32} is selected from hydrogen, alkyl, aralkyl, heterocyclalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclcarbonylaminoalkylene;

R^{33} is selected from hydrogen, alkyl, $-\text{C}(\text{O})\text{R}^{34}$, $-\text{C}(\text{O})\text{OR}^{35}$, $-\text{SO}_2\text{R}^{36}$, $-\text{C}(\text{O})\text{NR}^{37}\text{R}^{38}$, and $-\text{SO}_2\text{NR}^{39}\text{R}^{40}$, wherein R^{34} ,

arylthio, heterocyclylthio, carboxy, carboxyalkyl, carboxycycloalkyl, carboxycycloalkenyl, carboxyalkylamino, alkoxycarbonyl, heterocyclcarbonyl, alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl, alkoxycarbonylheterocyclcarbonyl, alkoxyalkylamino, alkoxycarbonylaminoalkylene, and heterocyclsulfonyl; wherein the aryl, heterocyclyl, heterocyclalkyl, cycloalkyl and cycloalkenyl groups are optionally substituted with one or more radicals independently selected from halo, keto, amino, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heterocyclalkyl, epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, aryloxy, aralkoxy, haloalkyl, alkylamino, alkynylamino, alkylaminoalkylene, heterocyclalkylalkylene, alkoxyalkyl, alkoxycarbonyl, alkoxyalkylsulfonyl, or arylsulfonyl, and aralkylsulfonyl; or R^2 has the formula:



wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R^{30} and R^{31} are independently selected from hydrogen, alkyl, aryl, heterocyclyl, aralkyl, heterocyclalkylene, aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and


R^{32} is selected from hydrogen, alkyl, aralkyl, heterocyclalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclcarbonylaminoalkylene;

R^{33} is selected from hydrogen, alkyl, $-\text{C}(\text{O})\text{R}^{34}$, $-\text{C}(\text{O})\text{OR}^{35}$, $-\text{SO}_2\text{R}^{36}$, $-\text{C}(\text{O})\text{NR}^{37}\text{R}^{38}$, and $-\text{SO}_2\text{NR}^{39}\text{R}^{40}$, wherein R^{34} ,


813

140 R^4 , R^7 , R^8 , R^9 and R^{10} are independently selected from hydrocarbon, heterosubstituted hydrocarbon and heterocyclyl; and

145 R^3 is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or R^3 is $-CR^4R^5$ wherein R^4 is aryl, and R^5 is hydroxy; and R^3 is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,



; and



(IV)

(V)

150 wherein R^4 is selected from hydrogen, alkyl, aminocarbonyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; and

155 wherein the R^3 pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy, carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino, cycloalkenylamino, arylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, aryloxy, aryloxyalkyl, heterocyclylalkoxy, alkoxy, alkoxyalkyl, alkoxyaralkyl, aminosulfinyl, aminosulfonyl, alkylaminocarbonyl, hydroxyalkylamino, aralkylamino, heterocyclylalkylamino, aralkylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, haloalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl,

814

170 arylhydrazinyl, or $-NR^4R^5$ wherein R^4 is alkylcarbonyl or amino, and R^5 is alkyl or aralkyl; and

175 R^6 is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R^6 is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfonylalkylene, arylsulfinylalkylene, arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, arylsulfonylalkylene, alkoxy, alkoxyalkyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxy, alkoxyalkyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminocarbonyl, arylaminocarbonyl, aminoalkylamino, and hydroxy; or a pharmaceutically-acceptable salt or tautomer thereof,

185 said method comprising the steps of forming an acyl hydrazone and condensing to form the substituted pyrazole.

134. The process of Claim 133 wherein the acyl hydrazone is formed by reaction of a ketone with an acyl hydrazide.


135. The process of Claim 133 wherein the condensation is performed at a temperature from about 25 °C to about 200 °C.

136. A method of preparing pyrazoles of Formula I

SUBSTITUTE SHEET (RULE 26)

SUBSTITUTE SHEET (RULE 26)

815



(I)

wherein

R¹ is selected from hydrido, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclyl, cycloalkylalkylene, cycloalkenylalkylene,

heterocyclylalkylene, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, hydroxyalkenyl, hydroxyalkynyl, aralkyl, aralkenyl, aralkynyl,

arylheterocyclyl, carboxy, carboxyalkyl, alkoxyalkyl, alkenoxyalkyl, alkynoxyalkyl, aryloxyalkyl, heterocycliloxyalkyl, alkoxyalkoxy, mercaptoalkyl, alkylthioalkylene, alkenylthioalkylene,

alkylthioalkenylene, amino, aminoalkyl, alkylamino, alkenylamino, alkynylamino, arylamino, heterocyclylamino, alkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, arylsulfinyl, heterocyclylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, arylsulfonyl, heterocyclylsulfonyl, alkylaminoalkylene,

alkylsulfonylalkylene, acyl, acyloxycarbonyl, alkoxycarbonylalkylene, aryloxycarbonylalkylene, heterocycliloxycarbonylalkylene, alkoxycarbonylarylene, aryloxycarbonylarylene, heterocycliloxycarbonylarylene, alkylcarbonylalkylene, arylcarbonylalkylene,


heterocyclylcarbonylalkylene, alkylcarbonylarylene, arylcarbonylarylene, heterocyclylcarbonylarylene, alkylcarbonyloxyalkylene, arylcarbonyloxyalkylene, heterocyclylcarbonyloxyalkylene, alkylcarbonyloxyarylene, arylcarbonyloxyarylene, and

SUBSTITUTE SHEET (RULE 26)

816

30 heterocyclylcarbonyloxyarylene; or

R¹ has the formula



(II)

wherein:

i is an integer from 0 to 9;

R²⁵ is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl,

alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene; and

R²⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkylalkylene, aralkyl, alkoxycarbonylalkylene, and alkylaminoalkyl; and

R²⁷ is selected from alkyl, cycloalkyl, alkynyl, aryl, heterocyclyl, aralkyl, cycloalkylalkylene,

cycloalkenylalkylene, cycloalkylarylene,

cycloalkylcycloalkyl, heterocyclylalkylene, alkylarylene, alkylaralkyl, aralkylarylene, alkylheterocyclyl, alkylheterocyclylalkylene, alkylheterocyclylarylene, aralkylheterocyclyl, alkoxyalkylene, alkoxyarylene,

alkoxyaralkyl, alkoxyheterocyclyl, alkoxyalkoxyarylene, aryloxyarylene, aralkoxyarylene,

alkoxyheterocyclylalkylene, aryloxyalkoxyarylene,

alkoxycarbonylalkylene, alkoxycarbonylheterocyclyl,

alkoxycarbonylheterocyclylcarbonylalkylene, aminoalkyl, alkylaminoalkylene, arylaminocarbonylalkylene,

alkoxyarylaminocarbonylalkylene, aminocarbonylalkylene,

arylaminocarbonylalkylene, alkylaminocarbonylalkylene,

arylcarbonylalkylene, alkoxycarbonylarylene,

aryloxycarbonylarylene, alkylaryloxycarbonylarylene,

arylcarbonylarylene, alkylarylcarbonylarylene,

alkoxycarbonylheterocyclylarylene,

SUBSTITUTE SHEET (RULE 26)

817

alkoxycarbonylalkoxylarylene,
 heterocyclylcarbonylalkylarylene, alkylthioalkylene,
 cycloalkylthioalkylene, alkylthioarylene,
 aralkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, arylsulfonylaminoalkylene,
 alkylsulfonylarylene, alkylaminosulfonylarylene; wherein
 said alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl,
 heterocyclylalkylene, alkylheterocyclylarylene,
 alkoxylarylene, arylloxylarylene, arylaminocarbonylalkylene,
 arylloxycarbonylarylene, arylcarbonylarylene,
 alkylthioarylene, heterocyclylthioarylene,
 arylthioalkylarylene, and alkylsulfonylarylene groups
 are optionally substituted with one or more radicals
 independently selected from alkyl, halo, haloalkyl,
 alkoxy, keto, amino, nitro, and cyano; or

R² is -CHR³R⁴ wherein R³ is alkoxycarbonyl, and R⁴
 is selected from aralkyl, aralkoxyalkylene,
 heterocyclylalkylene, alkylheterocyclylalkylene,
 alkoxycarbonylalkylene, alkylthioalkylene, and
 aralkylthioalkylene; wherein said aralkyl and
 heterocyclyl groups are optionally substituted with one
 or more radicals independently selected from alkyl and
 nitro; or


R⁴ and R⁷ together with the nitrogen atom to which
 they are attached form a heterocycle, wherein said
 heterocycle is optionally substituted with one or more
 radicals independently selected from alkyl, aryl,
 heterocyclyl, heterocyclylalkylene,
 alkylheterocyclylalkylene, arylloxylalkylene,
 alkoxyarylene, alkylarylloxylalkylene, alkylcarbonyl,
 alkoxycarbonyl, aralkoxycarbonyl, alkylamino and
 alkoxycarbonylamino; wherein said aryl,
 heterocyclylalkylene and arylloxylalkylene radicals are
 optionally substituted with one or more radicals
 independently selected from halogen, alkyl and alkoxy;
 and

SUBSTITUTE SHEET (RULE 26)

818

R¹ is selected from hydrido, halogen, alkyl, alkenyl,
 alkynyl, aryl, heterocyclyl, haloalkyl, hydroxyalkyl,
 aralkyl, alkylheterocyclyl, heterocyclylalkyl,
 alkylamino, alkenylamino, alkynylamino, arylamino,
 heterocyclylamino, heterocyclylalkylamino, aralkylamino,
 aminoalkyl, aminoaryl, aminoalkylamino,
 arylaminoalkylene, alkylaminoalkylene, arylaminoarylene,
 alkylaminoarylene, alkylaminoalkylamino, cycloalkyl,
 cycloalkenyl, alkoxy, heterocyclyloxy, alkylthio,
 arylthio, heterocyclylthio, carboxy, carboxylalkyl,
 carboxycycloalkyl, carboxycycloalkenyl,
 carboxylalkylamino, alkoxycarbonyl, heterocyclylcarbonyl,
 alkoxycarbonylalkyl, alkoxycarbonylheterocyclyl,
 alkoxycarbonylheterocyclylcarbonyl, alkoxyalkylamino,
 alkoxycarbonylaminoalkylamino, and heterocyclylsulfonyl;
 wherein the aryl, heterocyclyl, heterocyclylalkyl,
 cycloalkyl and cycloalkenyl groups are optionally
 substituted with one or more radicals independently
 selected from halo, keto, amino, alkyl, alkenyl, alkynyl,
 aryl, heterocyclyl, aralkyl, heterocyclylalkyl,
 epoxyalkyl, amino(hydroxyalkyl) carboxy, alkoxy, arylloxy,
 aralkoxy, haloalkyl, alkylamino, alkynylamino,
 alkylaminoalkylamino, heterocyclylalkylamino,
 alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl,
 arylsulfonyl, and aralkylsulfonyl; or

R² has the formula:



wherein:

j is an integer from 0 to 8; and

m is 0 or 1; and

R³⁰ and R³¹ are independently selected from hydride,
 alkyl, aryl, heterocyclyl, aralkyl, heterocyclylalkylene,

SUBSTITUTE SHEET (RULE 26)

130 aminoalkyl, alkylaminoalkyl, aminocarbonylalkyl, alkoxyalkyl, and alkylcarbonyloxyalkyl; and

R¹² is selected from hydrogen, alkyl, aralkyl, heterocyclylalkyl, alkoxyalkylene, aryloxyalkylene, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, alkylcarbonylalkylene, arylcarbonylalkylene, and heterocyclylcarbonylaminoalkylene;

R¹³ is selected from hydrogen, alkyl, -C(O)R¹⁵, -C(O)OR¹⁶, -SO₂R¹⁶, -C(O)NR¹⁷R¹⁸, and -SO₂NR¹⁷R¹⁸, wherein R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ are independently selected from hydrogen, heterosubstituted hydrocarbon and heterocyclyl; and

R¹⁴ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or R¹ is -CR¹⁴R¹⁴ wherein R¹⁴ is aryl, and R² is hydroxy; and

145 R¹ is selected from pyridinyl, pyrimidinyl, quinolinyl, purinyl,

wherein R¹ is selected from hydrogen, alkyl, aminocarbonyl, alkylaminocarbonyl, and arylaminocarbonyl; or

R¹ is -CR¹⁴R¹⁴ wherein R¹⁴ is aryl, and R² is hydroxy; and

145 R¹ is selected from pyridinyl, pyrimidinyl,



(IV)

(V)

wherein R¹ is selected from hydrogen, alkyl,

150 aminoalkyl, alkoxyalkyl, alkenoxyalkyl, and aryloxyalkyl; and

wherein the R¹ pyridinyl, pyrimidinyl, quinolinyl and purinyl groups are optionally substituted with one or more radicals independently selected from halo, alkyl, aralkyl, aralkenyl, arylheterocyclyl, carboxy,

155 carboxyalkyl, alkoxy, aryloxy, alkylthio, arylthio,

alkylsulfinyl, arylsulfinyl, alkylsulfonyl, arylsulfonyl, aralkoxy, heterocyclylalkoxy, amino, alkylamino, alkenylamino, alkynylamino, cycloalkylamino,

160 cycloalkenylamino, arylamino, heterocyclylamino, aminocarbonyl, cyano, hydroxy, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, heterocyclyloxyalkyl, alkoxyalkyl, alkoxyalkylene, alkoxyalkylamino, aminosulfinyl, aminosulfonyl, alkylaminoalkylamino, hydroxyalkylamino, aralkylamino, heterocyclylalkylamino,

165 aralkylheterocyclylamino, nitro, alkylaminocarbonyl, alkylcarbonylamino, halosulfonyl, aminoalkyl, haloalkyl, alkylcarbonyl, hydrazinyl, alkylhydrazinyl, arylhydrazinyl, or -NR¹⁴R¹⁴ wherein R¹⁴ is alkylcarbonyl or amino, and R¹⁴ is alkyl or aralkyl; and

170 R¹ is selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, and heterocyclyl, wherein R¹ is optionally substituted with one or more radicals independently selected from halo, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, alkylthio, arylthio, alkylthioalkylene, arylthioalkylene, alkylsulfinyl, alkylsulfonylalkylene, arylsulfonylalkylene, alkylsulfonyl, alkylsulfonylalkylene,

175 arylsulfonylalkylene, alkoxy, aryloxy, aralkoxy, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxyalkyl, aryloxyalkyl, haloalkyl, amino, cyano, nitro, alkylamino, arylamino, alkylaminoalkylene, arylaminoalkylene, aminoalkylamino, and hydroxy; or a pharmaceutically-acceptable salt or tautomer thereof,

185 said method comprising the steps of treating a substituted ketone with an acyl hydrazide to give the pyrazole.

137. The process of Claim 136 wherein it is carried out in an acidic solvent.

138. The process of Claim 137 wherein the acidic solvent is acetic acid.

INTERNATIONAL SEARCH REPORT

Int. Serial Application No.
PCT/US 98/10436

821

139. The process of Claim 137 wherein the acidic solvent is an organic solvent containing an acid.

SUBSTITUTE SHEET (RULE 26)

1. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07D401/04 A61K31/415 A61K31/44 A61K31/505 C07D401/14 C07D409/14 C07D413/14 C07D405/14 C07D471/04 C07D417/14 C07D453/02 //(C07D471/04, 237:00, 231:00), (C07D471/04, 237:00, According to International Patent Classification (IPC) or to both national classification and IPC	
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07D A61K	
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched	
Electronic data bases consulted during the international search (name of data base and, where practical, search terms used)	
C. DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Relevant to claim No.
X	NO 96 03385 A (SEARLE & CO.; LEE LEN F (US); PENNING THOMAS D (US); KRAMER STEVEN) 8 February 1996 cited in the application see abstract; claims 1,8,10 see page 10 - page 13 see page 17 - page 26 see page 24 - page 26 see page 41 - page 44
X	US 5 559 137 A (ADAMS JERRY L ET AL) 24 September 1996 cited in the application see abstract; claim 1; example 1
X	1-139
-/-	
* Further documents are listed in the continuation of box C.	
Special categories of cited documents:	
Y* document relating to the prior art of the art which is not considered to be of particular relevance	T* later document published after the international filing date which is cited to understand the principle of theory underlying the invention
Y* earlier document not published on or after the international filing date	X* document published after the international filing date which is cited to show the prior art of the invention or other reasons (as specified)
Y* document relating to an oral disclosure, use, exhibition or other means	T* document of particular relevance (the claimed invention is cited in the application)
Y* document published prior to the international filing date but later than the priority date claimed	X* document relating to a person skilled in the art
Date of the actual completion of the international search	
11 September 1998	Date of mailing of the international search report
Name and mailing address of the ISA	
No. 2280 HW Highway Tel. (431-70) 340-2040, Tx. 31 651 ext. 41 Fax. (431-70) 340-2018	
Authorized officer Patsdor, B	

INTERNATIONAL SEARCH REPORT

<p>A. CLASSIFICATION OF SUBJECT MATTER IPC 6 233:00</p>		<p>International Application No PCT/US 98/10436</p>																					
<p>B. FIELD OF SEARCH According to International Patent Classification (IPC) or to both national classification and IPC</p>																							
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Reference to claim No.</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>CATVIELA C ET AL: "On the synthesis of 3(5)-(cardomethoxy)-4-hetarylpyrazoles" J. HETEROCYCL. CHEM. (JHICAD, 0022152X);88; VOL.25 (3); PP. 851-5, XP002077334 Univ. Zaragoza; Inst. Cienc. Mater. Aragón; Zaragoza; 50009; Spain (ES) see page 851; examples 3E, 3F, 4E, 4F see page 854</td> <td>1-3, 9-11, 15, 16, 20, 21</td> </tr> <tr> <td>X</td> <td>---</td> <td>88-95</td> </tr> <tr> <td></td> <td>---</td> <td>-/-</td> </tr> </tbody> </table>			Category	Citation of document, with indication, where appropriate, of the relevant passages	Reference to claim No.	A	CATVIELA C ET AL: "On the synthesis of 3(5)-(cardomethoxy)-4-hetarylpyrazoles" J. HETEROCYCL. CHEM. (JHICAD, 0022152X);88; VOL.25 (3); PP. 851-5, XP002077334 Univ. Zaragoza; Inst. Cienc. Mater. Aragón; Zaragoza; 50009; Spain (ES) see page 851; examples 3E, 3F, 4E, 4F see page 854	1-3, 9-11, 15, 16, 20, 21	X	---	88-95		---	-/-									
Category	Citation of document, with indication, where appropriate, of the relevant passages	Reference to claim No.																					
A	CATVIELA C ET AL: "On the synthesis of 3(5)-(cardomethoxy)-4-hetarylpyrazoles" J. HETEROCYCL. CHEM. (JHICAD, 0022152X);88; VOL.25 (3); PP. 851-5, XP002077334 Univ. Zaragoza; Inst. Cienc. Mater. Aragón; Zaragoza; 50009; Spain (ES) see page 851; examples 3E, 3F, 4E, 4F see page 854	1-3, 9-11, 15, 16, 20, 21																					
X	---	88-95																					
	---	-/-																					
<p>D. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Reference to claim No.</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>FISCHER U ET AL: "1,3-Dipolar additions to 7-methylthieno 2,3-cipyridine 1,1-dioxide" HELV. CHIM. ACTA (HCACAV, 0018019X);80; VOL.63 (6); PP. 1719-27, XP002077335 F. Hoffmann-La Roche und Co.; A.-G.; Pharm. Forschungsabt.; Basel; CH-4002; Switz. see page 1719; example 4 see page 1720; examples 10, 13 see page 1721; examples 16, 17, 19, 20</td> <td>1-5, 9-11, 15-22</td> </tr> <tr> <td>X</td> <td>---</td> <td>88-95</td> </tr> <tr> <td>A</td> <td>CHEMICAL ABSTRACTS, vol. 098, no. 1, 3 January 1983 Columbus, Ohio, US; abstract no. 004498, POPOVA A N ET AL: "Synthesis of 4-(pyrazol-4-yl)-substituted salts of pyrylium and pyridines" XP002077337 see abstract</td> <td>1-3, 9-11, 15, 16, 20, 21</td> </tr> <tr> <td>X</td> <td>---</td> <td>88-95</td> </tr> <tr> <td>A</td> <td>BAUER V J ET AL: "4-(3(5)-pyrazolyl)pyridinium salts. A new class of hypoglycemic agents" J. MED. CHEM. (JMCMAR);68; VOL.11 (5); PP. 981-4, XP002077336 Div. of Amer. Cyanamid Co.; Lederle Lab.; Pearl River; N. Y. see page 981; examples 1-5 see page 982; table I see page 983; table II</td> <td>1-3, 9-11, 15, 16, 20, 21</td> </tr> <tr> <td>X</td> <td>---</td> <td>88-95</td> </tr> </tbody> </table>			Category	Citation of document, with indication, where appropriate, of the relevant passages	Reference to claim No.	A	FISCHER U ET AL: "1,3-Dipolar additions to 7-methylthieno 2,3-cipyridine 1,1-dioxide" HELV. CHIM. ACTA (HCACAV, 0018019X);80; VOL.63 (6); PP. 1719-27, XP002077335 F. Hoffmann-La Roche und Co.; A.-G.; Pharm. Forschungsabt.; Basel; CH-4002; Switz. see page 1719; example 4 see page 1720; examples 10, 13 see page 1721; examples 16, 17, 19, 20	1-5, 9-11, 15-22	X	---	88-95	A	CHEMICAL ABSTRACTS, vol. 098, no. 1, 3 January 1983 Columbus, Ohio, US; abstract no. 004498, POPOVA A N ET AL: "Synthesis of 4-(pyrazol-4-yl)-substituted salts of pyrylium and pyridines" XP002077337 see abstract	1-3, 9-11, 15, 16, 20, 21	X	---	88-95	A	BAUER V J ET AL: "4-(3(5)-pyrazolyl)pyridinium salts. A new class of hypoglycemic agents" J. MED. CHEM. (JMCMAR);68; VOL.11 (5); PP. 981-4, XP002077336 Div. of Amer. Cyanamid Co.; Lederle Lab.; Pearl River; N. Y. see page 981; examples 1-5 see page 982; table I see page 983; table II	1-3, 9-11, 15, 16, 20, 21	X	---	88-95
Category	Citation of document, with indication, where appropriate, of the relevant passages	Reference to claim No.																					
A	FISCHER U ET AL: "1,3-Dipolar additions to 7-methylthieno 2,3-cipyridine 1,1-dioxide" HELV. CHIM. ACTA (HCACAV, 0018019X);80; VOL.63 (6); PP. 1719-27, XP002077335 F. Hoffmann-La Roche und Co.; A.-G.; Pharm. Forschungsabt.; Basel; CH-4002; Switz. see page 1719; example 4 see page 1720; examples 10, 13 see page 1721; examples 16, 17, 19, 20	1-5, 9-11, 15-22																					
X	---	88-95																					
A	CHEMICAL ABSTRACTS, vol. 098, no. 1, 3 January 1983 Columbus, Ohio, US; abstract no. 004498, POPOVA A N ET AL: "Synthesis of 4-(pyrazol-4-yl)-substituted salts of pyrylium and pyridines" XP002077337 see abstract	1-3, 9-11, 15, 16, 20, 21																					
X	---	88-95																					
A	BAUER V J ET AL: "4-(3(5)-pyrazolyl)pyridinium salts. A new class of hypoglycemic agents" J. MED. CHEM. (JMCMAR);68; VOL.11 (5); PP. 981-4, XP002077336 Div. of Amer. Cyanamid Co.; Lederle Lab.; Pearl River; N. Y. see page 981; examples 1-5 see page 982; table I see page 983; table II	1-3, 9-11, 15, 16, 20, 21																					
X	---	88-95																					
<p>E. OTHER INFORMATION</p> <p>Electronic data base consulted during the international search (name of data base and, where practical, search terms used)</p>																							
<p>F. STATEMENT OF THE INVENTOR</p> <p>Date of the actual completion of the international search: 11 September 1998</p> <p>Name and mailing address of the ISA: ISA, 2200 AV. RIVIERE, F.R. 5818 Payerette 2, T.M. (+31-70) 540-5040, Tr. 31 651 6014, Fax: (+31-70) 540-5016</p> <p>Authorized officer: Païsdor, 8</p>																							

INTERNATIONAL SEARCH REPORT

<p>C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Reference to claim No.</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>FISCHER U ET AL: "1,3-Dipolar additions to 7-methylthieno 2,3-cipyridine 1,1-dioxide" HELV. CHIM. ACTA (HCACAV, 0018019X);80; VOL.63 (6); PP. 1719-27, XP002077335 F. Hoffmann-La Roche und Co.; A.-G.; Pharm. Forschungsabt.; Basel; CH-4002; Switz. see page 1719; example 4 see page 1720; examples 10, 13 see page 1721; examples 16, 17, 19, 20</td> <td>1-5, 9-11, 15-22</td> </tr> <tr> <td>X</td> <td>---</td> <td>88-95</td> </tr> <tr> <td>A</td> <td>CHEMICAL ABSTRACTS, vol. 098, no. 1, 3 January 1983 Columbus, Ohio, US; abstract no. 004498, POPOVA A N ET AL: "Synthesis of 4-(pyrazol-4-yl)-substituted salts of pyrylium and pyridines" XP002077337 see abstract</td> <td>1-3, 9-11, 15, 16, 20, 21</td> </tr> <tr> <td>X</td> <td>---</td> <td>88-95</td> </tr> <tr> <td>A</td> <td>BAUER V J ET AL: "4-(3(5)-pyrazolyl)pyridinium salts. A new class of hypoglycemic agents" J. MED. CHEM. (JMCMAR);68; VOL.11 (5); PP. 981-4, XP002077336 Div. of Amer. Cyanamid Co.; Lederle Lab.; Pearl River; N. Y. see page 981; examples 1-5 see page 982; table I see page 983; table II</td> <td>1-3, 9-11, 15, 16, 20, 21</td> </tr> <tr> <td>X</td> <td>---</td> <td>88-95</td> </tr> </tbody> </table>		Category	Citation of document, with indication, where appropriate, of the relevant passages	Reference to claim No.	A	FISCHER U ET AL: "1,3-Dipolar additions to 7-methylthieno 2,3-cipyridine 1,1-dioxide" HELV. CHIM. ACTA (HCACAV, 0018019X);80; VOL.63 (6); PP. 1719-27, XP002077335 F. Hoffmann-La Roche und Co.; A.-G.; Pharm. Forschungsabt.; Basel; CH-4002; Switz. see page 1719; example 4 see page 1720; examples 10, 13 see page 1721; examples 16, 17, 19, 20	1-5, 9-11, 15-22	X	---	88-95	A	CHEMICAL ABSTRACTS, vol. 098, no. 1, 3 January 1983 Columbus, Ohio, US; abstract no. 004498, POPOVA A N ET AL: "Synthesis of 4-(pyrazol-4-yl)-substituted salts of pyrylium and pyridines" XP002077337 see abstract	1-3, 9-11, 15, 16, 20, 21	X	---	88-95	A	BAUER V J ET AL: "4-(3(5)-pyrazolyl)pyridinium salts. A new class of hypoglycemic agents" J. MED. CHEM. (JMCMAR);68; VOL.11 (5); PP. 981-4, XP002077336 Div. of Amer. Cyanamid Co.; Lederle Lab.; Pearl River; N. Y. see page 981; examples 1-5 see page 982; table I see page 983; table II	1-3, 9-11, 15, 16, 20, 21	X	---	88-95	<p>International Application No PCT/US 98/10436</p>
Category	Citation of document, with indication, where appropriate, of the relevant passages	Reference to claim No.																					
A	FISCHER U ET AL: "1,3-Dipolar additions to 7-methylthieno 2,3-cipyridine 1,1-dioxide" HELV. CHIM. ACTA (HCACAV, 0018019X);80; VOL.63 (6); PP. 1719-27, XP002077335 F. Hoffmann-La Roche und Co.; A.-G.; Pharm. Forschungsabt.; Basel; CH-4002; Switz. see page 1719; example 4 see page 1720; examples 10, 13 see page 1721; examples 16, 17, 19, 20	1-5, 9-11, 15-22																					
X	---	88-95																					
A	CHEMICAL ABSTRACTS, vol. 098, no. 1, 3 January 1983 Columbus, Ohio, US; abstract no. 004498, POPOVA A N ET AL: "Synthesis of 4-(pyrazol-4-yl)-substituted salts of pyrylium and pyridines" XP002077337 see abstract	1-3, 9-11, 15, 16, 20, 21																					
X	---	88-95																					
A	BAUER V J ET AL: "4-(3(5)-pyrazolyl)pyridinium salts. A new class of hypoglycemic agents" J. MED. CHEM. (JMCMAR);68; VOL.11 (5); PP. 981-4, XP002077336 Div. of Amer. Cyanamid Co.; Lederle Lab.; Pearl River; N. Y. see page 981; examples 1-5 see page 982; table I see page 983; table II	1-3, 9-11, 15, 16, 20, 21																					
X	---	88-95																					

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/10436

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos. 112-132

because they relate to subject matter not required to be searched by the Authority, namely:

Remark: Although claims 112-132 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not entitled in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

The International Searching Authority found multiple inventions in this International Application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not involuntarily pay any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (Continuation of first sheet (1)) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.
PCT/US 98/10436

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9603385 A	08-02-1996	US 5486534 A	23-01-1996
		AU 3126795 A	22-02-1996
		CA 2195123 A	08-02-1996
		EP 0772597 A	14-05-1997
		JP 10503201 T	24-03-1998
		US 5580985 A	03-12-1996
		US 5756530 A	26-05-1998
US 5559137 A	24-09-1996	JP 10500413 T	13-01-1998
		WO 9531451 A	23-11-1995

Form PCT/ISA/210 (Continuation of first sheet (1)) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)

1

